



**MEMORANDUM
AND
ARTICLES OF ASSOCIATION**

DABUR INDIA LIMITED



FORM I. R

Certificate of Incorporation

No. 7908.....of1975-76

I hereby certify that VISHAL CHEMICALS (INDIA) LIMITED

.....
is this day incorporated under the Companies Act, 1956 (No. 1 of 1956) and that the
company is limited.

Given under my hand at New Delhi

this SIXTEENTH day of SEPTEMBER (BHADRA) ;

One thousand nine hundred SEVENTY FIVE (SAKA.....)

Sd/-
(S. KUMAR)
Registrar of Companies
Delhi & Haryana

(Seal)
Registrar of Companies
Delhi & Haryana

FRESH CERTIFICATE OF INCORPORATION
CONSEQUENT ON CHANGE OF NAME

Company No. 790R.

In the Office of the Registrar of Companies DELHI & HARYANA
(Under the Companies Act, 1956 (1 of 1956))
IN THE MATTER OF VISHAL CHEMICALS (INDIA) LIMITED

I hereby certify that Vishal Chemicals (India)
Limited, which was originally incorporated on 10th day of
September, 1975 under the ~~Indian Companies Act~~
~~Companies Act, 1956~~ and under the name Vishal Chemi-
cals (India) Ltd., having duly passed
the necessary resolution in terms of section 21/22(1)(a)/22(1)(b)
of Companies Act, 1956 and the approval of the Central Government
signified in writing having been accorded thereto in the Ministry
of Law, Justice & Company Affairs (Company Law Board) Regional
Director, Northern Region, Kanpur letter No. 3105-D/5577
dated 11-8-1981 the name of
the said company is this day changed to VIDOGUN AND CHEMICALS
Limited and this Certi-
ficate is issued pursuant to section 23(1) of the said Act.

Given under my hand at NEW DELHI this 19th day of
September, 1981 (One thousand nine hundred &
Eighty one)

S. S. Singh
(SARVENDRA SINGH)

ASSTT. REGISTRAR OF COMPANIES
DELHI & HARYANA

OP/43097R*



COMPANY NO. 7908

FRESH CERTIFICATE OF INCORPORATION
CONSEQUENT OF CHANGE OF NAME

IN THE OFFICE OF THE REGISTRAR OF COMPANIES DELHI & HARYANA
(Under the Companies Act, 1956 (1 of 1956))

IN THE MATTER OF VIDOGUM AND CHEMICALS LIMITED

I hereby certify that VIDOGUM AND CHEMICALS LIMITED

which was originally incorporated on 16TH day of SEPTEMBER
One Thousand Nine Hundred and SEVENTY FIVE under the
~~Indian Companies Act, 1956~~ / Companies Act, 1956 and under
the Name VISHAL CHEMICALS (INDIA) LIMITED


having duly passed the necessary resolution in terms of section
~~21(1)(a) of~~ Companies Act, 1956 and the approval
of the Central Government signified in writing having been
accorded thereto in the Ministry of Industry, Department of
Company Affairs, Office of the Registrar of Companies, Delhi &
Haryana, NEW DELHI vide their letter No. ROC/Approval/21/7908/2666
dated 19/09/1986 the name of the said company is
this day changed to DABUR INDIA LIMITED
and this certificate is issued pursuant
to section 23(1) of the said Act.

Given under my hand at NEW DELHI 15TH
day of OCTOBER One thousand Nine Hundred EIGHTY SIX .)



(Signature)
(N.S. GUPTA)
ADDITIONAL REGISTRAR OF COMPANIES
DELHI & HARYANA
NEW DELHI

T/ *anil's



Cd. No. 7908

Certificate for Commencement of Business

Pursuant of section 149 (3) of the Companies Act, 1956

I hereby certify that the VISHAL CHEMICALS(INDIA)
LIMITED

which was incorporated under the Companies Act, 1956, on
the 16th day of September 1975,

and which has this day filed a duly verified declaration in this prescribed
form that the conditions of section ~~149 (1) (a) to (d)~~ 149 (2) (a) to (c)
of the said Act, have been complied with is entitled to commence
business.

Given under my hand at NEW DELHI

this 19th day of NOVEMBER

One thousand nine hundred and SEVENTY FIVE


(S. KUMAR)
Registrar of Companies,
Delhi & Haryana.



Cs No. 7908



[कम्पनी अधिनियम, 1956 की धारा 18 (1)]
[Section 18 (1) of Companies Act, 1956]

उद्देश्यों के परिवर्तन की पुष्टि करने वाले न्यायालय के आदेश
के रजिस्ट्रेशन का प्रमाण पत्र *Company Law Board*
CERTIFICATE OF REGISTRATION OF ORDER OF COURT *Bench*
CONFIRMING ALTERATION OF OBJECTS

ने विशेष
संघल्प द्वारा उद्देश्यों की वास्तु अपने संगम-शासन, उपबन्धों में परिवर्तन कर दिया है और ऐसे
परिवर्तन की तारीख के आदेश द्वारा
पुष्टि कर दी गई है।

The *Vidyanand Chemicals Limited* having
by special resolution altered the provisions of its Memorandum of Association with respect
to its objects and such alterations having been confirmed by order of *Company*
Law Board at New Delhi
with C.L.B. No. 3517/1956 bearing
dated the *15th day of July 1956*

ने एतद्वारा प्रमाणित करता है कि उक्त आदेश की प्रमाणित प्रति असाप्रतिबद्ध संगम शासन
की मूद्रित प्रति सहित इस दिन रजिस्ट्रेशन कर दी गई है।

I hereby certify that certified copy of the said order together with the printed copy of
the Memorandum of Association as altered has this day been registered.

मेरे हस्ताक्षर से उन्नीस वी और तारीख की तारीख
को दिया गया।

Given under my hand at *New Delhi* this *15th*
of *September* one thousand nine hundred and *eighty six*



(S-M. Anand)

जे० एस० सी०-5
J.S.C-5

प्रभासमटेक-381-19/मुंबई-400078-79-भासमटेक-(सी-326)-30-5-79-7,000
MGIPTC-161-19 Gen. Manager-79-GIPTC-(C-326)-30-5-79-7,000.

Co No 7908



[कम्पनी अधिनियम, 1956 की धारा 103 (4)]
[Section 103 (4) of Companies Act, 1956]

इसके बटाने की पुष्टि करने वाले न्यायालय के आदेश के
रजिस्ट्रीकरण का प्रमाण-पत्र
CERTIFICATE OF REGISTRATION OF ORDER OF COURT
CONFIRMING REDUCTION OF CAPITAL

.....पंजीकृत निम्नलिखित संस्थान द्वारा
कम्पनी पूंजी बटा दी है और ऐसे बटाने की शर्तों

के आदेश द्वारा पुष्टि की जा चुकी है।
The Kidoguan and Chemicals Limited having by
special resolution reduced its Capital, and such reduction having been confirmed by an order of
the High Court of Delhi C.P No 57 of 1986

bearing date the 12th day of September 1986

मैं एतद्वारा प्रमाणित करता हूँ कि उक्त आदेश को और उक्त आदेश द्वारा तथा परिवर्तित कम्पनी
की पूंजी और शेयरों की विविष्टियां प्रदर्शित करने वाले न्यायालय द्वारा अनुमोदित दस्तावेज की एक प्रति
आज रजिस्ट्रीकरण कर दी गई है।

I hereby certify that a copy of the said order and a minute approved by the Court showing
particulars of the Capital and shares of the Company as altered by the said order have
this day been registered.

मेरे हस्ताक्षर के साथ जारी

एक हजार नौ सौ और दिनांक
Given under my hand at New Delhi this 13th
day of Sept October
and Eighty Six One thousand nine hundred

B. N. Anand
कम्पनियों का रजिस्ट्रार
Registrar of Companies



Admin 74-75-GPFC-(C-120)-6-9-75-2,700.

1

(THE COMPANIES ACT, 1956)
COMPANY LIMITED BY SHARES
MEMORANDUM OF ASSOCIATION
OF

DABUR INDIA LIMITED

- i. The name of the Company is DABUR INDIA LIMITED.
- ii. The Registered Office of the Company will be situated in the Union Territory of Delhi.
- iii. The objects for which the Company is established are :
 - (A) Main Objects to be pursued by the Company on its incorporation :
 1. To carry on the business of manufacturers, buyers, sellers and exporters of and dealers in guar gum, guar meal, guar gum derivatives and all other allied products of guar gum.
 2. To carry on the business of importers and exporters of all kinds of chemicals, chemical products, deoiled cakes, animal feeds and concentrates and to carry on business as manufacturers, buyers, sellers of and dealers in all kind of chemicals and chemical products including acids, alkalies, salts, manures, fertilizers, dyes, caustic soda, soda ash, nitric acid, sodium nitrate sodium nitrite, sodium bicarbonate, ammonia and all other types of acids, solvents and industrial chemicals and minerals, pigments, methanol and other organic and inorganic chemicals.
 3. To carry on the business of manufacturers and dealers in insecticides, pesticides, repellants and all kinds of agricultural chemicals and to carry on the said business in all their branches.
 - **4. To carry on the business of manufacturers of and dealers in Anatomical Orthopaedic and Surgical appliances, provisions and requisites of all kinds of Surgical apothecaries, Medical Practitioners, Hospital and Invalids.
 - **5. To carry on the business of Chemists, Druggists, drysalters, oil and colourmen, importers and manufacturers of and dealer in different classes of pharmaceutical, medicinal, chemical, industrial and other preparations and articles, Patent Medicines, mineral water, cordials, restoratives, foods, Drugs, Tinctures, Inks, Paints, Pigments, Varnishes, Drugs, dyeware paint and colour grinders, makers of and dealers in Proprietary and sanitary articles, hair oils, scents, snows, perfumes and other preparations of all kinds according to the methods and systems of Allopathy, Homeopathy, Unani, Ayurveda and Biochemistry as a firm of Chemists and Druggists and also for makers and dealers in electrical, chemical, photographic and surgical and scientific apparatus materials and to buy, sell, manufacture, refine, manipulate, import, export and deal in all substances, apparatus and things capable of being used in any such business as aforesaid or required by any customers of or persons having dealing with the company, either by wholesale or retail and to carry on other business or businesses which it may possibly be desirable to carry on in conjunction with or in lieu of or independently of any business of the company.
 - ***6. To set up, establish, participate, build, lease, sell, operate and maintain software /information technology Parks in India or abroad and to engage into all activities relating to Information Technology products and IT enabled services including, but not limited to, development, manufacture, design, repair, enhance, assemble, deal, buy, sell, license, distribute, import and export Softwares /Hardware along with the system and accessories analogous or complimentary to the above and to engage in research, consultancy, data processing, manufacture, import, export, market, distribute and to generally deal in all fields of Information Technology products and services and to take up annual maintenance contracts with respect to above.

*As per Special Resolution passed on 23rd February, 1986.

**As per Special Resolution passed on 23rd February, 1986.

***As per Special Resolution passed on 22nd September, 2008.

- (B) The Objects, incidental or ancillary to the attainment of the Main objects of the Company are :
1. To buy and sell (in wholesale or retail), manufacture, repair, alter and exchange, let on hire, import, export and deal in all kinds of articles and things which may be required for the purposes of any of the businesses or which are commonly manufactured, supplied or dealt in by persons engaged in any such business or which may seem capable of being profitably dealt with in connection with any of the said businesses.
 2. To carry on any other business, manufacturing or otherwise (except the issuing of policies on human life) which may seem to the company capable of being conveniently carried on in connection with any of the above specified businesses or calculated directly or indirectly to enhance the value of or render profitable any of the Company's property or rights.
 3. To acquire, construct, carry out, equip, maintain, alter, improve, develop, manage, work, control and superintend any electricity, light and gas work and power plant, telegraphs and telephones and any market, reservoirs, waterworks, tanks, bridges, coolie lines and houses and bustees, villages, roads, ways, railways, canals, aqueducts, watercourses, dykes, drains, wharves, dyeworks, furnaces, crushing works, workshop, hydraulic works, factories, warehouses, sheds, dwellings, offices, shops, stores, buildings and other works and conveniences which may seem directly or indirectly conducive to any of the objects of the Company and to contribute to, subsidise or otherwise aid by taking part in any such operations.
 4. To buy, sell, repair, alter, improve, exchange, let out on hire, import, export and deal in all factories, works, plant, machinery, tools, utensils, appliances, apparatus, products, materials, substances, articles and things capable of being used in any business which this Company is competent to carry on or required by any customers of or persons having dealings with the Company or commonly dealt in by persons engaged in any such business or which may seem capable of being profitably dealt with in connection there with and to manufacture, experiment with, render marketable and deal in all products of residual and by-products incidental to or obtained in any of the business carried on by the Company.
 5. To purchase, take on lease or tenancy or in exchange, hire, take, options over or otherwise acquire for any estate or interest whatsoever and to hold, develop work, cultivate, deal with and turn to account concessions, grants, decrees, licences, privileges, claims, options, leases, property, real or personal or rights or powers of any kind which may appear to be necessary or convenient for any business of the Company.
 6. To sell, exchange, mortgage, let on lease, royalty or tribute, grants, licences, easements, options and other rights over and in any other manner deal with or dispose off the undertaking, property, assets, rights and effects of the Company or any part thereof for such consideration as may be thought fit and in particular for stocks, shares whether fully or partly paid up or securities of any other company having objects similar to the objects of the Company.
 7. To apply for, purchase or otherwise acquire and protect, prolong and renew whether in India or elsewhere any patents, patent rights, brevets, invention

trade marks, designs, licences, protections, concessions and the like conferring any exclusive or non-exclusive or limited right to use any secret or other information as to any invention, process or privilege which may seem capable of being used for any of the purposes of the company or the acquisition of which may seem calculated directly or indirectly to benefit the company and to use, exercise, develop, manufacture under or grant licences or privilege in respect of, or otherwise turn to account the property, rights and information so acquired and to carry on any business in any way connected therewith.

8. To expend money in the experimenting on and testing and in improving or seeking to improve any patents, rights, inventions, discoveries, processes or information of the company or which the Company may acquire or propose to acquire.
9. To establish, provide, maintain and conduct research and other laboratories, training colleges, schools and other institutions for the training, education and instruction of students and others who may desire to avail themselves of the same and to provide for the delivery and holding of lectures, demonstrations, exhibitions, classes, meeting and conferences in connection therewith.
10. To acquire and undertake all or any part of the business, property and liabilities, of any person or company carrying on any business which this company is authorised to carry on or possessed of property suitable for the purpose of the Company.
11. To take part in the management, supervision or control of the business or operations of any Company or undertaking and to act as of Secretaries thereof and for that purpose to appoint and remunerate any Accountant or other experts or agents.
12. To procure the registration or incorporation or recognition of the Company in or under the laws of any place outside India.
13. To enter into partnership or into any arrangement for sharing profits or into any union of joint venture, interest, reciprocal concession or co-operation with any person or persons or company or companies carrying on or engaged in or about to carry on or engage in or being authorised to carry on or engage in any business or transaction which this Company is authorised to carry on or capable of being conducted so as directly or indirectly to benefit this Company.
14. To enter into any arrangements and to take all necessary or proper steps, with Governments or with other authorities, imperial, supreme, national, local municipal or otherwise of any place in which the Company may have interests and to carry on any negotiations or operations for the purpose of directly or indirectly carrying out the objects of the Company or effecting any modification in the constitution of the Company or furthering the interest of its members and to oppose any such steps taken by any other company, firm or person which may be considered likely directly or indirectly to prejudice the interests of the Company or its members and to promote or assist the promotion, whether directly or indirectly, any legislation which may appear to be in the interests of the Company and to oppose and resist, whether directly or indirectly, any legislation which may seem disadvantageous to the Company and to obtain from any such Government authority or any company, any charter, contracts, decrees, rights, loans, privileges or concessions which the Company may think desirable to obtain and to carry out, exercise and comply with any such arrangements, charters, decrees, rights, privileges or concessions.

15. To adopt such means of making known the products of the company as may seem expedient and in particular by advertising in the press by circulars, by purchase and exhibition of works of art or interest, by publication of books and periodical and by granting prizes, awards and donations.
16. To carry on any other business whether manufacturing or otherwise that may seem to Company capable of being conveniently carried on in connection with the above objects or calculated directly or indirectly to enhance the value of or render profitable any of the Company's property or rights or which may be advisable to undertake with a view to improving, developing, rendering valuable or turning to account any property, real or personal belonging to the Company or in which the Company may be interested and to do all or any of the above things, either as principals, agents, sub-contractors, trustees or otherwise and to do all such things as are incidental or conducive to the attainment of the above object.
17. To advance, deposit with or lend money, not immediately required, securities and property to or receive loans or grants or deposits from the Governments.
18. To lend money either with or without security and generally to such persons and upon such terms and conditions as the Company may think fit.
19. To subscribe for absolutely, or conditionally, purchase or otherwise acquire and to hold, dispose off and deal in shares, stocks and securities or obligations of any other company having objects similar to the objects of the company whether Indian or foreign.
20. To invest any moneys of the Company not for the time being required for any of the purposes of Company in such investments (other than Shares or stock in the Company) as may be thought proper and to hold, sell or otherwise deal with such investments.
21. To borrow, raise or secure the payment of money in such manner as the Company shall think fit and in particular by the issue of debentures or debenture stock, perpetual or otherwise, charged upon all or any of the Company's property (both present and future) including its uncalled capital and to purchase, redeem and pay off any such securities.
22. To draw, make, accept, discount, execute and issue bills of exchange, Government of India and other promissory notes, bills of lading, warrants, debentures and other negotiable or transferable instrument or securities.
23. To form, incorporate or promote any company or companies, whether in India or any foreign country, having amongst its or their objects the acquisition of all or any of the assets or control, management or development of the Company or any other objects or object which in the opinion of the Company could or might directly or indirectly assist the Company in the management of its business or the development of its properties or otherwise prove advantageous to the Company and to pay all or any of the costs and expenses incurred in connection with any such promotion or incorporation and to remunerate any person or

company in any manner it shall think fit for services to be rendered in obtaining subscription for or placing or assisting to place or to obtain subscription for or for guaranteeing the subscription of or the placing of any shares in the capital of the Company or any bonds, debentures, obligations or securities of the Company or in which the Company may have an interest or in or about the formation or promotion of the Company or the conduct of its business.

24. To undertake and execute any trust the undertaking of which may seem to the Company desirable and either gratuitously or otherwise.
25. To apply the assets of the Company in any way in or towards the establishment, maintenance or extension of any association, institution or fund in any way connected with any particular trade or business or with trade or commerce generally including any association, institution or fund for the protection of interests of masters, owners and employers against the loss by bad debts, strikes, combinations, fire, accident or otherwise or for the benefit of any clerks, workmen or others at any time employed by the Company or any of its predecessors in business or their families or dependants and whether or not in common with other persons of classes of persons and in particular of friendly, co-operative and other societies, reading rooms, libraries, educational and charitable institutions, dining and recreation rooms, temples, churches, chapels, schools and hospitals and to grant gratuities, pensions and allowances and to contribute to any funds raised by public or local subscriptions for any purpose whatsoever.
26. To aid, pecuniarily or otherwise, any association, body or movement having for an object the solution, settlement or surmounting of industrial or labour problems or troubles or the promotion of industry or trade.
27. To subscribe or guarantee money for any national, charitable, benevolent, public, general or useful objects or for any exhibition.
28. To establish and support or aid in the establishment and support of associations, institutions, funds, trusts and conveniences calculated to benefit persons who are or have been Directors or debtors or who are or have served the Company or any Company which is a subsidiary or associate of the Company or its predecessors in business or the dependants or connections of such persons and to grant pensions and allowances and to make payments towards insurance.
29. To distribute all or any of the properties of the Company amongst the members in specie or kind in the event of its winding up.
- *30. To enter into arrangements for joint working in the business or for sharing of profit or for amalgamation or for reciprocal concession or otherwise any company, firm or persons carrying on business within the objects of the Company.

*As per Special Resolution passed on 23rd February, 1966.

(C) OTHER OBJECTS:

1. To manufacture, buy, sell and deal in mineral waters, wines, cordials, liquors, soups and also to deal in medical goods such as contraceptives, oils, perfumes, cosmetics.
2. To undertake spraying of such chemicals through manual, mechanical and/or aerial operations, alone or in association with other agencies and/or Companies.
3. To produce, manufacture, treat, purchase, sell or otherwise deal with either as principals or agents, either solely or in partnership with others :
 - (a) Foodstuffs such as wheat, barley, rice, maize, millet, sugarcane, sugar, all kinds of grains, cereals, and oil seeds, butter, cheese condensed milk, chocolates, aerated water, tinned fruits, biscuit, starch, confectionaries, sugar candy.
 - (b) Building materials, including iron, steel, limestone, cement, asbestos, timber, paints, oils, greases, bricks, firebricks, fireclay, potteries, pillars, angles, tees, railings, trusses, columns, glassware, hardware, brassware and other materials.
 - (c) Machineries of all kinds, tools, agriculture implements, weighbridges, tractors and sewing machines.
 - (d) Printing presses, types, papers, inks, stationery, books, cardboards and all kinds of printing materials.
4. To carry on the business as food preserves including tinning foods stuffs, fruits, vegetables, pickles and other allied products and to establish, own, operate, acquire, run and manage canning factory for the purpose of packing, preserving and canning such articles and products.
5. To purchase, acquire, keep, maintain, breed, sell or otherwise deal in all kinds of cattle, cows, buffaloes, poultry, game and livestock of all description.
6. To carry on and work the business of cultivators, and buyers of every kinds of vegetable or other produce of the soil, to prepare, manufacture and tender marketable any such produce and to sell, dispose off and deal in any such produce either in its prepared, manufactured or raw state and either by wholesale or retail.
7. To purchase, charter, hire, built or otherwise acquire vehicles of any or every sort or description for use on or under land or water or in the air and to employ them in the carriage of merchandise of all kind of passengers and to carry on the business of owners of trucks, trams, lorries, motor cars and of ship-owners and lightermen and owners of aircraft in all or any of their respective branches.
8. To undertake financial and commercial obligations, transactions and operations of all kinds.

* Carrying out activities under this clause have been approved vide Special Resolution passed on 15th July, 2009.

9. To guarantee the performance of the obligations of and the payment of dividends and interest on any stock, shares or sureties of any company, corporation, firm or person.
10. To guarantee the payment of money unsecured by or payable under or in respect of promissory notes, bonds, debentures, debenture-stock, contracts, mortgages, charges, obligations, instruments and securities of any company or any authority, supreme, municipal, local or otherwise or of any persons whomsoever whether incorporated or not incorporated and generally to guarantee or become sureties for the performance of any contract or obligation.

Provided that nothing herein contained shall be deemed to empower the Company to carry on the business of banking.

And it is hereby declared that the word "Company" save when used in reference to this Company, in this clause, shall be deemed to include any partnership or other-body of persons, whether incorporated or not incorporated, whether domiciled in India or elsewhere.

- *11. To manufacture, prepare, process, repair, buy & sell, resell, export, import and marketing of all kinds of packaging articles made of plastics including high density polyethylene, polyprothelene, low density polyethylene and other types of plastic packaging goods and products, synthetic resins and compounds ancillary and auxiliary materials and derivatives, intermediates and compositions related thereto.
- *12. To manufacture, process, import, export, market, trade and distribute all kinds of food products, fruit pulp, fruit juice, vegetables, canned and tinned processed foods, instant food of all kinds including beverages, tonics, aerated mineral water, ice creams other milk products and consumable provisions of every description for human or animal consumption.

IV. The liability of the members is limited.

- **V. The Authorized Share Capital of the Company is Rs.207,00,00,000/- (Rupees Two Hundred Seven Crores only) divided into 207,00,00,000 (Two Hundred Seven Crores) equity shares of Re. 1 each.

*As per Special Resolution passed on 9th September, 1999.

**As per Court order effective on 18th June 2010 and further as per Special Resolution passed on 31st August, 2010.

We, the several persons whose names and addresses are subscribed, are desirous of being formed into a company in pursuance of this Management of Association and we respectively agree to take the number of shares in the capital of the company set opposite our respective names :

Name, address, description and occupation of the Subscribers	No. of Equity Shares taken by each subscriber	Signature of Subscriber	Name, address, description, occupation and Signature of the Witness
1. OMESH GOYAL S/o Shri Prem Kumar Goyal Kaithal Road, Pehowa (Haryana) Distt. Kurukshetra Business.	Five hundred Shares	Sd/- Omesh Goyal	Sd/- Prem Kumar Goyal S/o Shri Bishna Mal 2, Flag Staff Road, Delhi-110006 Business
2. LACHMI DAS AGGARWAL S/o Shri Gujar Mal 1-C/30, New Rohtak Road, New Delhi Retired from Defence H.Q. Civil Services.	Ten Shares	Sd/- Lachmi Das Aggarwal	
3. BERJESH K. GOYAL S/o Shri Prem Kumar Goyal 2, Flag Staff Road, Delhi-6 Business.	Five hundred Shares	Sd/- Berjesh K. Goyal	
4. ROSHAN LAL GUPTA S/o Shri Safig Ram Shanti Niketan, Hira Singh Road, Ludhiana Business.	Ten Shares	Sd/- Roshan Lal Gupta	
5. A.N. GOYAL S/o Shri Bishna Mal S-115, Panchsheel Park, New Delhi Business.	Five hundred Shares	Sd/- A.N. Goyal	
6. ANIL KUMAR GUPTA S/o Shri R.L. Gupta 51-B, East Friends Colony, New Delhi Business	Ten Shares	Sd/- Anil Kumar Gupta	
7. SUBASH CHANDER KOHLI S/o Shri G.L. Kohli 153, Sector 22-A Chandigarh Engineer.	Ten Shares	Sd/- Subash Chander Kohli	

Dated this 14th day of July, 1975.

THE COMPANIES ACT, 2013
COMPANY LIMITED BY SHARES
ARTICLES OF ASSOCIATION *
OF
DABUR INDIA LIMITED

PRELIMINARY

1. The regulations contained in Table F of Schedule I of the Companies Act, 2013 (as amended from time to time) shall apply to the Company so far as they are not inconsistent with or repugnant to any of the regulations contained in these Articles. Application of regulations contained in Table F

INTERPRETATION

2. In the interpretation of these Articles, the following words and expression shall have the meanings assigned herein, unless repugnant to the subject or context hereof. Interpretation Clause
- “**Act**” means the Companies Act, 2013, to the extent notified, as amended from time to time and includes any re-enactment thereof, with all schedules and tables thereunder, as notified, with effect from the date of such notification in the official Gazette of India including all the rules, notifications, clarifications, orders and circulars issued there under including certain provisions of the Companies Act, 1956 as and where specified. “Act”
- “**Annual General Meeting**” means a General Meeting of the Members held in accordance with the provisions of Section 96 of the Act, and any adjournments thereof. “Annual General Meeting”
- “**Articles**” means these Articles of Association of the Company or as altered from time to time. “Articles”
- “**Beneficial Owner**” means a Person as defined under the Depositories Act and whose name is recorded as such with a Depository. “Beneficial Owner”
- “**Bye Laws**” means bye-laws made by a Depository under Section 26 of the Depositories Act, 1996. “Bye-Laws”
- “**Depositories Act**” means the Depository Act, 1996 (22 of 1996) including any statutory modification or re-enactment thereof including all the rules, notifications, circulars issued thereof and for the time being in force. “Depositories Act”
- “**Depository**” means a depository as defined in clause (e) of sub-section (1) of section 2 of the Depositories Act, 1996. “Depository”
- “**Director**” means a member of the Board appointed in accordance with these Articles, including any additional and/ or alternate director. “Director”

** The Articles of Association were adopted vide resolution passed by the members of the Company in the Annual General Meeting of the Company held on August 10, 2023.*

“ Dividend ” includes interim Dividend.	“Dividend”
“ Debenture ” includes Debenture stock, bonds or any other instrument of a Company evidencing a debt, whether constituting a charge on the assets of the Company or not;	“Debenture”
Provided that—	
(a) the instruments referred to in Chapter III-D of the Reserve Bank of India Act, 1934; and	
(b) such other instrument, as may be prescribed by the Central Government in consultation with the Reserve Bank of India, issued by a company, shall not be treated as debenture.	
“ Extra Ordinary General Meeting ” means an extra ordinary general meeting of the Members duly called in accordance with the provisions of Section 100 of the Act, and any adjournments thereof.	“Extra Ordinary General Meeting”
“ Independent Director ” shall have the meaning ascribed to it in the Act.	“Independent Director”
“ Key Managerial Personnel ” means the Chief Executive officer or the Managing Director or the Manager; the Company secretary; Whole-time director; Chief Financial Officer; such other officer, not more than one level below the Directors who is in whole-time employment, designated as key managerial personnel by the Board; and such other officer as may be notified from time to time in the Rules.	“Key managerial personnel”
“ Month ” means a period of thirty days and a “Calendar month” means an English Calendar Month.	“Month” and “Calendar Month”
“ Person ” includes an individual, an association of persons or body of individual, whether incorporated or not and a firm.	“Person”
“ Record ” includes the records maintained in the form of books or stored in computer or in such other form or medium as may be determined by Regulations.	“Record”
“ Register and Index of beneficial owners ” maintained by a depository under Section 11 of the Depositories Act shall be deemed to be the Register and Index of Members for the purpose of the Act and these Articles.	“Register and Index of beneficial owners”
“ Register of Members ” or “ Register ” means the Register of Member to be kept in pursuance to the provisions of the Act.	“Register of the Members”
“ Registered Office ” or “ Office ” means the registered office for the time being of the Company.	“Registered Office”
“ Seal ” means the Common Seal for the time being of the Company.	“Seal”
“ SEBI ” means the, Securities and Exchange Board of India.	“SEBI”
“ SEBI Regulations ” means the regulations issued by SEBI from time to time under the Securities and Exchange Board of India Act, 1992.	“SEBI Regulations”
“ Security(ies) ” means the securities as defined in clause (h) of section 2 of the Securities Contracts (Regulation) Act, 1956.	“Security”

<p>“Shares” means the shares of the Company issued from time to time and carrying the rights as set out in these Articles including preference shares and the Equity Shares;</p>	<p>“Shares”</p>
<p>“Share Certificate” or “Securities Certificate” or “Certificate” means a certificate or such other written document as specified under the Act or prescribed by SEBI from time to time, evidencing legal title or ownership of the securities of the Company as specified therein.</p>	<p>“Share Certificate” or “Securities Certificate” or “Certificate”</p>
<p>“Stock Exchange” means the recognized stock exchange(s) where the securities of Company are listed.</p>	<p>“Stock Exchange”</p>
<p>“Secretary” means the Company Secretary of the Company appointed by the Directors to perform any of the duties of a Company Secretary as per the provisions of the Act.</p>	<p>“Secretary”</p>
<p>“The Board” or “The Board of Directors” “Board of Directors” or “Board”, shall mean the board of Directors for the time being of the Company and shall include a Committee thereof.</p>	<p>“The Board” or “The Board of Directors”</p>
<p>“The Company” or “This Company” means DABUR INDIA LIMITED, a company incorporated under the Companies Act, 1956.</p>	<p>“The Company”</p>
<p>“The Registrar” means the Registrar of Companies of the State in which the Registered Office of the Company is for the time being situated.</p>	<p>“Registrar”</p>
<p>“Writing” shall include printing and lithography and any other mode or modes representing or reproducing words in a visible forms.</p>	<p>“Writing”</p>
<p>“Year” means the calendar year and “Financial Year” in relation to the Company means the period starting from 1st day of April and ending on the 31st day of March every year.</p>	<p>“Year” and “Financial year”</p>
<p>Words importing the masculine gender include the feminine gender.</p>	<p>“Gender”</p>
<p>Words importing the singular number include the plural number.</p>	<p>“Singular number”</p>
<p>Subject as aforesaid, any words and expressions defined in the said Act as modified up to the date on which these Articles become binding on the Company shall, except where the subject or context otherwise requires, bear the same meaning in these Articles.</p>	<p>“Words and Expressions defined in the Companies Act”</p>
<p>Word and concepts not defined in these articles shall have the same meaning as defined under Section 2 of the Act and Rules made there under.</p>	<p>“Word to have same meaning as under the Act and Rules”</p>
<p>3. The marginal notes shall not affect the construction hereof and in these presents unless there be something in the subject or context, inconsistent therewith.</p>	<p>“Marginal Notes”</p>

PUBLIC COMPANY

4. The Company is a Public Company in terms of sub-section 71 of Section 2 of the Act.

SHARE CAPITAL

5. The authorized share capital of the Company shall be such amount and be divided into such Shares as may, from time to time, be provided in Clause V of the Memorandum of Association, each Share with rights, privileges and conditions attached thereto as are provided by these Articles for the time being, and with the power to increase, consolidate, divide, sub-divide, cancel and reduce the share capital of the Company and to convert Shares into stocks and re-convert that and to divide the Shares for the time being into several classes and to attach thereto respectively such preferential rights, privileges or conditions as may be determined by or in accordance with these Articles and to vary, modify, amalgamate or abrogate any such rights, privileges in such manner as may for the time being be provided in these Articles and in accordance with the Act. Share Capital
6. Subject to the provisions of the Act and these Articles, the Shares shall be under the control of the Board of Directors who may issue, allot or otherwise dispose of the same or any of them to such Persons, in such proportion and on such terms and conditions and either at a premium or at par and at such time as they may from time to time think fit. Shares under control of Director
7. The shares may be issued by the Board of Directors at a discount in compliance of Section 53 of the Act. Issue of shares at a discount
8. In addition to, and without derogating from the power for that purpose conferred on the Board of Directors under these Articles, the Company in a General Meeting may, subject to the compliances of Sections 42 and 62 of the Act as the case may be and Rules issued there under, determine to issue further Shares out of the authorized but unissued share capital of the Company and may determine that any Shares shall be offered to such Persons (whether Members or holders of Debentures of the Company or not) in such proportions and on such terms and conditions and either at a premium or at par, as such General Meeting shall determine and with full power to give any Person (whether a Member or holder of Debentures of the Company or not) option to be exercisable at such times and for such consideration as may be directed by such General Meeting and subject to such other provisions whatsoever as the case may be, stipulated by the General Meeting, for the issue, allotment or disposal of any Share. Power of General Meeting to offer Shares to such Persons as the Company may resolve.
9. Subject to the provisions of the Act and these Articles, the Board of Directors may allot and issue Shares in the place of payment or part repayment for any property or assets of any kind whatsoever (including the good-will of any business) sold or transferred or goods or machinery or know-how supplied or for services rendered to the Company either in about the formation or promotion of the Company or the conduct of its business and any Shares which may be so allotted may be issued as fully paid up or partly paid up otherwise than for cash and if so issued shall be deemed to be fully paid up or partly paid up Shares as aforesaid. The Board of Directors shall cause returns to be filed of any such allotment as may be required under the provisions of the Act. Directors may allot Shares as fully paid up or partly paid up Shares.
10. The Company be and is hereby empowered to issue Sweat Equity Shares and shares under the Employee Stock Option Plan subject to the provisions Section 53, 54 and 62 of the Act and Rules issued thereunder, guidelines and regulations issued by SEBI and other laws as applicable. As regards all allotments, from time to time made, the Board of Directors shall duly comply with Section 39 of the Act. Employee Stock Options/Sweat Equity Shares
11. The Shares shall be numbered progressively according to their several denominations. Shares to be numbered progressively

- | | | |
|-----|---|---|
| 12. | The money (if any) which the Board of Directors shall, on the allotment of any Shares being made by them, require or direct to be paid by way of deposits, call or otherwise in respect of any Shares allotted by them, immediately on the insertion of the name of the allottee in the Register of Members as the holder of such shares, shall become a debt due to and recoverable by the Company from the allottee thereof, and shall be paid by such allottee accordingly. | Deposit and calls etc. /to be a debt payable immediately. |
| 13. | If by the conditions of allotment of any Share, the whole or part of the amount or issue price thereof shall be payable by installments, every such installment shall when due, be paid to the Company by the Person who for the time being and from time to time shall be the registered holder of the Share or his legal representative / executor / administrator. | Installments on shares to be duly paid |
| 14. | Except when required by law or ordered by a court of competent jurisdiction, the Company shall not be bound to recognize any person as holding any share upon any trust and the Company shall not be bound by, or be compelled in any way to recognize (even when having notice thereof) in equitable, contingent, future or partial interest in any share or any interest in any fractional part of a share, or (except only as by these Articles or as ordered by a court of competent jurisdiction or by law otherwise provided) any other rights in respect of any share except an absolute right to the entirety thereof in the registered holder. | Company not bound to recognize any interest in shares other than that of the registered holder. |
| 15. | Subject to conditions prescribed in these Articles, none of the funds of the Company shall be applied in the purchase of any Shares of the Company and itself not give, directly or indirectly, any financial assistance, whether by way of a loan, guarantee, provision of security or otherwise, for or in connection with the purchase or subscription of any Shares in the Company or in its holding company save as provided by provisions of the Act. | Funds of Company shall not be applied in purchase of shares of the Company. |

This Article shall not be deemed to affect the power of the Company to enforce repayment of loans to members or to exercise a lien conferred by Article 41.

UNDERWRITING AND BROKERAGE

- | | | |
|-----|--|---|
| 16. | The Company may, subject to the applicable provisions of the Act, at any time pay a commission to any Person in consideration of his/her subscribing or agreeing to subscribe or such Person procuring or agreeing to procure subscriptions, whether absolutely or conditionally, for any Shares or Debentures or debenture-stock or other securities of the Company, but the rate of such commission shall not exceed the permissible rates under the provisions of the Act. The commission may be satisfied by the payment of cash or the allotment of fully or partly paid Shares or Debentures or partly in the one way and partly in the other. The Company may also on any issue of Shares or Debentures, pay such brokerage as may be lawful. | Commission for placing shares, debentures, etc. |
|-----|--|---|

LIEN

- | | |
|-----|---|
| 17. | (i) The Company shall have a first and paramount lien— |
| | (ii) on every share (not being a fully paid Share), for all monies (whether presently payable or not) called, or payable at a fixed time, in respect of that share; and |
| | (iii) on all Shares (not being fully paid Shares) standing registered in the name of a single person, for all monies presently payable by him/her or his/her estate to the Company: |

Provided that the Board of Directors may at any time declare any Share to be wholly or in part exempt from the provisions of this Article.

- (iv) The Company's lien, if any, on a Share shall extend to all dividends payable and bonuses declared from time to time in respect of such Shares.
- (v) The Company may sell, in such manner as the Board thinks fit, any Shares on which the Company has a lien:

Provided that no sale shall be made—

- (vi) unless a sum in respect of which the lien exists is presently payable; or
- (vii) until the expiration of fourteen (14) days after a notice in writing stating and demanding payment of such part of the amount in respect of which the lien exists as is presently payable, has been given to the registered holder for the time being of the Share or the person entitled thereto by reason of his death or insolvency.
- (viii) To give effect to such sale, the Board of Directors may authorise some person to transfer the shares sold to the purchaser thereof and the purchaser shall be registered as the holder of the shares comprised in any such transfer. The purchaser shall not be bound to see to the application of the purchase money, nor shall his title to the shares be affected by any irregularity or invalidity in the proceedings in reference to the sale.
- (ix) The net proceeds of the sale after payment of the costs of the sale shall be received by the Company and applied or towards payment or such part of the amount in respect of which the lien exists as is presently payable and the residue, if any, shall (subject to a like lien for debts or liabilities not presently payable as existed upon the shares before the sale) be paid to the person entitled to the shares at the date of the sale.
- (x) In exercising its lien, the Company shall be entitled to treat the registered holder of any share as the absolute owner thereof and accordingly shall not (except as ordered by a court of competent jurisdiction or unless required by any statute) be bound to recognise any equitable or other claim to, or interest in, such share on the part of any other person, whether a creditor of the registered holder or otherwise. The Company's lien shall prevail notwithstanding that it has received notice of any such claim.
- (xi) The provisions of these Articles relating to lien shall mutatis mutandis apply to any other securities including debentures of the Company.

CERTIFICATES

- 18. (i) Subject to compliance with the Act and SEBI Regulations, every Person whose name is entered as a Member in the Register of Members shall be entitled to receive within two (2) months after incorporation, in case of subscribers to the Memorandum of Association or after allotment or within one (1) month after the application for the registration of transfer or transmission or within such other period as the conditions of issue shall be provided,— Share Certificates.

- (a) one Certificate for all his/her Shares without payment of any charges; or
 - (b) if the Board so approves, several Certificates, each for one or more of his/her Shares, upon payment of fifty (50) rupees for each certificate after the first or such lesser fees as determined by the Board.
- (ii) Every Certificate shall specify the Shares to which it relates and the amount paid-up thereon.
 - (iii) In respect of any Share or Shares held jointly by several persons, the Company shall not be bound to issue more than one certificate, and delivery of a certificate for a Share to one of several joint holders shall be sufficient delivery to all such holders.
 - (iv) Particulars of every certificate issued shall be entered in the Register of Members against the name of the person to whom it has been issued indicating the date of issue.
19. The Board of Directors may in their absolute discretion refuse sub-division of Share/Debenture certificate where such sub-division will result in the issue of certificate for number of Shares and/or Debentures which is less than the marketable lot, unless the sub-division is required to be made to comply with a statutory provision or an order of a competent court of law. Right to refuse to issue share / debenture Certificate not in consonance with marketable lot.
20. (i) If any certificate of any share or shares be surrendered to the Company for Sub-division or consolidation or if any certificate be defaced, torn or old, decrepit, worn-out or where the cages in the reverse for recording transfers have been fully utilised, then upon surrender thereof to the Company, the Board may order the same to be cancelled and may issue a new certificate in lieu thereof, and if any certificate be lost or destroyed, then upon proof thereof to the satisfaction of the Board, and on such indemnity as the Board thinks fit being given, a new certificate in lieu thereof shall be given to the party entitled to the shares to which such lost or destroyed certificate shall relate. As to issue of new Certificate
- (ii) When a new share certificate has been issued in pursuance of this Article, it shall state on the face of it and against the stub or counterfoil to the effect that it is "Issued in lieu of Share Certificate No. _____". The word "Duplicate" shall be stamped or punched in bold letters across the face of the share certificate.
 - (iii) The Company shall not charge any fee for registration of transfer of shares and Debentures, sub-division or consolidation of shares and debenture certificates, letter of allotment and split, consolidation, renewal and issue of pucca transfer receipts into denominations corresponding to the market units of trading; for subdivision of renounceable letter of right; for issue of new certificates in replacement of those which are old, decrepit or worn out of where the cages on the reverse for recording transfers have been fully utilised; for registration of any Attorney, probate, letters of administration or similar other documents.

Provided further that the Company will not charge any fees exceeding those which may be agreed upon with the Stock Exchange(s) where Shares / Debentures are listed for issue of new certificate in replacement to those that are torn, defaced, lost or destroyed; for sub-division and consolidation of share and debenture certificates and for sub-division of letters of allotment and split, consolidation, renewal and issue of pucca transfer receipts into denomination other than fixed for the market units of trading.

- (iv) Where a new share certificate has been issued in pursuance of this Article, particulars of every such share certificate shall be entered in a Register of Renewed and Duplicate Certificate indicating against the names of the persons to whom the certificate is issued the number and date of issue of the share certificate in lieu of which the new share certificate is issued, and the necessary, changes indicated in the Register of Members by suitable cross reference in the "Remarks" column. All entries made in the Register of Renewed and Duplicate Certificate shall be authenticated by the Secretary or such other person as may be authorized by the Board for this purpose.
- (v) All blank forms to be issued for share certificates shall be printed and the printing shall be done only on the authority of a resolution of the Board. The blank form shall be consecutively machine numbered and the forms and the blocks, engravings, facsimiles and hues relating to the printing of such forms shall be kept in the custody of the Secretary or such other person as the Board may appoint for the purpose, and the Secretary or other persons aforesaid shall be responsible for rendering an account of these forms to the Board.
- (vi) All the books and documents referred to in this Article shall be preserved in good order permanently.

- | | | |
|-----|--|---|
| 21. | Every endorsement upon a share certificate in favour of any transferee thereof shall be signed by such person for the time being authorized by the Board of Directors in that behalf. | Endorsement of Certificate. |
| 22. | The Board shall comply with requirements of section 46 and prescribed rules made under the said Act and requirements of any Stock Exchange relating to the issue and execution of share certificates. The provisions of these Articles relating to the issue and execution of share certificates shall <i>mutatis mutandis</i> apply to Debentures of the Company. | Board of Directors to comply with the Act and the rules/ Stock Exchanges. |

CALLS

- | | | |
|-----|---|--|
| 23. | The Board may, from time to time, make calls upon the Members in respect of any monies unpaid on their Shares (whether on account of the nominal value of the Shares or by way of premium) and not by the conditions of allotment thereof made payable at fixed times:

Provided that no call shall be payable at less than one month from the date fixed for the payment of the last preceding call. | Calls |
| 24. | Each Member shall, subject to receiving at least fourteen (14) days' notice specifying the time or times and place of payment, pay to the Company, at the time or times and place so specified, the amount called on his/her Shares. | Payment on call by a member |
| 25. | A call may be revoked or postponed at the discretion of the Board. | Revocation of Call |
| 26. | A call shall be deemed to have been made at the time when the resolution of the Board authorizing the call was passed and may be required to be paid by installments. | Call when deemed to have been made |
| 27. | The joint holders of a Share shall be jointly and severally liable to pay all calls in respect thereof. | Liability of members registered jointly in respect of shares |

28. (i) If a sum called in respect of a Share is not paid before or on the day appointed for payment thereof, the person from whom the sum is due shall pay interest thereon at the rate of 18 percent per annum, from the day appointed for payment thereof to the time of actual payment or at such lower rate as the Board may determine. When interest on call payable
- (ii) The Board shall be at liberty to waive payment of any such interest wholly or in part.
29. (i) Any sum which by the terms of issue of a Share becomes payable on allotment or at any fixed date, whether on account of the nominal value of the share or by way of premium, shall, for the purposes of these regulations, be deemed to be a call duly made and payable on the date on which by the terms of issue such sum becomes payable. Amount payable at fixed times
- (ii) In case of non-payment of such sum, all the relevant provisions of these Articles as to payment of interest and expenses, forfeiture or otherwise shall apply as if such sum had become payable by virtue of a call duly made and notified.
30. The Board— Payment of call in advance
- (a) may, if it thinks fit, receive from any Member willing to advance the same, all or any part of the monies uncalled and unpaid upon any Shares held by him; and
- (b) upon all or any of the monies so advanced, may (until the same would, but for such advance, become presently payable) pay interest at such rate not exceeding 8 percent per annum as may be agreed upon between the Board and the Member paying the sum in advance. Money so paid in advance shall not rank for dividends or participate in the profits of the Company. The Board may at any time, repay the amount so advanced upon giving to such members not less than three months' notice in writing.
31. Subject to the provisions of Section 95 of the Act, on the trial or hearing of any action or suit brought by the Company against any member or his representative to recover any debt or money claimed to be due to the Company in respect of his shares it shall be sufficient to prove that the name of the defendant is or was when the claim arose, on the Register as a member or one of the members, in respect of the share for which such claim is made, and that the amount claimed is not entered as paid in the books of the Company and it shall not be necessary to prove the appointment of the Board who made any call nor that a quorum was present at the Board Meeting at which any call was made nor that the meeting at which any call was made duly convened or constituted, nor any other matter whatsoever, but the proofs of the matters aforesaid shall be conclusive evidence of the debt. Evidence in action by Company against a member

The provisions of these Articles relating to calls shall mutatis mutandis apply to any other securities including debentures of the Company.

FORFEITURE AND SURRENDER

32. If any Member fails to pay the whole or any part of any call or installment, any money due in respect of any Shares either by way of principal or interest, on or before the day appointed for the payment of the same, the Board of Directors may, at any time thereafter, during such time as the call or installment or any part thereof or other money as aforesaid remain unpaid, or a judgment or decree in respect thereof remains unsatisfied in whole or in part, serve a notice on such Member or If call or installment not paid notice may be given.

on the person (if any) entitled to the Shares by transmission, requiring him to pay such call or installment or such part thereof or other moneys as remain unpaid together with any interest that may have accrued and all expenses (legal or otherwise) that may have been incurred by the Company by reason of such non-payment.

- | | | |
|-----|---|--|
| 33. | The notice aforesaid shall— | Terms of notice. |
| | (a) name a further day (not being earlier than the expiry of fourteen (14) days from the date of service of the notice) on or before which the payment required by the notice is to be made; and | |
| | (b) state that, in the event of non-payment on or before the day so named, the Shares in respect of which the call was made shall be liable to be forfeited. | |
| 34. | If the requirements of any such notice as aforesaid shall not be complied with, any of the Shares in respect of which such notice has been given, may, at any time thereafter but before payment of all calls or installments, interest and expense and other monies due in respect thereof, be forfeited by a resolution of the Board of Directors to that effect. Such forfeiture shall include all dividends declared in respect of the forfeited Shares and not actually paid before the forfeiture. | Shares to be forfeited in default of payment. |
| 35. | When any Shares shall have been so forfeited, an entry of the forfeiture, with the date thereof, shall be made in the Register of Members and notice of the forfeiture shall be given to the Member in whose name they stood immediately prior to the forfeiture, but no forfeiture shall be in any manner invalidated by any omission or neglect to give such notice or to make any entry as aforesaid. | Entry of forfeiture in register of Members. |
| 36. | Any Share so forfeited shall be deemed to be the property of the Company and may be sold, re-allotted or otherwise disposed of either to the original holder thereof or to any other person upon such terms and in such manner as the Board shall think fit. | Forfeited Shares to be property of the Company |
| 37. | The Board of Directors may, at any time before any Shares so forfeited shall have been sold, re-allotted or otherwise disposed off, annul the forfeiture thereof upon such conditions as they think fit. | Board of Directors may annul forfeiture |
| 38. | Any person whose Shares have been forfeited shall, notwithstanding the forfeiture, be liable to pay and shall forthwith pay to the Company all calls, installments, interest, expenses and other moneys owing upon or in respect of such Shares, at the time of the forfeiture together with interest thereon from the time of the forfeiture until actual payment, at such rates as the Board of Directors may determine. The Board of Directors may, and shall be under no obligation to do so, enforce the whole or a portion of the payment, as if it were a new call made at the date of the forfeiture. | Share holder still liable to pay money owing at the time of forfeiture and interest. |
| 39. | The forfeiture of a Share shall involve the extinction, at the time of the forfeiture, of all interest in and all claims and demands against the Company in respect of the Shares forfeited and all other rights incidental to such Shares, except those rights as are expressly saved by these Articles. | Effect of forfeiture. |
| 40. | The Board of Directors may, subject to the provisions of the Act, accept the surrender of any Shares from or by any Member desirous of surrendering them, on such terms as they think fit. | Surrender of shares |
| 41. | (i) For the purpose of enforcing the aforesaid lien on the partly paid-up shares, the Board of Directors may sell the Shares, subject to the terms hereof, in such manner as they shall think fit. However, no sale shall be | Enforcement of lien by sale |

consummated, unless the sum in respect of which the lien exists is presently payable and until notice in writing of the intention to sell shall have been served on such Member, his executors or administrators or his committee, or other legal representatives as the case may be, and a default shall have been made by him or them in the payment of such sums payable as aforesaid, for a period of seven (7) days from the date of notice.

- (ii) To give effect to any such sale, the Board may authorize any person to transfer the Shares sold to the purchaser thereof and the purchaser shall be registered as the holder of the Shares comprised in any such transfer. Upon any such sale as aforesaid, the certificates in respect of the Shares sold, shall stand cancelled and become null and void and of no effect and the Board of Directors shall be entitled to issue a new certificate or certificates in lieu of the sale to the purchaser or purchasers concerned.

42. The net proceeds of any such sale, after payment of the costs of such sale, shall be applied in or towards the satisfaction of the debts, liabilities or engagements of the defaulting Member and the residue, (if any) shall, subject to a like lien for sums not presently payable as existed upon the Shares before the sale, be paid to such Member or the person (if any) entitled by transmission to the Shares so sold. Application of proceeds of sale.
43. A duly verified declaration in writing that the declarant is a Director, a manager or the secretary of the Company and that a Share in the Company has been duly forfeited on a date stated in such declaration, shall be conclusive evidence of the facts stated therein, as against all persons claiming to be entitled to the Share. Verification of forfeiture.
44. Upon any sale after forfeiture or for enforcing a lien in the exercise of the powers herein before given, the Board may appoint a person to execute an instrument of transfer of the Share sold and cause the purchaser's name to be entered in the Register of Members in respect of the Shares so sold, and the Company may receive the consideration, if any, given for the Share on any sale, re-allotment or other disposition thereof and the person to whom such Shares are sold, re-allotted or disposed off, may be registered as the holder of the Share and he shall not be bound to see to the application of the consideration/purchase money, if any, nor shall his title to the Share be affected by any irregularity or invalidity in the proceedings in reference to the forfeiture, sale, re-allotment or other disposal of the Share, and after his name has been entered in the Register of Members in respect of such sold Shares, the validity of the sale shall not be impeached by any person, and the remedy of any Person aggrieved by the sale shall be in damages only and against the Company exclusively. Title of purchase of forfeited share of shares sold in exercise of lien.
45. Upon any sale, re-allotment or other disposal of the Shares, under the provisions of the preceding Articles, the certificate or certificates originally issued in respect of the relevant Shares shall (unless the same shall, on demand by the Company, have been previously surrendered to it by the defaulting Member) stand cancelled and become null and void and of no effect and the Board of Directors shall be entitled to issue a new certificate or give the credit of said shares in the demat account of the person or persons entitled thereto. Board may issue new certificate or credit the shares in the Demat account of persons entitled thereto.

TRANSFER OF SHARES

46. Subject to compliance of and to the extent permissible under the Companies Act, 2013 and SEBI Regulations, the Board may register transfer / transmission of securities of the Company held in physical form and the said transfer / transmission shall be governed by these Articles. Board to accept transfer / transmission of physical shares.

- | | | |
|-----|---|---|
| 47. | The instrument of transfer of any Shares shall be in such form as may be prescribed under the Act and in writing, and all the applicable provisions of the Act for the time being in force shall be duly complied with, in respect of all transfers of Shares and the registrations thereof. | Form of Transfer. |
| 48. | Every such instrument of transfer shall be executed by or on behalf of the transferor and by or on behalf of the transferee and the transferor shall be deemed to remain the holder of such Share until the name of the transferee is entered in the Register of Members in respect thereof. | Instrument of transfer to be executed by the transferor and transferee. |
| 49. | The Company shall not register a transfer of Shares in the Company unless a proper instrument of transfer duly stamped and executed by or on behalf of the transferor and by or on behalf of the transferee and specifying the name, address and occupation, if any, of the transferee has been delivered to the Company, along with the certificate relating to the Shares, unless no such share certificate is in existence along with the letter of allotment of the Shares, in which case, an application in writing may be made to the Company by the transferee and bearing the stamp required for an instrument of transfer, such that it is proved to the satisfaction of the Board of Directors that the instrument of transfer signed by or on behalf of the transferor and by or on behalf of the transferee, has been lost. The Company may register the transfer on such terms as to indemnity as the Board may think fit provided further that nothing in these Articles shall prejudice the power of the Company to register as shareholder any person to whom the right to any Shares in the Company has been transmitted by operation of law. | Transfer not to be registered except on production of instrument of transfer. |
| 50. | Application for the registration of transfer of a share may be made either by the transferor or transferee, however, where the application has been made by the transferor, the Board shall not register a transfer of partly paid shares, unless the company has given a notice to the transferee and the transferee has given no objection to the transfer within two weeks from the date of receipt of notice. | Transfer of partly paid shares |
| 51. | The Board, after giving sufficient cause, may refuse to register the transfer of securities within a period of thirty days from the date on which the instrument of transfer or the intimation of transmission, as the case may be, was delivered to the company. | Refusal for transfer |
| 52. | <p>(a) Subject to the provisions of the Act and other restrictions contained in these Articles, if any, the shares of the Company shall be freely transferable provided that no transfer shall be made to a person of unsound mind except as permitted under the Act or any other applicable law.</p> <p>(b) No fee shall be charged for any registration under the transmission clause hereinafter contained and also upon the registration of any transfer.</p> <p>(c) Every instrument of transfer shall be left at the office duly stamped for registration, accompanied by the certificate of shares proposed to be transferred and such other evidence as the Board of Directors may require to prove the title of the transferor or his right to transfer the share(s). The Board of Directors may waive the production of the certificate upon satisfactory evidence tendered to them of its loss or destruction.</p> <p>(d) All instruments of transfer which shall be registered shall be retained by the Company, but any instrument of transfer which the Board of Directors may decline to register shall (except in any case of fraud) be returned to the person depositing the same.</p> | Transfer of shares |

- (e) The transfer books and the register of members may be closed for such period as may be determined by the Board, immediately preceding the Annual General Meeting every year.
- (f) (i) On the death of a member, the survivors where the member was a joint holder and his legal representatives where he was a sole holder, shall be the only person recognized by the Company as having any title to his interest in the shares.
- (ii) Nothing in the above clause shall release the estate of a deceased joint holder from any liability in respect of any share(s) which had been jointly held by him with other persons.

NOMINATION OF SHARES

- 53. i) Notwithstanding anything contained hereinabove, every shareholder of the Company may at any time, nominate, in the prescribed manner, a person to whom his shares in the Company shall vest in the event of his death. Nomination of Shares.
- ii) Where the shares in the Company are held by more than one person jointly, the joint holders may together nominate, in the prescribed manner, a person to whom all the rights in the shares in the company, shall vest in the event of death of all the joint-holders. Nomination in case of Joint Holders.
- iii) Notwithstanding anything contained in any other law for the time being in force or in any deposition, whether testamentary or otherwise, in respect of such shares in the Company, where a nomination made in the prescribed manner purports to confer on any person the right to vest the shares in the Company, the nominee shall, on the death of the shareholder or as the case may be, on the death of the joint holders become entitled to all the rights in such shares, to the exclusion of all other persons, and unless the nomination is varied or cancelled in the prescribed manner.
- iv) Where the nominee is a minor, it shall be lawful for the holder of the shares, to make the nomination to appoint in the prescribed manner, any person to become entitled to shares in the Company, in the event of his death, during the minority.

TRANSMISSION OF SHARES

- 54. Any person becoming entitled to a share in consequence of the death or insolvency of a member may, upon such evidence being produced as may from time to time properly be required by the Board and subject as hereinafter provided, elect, either - Transmission Article
 - (a) to be registered himself as holder of the share; or
 - (b) to make such transfer of the share as the deceased or insolvent member could have made.
- 55. i) If the person so becoming entitled shall elect to be registered as holder of the share himself, he shall deliver or send to the Company a notice in writing signed by him stating that he so elects.
- ii) If the person aforesaid shall elect to transfer the share, he shall testify his election by executing a transfer of the share.
- iii) All the limitations, restrictions and provisions of these Articles relating to the right to transfer and the registration of transfers of shares shall be applicable to

any such notice or transfer as aforesaid as if the death or insolvency of the member had not occurred and the notice or transfer were a transfer signed by that member.

56. i) A nominee, upon production of such evidence as may be required by the Board, and subject to the provisions hereinafter provided, elect either: Transmission of shares by a Nominee
- (a) himself/herself to be registered as holder of the Share; or
 - (b) to make a transfer of the Share or Debenture, as the deceased shareholder or debenture holder, as the case may be, could have made.
- ii) If the nominee elects to be registered as holder of the Share himself/herself, as the case may be, he/she shall deliver or send to the Company, a notice in writing signed by him/her stating that he/she so elects and such notice shall be accompanied with the death certificate of the deceased shareholder or the debenture holder, as the case may be.
57. A Person, upon becoming entitled to a Share/ Debenture by reason of the death of the holder shall be entitled to the same dividends and other advantages to which he/she would be entitled to, if he/she were the original registered holder of the Share/ Debenture, except that he/she shall not, before being registered as a Member in respect of his Share or Debenture, be entitled in respect of such Share/ Debenture, to exercise any right conferred by Membership in relation to meetings of the Company. Rights of persons entitle to shares under the Transmission Article
- Provided that the Board may, at any time, give notice requiring any such person to elect either to be registered himself/herself or to transfer the Share and if the notice is not complied with by such nominee within ninety (90) days from the date of notice, the Board may thereafter withhold payment of all dividends, bonuses or other moneys payable or rights accruing in respect of such Share/Debenture, until the requirements of the notice have been complied with.
58. A person entitled to a Share by transmission shall subject to the right of the Board of Directors to retain such dividends or monies as hereinafter provided, be entitled to receive and may give a discharge for any dividends or other moneys payable in respect of the Share. Persons entitled may receive dividend without being registered as Member.
59. Every transmission of a Share shall be verified in such manner as the Board of Directors may require and the Company may refuse to register any such transmission until the same be so verified or until or unless an indemnity be given to the Company with regard to such registration which the Board of Directors at their discretion shall consider sufficient provided nevertheless that there shall not be any obligation on the Company or the Board of Directors to accept any indemnity. Board may require evidence of transmission.
60. The Company shall incur no liability or responsibility whatsoever in consequence of their registering or giving effect to any transfer of Shares made or purporting to be made upon production of valid documents of transfer by any apparent legal owner thereof (as shown or appearing in the Register of Members) to the prejudice of persons having or claiming any equitable right title or interest (to or in such Shares), notwithstanding that the Company may have received a notice prohibiting registration of such transfer and may have entered such notice as referred thereto in any book of the Company, and save as provided by Section 89 of the Act, the Company shall not be bound or required to regard or attend or give effect to any notice which may be given to it of any equitable right, title or interest of any person, or be under any liability whatsoever for refusing or neglecting so to do, though it Company not liable for disregard of a notice prohibiting registration of transfer.

may have been entered or referred to in some book of the Company, but the Company shall nevertheless be at liberty to regard and attend to any such notice and give effect thereto, if the Board of Directors so think fit.

61. The Company shall keep a book called the “Register of Transfer” and therein shall be fairly and distinctly entered the particulars of every transfer and transmission of any Share in the Company. Register of transfers.
62. The Company shall be entitled to treat the person whose name appears on the Register of Members as the holder of any shares or other securities or whose name appears as the Beneficial owner of shares or other securities in the records of Depository, as the absolute owner thereof. Beneficial ownership of shares

DEMATERIALISATION OF SECURITIES

63. (a) Notwithstanding anything contained in these Articles, the Company shall be entitled to dematerialize its Securities and to offer Securities in a dematerialized form pursuant to the provisions of the Depositories Act and the rules framed thereunder.
- (b) **Securities in depositories to be in fungible form:**
- (i) All Securities held by a Depository shall be dematerialized and shall be in fungible form.
- (ii) Nothing contained in Sections 89 of the Act shall apply to a Depositor in respect of the Securities held by it on behalf of the Beneficial Owners.
- (c) **Section 45 of the Act not to apply:** Nothing contained in the Act or these Articles regarding the necessity of having distinctive number for Securities issued by the Company shall apply to securities held in a depository.
64. **Option to receive Security Certificates or hold Securities with depository:**
- (a) Subject to compliance with the Act and SEBI Regulations, every person subscribing to Securities offered by the Company shall have the option to receive the Security Certificates or to hold the Securities with a Depository.
- (b) Where a person opts to hold the security of the Company with the Depository, the Company shall intimate such Depository the details of allotment of the Security and on receipt of such information the Depository shall enter in its record the name of the allottees as the Beneficial Owner of such Security(ies).
- (c) **Rights of Depositories And Beneficial Owners:**
- (i) Notwithstanding anything to the contrary contained in the Articles or any other law for the time being in force, a Depository shall be deemed to be the registered owner for the purposes of effecting transfer of ownership of the Security on behalf of the Beneficial Owner.
- (ii) Save as otherwise provided in (i) hereinabove, the Depository as a registered owner shall not have any voting rights or any other rights in respect of Securities held by it.
- (iii) Every person holding Securities of the Company and whose name is entered as a Beneficial Owner in the records of the Depository shall be

deemed to be a Member of the Company. The Beneficial Owner shall be entitled to all the rights and benefits and be subjected to all the liabilities in respect of his Securities held by a Depository.

(d) Depository to furnish information:

Every Depository shall furnish to the Company, information regarding the transfer of Securities in the name of the Beneficial owners at such interval and in such manner as may be specified by the Bye Laws and the Company in that behalf.

(e) Notwithstanding anything in the Act or these Articles to contrary where Securities are held in a depository the records of beneficial ownership may be served by such depository on the Company means of electronic mode or by delivery of floppies or discs.

(f) Notwithstanding anything contained in the Act or these Articles, where securities are dealt within a Depository, the Company shall intimate the details of allotment of securities thereof to the depository immediately on allotment of such securities.

(g) Option to opt out in respect of any security.

(i) If a Beneficial Owner seeks to opt out of a Depository in respect of any Security if permitted by law, the Beneficial Owner shall inform the Depository accordingly.

(ii) The Depository shall on receipt of an intimation as above, make appropriate entries in its records and shall inform the Company.

(iii) The Company shall within the prescribed time from the receipt of intimation from the Depository and on fulfillment of such conditions and on payment of such fees as may be specified by these Articles, issue the certificate of securities to the Beneficial Owner of the transferee as the case may be.

65. Nothing contained in section 56 of the Act, shall apply to transfer of Securities effected by the transferor and the transferee both of whom are entered as Beneficial Owner in the record of the Company.

66. The Register and Index of Beneficial Owners, maintained by a Depository shall be deemed to be the Register and Index of members and security holders, as the case may be for the purpose of these Articles.

67. Save as otherwise herein provided, the Company shall be entitled to treat the Person whose name appears on the Register of Members as the holder of any share, as also the Beneficial Owner of the shares in the records of the Depository as the absolute owner thereof as regards the receipt of dividends or bonus or the service of notices and all other matters connected with the Company and accordingly, the Company shall not except as ordered by a Court of competent jurisdiction or as required by law be bound to recognize any benami trust or equity or equitable, contingent or other claim to or interest in such share on the part of any other person whether or not it shall have express or implied notice thereof.

Notwithstanding anything in the Act or these Articles, where securities are dealt with in a depository, the Company shall intimate the details thereof to the depository immediately on allotment of such securities.

CONVERSION OF SHARES INTO STOCK

68. The Company in its General Meeting may alter its Memorandum to:
- (a) convert all or any of its fully Paid-Up Shares into stock; and
 - (b) re-convert any stock into fully Paid-Up Shares of any denomination.
69. The holders of stock may transfer the same or any part thereof in the same manner as and subject to the same regulations under which the Shares from which the stock arose, might before the conversion, have been transferred, or as near thereto as circumstances admit, provided that, the Board may from time to time, fix the minimum amount of stock transferable, so however that such minimum shall not exceed the nominal amount of shares from which the stock across.
70. The holders of stock shall, according to the amount of stock held by them, have the same rights, privileges and advantages as regards dividends, participation in profits, voting and meetings of the Company, and other matters, as if they held the Shares from which the stock arose but no such privilege or advantage (except as regard dividends, participation in the profits of the Company and in the assets on winding up) shall be conferred by an amount of stock which would not, if existing in shares, have conferred that privilege or advantage.
71. Such of the regulations of the Company (other than those relating to share warrants) as are applicable to Paid-Up Shares shall apply to stock and the words “Share” and “Shareholders” in these Articles shall include stock and stockholders respectively.

Conversion of shares into stock and reconversion.

Transfer of stock.

Right of Stock holders.

Articles to apply to stocks.

INCREASE, REDUCTION AND ALTERATION OF CAPITAL

72. The Company may, from time to time, by ordinary resolution increase the share capital by such sum, to be divided into Shares of such amount, as may be specified in the resolution.
73. Subject to the provisions of Section 61 of the Act, the company may, by ordinary resolution in its General Meeting,—
- (a) increase its authorized share capital by such amount as it thinks expedient;
 - (b) consolidate and divide all or any of its share capital into Shares of larger amount than its existing Shares;
 - (c) convert all or any of its fully paid-up Shares into stock, and reconvert that stock into fully paid-up Shares of any denomination;
 - (d) sub-divide its existing Shares or any of them into Shares of smaller amount than is fixed by the memorandum;
 - (e) cancel any Shares which, at the date of the passing of the resolution, have not been taken or agreed to be taken by any person and diminish the amount of its share capital by the amount of the Shares so cancelled.
74. The resolution whereby any share capital is sub-divided may determine that as between the holders of the shares resulting from such sub-division, one or more of such shares shall have some preference or special advantage as regards dividend, capital, voting or otherwise over or as compared with the others, subject, nevertheless to the applicable provisions of the Act.

Increase of Capital.

Sub-division into preference and ordinary

75. The Company may, by special resolution, reduce in any manner and with, and subject to, any incident authorized and consent required by law -
- (a) its share capital;
 - (b) any capital redemption reserve account; or
 - (c) any share premium account.
76. Subject to any special rights or privileges for the time being attached to any shares in the capital of the Company then issued, the new shares may be issued upon such terms and conditions and with such rights and privileges attached thereto as the general meeting resolving upon the creation thereof, shall direct, and if no direction be given, as Board shall determine, and in particular, such shares may be issued with a preferential or a qualified right to dividends and in the distribution of the assets of the Company.
77. (1) Where at any time, the Company proposes to increase its subscribed capital by the issue of further Shares, such Shares shall be offered –
- (a) to persons who, at the date of the offer, are holders of equity Shares of the Company in proportion, as nearly as circumstances admit, to the paid-up share capital on those Shares by sending a letter of offer subject to the following conditions, namely:
 - (i) the offer shall be made by notice specifying the number of Shares offered and limiting a time not being less than fifteen (15) days and not exceeding thirty (30) days from the date of the offer within which the offer, if not accepted, shall be deemed to have been declined;
 - (ii) subject to the provisions of these Articles the offer aforesaid shall be deemed to include a right exercisable by the person concerned to renounce the Shares offered to him or any of them in favour of any other person; and the notice referred to in clause (i) herein above shall contain a statement of this right;
 - (iii) after the expiry of the time specified in the notice aforesaid, or on receipt of earlier intimation from the person to whom such notice is given that he declines to accept the Shares offered, the Board of Directors may dispose of them in such manner which is not dis-advantageous to the shareholders and the Company;
 - (b) to employees under a scheme of employees' stock option, subject to shareholders' approval and subject to such conditions as may be prescribed under the Act and any other law in force at the time, including the conditions set out under the employees' stock option guidelines issued by the SEBI (as may be applicable); or
 - (c) to any persons, if it is authorized by a special resolution, whether or not those persons include the persons referred to in clause (a) or clause (b) hereinabove, either for cash or for a consideration other than cash by way of preferential offer or private placement, if the price of such Shares is determined by the valuation report of a registered valuer subject to such conditions as may be prescribed under the Act and rules framed thereunder and applicable provisions of SEBI Regulations.
- On what conditions new shares may be issued
- Right of Equity Shareholders to further issue of Capital.

78. Nothing in the Article above shall apply to the increase of the subscribed capital of the Company caused by the exercise of an option as a term attached to the Debentures issued or loan raised by the Company to convert such Debentures or loans into Shares in the Company:

Provided that the terms of issue of such Debentures or loan containing such an option have been approved before the issue of such Debentures or the raising of loan by a special resolution passed by the Company in a General Meeting.

79. (1) Except so far as otherwise provided by the conditions of issue or by these Articles, any capital raised by the creation of new Shares shall be considered part of the original capital and shall be subject to the provisions herein contained with reference to the payment of calls and installments, transfer and transmission, forfeiture, lien, surrender, voting or otherwise. Further issue of Capital to be governed by same rules.

(2) Subject to the provisions of the Act and the rules framed thereunder, the Company shall have the power to issue preference shares (cumulative or non-cumulative) of one or more classes which are, or at the option of the Company, liable to be redeemed within twenty (20) years from the date of issue, convertible into equity shares at a premium or otherwise and the redemption may, subject to the provisions of the Article hereof and the Act and rules framed thereunder, be effected in the manner decided by the Board of Directors at the time of its issue and subject to the provisions of the Act and SEBI Regulations.

(3) On the issue of redeemable Preference Shares under the provisions of sub-clause (2) herein above, the following provisions shall take effect:

(a) no such Shares shall be redeemed except out of profits of the Company which would otherwise be available for dividend or out of the proceeds of the fresh issue of Shares made for the purpose of redemption.

(b) no such Shares shall be redeemed unless they are fully paid;

(c) the premium if any payable on redemption must have been provided, for out of the profits of the Company or the Company's Securities Premium Account before the Shares are redeemed;

(d) where any such Shares proposed to be are redeemed out of the profits of the Company there shall, out of the profits, transfer a sum equal to the nominal amount of the Shares to be redeemed, which would otherwise have been available for dividend, to a reserve fund, to be called the "Capital Redemption Reserve Account", and the provisions of the Act relating to the reduction of the Shares Capital of the Company shall ,except as provided in section 55 of the Act, apply as if the Capital Redemption Reserve Account were paid-up share capital of the Company

80. The Company may, subject to the provisions of the Act, from time to time by special resolution reduce its share capital and in particular may pay off any paid up share capital upon the footing that it may be called up again or otherwise and may, if and so far as is necessary, alter its Memorandum by reducing the amount of its share capital and of its Shares accordingly. Provided that no such reduction shall be made if the Company is in arrears in the repayment of any deposits it may have accepted, or the interest payable thereon. Reduction of Capital.

81. The right conferred upon the holders of Shares of any class issued with preferred or other rights shall not, unless otherwise expressly provided by terms of issue of the Shares of that class, be deemed to be varied by the creation or issue of further Issue of further *pari-passu* shares not to affect the rights of

Shares ranking *pari-passu* herewith.

shares already
issued.

MODIFICATION OF RIGHTS

82. If at any time the share capital is divided into different classes, the rights attached to any class of Shares (unless otherwise provided by the terms of issue of the Shares of that class) may, subject to the provisions of the Act, be modified, commuted, affected, abrogated or varied (whether or not the Company is being wound up) with the consent in writing of the holders of not less than three fourths of the issued Shares of that class, or with the sanction of a special resolution passed at a separate general meeting of the holders of the shares of that class and all the provisions hereinafter contained as to General Meeting shall *mutatis mutandis* apply to every such meeting.
- Rights attached to class of Shares may be varied.

JOINT HOLDERS

83. Where two or more persons are registered as the holders of any Share they shall be deemed to hold the same as joint tenants with benefits of survivorship, subject to the following and other provisions in the Articles;
- (a) The Company may be entitled to decline to register more than three (3) persons as the joint holders of any Share(s).
 - (b) The joint holders of any Share shall be liable severally as well as jointly for and in respect of all calls and other payments which ought to be made in respect of such Share.
 - (c) On the death of any such joint holder the survivor or survivors shall be the only person or persons recognized by the Company as having any title to the Share but the Board of Directors may require such evidence of deaths they may deem fit and nothing herein contained shall be taken to release the estate of deceased joint holder from any liability in respect of the Shares held by him jointly with any other person.
 - (d) Only the person whose name stands first in the Register of Members may give effectual receipts for any dividends or other moneys payable in respect of such share.
 - (e) Only the person whose name stands first in the Register of Members as one of the Joint holders of any Share shall be entitled to delivery of the Certificate relating to such Share or to receive documents) from the Company and any documents served on or sent to such person shall be deemed service on all the joint holders.
 - (f) Any one of two or more joint holders may vote at any meeting either personally or by proxy in respect of such Shares as if he were solely entitled thereto and if more than one of such joint holders be present at any meeting personally or by proxy than that one of such persons so present whose name stands first or higher (a the case may be) on the Register in respect of such Shares shall be entitled to vote in respect thereof but the other or others of the joint holders shall be entitled to be present at the meeting provided always that joint holders present at any meeting personally shall be entitled to vote in preference to a joint holder present by proxy although the name of such joint holder present by proxy stands first or higher in the Register in respect of such Shares, several executors or administrators of a deceased Member in whose (deceased Member's) sole name any Share stands shall for the purposes of this

sub-clause be deemed joint holders.

DECLARATION BY PERSON NOT HOLDING BENEFICIAL INTEREST IN ANY SHARE

84. (a) Notwithstanding anything herein contained, a person whose name is at any time entered in the Register of Members of the Company as the holder of a Share in the Company, but who does not hold the beneficial interest in such share shall, within such time and in such form as prescribed under the Act, make a declaration to the Company specifying the name and other particulars of the person or persons who hold the beneficial interest in such Share in such manner as may be required under the provisions of the Act.
- (b) A person who holds a beneficial interest in a Share or a class of Shares of the Company, shall within the time prescribed under the Act after his becoming such Beneficial Owner, make a declaration to the Company specifying the nature of his interest, particulars of the person in whose name the shares stand in the Register of Members of the company and such other particulars as may be required under the provisions of the Act.

Whenever there is a change in the beneficial interest in the Share referred to above, the Beneficial Owner shall within a period of thirty (30) days from the date of such change make a declaration to the Company in such form and containing such particulars may be required under the provisions of the Act.

Notwithstanding anything contained in the provisions of the Act and the Articles hereof, where any declaration referred to above is made to the Company the Company shall make a note of such declaration in the Register of Members and file within the time prescribed from the date of receipt of the declaration a return in the prescribed form with the Registrar with regard to such declaration.

85. Notwithstanding anything contained in these Articles but subject to the provisions of Sections 68 to 70 of the Act and any other applicable provision of the Act and rules there under or any other law for the time being in force, the Company may purchase its own shares or other specified Securities. Buy-back of shares.

BORROWING POWERS

86. Subject to the provision of Section 180 (1) (c) of the Act (as may be applicable) and these Articles and without prejudice to the other powers conferred by these Articles, the Board of Directors shall have the power from time to time at their discretion, by a resolution passed at a meeting of the Board and not by circular resolution, to borrow monies. Power to borrow.
87. Subject to the provisions of the Act (as may be applicable) and these Articles, the Board of Directors may by a resolution passed at a meeting of the Board and not by circular resolution, secure the payment of such sum or sums in such manner and upon such issue of bonds, perpetual or redeemable debentures or debenture stock, or any mortgage or charge or other security on the undertaking of the whole or any part of the property, undertaking of the company (both present and future). Provided that consent of the Members by way of special resolution would be necessary for security to be created on whole or substantially whole of the undertaking. For the purposes of this Article: Conditions on which monies may be borrowed.
- (i) "undertaking" shall mean an undertaking in which the investment of the company exceeds twenty per cent of its net worth as per the audited balance

sheet of the preceding financial year or an undertaking which generates twenty per cent. of the total income of the company during the previous financial year;

- (ii) the expression “substantially the whole of the undertaking” in any financial year shall mean twenty per cent or more of the value of the undertaking as per the audited balance sheet of the preceding financial year .

88. Any bonds, Debentures, debenture-stock or other Securities issued or to be issued by the Company, shall be under the control of the Board of Directors, who may issue them upon such terms and conditions and in such manner and for such consideration as they shall consider to be for the benefit of the Company. Bonds, debentures, etc. to be subject to control of Directors.
89. The provisions in these Articles pertaining to transfer of shares shall, mutatis-mutandis apply to transfer of debentures, debenture-stock, bonds or other securities. Transfer of securities
90. Subject to the provisions of the Act and these Articles, any bond, Debentures, debenture stock or other Securities, may be issued at par, premium or otherwise and with any special rights, privileges and conditions as to redemption, surrender, drawings, allotment of Shares, attending (but not voting) at a General Meeting, appointment of Directors or otherwise. Provided that the Debentures with the right to allotment of or conversion into Shares shall not be issued except with the sanction of the Company in a General meeting. Condition on which bonds, debentures, etc. may be issued.
91. The Board shall cause a proper Register to be kept in accordance with the provisions of the Act, of all mortgages, Debentures and charges specifically affecting the property of the Company including all floating charges on current assets of the Company and fixed charges on the undertaking or any property of the Company, and shall cause the requirements of the Act in relation to charges be duly complied with.

DEBENTURES

92. The Company shall have the power to issue debentures whether convertible or non-convertible, and whether linked to issue of equity shares or not, among Members, but in exercising, this power, provisions of these Articles and the Act and any statutory modifications thereof shall be complied with.

GENERAL MEETINGS

93. Subject to the provisions of the Act, the Company shall, in addition to any other meeting, hold a General Meeting (hereinafter called “**Annual General Meeting**”) at the intervals and in accordance with the requirement of the Act and unless permitted under the Act, not more than fifteen (15) months shall elapse between the date of one Annual General Meeting of the Company and that of the next. Provided that if the Ministry of Corporate Affairs / Registrar/ SEBI for any special reason, extends the time within which any Annual General Meeting shall be held, then such Annual General Meeting may be held within such extended period. Annual General Meeting.
94. The Board of Directors may call an Extraordinary General Meeting whenever they think fit. Board of Directors may call Extra-Ordinary General Meeting.
95. (1) The Board of Directors shall at the requisition made by such number of Members who hold, on the date of the receipt of the requisition, not less than one-tenth of such of the paid-up share capital of the Company as on that date Board of Directors call Extra-ordinary General Meeting on

carries the right of voting, proceed duly to call an Extraordinary General Meeting of the Company and the provisions the Act and the provisions of the Articles herein below contained shall be applicable to such Extraordinary General Meeting in accordance with the applicable provisions of the Act. requisition.

- (2) The requisition shall set out the matters for the consideration of which the meeting is to be called, shall be signed by the requisitionists, and shall be deposited at the Registered Office of the Company.
- (3) The requisition may consist of several documents of the like form each signed by one or more requisitionists.
- (4) Where two or more distinct matters are specified in the requisition, the provisions of sub-clause (1) above shall apply separately in regard to each such matter, and the requisition shall accordingly be valid only in respect of those matters in regard to which the conditions specified in that clause are fulfilled.
- (5) If the Board of Directors do not, within twenty one days from the date of the receipt of a valid requisition in regard to any matter, proceed duly to call a meeting for the consideration of those matter, on a day not later than forty five days from the date of the receipt of the requisition, the meeting may be called by the requisitionists themselves within three months from the date of the requisition.
- (6) Any meeting called under this Article by the requisitionists shall be called in the same manner as nearly as possible as that in which meetings are to be called by the Board.
- (7) Where two or more persons hold any shares jointly, a requisition or notice calling the meeting, signed by one or only some of them shall for the purpose of this Article, have the same force and effect as if it had been signed by all of them.
- (8) Any reasonable expenses incurred by the requisitionists by reason of the failure of the Board duly to call a meeting shall be repaid to the requisitionists by the Company and any sum so and the sums so paid shall be deducted from any fee or other remuneration under section 197 payable to such of the Directors who were in default in calling the meeting.

96. (1) A General Meeting of the Company may be called by giving not less than clear twenty one days' notice in writing or by electronic mode in the manner set out under the Act. Notice of Meeting.

- (2) However, the General Meeting may be called after giving a shorter notice (i.e. lesser than 21 days), if the consent is accorded thereto in writing or by electronic mode by not less than such number of members as prescribed under the Act.

97. (1) Every notice of a meeting of the Company shall specify the place, the date and hour of the meeting and shall contain a statement of the business to be transacted at such General Meeting. Content of Notice.

- (2) In every notice there shall appear with reasonable prominence a statement that a Member entitled to attend and vote is entitled to appoint a proxy to attend and vote instead of himself and that a proxy need not be a Member of the Company.

(3) The business at a general meeting shall also include any resolution by members

of which notice is given in accordance with Section 111 of the Act.

98. (1) In the case of an Annual General Meeting all business to be transacted at the meeting shall be deemed special, with the exception of business relating to: Special Business.
- (i) the consideration of the financial statements including balance sheet and the profit and loss account statements and the report of Board of Directors and the auditors.
 - (ii) the declaration of dividend.
 - (iii) the appointment of and the fixing of the remuneration of the auditors.
 - (iv) the appointment of Directors in the place of those retiring.
- (2) In the case of any other meeting all business shall be deemed special.
- (3) Where any item of business to be transacted at the meeting is deemed to be special as aforesaid, there shall be annexed to the notice of the meeting, a statement setting out all material facts concerning each item of special business to be transacted at a General Meeting, shall be annexed to the notice calling such meeting, namely:
- (a) the nature of concern or interest, financial or otherwise, if any, in respect of each items of—
 - (i) every director and the manager, if any;
 - (ii) every other key managerial personnel; and
 - (iii) relatives of the persons mentioned in sub-clauses (i) and (ii);
 - (b) any other information and facts that may enable Members to understand the meaning, scope and implications of the items of business and to take decision thereon.
- (4) Where any item of business to be transacted at the meeting consists of according approval of the meeting to any document, the time and place where the document can be inspected shall be specified in the explanatory statement.
- (5) Notices and other documents of General Meeting of the Company may also be given to every Member of the Company by e-mail, provided that every Member should be given an advanced opportunity to register their e-mail address and changes therein from time to time with the Company or its Registrar and Share transfer agents. In case any Member has not registered his e-mail address with the Company, the service of notice and documents shall be in physical and in accordance with the provisions of Act.
99. Notice of every meeting shall be given to every Member of the Company in any manner authorized by the Act and by these Articles, it shall be given to the persons entitled to a Share in consequence of the death or insolvency of a Member by sending it through the post in a prepaid letter addressed to them by name, or by the time of the representative of the deceased or assignees of the insolvent or by any like description at the address, if any, in India supplied for the purpose by the persons claiming to be so entitled or until such an address has been so supplied, by giving the notice in any manner in which it might have been given if the death or insolvency had not occurred provided that where notice of a meeting is given by advertising the same in a newspaper circulating in the neighborhood of the Notice in case of death of a Member.

registered office of the Company under sub-section (3) of Section 53 of the Act, the explanatory statement need not be annexed to the notice as required by Section 173 of the said Act, but it shall be mentioned in the advertisement that the statement has been forwarded to the Members of the Company.

- | | | |
|------|--|--|
| 100. | Notwithstanding anything contrary contained in the Articles of Association, the Company may, in pursuance of and subject to compliance with the provisions of applicable rules, regulations, circulars, guidelines, notifications, etc. as may be specified by the Ministry of Corporate Affairs (MCA), Securities & Exchange Board of India (SEBI), or any competent authority and the provisions, if any, which may be laid down in this regard by any amendment in or re-enactment of the Companies Act or by the rules, regulations made there under or the SEBI guidelines and notifications, from time to time, allow the Member(s) of the Company to participate in the General Meeting(s) of the Members through any type of electronic mode like video conferencing, etc. and the Members so participating shall be deemed to be present in such General Meeting(s) for the purpose of the quorum, voting, recording and all other relevant provisions in this regard. | Meetings by Video Conference. |
| | For conducting the aforesaid meetings, the Company shall follow the procedure specified under the applicable laws for the time being in force and the rules, regulations, circulars, notifications, guidelines, etc. issued / to be issued from time to time by MCA, SEBI or any other competent authority(ies) in this regard. | |
| 101. | Notice of every meeting of the Company and every other communication relating to any General Meeting of the Company which any Member of the Company is entitled to have sent to him, shall be given to the Auditor or Auditors for the time being of the Company in the manner authorized by the provisions of the Act, as in the case of any Member or Members of the Company. | Service of Notice of General Meeting |
| 102. | The accidental omission to give notice of any meeting to or the non-receipt of any notice by any Member or to the other person to whom it should be given shall not invalidate the proceedings at the meeting or the resolutions passed thereat. | Omission to give Notice |
| 103. | <p>(1) Where by any provision contained in the Act or in these Articles, a special notice is required for any resolution, notice of the intention to move the resolution shall be given to the Company not earlier than three months but at least fourteen days (14) days before the meeting at which it is to be moved exclusive of (i) the days on which the notice is served or deemed to be served; and (ii) the day of the meeting.</p> <p>(2) The Company shall, immediately after the notice of the intention to move any such resolution has been received by it give its Members, notice of the resolution in the same manner as it gives notices of the meeting, or if that is not practicable, then the notice shall be published in English language in English newspaper and in vernacular language in a vernacular newspaper, both having wide circulation in the State where the registered office of the Company is situated and such notice shall also be posted on the website, if any, of the Company, not less than seven days before the meeting, exclusive of the day of publication of the notice and day of the meeting.</p> | Special Notice of a resolution |
| 104. | Upon requisition in writing of such number of Members as required in Section 115 of the Act, the Directors shall duly comply with the obligation of the Company under the said Act relating to circulation of Members resolutions and statement. | Circulation of members' resolution |
| 105. | A certificate in writing, signed by the Secretary or by a Director or some officer appointed by the Directors for the purpose, to the effect that according to the best of his belief the notice convening the meeting have been duly given, shall be | Certificate in writing by Secretary/ Director shall be |

conclusive evidence thereof.

conclusive evidence

106. No Annual General Meeting or Extraordinary General Meeting shall be competent to enter upon, discuss or transact any business, a statement of which has not been specified in the notice convening such meeting, except as provided in the said Act. Business which may not be transacted at the meeting.

PROCEEDING AT GENERAL MEETINGS

107. Save as otherwise provided herein, the quorum for the general meetings shall be as provided in Section 103 of the Act. Quorum at General Meeting.
108. If within half an hour after the time appointed for the holding of a General Meeting, valid quorum is not present, the meeting, if convened on the requisition of shareholders shall be cancelled and in every other case shall stand adjourned to the same day in the next week or if the day is a public holiday until the next succeeding day which is not a public holiday at the same time and place or to such other day, time and place as the Board of Directors may by notice to the shareholders appoint. If at such adjourned meeting, a valid quorum is not present within half an hour, those Members present shall be a quorum and may transact the business for which the meeting was called. Proceedings when quorum not present.
109. No business shall be transacted at any adjourned meeting other than the business which might have been transacted at the meeting from which the adjournment took place. Business of adjourned meetings.
110. The Chairman of the Board of Directors shall be entitled to take the Chair at every General Meeting if there is no Chairman, or if at any meeting Chairman is not present within 15 minutes after the time appointed for holding such meeting or is unwilling to act, the Vice-Chairman, or in the case of his absence or refusal, the Directors present may choose a Chairman, and in default of their doing so the Members present shall choose one of the Directors to be the Chairman, and if no Director present be willing to take the Chair, the Members personally present shall choose one of the Member to be the Chairman. Chairman
111. (1) No business shall be discussed at any General meeting, except the election of Chairman whilst the Chair is vacant. Business confined to decision of Chairman whilst Chair vacant.
- (2) If a poll is demanded on the election of the Chairman, it shall be taken forthwith in accordance with the provisions of the Act and these Articles, and the Chairman so elected on a show of hands shall continue to be the Chairman of the meeting and exercise all the powers of the Chairman under the Act and these Articles, until some other person is elected as Chairman as a result of the poll and such other person shall be the Chairman for the rest of the meeting.
112. The Chairman with the consent of any meeting at which a quorum is present, can adjourn any meeting from time to time and from place to place, provided no business shall be transacted at the adjourned meeting other than the business left unfinished at the meeting from which the adjournment took place. Chairman may adjourn meeting.
113. At any General Meeting a resolution put to the vote at the meeting shall, unless a poll is (before or on the declaration of the result on a show of hands) demanded, be decided on a show of hands and unless a poll is so demanded, a declaration by the Chairman that a resolution has been carried, either unanimously or by a particular majority, and an entry to that effect in the books containing the minutes of the proceedings of the Company, shall be conclusive evidence of the fact, without proof of the number or proportion of the votes cast in favour of or against such resolution. Evidence of the passing of a resolution where poll not demanded.

114. Before or on declaration of the result of the voting on a show of hands, the Chairman may on his own motion, order a poll to be taken. Poll shall also be ordered by Chairman if it is demanded by one or more Members present at the meeting in person or by proxy and holding shares or being entitled to votes at least to the extent stipulated under the provisions of the Act. The demand for a poll may be withdrawn at any time by the person or persons who made the demand. Demand for Poll.
115. A poll demanded on any question (other than the election of the Chairman or on question of adjournment, which shall be taken forthwith) shall be taken at such place in the city/town or village in which the Registered Office of the Company is situate and at such time not being later than forty eight hours from the time when the demand was made as the Chairman may direct. Subject to the provisions of the Act, the Chairman of the meeting shall have power to regulate the manner in which a poll shall be taken, including the power to take the poll by open voting or by secret ballot and either at once or after the interval or adjournment or otherwise and the result of the poll shall be deemed to be the decision of the meeting on the resolution, on which the poll was taken. Time and manner of taking poll.
116. Where a poll is to be taken, the Chairman of the meeting shall appoint such number of persons, as he deems necessary, to scrutinize the poll process and votes given on the poll and to report thereon to him in the manner as may be prescribed under the Act. The Chairman of the meeting shall have power to regulate the manner in which the poll shall be taken. Chairman to regulate the poll.
117. On a Poll, a member entitled to more than one vote, or his proxy or other person entitle to vote for him, as the case maybe, need not, if he votes, use all his votes or cast in the same way all the votes he uses.
118. The demand for a poll shall not prevent the continuance of a meeting for transaction of any business other than the question on which the poll has been demanded. Demand for poll not to prevent transactions of other business.
119. In the case of an equality of votes, whether on a show of hands or on a poll, the Chairman of the meeting at which the show of hands has taken place) or at which the poll is demanded, shall be entitled to second or casting vote in addition to the vote or votes to which he may be entitled as a Member. Resolutions to be decided in case of equality of votes.
120. The. Company shall cause minutes of all proceedings of every General Meeting to be kept in accordance with the provisions of the Act by making, within thirty (30) days of the conclusion of each such meeting, entries thereof in books kept for that purpose with their pages consecutively numbered. Each page of every such book shall be initiated or signed and the last page of the record of proceedings of each meeting in such books shall be dated and signed by the Chairman of the same meeting. Any such minutes kept as aforesaid shall be evidence of the proceedings recorded therein. Minutes of General Meeting.
121. The books containing the aforesaid minutes shall be kept at the registered office and be open during business hours to the inspection of any Member without charge, subject to such reasonable restrictions the Company may by these Articles or in General Meeting impose in accordance with provisions of the Act. Any Member shall be entitled to be furnished, within seven (7) days after he had made a request in that behalf to the Company, with a copy of the minutes on payment of such sum as prescribed under the Act. Inspection of Minutes Books of General Meeting.

Provided that a member who has made a request for provision of a soft copy of the minutes of any previous general meeting held during the period immediately preceding three financial years, shall be entitled to be furnished with the same free of cost.

122. No report of the proceedings of any General Meeting of the Company shall be circulated or advertised at the expenses of the Company unless it includes the matters required by these Articles or such information as required by the Act to be contained in the Minutes of the proceedings of such meeting. Publication of report of proceedings of General Meeting.

VOTES OF MEMBERS

123. Subject to the provisions of the Act and these Articles, votes may be given either personally or by proxy or in the case of a body corporate also by a representative duly authorized. Votes may be given by proxy of attorney.
124. (1) Subject to any rights or restrictions for the time being attached to any class or classes of Shares :-
- (a) on a show of hands, every Member present in person shall have one vote; and
 - (b) on a poll, the voting rights of Members shall be in proportion to his share in the Paid-Up equity share capital of the Company.
- (2) A Member may exercise his vote at a meeting by electronic means in accordance with the provisions of the Act.
- (3) (i) In the case of joint holders, the vote of the senior who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other joint holders.
- (ii) For this purpose, seniority shall be determined by the order in which the names stand in the Register of Members.
- (4) A Member of unsound mind, or in respect of whom an order has been made by any court having jurisdiction in lunacy, may vote, whether on a show of hands or on a poll, by his committee or other legal guardian, and any such committee or guardian may, on a poll, vote by proxy.
- (5) Any business other than that upon which a poll has been demanded may be proceeded with, pending the taking of the poll.
- (6) No Member shall be entitled to vote at any General Meeting unless all calls or other sums presently payable by him in respect of his Shares in the Company have been paid.
- (7) (i) No objection shall be raised to the qualification of any voter except at the meeting or adjourned meeting at which the vote objected to is given or tendered, and every vote not disallowed at such meeting shall be valid for all purposes.
- (ii) Any such objection made in due time shall be referred to the Chairperson of the meeting, whose decision shall be final and conclusive.
125. A body corporate, whether a company within the meaning of this Act or not, may, if it is a member of a company within the meaning of this Act, by resolution of its Board of Directors or other governing body, authorise such person as it thinks fit to act as its representative at any meeting of the company, or at any meeting of any class of members of the company. A person authorised by resolution above shall be entitled to exercise the same rights and powers, including the right to vote by proxy and by postal ballot, on behalf of the body corporate which he represents as Procedure where a body corporate is a member of the Company

that body could exercise if it were an individual member of the company.

- | | | |
|------|--|--|
| 126. | The holders of any preference share capital of the Company shall, in respect of such capital, have a right to vote only:

(a) where the dividend in respect of a class of preference shares has not been paid for a period of two years or more, such class of preference shareholders shall have a right to vote on all the resolutions placed before the company; or

(ii) on resolutions placed before the Company which directly affect the rights attached to his preference shares and, any resolution for the winding up of the company or for the repayment or reduction of its equity or preference share capital and his voting right on a poll shall be in proportion to his share in the paid-up preference share capital of the company:

Provided that the proportion of the voting rights of equity shareholders to the voting rights of the preference shareholders shall be in the same proportion as the paid-up capital in respect of the equity shares bears to the paid-up capital in respect of the preference shares. | Voting rights of Preference shareholders |
| 127. | Notwithstanding anything contained in the articles of association of the Company, the Company may adopt the mode of passing the resolution by its members by means of a Postal Ballot (including voting by electronic means) and / or other ways as may be permitted under the Act or prescribed by the Govt. of India. | Passing of resolutions by Postal Ballot |
| 128. | Any person entitled under the transmission clause to transfer any Share, shall not be entitled to be present; or to vote at any meeting either personally or by proxy in respect of such Shares, unless a least forty eight (48) hours before the time for holding the meeting or adjourned meeting as the case may be; at which he proposes to be present and to vote, he shall have satisfied the Directors of his right to transfer such Shares (as to which the opinion of the Directors shall be final) or unless the Directors shall have previously admitted his right to vote in respect thereof. | Votes of a person entitled to a share on transmission. |
| 129. | Any Member entitled to attend and vote at a meeting of the Company shall be entitled to appoint another person (whether a Member or not) as his proxy to attend and vote instead of himself but a proxy so appointed shall not have any right to speak at the meeting. | Appointment of proxy. |
| 130. | Every proxy shall be appointed by an instrument in writing signed by the appointer or his attorney duly authorized in writing, or if the appointer is a body corporate, be under its seal or be signed by an Officer or an attorney duly authorized by it. | Proxy how appointed |
| 131. | (1) The instrument of proxy shall be deposited at the office of the Company not less than forty eight (48) hours before the time for holding the meeting at which the person named in the instrument proposes to vote and in default, the instrument proxy shall not be treated as valid.

(2) Every Member entitled to vote at a meeting of the Company according to the provisions of these Articles on any resolution to be moved thereat, shall be entitled during the period beginning twenty four hours before the time fixed for the commencement of the meeting and ending with the conclusion of the meeting, to inspect, the proxies lodged at any time during the business hours of the Company provided not less than three days' notice in writing of the intention so to inspect is given to the Company. | Deposit of and inspection of instrument of Proxy |
| 132. | An instrument appointing a proxy shall be in such form as may be prescribed by the Act from time to time. | Form of Proxy. |

133. No member shall be entitled to exercise any voting rights either personally or by Proxy at any meeting of the Company in respect of any shares registered in his name on which any calls or other sums presently payable by him have not been paid or in regard to which the Company has and has exercised any rights of lien. Restrictions on voting
134. A vote given in accordance with the terms of an instrument appointing a proxy shall be valid notwithstanding the previous death or insanity of the principal or revocation of the instrument, or transfer of the share in respect of which the vote is given provided no intimation in writing, of the death, insanity, revocation or transfer of the share, shall have been received by the Company at the office before the vote is given, provided nevertheless that the Chairman of any meeting shall be entitled to require such evidence as he may in his discretion, think fit of the due execution of an instrument of proxy and that the same has not been revoked. When vote by proxy valid through authority revoked
135. If any such instrument be confined to the object of appointing a proxy for voting at a meeting of the Company, it shall remain permanently or for such time as the Board of Directors may determine, in the custody of the Company, and if embracing other object, a copy thereof, examined with the original shall be delivered to the Company to remain in the custody of the Company. Custody of the instrument of proxy.
136. (i) Any objection as to the admission or rejection of a vote, either on a show of hand or on a poll made in due time, shall be referred to the Chairman who forthwith shall determine the same, and such determination made in good faith shall be final and conclusive. Admission or rejection of votes
- (ii) No objection shall be raised to the qualification, of any voter except at the meeting or adjourned meeting at which the vote objected to is, given or tendered and every vote not disallowed at such meeting shall be valid for all purposes.

DIRECTORS

137. Subject to the provisions of the Act, the number of Directors shall not be less than number specified under the Act and SEBI Regulations and unless otherwise determined by the members of the Company by way of a Special Resolution in General Meeting, more than twenty (20)*. Number of Directors
- * As per approval of Central Government vide letter no. 4/62001-CL.VII dated 20.08.2001.
138. The first Directors of the Company are:
1. Shri A. N. Goyal
 2. Shri Omesh Goyal
 3. Shri Berjesh K. Goyal
139. Not less than two-thirds of the total number of directors of the Company shall be persons whose period of office is liable to determination by retirement of directors by rotation. The term "total number of directors" shall not include independent directors, whether appointed under this Act or any other law for the time being in force, on the Board of the Company. Directors to retire by rotation
140. At each Annual General Meeting of the Company, one-third of such Directors for time being as are liable to retire by rotation, or if their number is not three or a multiple of three, then the number nearest to one-third shall retire from office. An Rotation and retirement of Directors

additional director appointed by the Board shall not be liable to retire by rotation within the meaning of this Article.

141. The Directors to retire by rotation at every Annual General Meeting shall be those who have been longest in office since their last appointment but as between persons who became Directors on the same day those to retire shall in default of and subject to any agreement among themselves, be determined by lot. Which directors to retire

142. The Company at the Annual General Meeting at which a Director retires by rotation in manner aforesaid may fill up the vacated office by appointing the retiring Director so or some other persons thereto.

If the vacancy of the retiring director is not so filled up and the meeting has not expressly resolved not to fill the vacancy, the meeting shall stand adjourned till the same day in the next week, at the same time and place, or if that day is a national holiday, till the next succeeding day which is not a holiday, at the same time and place. If at the adjourned meeting also, the vacancy of the retiring directors is not filled up and that meeting also has not expressly resolved not to fill the vacancy, the retiring director shall be deemed to have been re-appointed at the adjourned meeting unless:

(a) At the meeting or at the previous meeting a resolution for the appointment of such director has been put to the vote and lost, or

(b) the retiring director has by notice in writing addressed to the Company or the Board, expressed his unwillingness to be re-appointed: or

(c) who is not qualified or is disqualified for appointment: or

(d) a resolution, whether special or ordinary, is required for his appointment or re-appointment by virtue of any provisions of the Act; or

(e) Section 162 of the Act is applicable to the case.

143. A person who is not a retiring director in terms of the Articles above shall, subject to the provisions of these Articles and the Act, be eligible for appointment to the office of a director at any general meeting, if he, or some member intending to propose him as a director, has, not less than fourteen days before the meeting, left at the registered office of the company, a notice in writing under his hand signifying his candidature as a director or, as the case may be, the intention of such member to propose him as a candidate for that office, along with the deposit of such sum as may be prescribed which shall be refunded to such person or, as the case may be, to the member, if the person proposed gets elected as a director or gets more than twenty-five per cent of total valid votes cast either on show of hands or on poll on such resolution. Right of other persons to stand for directorship

Provided that requirements of deposit of amount shall not apply in case of appointment of an independent director or a director recommended by the Nomination and Remuneration Committee of the Board of the Company or a director recommended by the Board of Directors of the Company, in the case of a company not required to constitute Nomination and Remuneration Committee.

144. The Company may agree with any bank or financial institution or any authority or person or Government that in consideration of any loan or financial assistance of any kind whatsoever, which may be rendered by it to the Company, it shall till such time as the loan or financial assistance is outstanding have power to nominate one or more Directors on the Board of the Company and from time to time remove and re-appoint such Directors and to fill in any vacancy caused by the death or Nominee Directors.

resignation of such Directors otherwise ceasing to hold office. Such Directors shall not be required to hold any qualification shares and at the option of such bank or financial institution or any authority or person or Government, shall not be liable to retire by rotation. The Nominee Director shall be entitled to the same rights and privileges and be subject to the same obligations as any other Director of the Company. The Board of Directors of the Company shall have no power to remove from such office, any person so appointed and to appoint a person in his place.

145. Any trust Deed for securing Debenture, debenture stock may if so arranged, provide for the appointment from time to time by the trustees thereof or by the holders of the Debentures or debentures stock of some person to be a Director of the Company and may empower such trustees or holders of Debentures or debenture stock from time to time to remove any Director so appointed. The Director appointed under this Article is herein referred to as the “**Debenture Director**” and the term Debenture Director means the Director for the time being in office under this Article. The Debenture Director shall not be bound to hold any qualification shares and shall, at the option of the Debenture Trustee or Debenture holders or holders of Debenture Stock, not be liable to retire by rotation or, subject to the provision of the Act, not be removed by the Company. The Debenture Trustee or Debenture holders or holders of Debenture Stock shall also have right to appoint another person in place of Debenture Director so appointed who resigns or otherwise vacate his office. The trust deed may contain such ancillary provisions as may be arranged between the Company and the trustees and all such provisions shall have effect notwithstanding any of the other provisions herein contained. The Debenture Director shall be entitled to the same rights and privileges and be subject to the same obligations as any other Director of the Company. The Board of Directors of the Company shall have no power to remove from such office, any person so appointed and to appoint a person in his place. Debenture Director.
146. The Board of Directors may appoint a person, not being a person holding any alternate directorship for any other director in the Company, to act as an alternate director for a Director during his absence for a period of not less than three (3) months from India. Appointment of Alternate Directors.
- No person shall be appointed as an Alternate Director for an Independent Director unless he is qualified to be appointed as an Independent Director under the provisions of the Act.
- An Alternate Director shall not hold office for a period longer than that permissible to the Director in whose place he has been appointed and shall vacate the office if and when the Director in whose place he has been appointed returns to India.
147. Subject to the provisions of the Act, any casual vacancy occurring for the office of a Director whose period of office is liable to determine by retirement by rotation may be filled up by the Directors at a meeting of the Board. Any person so appointed shall hold office till such time, the original directors would have held office, if the vacancy had not occurred. Casual Vacancy.
148. Subject to the provisions of the Act, the Director shall have power at any time and from time to time to appoint a person or persons as Additional Director or Directors. Provided that any person who fails to get appointed at a General Meeting, shall not be eligible for appointment as an Additional Director. Appointment of Additional Directors.
149. Such Additional Director shall hold office only up to the date of the next Annual General Meeting of the Company or the last date on which the annual general meeting should have been held, whichever is earlier, but shall be eligible for re-election at that meeting as a Director, provided that the number of Directors and the Additional Director together, shall not exceed the maximum strength fixed by Tenure of office of Additional Director

the Articles.

150. The Company shall appoint such number of directors as Independent Directors as may be required under the provisions of the Act and rules thereunder, if applicable. The candidates to be appointed as Independent Director shall hold such qualifications and shall comply with such conditions as may be prescribed under the Act. Appointment of Independent Directors.
151. The Company shall appoint such number of women directors as may be required under the provisions of the Act and rules made thereunder. Appointment of Women Directors
152. A Director of the Company shall not be bound to hold any qualification shares. Qualification Shares.
153. Subject to the provisions of the Act and schedules made there under, the remuneration payable to the Director of the Company shall be as hereinafter provided. Remuneration of Directors.
- (1) The fees payable to a Director for attending a meeting of the Board or a committee of the Board or a General Meeting (if permitted) shall be decided by the Board of Directors from time to time within the maximum limits of such fees that may be prescribed under relevant provisions of the Act, or if, not so prescribed in such manner as the Directors may determine from time to time in conformity with the provisions of law. Subject to the provisions of Section 197 and Schedule V to the Act, the Directors may be paid such further remuneration either on the basis of percentage of the net profits of the Company or otherwise, as the Company in General Meeting shall from time to time determine, and such additional remuneration and further remuneration shall be divided amongst the Directors in such proportion and manner as the Board may from time to time determine. Provided that the total Managerial Remuneration shall not exceed the overall maximum remuneration as may be prescribed under the Act.
- (2) The Board of Directors may in addition allow and pay to any Director who is not a *bona fide* resident of the place where a meeting of the Board or Committee or a General Meeting of the Company is held, and who shall come to that place for the purpose of attending the meeting, such sum as the Board may consider fair compensation for his travelling, hotel, boarding, lodging and other expenses incurred in attending or returning from meetings of the Board of Directors, or any Committee thereof or General Meetings of the Company.
- (3) Subject to the limitations provided by the Act and this Article, if any Director shall be called upon to go or reside out of his usual place or residence on the Company's business or otherwise perform extra service outside the scope of his ordinary duties, the Board may arrange for such Director such special remuneration for such service either by way of salary, commission or the payment of stated sum of money as they shall think fit, in addition to or in substitution of his remuneration above provided, and all the Directors shall be entitled to be paid or reimbursed or repaid any travelling, hotel and other expenses incurred or to be incurred in connection with the business of the Company and also to be reimbursed with all fees for filling all documents which they may be required to file under the provisions of the Act.
154. a) The Board of Directors, may from time to time appoint one or more of their body to be a Managing Director or a Whole-time Director of the Company either for a fixed term not exceeding five (5) years for which he or they is or are to hold such office on terms and conditions as they may deem fit and delegate such power to him as they may deem proper and from time to time remove or dismiss him or them from office and appoint another in his/their place, in terms of provisions of the Act and rules made thereunder. Appointment of and Remuneration payable to Managing Director and/or Whole-time Director

- b) The Board may fix the remuneration of such Managing Directors and Whole-time Directors, whether by way of salary or commission or by conferring a right to participate in the profits of the Company or by combination of any of the above in terms of provisions of the Act, rules made thereunder and SEBI Regulations.

155. The continuing Directors may act notwithstanding any vacancy in their body but subject to the provisions of the Act, if the number falls below the minimum number above fixed and notwithstanding the absence of a quorum, the Directors may act for the purposes of filling up vacancies or for summoning a General Meeting of the Company. Directors may act notwithstanding vacancy.
156. (1) Subject to the provisions of Section 188 of the Act, no Director shall be disqualified by his office from contracting with the Company for any purpose and in any capacity whatsoever including either as vendor, purchaser, agent, broker, underwriter of Shares and Debentures of the Company or otherwise, nor shall any such contract, or any contract or arrangement entered into by or on behalf of the Company, in which any Director shall be in any way interested be avoided, nor shall any Director so contracting or being so interested be liable to account to the Company for any profit realised by any such contract or arrangement by reason only of such Director holding that office, or of the fiduciary relationship thereby established, but it is hereby declared that nature of his interest must be disclosed by him as provided hereunder. Directors may contract with Company.
- (2) Every Director who is in any way whether directly or indirectly concerned or interested in any contract or arrangement or proposed contract or arrangement entered into or to be entered into by or on behalf of the Company as prescribed under section 184 of the Act shall disclose the nature of his concern or interest at a meeting of the Board of Directors or as provided in these Articles hereof and shall not participate in such meetings. Disclosure of interest.
- (a) In the case of a proposed contract or arrangement, the disclosure required to be made by a Director under sub-clause (2) above shall be made at the meeting of the Board at which the question of entering into the contract or arrangement is first taken into consideration or if the Director was not at the date of the meeting, concerned or interested in the proposed contract or arrangement at the first, meeting of the Board after the Director becomes so concerned or interested.
- (b) In the ease of any other contract arrangement, the required disclosure shall he made at the first meeting of the Board held alter the Director becomes concerned or interested in the contract or arrangement.
- (3) For the purpose of this Article, a general notice given to the Board of Directors by a Director to the effect that he is a Director or Member of a specified body corporate or is a Member of a specified firm and is to be regarded as concerned or interested in any contract or arrangement which may after the date of the notice be entered into with that body corporate or firm sail be deemed to be sufficient disclosure of such concern or interest in relation to any contract or arrangement so made. Such general notice shall expire at the end of the financial year in which it is given but may be renewed for a further period of one financial year at a time by a fresh notice given in the last month of the financial year in which it would have otherwise expired. The General Notice as aforesaid and any renewal thereof shall be given at a meeting of the Board of Directors or the Director concerned shall take reasonable steps to secure that it is brought up and read at the first meeting. General Notice of interest.

of the Board after it is given.

- (4) A Director shall not take part in the discussion of or vote on any contract or arrangement entered into, or to be entered into by or on behalf of the Company, if he is in any way directly or indirectly, concerned or interested in the contract or arrangement nor shall his presence count for the purpose of forming a quorum at the time of any such discussion or vote, and if he does vote, his vote shall be void. This prohibition shall not apply to (a) any contract of indemnity against any loss which a director suffers by reason of becoming or being surety for the Company; or (b) any contract or arrangement entered into by the Company with (a) a body corporate in which such director or such director in association with any other director, holds not more than two per cent. shareholding of that body corporate, or is not a promoter, manager, Chief Executive Officer of that body corporate; or (b) a firm or other entity in which, such director is not a partner, owner or member, as the case may be.

157. (1) The Company shall keep one or more Registers in accordance with the provisions of the Act, in which shall be entered separately, particulars of all contracts or arrangements in which the Directors interested. The Registers shall include details of the contracts and name of parties and such other details as may be required under the prevailing provisions of the Act. Register of Contracts in which Directors are interested
- (2) The Register aforesaid shall also specify, in relation to each Director of the Company, the names of the firms and bodies corporate of which notice has been given by him General Notice of interest.
- (3) The Registers as aforesaid shall be kept at the registered office of the Company and they shall be open to inspection at such office during business hours and extracts may be taken therefrom and copies thereof as may be required by any Member of the Company shall be furnished by the Company to such extent, in such manner, and on payment of such fees as prescribed under the Act and rules made thereunder.
158. A Director of the Company may be or may become a Director of any Company promoted by the Company, or in which it may be interested as vendor, Member or otherwise and subject to the provisions of the Act and these Articles. Directors may be Directors of Companies promoted by the Company.
159. No Director of the Company and no related party shall hold any office or place of profit under the Company, or any subsidiary of the Company except as provided in and subject to the provisions of section 188 of the Act and rules made there under. Holding of Office of profits by Directors.

DIRECTORS REMOVAL AND APPOINTMENT BY MEMBERS

160. At a General Meeting of the Company, a motion shall not be made for the appointment of two or more persons as Directors of the Company by a single resolution. A resolution moved in contravention of this Article shall be void whether or not objection so moved is passed no provision for the automatic reappointment of retiring Directors by virtue of these Articles or the Act in default of another appointment shall apply. Individual Resolution for Directors appointment.
161. (1) The Company may, subject to the provisions of the Act and these Articles remove any Director before the expiry of his period of office. Removal of Directors

- (2) Special notice shall be given, of any resolution to remove a Director under this Article or to appoint some other person in place of a Director so removed at the meeting at which he is removed.
- (3) On receipt of notice of any such resolution to remove a Director under this Article, the Company shall forthwith send a copy thereof to the Director concerned and the Director (whether or not he is a Member of the Company) shall be entitled to be heard on the resolution at the meeting.
- (4) Where notice is given of a resolution to remove a Director under this Article and the Director concerned makes with respect thereto, representation in writing to the Company (not exceeding a reasonable length) and requests its notification to the Members of the Company, the Company shall unless the representation is received by it too late for it to do so; (a) in the notice of the resolution given to the Members of the Company state the fact of the representation having being made; and (b) send a copy of the representation to every Member of the Company and if a copy of the representation is not sent as aforesaid because it has been received too late or because of the Company's default, the Director may (without prejudice to his right to be heard orally) require that the representation shall be read out at the meeting. Provided that copies of the representation shall not be read out at the meeting if, on the application either of the Company or of any other person who claims to be aggrieved, the Court is satisfied that the rights conferred by this sub-clause are being abused to secure needless publicity for defamatory matter.
- (5) A vacancy created by the removal of Director under this Article may, if he had been appointed by the Company in General Meeting or by the Board be filled by the appointment of another Director in his place by the meeting at which he is removed provided special notice of the intended appointment has been given under sub-clause (2) of this Article. A Director so appointed shall hold office until the date up to which his predecessor would have held office if he had not been removed as aforesaid.
- (6) If the vacancy is not filled under Sub-Clause (5) it may be filled as casual vacancy in accordance with the provisions of the Act and all the provisions of the Act and the rules thereunder shall apply accordingly.
- (7) A Director who was removed from office under this Article shall not be reappointed as Director by the Board of Directors.
- (8) Nothing contained in this Article shall be taken:
 - (a) as depriving a person removed thereunder of any compensation or damages payable to him in respect of the termination of his appointment as Director as per the terms of contract or terms of his appointment as director, or of any other appointment terminating with that as director or; or
 - (b) as derogating from any power of the Company to remove a Director, which may exist apart from this Article.

MEETINGS OF DIRECTORS

162. The Directors may meet together as a Board from time to time and shall hold a minimum number of four (4) meetings of its Board of Directors every year in such a manner that not more than one hundred and twenty days shall intervene between two consecutive meetings of the Board. Meeting of Directors

- | | | |
|------|---|---|
| 163. | The participation of directors in a meeting of the Board or a Committee thereof, may be either in person or through video conferencing or audio visual means or teleconferencing, as may be permitted by the Rules or permitted under law. | Meetings by electronic mode |
| 164. | A Director may at any time and the Secretary or where there is no Company Secretary, any person authorised by the Board in this behalf, upon the request of a Director shall convene a meeting of the Directors. Notice of not less than seven (7) days shall be issued in respect of every meeting of the Board in writing to every Director for the time being in India and at his usual address registered with the Company and to every other Director as may be required under relevant provisions of the Act. Provided that a meeting of the Board may be called at shorter notice to transact urgent business subject to the condition that at least one independent director, if any, shall be present at such meeting of the Board. Provided further that in case of absence of independent directors from such a meeting of the Board, decisions taken at such a meeting shall be circulated to all the Directors and shall be final only on ratification thereof by at least one independent director, if any. | When meetings to be convened and notice thereof. |
| 165. | Subject to the provisions of the Act, the quorum for a meeting of the Board of Directors shall be one third of the total strength of the Board of Directors (excluding Directors, if any, whose places are vacant at that time, and any fraction contained that one-third being rounded off as to the next one) or two Directors including at least one independent director, if appointed, present in person or attending through any type of electronic mode like video conferencing, whichever is higher, provided that where at any time the number of interested Directors exceeds, that is to say, the number of Directors, who are not interested and are present at the meeting, not being less than two, shall be quorum during such meeting. A meeting of the Directors for the time being at which quorum is present shall be competent to exercise all or any of the authorities powers and discretion by or under the Act or the Articles of the Company, for the time being vested in or exercisable by the Board of Directors generally. | Quorum. |
| 166. | If a meeting of the Board of Directors cannot be held for want of quorum, then the meeting shall stand adjourned until such date and at such time and place as the Chairman may decide and in default of that date, to the same day in the next week at the same time and place or if that day is a public holiday till the next succeeding day which is not a public holiday, at the same time and place or to such day, time and place as the Directors present may determine. | Adjournment of meeting for want of quorum. |
| 167. | The Board shall elect one of its Members to be the Chairman of the Board and may also elect one of its Members to be Vice-Chairman of the Board and the Board shall determine the period for which each of them is to hold such office. | Appointment of Chairman and Vice Chairman. |
| 168. | All meetings of the Directors shall be presided over by the Chairman, if present, but if at any meeting of the Directors the Chairman be not present at the time appointed for holding the same, then in that case, the Vice-Chairman if present, shall be the Chairman of such meeting, and if the Vice-Chairman be not present, then in that case, the Directors shall elect one of their Member then present to preside at the meeting. | Who to preside at meeting at board. |
| 169. | A meeting of the Board at which a quorum is present, shall be competent to exercise all or any of the authorities, powers and discretions by of under these articles for the time being vested in or exercisable by the Board. | Power of Quorum |
| 170. | Questions arising at any meeting of the Board shall be decided by a majority of votes, and in case of an equality of votes, the Chairman of the meeting, whether the Chairman appointed by virtue of these Articles or the Director presiding at such meeting shall have second or casting vote. | Questions at Board meeting how to be decided (casting vote) |

171. Subject to the provisions of the Act and these Articles, the Directors may delegate any of their powers to a committee consisting of such Member or Members of their body, as they think fit and they may from time to time revoke and discharge any such committee either wholly or in part and either as to person or purposes, but every committee so formed shall, in the exercise of the powers so delegated to it conform to any regulations that may from time to time be imposed on it by the Directors. All acts done by any such committee in conformity with such regulations and in fulfillment of the purpose of their appointment but not otherwise shall have the like force and effect as it done by the Board. Subject to the provisions of the Act the Board may from time to time fix the remuneration to be paid to any Member or Members of their body constituting a committee appointed by the Board in terms of these Articles and may pay the same.
- Directors may appoint committee.
- The Company shall constitute the following Committees as and when required under provisions of the Act:
- a) Corporate Social Responsibility Committee as may be required under Section 135 of the Act.
 - b) Audit Committee as may be required under Section 177 of the Act.
 - c) Nomination and Remuneration Committee and Stakeholders Relationship Committee as required under Section 178 of the Act.
- The composition, quorum and duties of the aforesaid committees shall be as may be prescribed under the Act and rules made there under.
172. The meetings and proceedings of any such committee consisting of two or more Directors shall be governed by the provisions herein contained in respect of the meetings and proceedings of the Directors, so far as the same are applicable thereto and are not superseded by the provisions of the Act.
- Meeting of Committees how to be convened.
173. (1) Subject to the provisions of Section 175 of the Act, a resolution passed by circular without a meeting of the Board or a committee of the Board appointed under these Articles, shall subject to the provisions of sub clause (2) hereof, and the Act, be as valid and effectual as resolution duly passed at meeting of the Board or of a committee duly called and held.
- Resolution by Circular.
- (2) A resolution shall be deemed to have been duly passed by the Board or by a committee thereof by circulation, if the resolution has been circulated in draft together with the necessary papers, if any, to all the Directors or to all the Members of the Committee then in India (not being less in number than the quorum requisite for a meeting of the Board or of the Committee thereof as the case may be) and to all other Directors or Members of the Committee at their usual address in India by hand delivery, post, courier or prescribed electronic mode and has been approved by majority of the Directors or Members of the Committee as are entitled to vote on the Resolution.
- (3) Subject to the provisions of the Act, statement signed by the Managing Director or other person authorized in that behalf by the Board of Directors certifying the absence from India of any Directors shall for the purposes of this Article be conclusive evidence of the facts stated therein.
174. Subject to the provisions of the Act and these Articles, all acts done by any meeting of the Directors or by a Committee of Directors or by any person acting as a Director shall, notwithstanding that it shall afterwards be discovered that there was some defect in the appointment of such Director or person acting as aforesaid or that they or any of them were or was disqualified, or had vacated
- Act of Board or Committee valid notwithstanding defect in appointment.

office or that the appointment of any of them had been terminated by virtue of any provisions contained in the Act or in these Articles, may be as valid as if every such person had been duly appointed and was qualified to be a Director, provided that nothing in this Article shall be deemed to give validity to acts done by the Directors after their appointment had been shown to the Company to be invalid or to have terminated.

175. The Company shall cause minutes of the meeting of the Board of Directors and of Committees of the Board to be duly entered in a book or books provided for the purpose in accordance with the relevant provisions of Section 118 of the Act. The minutes shall contain a fair and correct summary of the proceedings of the meeting including the following:
- Minutes of proceedings of Board of Directors and Committees to be kept.
- (i) The names of the Directors present at the meeting of the Board of Directors or any Committee thereof;
 - (ii) All orders made by the Board of Directors;
 - (iii) All resolutions and proceedings of meetings of the Board of Directors and Committees thereof;
 - (iv) In the case of each resolution passed at a meeting of the Board of Directors or Committee thereof the names of Directors if any, dissenting from or not concurring in the resolution.

There shall not be included in the minutes, any matter which, in the opinion of the Chairman of the meeting,—

- (a) is or could reasonably be regarded as defamatory of any person; or
- (b) is irrelevant or immaterial to the proceedings; or
- (c) is detrimental to the interests of the company.

The Chairman shall exercise absolute discretion in regard to the inclusion or non-inclusion of any matter in the minutes on the grounds specified in (a) to (c) above.

176. All such minutes shall be signed by the Chairman of the Concerned meeting or by the person who shall preside as Chairman at the next succeeding meeting and all the minutes purported to be so signed shall for all actual purposes whatsoever be prima facie evidence of the actual passing of the resolution recorded and the actual and regular transaction or occurrence of the proceedings so recorded and of the regularity of the meetings at which the same shall appear to have taken place.
- By whom minutes to be signed and the effect of minutes recorded.
177. (1) Subject to the provisions of the Act and these Articles, the Board of Directors of the Company shall be entitled to exercise all such powers and to do all such acts and things as the Company is authorized to exercise, and do. Provided that the Board shall not exercise any power or do any act or thing which is directed or required whether by the Act or any other Act or by the Memorandum or these Articles or otherwise to be exercised or done by the Company in General Meeting. Provided further that in exercising any such act or thing the Board shall be subject to the provisions contained in that behalf in the Act or in the Memorandum or in these Articles or in any regulations not inconsistent therewith duly made thereunder including regulations made by the Company in General Meeting.
- General Powers of Directors.
- (2) No regulation made by the Company in General Meeting shall invalidate any prior act of the Board which would have been valid if that regulation had not

- been made.
178. Subject to the provisions of the Act, the Board may from time to time, provide for management of affairs of the Company outside India (or any specified locality in India) in such manner as it shall think fit and the provisions contained in the four next paragraphs shall be without prejudice to the general powers conferred by this paragraph:
- Local Management
- (1) From time to time and at any time to establish any Local Board for managing any of the affairs of the Company in any specified locality in India or elsewhere and to appoint any person to be members of any such Local Board, or any managers or agents and to fix their remuneration. Local Board.
- (2) Subject to the provisions of the Act and the Articles, and at any time to delegate to any such Local Board, or any member or members thereof or any managers or agents so appointed any of the powers, authorities and discretions for the time being vested in the Board of Directors and to authorize the members for the time being of any such Local Board, or any of them to fill up any vacancies therein and to act notwithstanding such vacancies therein and any such appointment or delegation under this Article, may be made on such terms and subject to such conditions as the Board of Directors may think fit and the Board of Directors may at any time remove any persons so appointed and may annul or vary any such delegation. Delegation
- (3) At any time and from time to time by a power of attorney authorize any person or person to be the attorney or attorneys of the Company, for such purpose and with such powers, authorities and discretions (not exceeding those vested in or exercisable by the Board of Directors under these presents and excluding the power which may be exercised only by the Board of Directors at a meeting of the Board under the Act or the Articles of by the Company in General Meeting) and for such period and subject to such conditions as the Board of Directors may from time to time think fit and any such appointment may (if the Board of Directors think fit) be made in favour of the member or any of the members of any Local Board, established as aforesaid or in favour of any Company, or the members, directors, nominees or managers of any Company or firm or otherwise in favour of any body of persons whether nominated directly or indirectly by the Board of Directors and any such power of attorney may contain such powers for the protection or convenience of persons dealing with such attorneys as the Board of Directors may think fit, and may contain powers enabling any such delegate or attorneys as aforesaid to sub-delegate all or any of the powers and authorities for the time being vested in them. Power of Attorney.
- (4) Any such delegates or Attorneys aforesaid may be authorized by the Board to sub-delegate all or any of the powers, authorities and discretions for the time being vested in them. Sub-delegation

KEY MANAGERIAL PERSONS

179. Subject to the provisions of Section 203 of the Act and rules made thereunder and/or these Articles, as applicable, Power to appoint Key Managerial Persons.
- (i) a chief executive officer, manager, company secretary or chief financial officer may be appointed by the Board for such term, at such remuneration and upon such conditions as it may think fit; and any chief executive officer, manager, company secretary or chief financial officer so appointed may be removed by means of a resolution of the Board;
- (ii) A Director may be appointed as chief executive officer, manager, company secretary or chief financial officer.

- | | | |
|------|---|--|
| 180. | Subject to the provisions of the Act and these Articles, the Managing Director or Managing Directors or Whole-time Director or Whole-time Directors shall not while he or they continue to hold that office, be subject to retirement by rotation but he or they shall, subject to the provisions of any contract between him or them and the Company be subject to the same provisions as to resignation and removal as the other Director of the Company and he or they shall <i>ipso facto</i> and immediately cease to be Managing Director or Managing Directors or Whole time Director or Whole time Directors if he or they cease to hold the office of Director from any cause. | What provisions the Managing and Whole time Directors shall be subject to. |
| 181. | The remuneration of the Managing Director or Managing Directors or Whole-time Director or Whole-time Directors (subject to provisions of the Section 197 and Schedule V of the Act) shall be in accordance with the terms of his or their contract with the Company. | Remuneration of Managing Director and whole time Director |
| 182. | Subject to the provisions of the Act and to the terms of any Resolution of the Company in General Meeting or of any Resolution of the Board and to the term of any contract with him or them, the Managing Director or Managing Directors shall have substantial powers of management subject to the superintendence, control and direction of the Board of Directors. | Power and Duties of Managing Director. |

REGISTERS, BOOKS AND DOCUMENTS

- | | | |
|------|---|--------------------------------|
| 183. | (1) The Company shall maintain all Registers, books and documents as required by the Act or these Articles including the following, namely :

<ul style="list-style-type: none"> (a) Register of Members; (b) Register of Debenture Holders; (c) Register of other Security Holders; (d) Register of Securities/ Shares bought back; (e) Register of Charges; (f) Register of Directors, key managerial personnel; (g) Register of loans, investments, guarantees and securities; (h) Register of Investments not held by the Company in its own name; (i) Register of contracts, arrangements in which the directors are interested; (j) Books of Accounts; (k) All returns and forms filed with the Registrar of Companies; (l) Such other statutory registers as may be prescribed under the relevant and applicable provisions of the Act, from time to time. | Registers Books and Documents. |
| | (2) The said Registers, books and documents shall be maintained in conformity with the applicable provisions of the Act and these Articles and shall be kept open for inspection for such persons as may be entitled thereto respectively under the Act and these Articles on such days and during such business hours as may in that behalf be determined in accordance with the provisions of the Act these Articles and extracts therefrom shall be supplied to those persons entitled thereto in accordance with the provisions of the Act and these Articles and on payment of such charges as prescribed in the Act. | |
| | (3) The Company may keep a Foreign Register of Members in accordance with the provisions of the Act. The Directors may from time to time, make such provisions as they may think fit in respect of the keeping of the branch Registers of Members and/or Debenture holders. | Foreign register |

THE SEAL

184. The Board may have a Seal for the purpose of the Company, and shall have the power from time to time to destroy the same and substitute a new seal in lieu thereof, and the Directors shall provide for the safe custody of the Seal for the time being, and the Seal shall never be used except by or under the authority of the Directors or a committee of Directors previously given. Seal of the Company.
185. The Seal of the Company shall not be affixed to any instrument except by the authority of a resolution of the Board or a Committee of the Board authorized by it in that behalf, and save and except as provided in these Articles, at least one (1) Director shall sign such instrument to which the Seal is affixed and countersigned by the Secretary or such other person as the Board may appoint for the purpose. Deeds how executed.
186. The Company shall also be at liberty to use an official Seal in any territory, district or place outside India. Seal abroad.

DIVIDENDS

187. The company in general meeting may declare dividends, but no dividend shall exceed the amount recommended by the Board. Division of profits.
188. Subject to the provisions of Section 123 of the Act, the Board may from time to time pay to the Members, such interim dividends during the financial year out of the surplus in the profit and loss account and out of profits of the financial year in which such interim dividend is sought to be declared by the Company. Interim Dividend.
189. (i) The Board may, before recommending any dividend, set aside out of the profits of the Company, such sums as it thinks fit as a reserve or reserves which shall, at the discretion of the Board, be applicable for any purpose to which the profits of the Company may be properly applied, including provision for meeting contingencies or for equalizing dividends; and pending such application, may, at the like discretion, either be employed in the business of the company or be invested in such investments (other than shares of the company) as the Board may, from time to time, think fit.
- (ii) The Board may also carry forward any profits which it may consider necessary not to divide, without setting them aside as a reserve.
190. (i) Subject to the rights of persons, if any, entitled to Shares with special rights as to dividends, all dividends shall be declared and paid according to the amounts paid or credited as paid on the Shares in respect whereof the dividend is paid, but if and so long as nothing is paid upon any of the Shares in the Company, dividends may be declared and paid according to the amounts of the Shares. How profits shall be divisible
- (ii) No amount paid or credited as paid on a Share in advance of calls shall be treated for the purposes of this Article as paid on the Share.
- (iii) All dividends shall be apportioned and paid proportionately to the amounts paid or credited as paid on the shares during any portion or portions of the period in respect of which the dividend is paid; but if any share is issued on terms providing that it shall rank for dividend as from a particular date such share shall rank for dividend accordingly.
191. The Board may deduct from any dividend payable to any Member, all sums of money, if any, presently payable by him to the Company on account of calls or otherwise in relation to the Shares of the Company. Amounts may be deducted

192.	Any general meeting declaring a dividend may make a call on the members for such amount as the meeting fixes, but so that the call on each member shall not exceed the dividend, payable to him, and so that the call be made payable at the same time as the dividend and the dividend may, if so arranged between the company and the members, be-set off against the calls.	Dividend and call together
193.	Subject to Section 123 to 126 of the Act, no dividend shall be payable except in cash; Provided that nothing in the foregoing shall be deemed to prohibit the capitalisation of profits or reserves of the Company for the purposes of issuing fully paid up bonus shares or paying up any amount for the time being paid-up on the shares held by the members of the Company.	Dividends payable in cash
194.	No dividend shall be paid in respect of any share except to the members registered in respect of such share or to his order or to his bankers. A transfer of shares shall not pass the rights to any dividend declared thereon before registration of the transfer by the company.	Right to dividend
195.	(i) Any dividend, interest or other monies payable in cash in respect of Shares may be paid by cheque or warrant sent through the post directed to the registered address of the holder or, in the case of joint holders, to the registered address of that one of the joint holders who is first named on the register of Members, or to such person and to such address as the holder or joint holders may in writing direct. (ii) Every such cheque or warrant shall be made payable to the order of the person to whom it is sent.	Payment by Post
196.	Any one of two or more joint holders of a Share may give effective receipts for any dividends, bonuses or other monies payable in respect of such Share.	Members registered jointly
197.	Notice of any dividend that may have been declared shall be given to the persons entitled to share therein in the manner mentioned in the Act.	Notice of dividends
198.	No dividend shall bear interest against the Company.	Interest on Dividends
199.	No unclaimed dividend shall be forfeited by the Board and the unpaid and/ or unclaimed dividend shall be regulated in accordance with the provisions of the Act.	Unclaimed Dividends

RESERVES AND CAPITALISATION

200.	The Board may, before recommending any dividend set aside out of the profits of the Company such sums as it thinks proper as a reserve or reserves which shall at the discretion of the Board, be applicable for any purpose to which the profits of the Company may be properly applied and pending such application may, at the like discretion, either be employed in the business of the Company or as may be permitted by the Act, applied for payment of dividend or be invested in such investments and in such manner or as may be permitted by the Act and as the Board may from time to time think fit.	Reserves
201.	(i) The Company in General Meeting may, upon the recommendation of the Board, resolve: (a) that it is desirable to capitalize any part of the amount for the time being standing to the credit of any of the Company's reserve accounts, or to the credit of the profit and loss account, or otherwise available for	Capitalization

distribution; and

- (b) that such sum be accordingly set free for distribution in the manner specified in sub-clause (ii) below, amongst the Members who would have been entitled thereto, if distributed by way of dividend and in the same proportions.
- (ii) The sum aforesaid shall not be paid in cash but shall be applied, either in or towards—
 - (A) paying up any amounts for the time being unpaid on any Shares held by such Members respectively;
 - (B) paying up in full, unissued Shares of the Company to be allotted and distributed, credited as fully Paid-up, to and amongst such Members in the proportions aforesaid;
 - (C) partly in the way specified in sub-clause (A) and partly in that specified in sub-clause (B);
 - (D) A securities premium account and a capital redemption reserve account may, for the purposes of this Article, be applied in the paying up of unissued Shares to be issued to Members of the Company as fully paid bonus Shares;
 - (E) The Board shall give effect to the resolution passed by the Company in pursuance of this Article.

202. A general meeting may resolve that any surplus moneys arising from the realization of the capital assets of the Company or any investments representing the same or any other undistributed profits of the Company not subject to charge for income tax, be distributed amongst the members on the footing that they receive the same as capital. Surplus money

203. (i) Whenever such a resolution as aforesaid shall have been passed, the Board shall— Fractional certificates
- (a) make all appropriations and applications of the undivided profits resolved to be capitalized thereby, and all allotments and issues of fully paid Shares, if any; and
 - (b) generally do all acts and things required to give effect thereto.
- (ii) The Board shall have power—
- (a) to make such provisions, by the issue of fractional certificates or by payment in cash or otherwise as it thinks fit, for the case of Shares becoming distributable in fractions; and
 - (b) to authorize any person to enter, on behalf of all the Members entitled thereto, into an agreement with the Company providing for the allotment to them respectively, credited as fully paid-up, of any further Shares to which they may be entitled upon such capitalization, or as the case may require, for the payment by the Company on their behalf, by the application thereto of their respective proportions of profits resolved to be capitalized, of the amount or any part of the amounts remaining unpaid on their existing shares;

- (iii) Any agreement made under such authority shall be effective and binding on such Members.

ACCOUNTS

204. (1) The Company shall prepare and keep at its registered office books of account and other relevant books and papers and financial statement for every financial year which give a true and fair view of the state of the affairs of the Company, including that of its branch office or offices, if any, and explain the transactions effected both at the registered office and its branches:
- Books of Account to be kept.
- Provided that all or any of the books of account aforesaid may be kept at such other place in India as the Board of Directors may decide, and when the Board of Directors may decide the Company shall, within seven days of the decision, file with the Registrar a notice in writing giving the full address of that other place.
- (2) If the Company shall have branch office, whether in or outside India, proper books of account relating to the transactions effected at the office shall be kept at that office, and proper summarized returns, made up to date at intervals of not more than three months, shall be sent by the branch office of the Company to its Registered Office or other place in India, as the Board thinks fit where the main books of the Company are kept.
- (3) All the aforesaid books shall give a true and fair picture of the financial position of the Company.
205. The Board shall from time to time determine whether and to what extent and at what times and places and under what conditions and regulations the accounts and books of the Company or, any of them, shall be open to the inspection of Members not being Directors and no Member (not being Director) shall have any right of inspecting any account or books or documents of the Company except as conferred by law or authorized by the Company in General Meeting.
- Inspection by Member of accounts and books of the Company.
206. At every Annual General Meeting the Board shall lay before the Company, financial statements along with the reports thereto, prepared in accordance with the provisions of the Act and such financial statements shall comply with the requirements of the Act so far as they are applicable to the Company.
- Financial Statements to be furnished at General Meeting.
207. There shall be attached to every Financial Statements laid before the Company a Report by the Board of Directors complying with the provision of the Act.
- Board Report.
208. The Company shall comply with the requirements of the Act and make necessary arrangement for compliance of Section 136 of the Act.
- Right of Members to copies of Financial Statements
209. The Company shall comply with the provisions of the Act as to filing the copies of the Balance Sheet and Statement of Profit and Loss and the documents required to be annexed thereto, with the Registrar.
- Filing of Balance sheet with Registrar

ANNUAL RETURNS

210. The Company shall prepare and file the requisite annual returns in accordance with the provisions of the Act.
- Annual Return.

AUDIT

- | | | |
|------|---|---|
| 211. | Once, at least in every year, the books of account of the Company shall be examined by one or more auditors in accordance with the relevant provisions contained in that behalf in the Act and the rules thereunder. | Accounts to be Audited. |
| 212. | The appointment qualifications, powers, rights, duties and remuneration of the auditors shall be regulated by and in accordance with the relevant provisions of the Act. | Appointment powers, etc. of Auditors. |
| 213. | All notice of any other communication relating to any general meeting of the Company which any member of the Company is entitled to, shall also be forwarded to the Auditor of the Company and the Auditor shall be entitled to attend any general meeting and shall have the right to be heard at such meeting on any part of the business which concerns him as an Auditor. | Right of Auditor to attend general meetings |
| 214. | Every account when audited and approved by the Members in a General Meeting, shall be conclusive. | Accounts when conclusive |

DOCUMENTS AND SERVICE OF DOCUMENTS

- | | | |
|------|--|--|
| 215. | <p>(1) A document (which expression for this purpose shall be deemed to include and shall include any summons, notice, requisition, process, order, judgment or any other document in relation to or in the winding up of the Company) may be served or sent by the Company or to any Member either personally or by sending it by post to him at his registered address or (if he has no registered address in India) at the address, if any within India supplied by him to the Company or by such electronic mode as may be prescribed under the Act.</p> <p>(2) Where a document is sent by post:</p> <p style="margin-left: 20px;">(a) service thereof shall be deemed to be affected by properly addressing, preparing and posting a letter containing the notice, provided that where a Member, has intimated to the Company in advance that documents should be sent to him under certificate of posting or by registered post with or without acknowledgement due and has deposited with the Company, a sum sufficient to defray the expenses of doing so, service of the document shall not be deemed to be effected, unless it is sent in the manner intimated by the Member; and</p> <p style="margin-left: 20px;">(b) Such service shall be deemed to have been effected :</p> <p style="margin-left: 40px;">(i) in the case of a notice of a meeting, at the expiration of forty eight (48) hours after the letter containing the notice is posted; and</p> <p style="margin-left: 40px;">(ii) in any other case, at the time at which the letter would be delivered in the ordinary course of post.</p> | Manner of Service. |
| 216. | If a Member has no registered address in India and has supplied to the Company an address within India for the giving of notice to him, a document advertised in a newspaper circulating in the neighborhood of the Registered Office of the Company shall be deemed to be duly served on him on the day on which the advertisement appears. | Service on Members having no registered address. |
| 217. | All documents may be served by the Company on the persons entitled to a share in consequence of the death or insolvency of a Member by sending it through the post in a prepaid letter addressed to them by name or by the title of representative of the deceased or Assignee of the insolvent or by any like description at the address (if | Service on person acquiring shares on death or insolvency of Member. |

any) in India supplied for the purpose by the persons claiming to be so entitled or (until such as address has been so supplied) by serving the document in any manner been so supplied) by serving the documents in any manner in which the same might have been served if the death or insolvency has not occurred.

218. Subject to the provisions of the Act and these Articles, notices of the General Meetings shall be given; Persons entitled to notice of general meetings.
- (i) to all Members of the Company as provided and in the manner authorized by these Articles;
 - (ii) to the persons entitled to a Share in consequence of the death or insolvency of a Member;
 - (iii) to the Directors of the Company;
 - (iv) to the Auditor or Auditors for the time being of the Company, in any manner authorized by these Articles.
 - (iv) to such other persons as may be entitle to receive such notice under the provisions of the Act or any other law for the time being in force, in a manner authorized by these Articles.
219. Subject to the provisions of the Act any document required to be served or sent by the Company on or to the Members or any of them, and not expressly provided for by these presents shall be deemed to be duly served or sent if advertised once in one daily English and one daily vernacular newspaper circulating in the district in which the registered office of the Company is situated and shall be deemed to have been given on the day on which the advertisement shall first appear. Advertisement.
220. Every person who by operation of a transfer, or other means whatsoever, becomes entitled to any Share, shall be bound by every document in respect of such Share which previously to his name and address being entitled on the Register, has been duly served on or sent to the person from whom he derives his title to such Share. Members and by document given to previous holders.
221. Subject to the provisions of the Act and applicable law, in the event of winding up of the Company, every member of the Company who is not for the time being in New Delhi shall be bound, within eight weeks after the passing of an effective resolution to wind up the Company voluntarily or the making of an order to the winding up of the Company to serve notice in writing on the Company appointing some householders residing in the neighborhood of the office upon whom all summons, notices, process, orders and judgement in relation to or order of the winding-up of the Company may be served, and in default of such nomination, the Liquidator of the Company shall be at liberty, on behalf of such member, to appoint some person, and service upon any such appointee whether appointed by the member of the Liquidator shall be deemed to be good personal service on such member for all purposes, and where the Liquidator makes any such appointment, he shall, with convenient speed, give notice thereof to such member by advertisement in some daily newspaper circulating in the neighborhood of the office or by a registered letter sent by post and addressed to such member at his address as Registered in the Register of Members and such notice shall be deemed to be served on the day on which the advertisement appears or the letter would be delivered in the ordinary course of the post, The provision of this Article shall not prejudice the rights of the Liquidator of the Company to serve any notice or other document in any other manner prescribed by these Articles. Service of process in winding up
222. Any notice to be given by the Company shall be signed by the Managing Director or Secretary or by such Director or officer as the Directors may appoint and such Notice by company and signature

signature may be written or printed or lithographed.

thereto.

223. All notices to be given on the part of the Members to the Company shall be kept at or sent by speed post or by registered post or by any other method provided under the Act, to the registered office of the Company duly addressed to the Secretary of the Company.
- Service of notice by Members.

AUTHENTICATION OF DOCUMENTS

224. Save as otherwise expressly provided in the Act or these Articles, a document or proceedings requiring authentication by the Company may be signed by a Director the Managing Director or an authorized officer of the Company and need not be under its Seal.
- Authentication of documents and proceedings

RECONSTRUCTION

225. On any sale of an undertaking of the Company, the Board or a liquidator on a winding up, may if authorized by a special resolution, accept fully paid or partly paid-up shares, debentures or securities of any other company, whether incorporated in India or not, either then existing or to be formed for the purchase in whole or in part of the property of the Company, and the Board (if the profits of the Company permit) or the liquidator (in a winding up) may distribute such Shares or Securities or any other property of the Company amongst the Members without realization, or vest the same in trustees for them, and any special resolution may provide for the distribution or appropriation of cash, Shares or other Securities, benefit or property otherwise than in accordance with the strict legal rights of the Members or contributories of the Company and for the valuation of such Securities or property at such price and in such manner as the meeting may approve and all holders of shares shall be bound to accept and shall be bound by any valuation or distribution so authorized, and waive all rights in relation thereto, save only in case the Company is proposed to be or is in the course of being wound up, such statutory rights, if any, as are incapable of being waived or excluded by these Articles.
- Reconstruction.
226. If the Company shall be wound up, and the assets available for distribution among the Members as such shall be insufficient to repay the whole of the paid up capital such assets shall be distributed so that as nearly as may be, the losses shall be borne by the Members in proportion to the capital paid up or which ought to have been paid up at the commencement of the winding up on the shares held by them respectively; and if in a winding up the assets available for distribution among the Members shall be more than sufficient to repay the whole of the capital paid up at the commencement of the winding up, the excess shall be distributed among the Members in proportion to the capital paid up at the commencement of the winding up or which ought to have been paid up on the shares held by them respectively. But this Article is to be without prejudice to rights of the holders of Shares issued upon special terms and conditions.
- Distribution of Assets.
227. (1) If the Company shall be wound up, whether voluntarily or otherwise, the liquidators may, with the sanction of a special resolution, but subject to the rights attached to any preference shares capital, divide amongst the contributories, in specie or kind, any part of the assets of the Company and may, with the like sanction of a special resolution, but subject to the rights attached to any preference share capital, divide amongst the contributories, in specie or kind, any part of the assets of the Company and may, with the like sanction, vest any part of the assets of the Company in trustees upon such trusts for the benefit of the contributories or any of them, as the liquidators, with the like sanction shall think fit.
- Distribution of assets in specie or kind.

- (2) If thought expedient any such division may, subject to the provisions of the Act, be otherwise than in accordance with the legal right of the contributories (except where unalterably fixed by the Memorandum of Association) and in particular any class may be given preferential or special rights or may be excluded altogether or in part but in case any such division shall be determined, any contributory who would be prejudiced hereby shall have right to dissent and ancillary rights as if such determination were a special resolution passed in accordance with the relevant provisions of the Act.
- (3) In case any Shares to be divided as aforesaid involve a liability to calls or otherwise any person entitled under such division to any of the said Shares may within ten (10) days after the passing of the special resolution, by notice in writing, intimate to the liquidator to sell his proportion and pay him the net proceeds and the liquidator shall, if practicable, act accordingly.

228. A special resolution sanctioning a sale to any other Company duly passed under the relevant provisions of the Act may, subject to the provisions of the Act, in like manner as aforesaid determined that any Shares or other consideration receivable by the liquidator be distributed amongst the Members otherwise than in accordance with their existing rights and any such determination shall be binding upon all the Members subject to the rights of dissent and consequential rights conferred by the said sanction.

Right of shareholders in case of the Sale.

SECURITY

229. (1) Every director, manager, auditor, trustee, Member of a committee, officer, servant, agent, accountant or other person employed in the business of the Company, shall if so required by the Directors, before entering upon his duties, sign a declaration pledging himself to observe strict secrecy respecting all transaction and affairs of the Company with the customers and the state of the accounts with individuals and in realization thereto and shall by such declaration pledge himself not to reveal any of the matters which may come to his knowledge in the discharge of his duties except when required so to do by the Directors or by law or by the person to whom such matters relate and except so far as may be necessary in order to comply with any of the provisions in these presents contained.

(2) No Member or other person (not being a director) shall be entitled to visit or inspect the Company's premises without the permission of the Directors or the Managing Director or to require discovery of any information respecting any detail of the Company's trading or any matter which is or may be in the nature of a trade secret, mystery of trade, or secret process, which may relate to the conduct of the business of the Company and which in the opinion of the Director or the Managing Director it will be inexpedient in the interest of the Members of the Company to communicate to the public.

Secrecy Clause.

INDEMNITY AND RESPONSIBILITY

230. Every Director, officer, and key managerial personnel of the Company or any Person (whether as Officer of the Company or not) employed by the Company and any Person appointed as the Auditor shall be indemnified out of the assets of the Company against any liability incurred by him in defending any proceedings, whether civil or criminal, in which judgment is given in his favour or in which he is acquitted or in which relief is granted to him by the court or the Tribunal.

Directors and other right to indemnity.

231. Subject to the provisions of the Act, no Director, Managing Director or other officer of the Company shall be liable for the acts, omissions, neglects or defaults of any other Director or officer or for joining in any omission or other act for conformity or for any loss or expenses suffered by the Company through insufficiency or deficiency of title to any property acquired by order of the Directors for or on behalf of the Company or for the insufficiency or deficiency of any security in or upon which any of the monies of the Company shall be invested or for any loss or damage arising from the bankrupt, insolvency, or tortious act of any person, company or corporation, with whom any moneys, securities or effects' shall be entrusted or deposited or for any loss occasioned by any error of judgment or oversight on his part or for any other loss or damages, or misfortune whatever which shall happen in the execution of the duties of his office or in relation thereto, unless the same happens through his own dishonesty. Directors and others not responsible for acts of others.

GENERAL POWER

232. Whenever in the Act, it has been provided that the Company shall have any right privileges or authority or that the Company could carry out any transaction only if the Company is authorized by its articles, then and in that case this Article thereto authorizes and empowers the Company to have such rights, privilege or authority and to carry such transactions as have been permitted by the Act, without there being any specific regulation in that behalf herein provided. General Power.

Name, address, description and occupation of the Subscribers	Signature of Subscriber	Name, address, description, occupation and Signature of the Witness
1. OMESH GOYAL S/o Shri Prem Kumar Goyal Kaithal Road, Pehowa (Haryana) Distt. Kurukshetra Business.	Sd/- Omesh Goyal	Sd/- PREM KUMAR GOYAL S/o Shri Bishna Mal 2, Flag Staff Road, Delhi -6. Business
2. LACHMI DAS AGGARWAL S/o Shri Gujar Mal 1 -C/30, New Rohtak Road, New Delhi Retired from Defence H.Q. Civil Services.	Sd/- Lachmi Das Aggarwal	
3. BERJESH K. GOYAL S/o Shri Prem Kumar Goyal 2, Flag Staff Road, Delhi-6 Business.	Sd/- Berjesh K. Goyal	
4. ROSHAN LAL GUPTA S/o Shri Salig Ram Shanti Niketan, Hira Singh Road, Ludhiana Business.	Sd/- Roshan Lal Gupta	
5. A.N. GOYAL S/o Shri Bishna Mal S-115, Panchsheel Park, New Delhi Business	Sd/- A.N. Goyal	
6. ANIL KUMAR GUPTA S/o Shri R.L. Gupta 31-B, East Friends Colony, New Delhi Business	Sd/- Anil Kumar Gupta	
7. SUBASH CHANDER KOHLI S/o Shri G.L. Kohli 153, Sector 22-A, Chandigarh Engineer	Sd/- Subash Chander Kohli	

Dated this 14th day of July, 1975.




CERTIFIED TRUE COPY OF THE SPECIAL RESOLUTION PASSED BY THE SHAREHOLDERS OF DABUR INDIA LIMITED IN THEIR ANNUAL GENERAL MEETING HELD ON AUGUST 10, 2023

Approval and adoption of restated Articles of Association in place of existing Articles of Association of the Company

“**RESOLVED THAT** pursuant to the provisions of Sections 5, 14 and all other applicable provisions, if any, of the Companies Act, 2013 (the “Act”) and the Rules framed thereunder (including any statutory modification(s) or re-enactment thereof for the time being in force) and such other approvals, sanctions if and when necessary, desirable and expedient in law, the restated Articles of Association be and is hereby approved and adopted as Articles of Association in the place of existing Articles of Association of the Company.

RESOLVED FURTHER THAT for the purpose of giving full effect to this resolution, the Board of Directors be and is hereby authorized on behalf of the Company to do all such acts, deeds, matters and things as it may, in its absolute discretion, deem necessary, expedient, proper or desirable and to settle all questions, difficulties or doubts that may arise in this regard at any stage including acceptance of any changes as may be suggested by the Registrar of Companies and/or any other competent authority, without requiring the Board of Directors to secure any further consent or approval of the Members of the Company to the end and intent that they shall be deemed to have given their approval thereto expressly by the authority of this resolution.”

Certified as True
For Dabur India Limited


28.8.23

Ashok Kumar Jain
EVP (Finance) and Company Secretary
ICSI Mem. No.: FCS-4311
Corr. Address: Punjabi Bhawan, 10,
Rouse Avenue, New Delhi – 110002

1

IN THE HIGH COURT OF DELHI AT NEW DELHI
(ORIGINAL JURISDICTION)
IN THE MATTER OF COMPANIES ACT, 1956
AND
IN THE MATTER OF M/S DABUR (DR. S.K. BURMAN) (P) LTD.
(TRANSFEROR COMPANY)
AND
IN THE MATTER OF M/S VIDO GUM & CHEMICALS LTD.
(TRANSFeree COMPANY)

COMPANY PETITION NO. 57 OF 1986
(U/SS 391 & 394 of the Companies Act for
sanction of the Scheme of Amalgamation)

CONNECTED WITH

COMPANY APPLICATION NO. 73 OF 1986
M/S DABUR (DR. S.K. BURMAN) (P) LTD.
8/3, ASAF ALI ROAD, NEW DELHI

PETITIONER

AND

COMPANY PETITION NO. 58 OF 1986
(U/SS 391 & 394 of the Companies Act for
Scheme of the Amalgamation)

CONNECTED WITH

COMPANY APPLICATION NO. 74 OF 1986
M/S VIDO GUM & CHEMICALS LTD.
8/3, ASAF ALI ROAD, NEW DELHI

PETITIONER

AND

(U/s 101 of the Companies Act for reduction
of paid-up share capital)

M/S VIDO GUM & CHEMICALS LTD.
8/3 ASAF ALI ROAD, NEW DELHI

PETITIONER

BEFORE HON'BLE MR. JUSTICE S.B. WAD
DATED 12.9.1986

ORDER ON PETITIONS

The above petitions coming on for final hearing on 12.9.1986, upon reading the said petitions, the order dated 14.1.1986 whereby M/s Dabur (Dr. S.K. Burman) Private Ltd. (hereinafter referred to as the 'transferor company') and M/s Vidogum & Chemicals Ltd. (hereinafter referred to as the 'transferee company') were ordered to convene separate meetings of their respective shareholders for the purpose of considering, and if thought fit, approving with or without modification, the proposed scheme of amalgamation between the transferor company and transferee company, and the two affidavits of Shri Gyan Chand Burman and Shri Pradeep Burman

filed on 6.3.1986 in support of the petitions made on behalf of the transferor company and transferee company respectively, the 'Hindustan Times' dated 29.1.1986 and 30.1.1986 and the 'Nav Bharat Times' (Hindi) dated 29.1.1986 and 30.1.1986 each containing the advertisement of the said notice convening of the said meetings directed to be held by the said order dated 14.1.1986, the affidavits of Shri Manoj Arora, Advocate filed on 14.2.1986 showing the publication and despatch of the notices convening the said meetings, the report dated 27.2.1986 of Ms. Anjana Gosain, Advocate, chairman for the meetings of equity and preference shareholders of the transferor company, and the report dated 28.2.1986 of Shri A.K. Malhotra, advocate, chairman, for the meeting of equity shareholders of the transferee company, and upon reading the report of the O.L. dated 20.5.1986 as to the affairs of the transferor company, and the reply affidavit thereto of Shri P.D. Narang, Management Accountant of the Transferor company, the report dated 16.10.1985 of M/s Ramnath Iyer & co., Cost Accountants, and another report dated 9.7.1986 of M/s S.B. Billimoria & Co., Chartered Accountants, as to the valuation of shares of the transferor company and transferee company, and upon perusing C.P. 63/86 for reduction of subscribed and paid-up share capital of the transferee company, the 'Hindustan Times' and 'Nav Bharat Times' dated 19.4.1986 and 13.4.1986 respectively containing the advertisement of notice of this petition, and upon hearing Dr. V. Gourishanker, Sr. Advocate with Ms. Sujata Mehra, Advocate in support of the petition, the Central Government and Mr. V.V. Shastri, Advocate for the O.L. having no objection to the Scheme, and no creditor or shareholder having come forward to oppose the petitions, and it appearing from the reports of the Chairmen of the meetings that the proposed scheme of amalgamation has been approved unanimously by the shareholders of the transferor company and by a majority of not less than three-fourths in value by the shareholders of the transferee company, present and voting in person or by proxy.

This Court doth hereby sanction the scheme of amalgamation set forth in Part I of Schedule I hereto, and doth hereby declare the same to be binding on the shareholders and the members of the Transferor company and transferee company and also on the said companies.

And this Court doth further order :-

1. That reduction and reorganisation of the share capital of the transferee company effected by cancellation of paid-up Equity capital and issue of new equity shares and debentures as per the scheme and the special resolution dated 23.2.1986 which resolution is set forth in part II of the Schedule I hereto, be and the same is hereby approved;
2. That the minute set forth in part III of the Schedule I hereto, be and is hereby approved;
3. That notice of the registration by the Registrar of Companies of this order and of the minute be published once each in Hindustan Times and Nav Bharat Times (Hindi) within 14 days of the registration aforesaid;
4. That all the property, rights and powers of the transferor company specified in the first, second and third parts of the schedule hereto and all other property, rights and powers of the transferor company be transferred without further act or deed to the transferee company and accordingly the same shall pursuant to section

- 294 (4) of the Companies Act, 1956 be transferred to and vest in the transferee company for all the estate and interest of the transferor company therein but subject nevertheless to all charges now affecting the same.
5. That all the liabilities and duties of the transferor company be transferred without further act or deed to the transferee company and accordingly the same shall, pursuant to section 394(2) of the Companies Act, 1956 be transferred to and become the liabilities and duties of the transferee company;
 6. That all proceedings now pending by or against the transferor company be continued by or against the transferee company;
 7. That the transferor company do within 30 days after the date of this order cause a certified copy of this order to be delivered to the Registrar of Companies for registration and on such certified copy being so delivered the transferor company shall be dissolved and the Registrar of Companies shall place all documents relating to the transferor company and registered with him on the file kept by him in relation to the transferee company and the files relating to the said two companies shall be consolidated accordingly;
 8. That any person interested shall be at liberty to apply to the Court in the above matter for any directions that may be necessary;
 9. That the transferee company shall file a report in the court in regard to the operation and working of the scheme of amalgamation within six months.

SCHEDULE I
PART I

Scheme of Amalgamation (as sanctioned by the Court)

SCHEME OF AMALGAMATION
OF

DABUR (DR. S.K. BURMAN) PVT. LTD. an existing Company registered under the provisions of the Indian Companies Act, 1913 having its registered Office at 8/3, Asaf Ali Road, New Delhi - 110 002

WITH

VIDOGUM AND CHEMICALS LIMITED, a Company incorporated under the Companies Act, 1956, having its Registered Office at 8/3, Asaf Ali Road, New Delhi -110002.

1. DEFINITIONS

In this Scheme, unless inconsistent with the subject or context, the following expressions shall have the following meanings :

- 1.1 The Transferor company means Dabur (Dr. S.K. Burman) Pvt. Ltd., an existing Company registered under the provisions of the Companies Act, 1913, and having its registered office at 8/3, Asaf Ali Road, New Delhi - 110 002.
- 1.2 The Transferee Company means Vidogum And Chemicals Ltd., a company incorporated under Companies Act, 1956, having its registered office at 8/3, Asaf Ali Road, New Delhi - 110 002.

1.3 Undertaking of Transferor Company means and includes all rights, powers, interests, authorities, privileges and all properties and assets whether movable or immovable, real or personal, corporeal or incorporeal, in possession or reversion, present or contingent of whatsoever nature and wheresoever situate, including lease and tenancy rights and all other interests of rights in or arising out of any property together with all licences and liberties, patents, trade marks, telephones, telexes, logos, designs, copy rights, chose in action, goodwill, import entitlements and other quotas help by, applied for or/as may be obtained after the specified date by transferor Co. or which Transferor Co. is entitled to and all debts, liabilities, duties of Transferor Co. and all its other obligations of whatsoever kind, whether present or contingent, including taxation liabilities.

1.4 "Specified Date" means 1.7.1985.

1.5 "Effective Date" means the day on which the last of the approvals or sanctions specified in paragraph 11 (eleven) of this scheme shall be obtained.

2. AUTHORISED & PAID-UP CAPITAL

2.1 The authorised share capital of Transferor Co. is Rs. 1,00,00,000/- (Rupees one crore) divided into :-

- (i) 3,10,500 4% Non-cumulative Preference Shares of Rs. 10/- each.
- (ii) 1,03,500 12% Cumulative Preference Shares of Rs. 10/- each.
- (iii) 5,86,000 Equity Shares of Rs. 10/- each.

The issued, subscribed and fully paid-up share capital of the said Company is Rs. 45,60,000/- divided into -

- (i) 1,03,500 12% Cumulative Preference Shares of Rs. 10/- each, fully paid-up.
- (ii) 3,10,500 4% Non-cumulative Preference Shares of Rs. 10/- each, fully paid-up.
- (iii) 42,000 Equity Shares of Rs. 10/- each, fully paid-up.

2.2 Authorised share capital of Transferee Co. is Rs. 2,00,00,000/- divided into 19,50,000 Equity Shares of Rs. 10/- each and 5,000, 9.5% Redeemable Cumulative Preference Shares of Rs. 100/- each.

Issued and subscribed capital of the Transferee Company is Rs. 1,33,25,000/- divided into 13,32,500 Equity Shares of Rs. 10/- each. The Company has forfeited 56,350 Equity Shares for calls in arrears after 30.6.1985. Paid-up share capital after such forfeiture is Rs. 1,27,61,500/-.

3. BASIS OF SCHEME

- 3.1 The Scheme is subject to various sanctions, consents, approvals mentioned in paragraph 11 of the Scheme.
- 3.2 The Scheme is based on the financial position as shown in the respective balance sheets of Transferor and Transferee Company as on 30.6.1985.
- 3.3 The Undertaking of Transferor company shall without any further act of deed, stand transferred to and be vested in the Transferee Company w.e.f. the commencement of business on the specified date pursuant to and in terms of section 394 of the Companies Act, 1956, subject however to all charges, liens, mortgages, if any.
- 3.4 All the liabilities, duties and obligations, including for taxation, and whether present or contingent of Transferor Company shall also stand transferred without further act or deed to Transferee Company w.e.f. the specified date pursuant to and in terms of section 394 of the Companies Act, 1956, so as to become as from that date the liabilities, duties and obligation of Transferee Company.

All legal proceedings by or against the Transferor Company pending on the effective date shall be continued and be enforced by or against the Transferee Company, as the case may be.

Subject to the other provisions of this Scheme, all contracts, deeds, bonds, agreements and other instruments of whatsoever nature to, which the Transferor Company is a party subsisting or having effect immediately before this Scheme becomes finally effective shall be in full force and effect against or in the Transferee Company as the case may be and may be enforced as fully and effectively as if instead of the Transferor company, the Transferee company had been a party thereto.

- 3.5 With effect from the specified date till effective date, the Transferor company shall be deemed to have carried on all the business and activities and stand possessed of all properties so to be transferred for and on account of and in trust for the transferee company and the profits accruing to the transferor company or losses arising or incurred by it shall for all purposes be treated as the profits or losses of the transferee company as the case may be and the transferor company shall not alienate charge or otherwise deal with the said undertaking or any part thereof, except in the ordinary course of its business without the consent of the transferee company.
- 3.6 The amalgamation is conditional upon sanction of the High Court of Delhi at New Delhi to the Transferee Company to carry out the reduction of its subscribed and paid-up equity capital of Rs. 1,27,61,500/- consisting of 12,76,150 equity shares of Rs. 10/- each fully paid-up to Rs. 6,38,075/- by reducing the paid-up value of each of 12,76,150 equity shares from Rs. 10/- to Rs. 0.50/- each fully paid-up into 63,808 Equity Shares of Rs. 10/- each fully paid-up.

The amalgamation is also conditional upon the sanction of the High Court of Delhi at New Delhi to the Transferee Company to carry out further

reduction of its subscribed and paid-up equity capital out of the above said 63,808 equity shares to the extent of the following :-

- (a) At the rate of Rs. 10/- per share in respect of 1,52,700 shares which the transferor company is entitled as a member in view of the cancellation of their holding as specified hereinafter.
- (b) At the rate of Rs. 10/- per share to the extent of the number of shares for which the concerned shareholders of the transferee company opting to accept Debentures as hereinafter referred to.

3.7 No fractional certificate shall be issued pursuant to such reduction and consolidation of share capital of transferee company in favour of any member. All such fractions shall be consolidated as representing one new Equity Share and allotted to a transferee as may be nominated by the Board of Transferee Company and that he shall sell the same and distribute the proceeds to the members entitled thereto and the members of transferee company shall accept the same in lieu of such fractions. After such consolidation, if any fraction is left out, the same shall be ignored. This clause shall be applicable only in respect of those members of the Transferee Company who do not opt for conversion of their holding into Debentures as hereinafter referred to.

3.8 After the reduction and consolidation of capital as stated in para 3.6 and para 3.7 has taken place, the members of the transferee company shall be eligible to get at their option 6(six) 15% Secured Redeemable Debentures of the paid-up value of Rs. 100/- each in lieu of the reconstructed/consolidated 5 (five) Equity Shares of Rs. 10/- each. These Debentures will be Non-convertible and Redeemable at par after five years or earlier at the option of the Company from the date of issue in two equal annual instalments. The debentures will be secured by creation of Trust in whose favour, fixed assets of the Transferee Company will be mortgaged by the creation of a second charge.

The Transferee Company shall give notice to its members in this regard along with the notice for shareholders meeting to be convened as per the directions of the Court, with a prepaid reply letter and allow a period of 15 days from the date of notice to exercise the option to convert his/her/its entitlements/holding into Debentures as referred to above so that the final position regarding the number of shareholders, who opt for the conversion is available sufficiently in advance of the Court meeting. The Transferee Company is at liberty to presume that the shareholder opts for conversion into Debentures in case no communication in this regard is received by it within the prescribed time 15 days. In case of fractional entitlements for Debentures the same procedure as in the case of allotment of shares shall be followed.

3.9 Industrial Finance Corporation of India as lead institution for All India Financial Institutions has conveyed "No objection" to the Scheme of Amalgamation vide its letter No. C. IV/127/85-96322 dated 31st Dec., 1985.

It has also granted certain relief and concessions vide aforesaid letter read together with its earlier letter No. C. IV/127/85-50666 dated 18.7.1985, including, inter alia, waiver of penal/compound interest accrued and due

upto 30.6.1985, rescheduling the payment of principal amount of term loans and waiver of conversion clause etc.

State Bank of Patiala has also agreed vide its letter No. C & 1/264 dated 10.12.1985 to convert the outstanding balance in cash credit A/C into working capital term loans which will be repayable in six equal half yearly instalments beginning from 1.1.1986.

State Bank of Patiala has also granted some other reliefs and concessions vide its aforesaid letter to the Company such as :

- (i) Reduction in the rate of interest from 17.5% to 13.5% w.e.f 1.1.85
- (ii) Funding of interest w.e.f. 1.1.85 at the revised rates, i.e. 13.5% per annum and the amount of funded interest will be made a part of the working capital term loan.

The charge of the financial institutions/banks who have given loans to the transferor/transferee company shall remain unchanged and restricted to the respective undertakings of transferor/transferee company as these stood before amalgamation.

3.10 In Consideration of vesting of the properties, assets and debts, liabilities, duties and obligation of the transferor company in the transferee company, in terms of this scheme, the transferee company shall issue and allot shares at par credited as fully paid-up to the members of the transferor company as mentioned hereunder :

- (i) 2,58,750 12% Redeemable Cumulative Preference Shares of the face value of Rs. 10/- each fully paid up to the holders of 12% Cumulative Preference Shares of Rs. 10/- each or their heirs, executors, administrators, or other legal representatives or their successors in title, as the case may be on pro-rata basis.
- (ii) 3,10,500 4% Redeemable Non-Cumulative Preference shares of face value of Rs. 10/- each fully paid-up to the holders of 4% Non-Cumulative Preference Shares of Rs. 10/- each or their heirs, executors, administrators, or other legal representatives or their successors in title, as the case may be on pro-rata basis.
- (iii) 45,48,000 Equity Shares of the face value of Rs. 10/- each fully paid up to the Equity Shareholders or their heirs, executors, administrators or other legal representatives or their successors in title, as the case may be.

The consideration payable to the Equity Shareholders being mutually agreed on the basis of the value of Equity shares of the Transferor Company by the earnings yield method (being the lower of the two certified methods of valuation) which works out to an equivalent of 136 shares of the transferee company per Equity share of the transferor company. Accordingly the consideration would have been Rs. 571.2 lacs. As the Equity Shareholders will not be compensated for the reserves to the extent of Rs. 116.40 lacs, since those reserves will be taken over by the transferee company, the net consideration to the Equity Shareholders is determined and agreed to as Rs. 454.80 lacs.

- (iv) The Transferee Company shall obtain necessary approval from the Controller of Capital Issues for the issue of the above-said Preference and Equity shares to the shareholders of the Transferor company and for the Debentures to the extent applicable.
- (v) The Equity shares after reduction in the capital of Transferee company to be issued and allotted to the shareholders of the Transferor company pursuant hereto shall rank pari passu in all respect with the existing share capital of the Transferee Company.
- (vi) 1,52,700 Equity shares of the Transferee company to be held by the Transferor company shall be cancelled to the extent of 50 paise per share capital account and the balance against the reserve of the Transferee company after the undertaking is vested in the Transferred Company.
- (vii) To facilitate the allotment of shares of the Transferee company to the shareholders of the Transferor company as stated above, the transferee company shall increase its authorised share capital to Rs. 5.25 crores consisting of 46,30,750 Equity Shares of Rs. 10/- each, 2,58,750, 12% Redeemable Cumulative Preference Shares of Rs. 10/- each, 3,10,500, 4% Redeemable Non-Cumulative Preference Shares of Rs. 10/- each and 5,000, 9.5% Redeemable Cumulative Preference Shares of Rs. 100/- each.
The Transferee company shall arrange to pass the necessary resolutions and also to take other appropriate steps in this connection.
- (viii) The Transferee Company shall cause the necessary resolutions to be passed pursuant to Section 81(1 -A) of the Companies Act, 1956, for the offer and allotment of Preference and Equity Shares in the Transferee Company to the Shareholders of the Transferor Company in accordance and pursuant to the provisions of this scheme.
- (ix) Subject to Scheme being sanctioned and order being passed by the High Court of Delhi at New Delhi under Section 394 of the Act and on this Scheme becoming effective, the Transferor company shall be dissolved without winding up.

4. CHANGE OF NAME, OBJECTS AND ACCOUNTING YEAR

- 4.1 On amalgamation and on the dissolution of the Transferor company without winding up, the name of the Transferee company shall be changed from its existing name of Vidogum And Chemicals Ltd. to Dabur India Limited subject to compliance with the applicable provisions of the Companies Act, 1956. The Transferee company shall arrange to pass the necessary resolutions at its General Meeting and shall obtain the necessary approvals in this regard from the concerned authorities.
- 4.2 The Transferee company would be entitled to represent itself and carry on business under the Trade Name "Dabur" or under any other such name where "Dabur" appears; as leading essential or key portion with or without any prefix or suffix and shall also be entitled to use such names on the labels, cartons, packings, containers, wrappers, directions or any other material, whether affixed, engraved/embossed on the products or not.

The Transferee Company shall also be allowed to use packing materials including labels, cartons, stickers, Directions, Wrappers, Containers or any other material whether affixed, engraved/embossed on the products or not which would be in stock with the transferor company till such stocks exhaust without making any amendment on those packing materials.

4.3 The Transferee company shall incorporate in its Memorandum & Articles of Association such objects of the Transferor company which will enable the Transferee company to continue the business of the Transferor Company without any interruption. For this purpose, the Transferee company shall pass the necessary resolutions at its General Meeting and shall take all necessary steps to obtain approvals from the concerned authorities.

4.4 The financial year of the Transferee company shall be changed from 1st May to 30th April each year to 1st July to 30th June each year. However, for the current financial year of the Transferee company, i.e. from 1st May, 1985 the year will end on 30th June, 1986, thereby constituting a period of 14 months from 1st May, 1985 to 30th June, 1986. The Transferee Company shall obtain the necessary approvals from all the concerned authorities, for effecting the change in the accounting year.

5. PROTECTION OF EMPLOYMENT

The Transferee company shall employ all the existing employees of the Transferor Company on the terms and conditions not less favourable to them than the terms on which they were employed in the transferor company. Their services with the Transferor company prior to amalgamation shall not be treated as having been broken for the purposes of provident fund, gratuity and other benefits and will be reckoned for all such purposes from the date of their respective appointments with the transferor company. It shall be deemed that for all purposes, the continuity of service of the employees is not affected.

6. DIVIDEND

Notwithstanding anything contained in this Scheme, the shareholders of the Transferor Company shall be entitled to receive dividend as may be declared in the General Meeting of the Transferor Company. And the Board of Directors of the Transferor company shall remain competent to recommend declaration of dividend till this scheme of Amalgamation becomes effective.

7. MANAGEMENT

On the dissolution without winding up of the Transferor Company, the Directors of the Transferor Company will constitute the Board of Directors of the Transferee Company along with the Nominee Directors of the latter Co. The whole-time Directors of the Transferor Company will function with the same designations as the Whole-time Directors in the Transferee Company and their terms of appointment will remain unchanged subject to relevant provisions of the companies Act, 1956.

8. The Board of Directors of the Transferor Company and of the Transferee Company acting jointly or any person or persons duly authorised by them

respectively may consent on behalf of all concerned to any modifications, amendments and/or additions to this Scheme or agree to any conditions which the Court may deem fit to pass on or impose and may do all acts, deeds, matters and things necessary or desirable for carrying this scheme into effect. After the dissolution of the Transferor company, the Transferee company by its Directors be and is thereby authorised to take such steps as may be necessary, desirable or proper to resolve any doubts, difficulties or questions, whether by reason of any order of the court of any directive or order of any other authorities or otherwise howsoever arising thereunder or by virtue of this Scheme and/or any matters connected with to carry the same into effect.

9. APPLICATION U/S 391 AND 394 OF THE COMPANIES ACT, 1956.

9.1 The Transferor Company and the Transferee Company shall both with all reasonable despatch make applications u/s 391 and 394 of the Companies Act, 1956 to the High Court at New Delhi for sanctioning the Scheme of Amalgamation and dissolution of Transferor company without winding up.

9.2 In the event of any of the sanctions and approvals as mentioned in paragraph 11 of this Scheme not being obtained and /or the scheme not being sanctioned by the Court and/or the order or orders not being passed before 30th June 1986 or within such further period or periods as may be agreed upon between the transferor company by its Directors and the Transferee company by its Directors, this scheme shall become null and void.

10. EXPENSES OF AMALGAMATION

All costs and expenses in relation to or in connection with this Scheme and in carrying out and completing the terms and provisions of this scheme and incidental to the completion of amalgamation of the said undertaking of Transferor company in pursuance of this Scheme shall be and paid on attorney and client basis by the transferee company alone upon amalgamation being finalised, otherwise it shall be borne by the transferor company.

11. CONDITIONS OF THE SCHEME TO BE OPERATIVE

The Scheme is subject to the following conditions and shall become operative and effective as soon as, but not before :-

- (i) The sanction of the High Court of Delhi at New Delhi as provided in Sections 391 and 394 of the Companies Act, 1956; on behalf of the Transferor and the Transferee companies is obtained.
- (ii) Approval of the scheme by the requisite majority of the members of the transferor company and transferee company is obtained.
- (iii) All necessary resolutions are passed by the transferee company for issuing the necessary share capital, Debentures, change of name and objects clause of the Memorandum of Associations required for the purpose of carrying into effect this scheme of amalgamation.

- (iv) Application for reduction of share capital made u/s 100 of the Companies Act, 1956 by the transferee company is approved by the High Court of Delhi at New Delhi.

PART II

(special resolution dated 23.2.1986
of the transferee company)

"Resolved that pursuant to section 100 of the Companies Act, 1956 and subject to the confirmation by the High Court of Delhi at New Delhi, the share capital of the company be reorganised (i) by reducing the subscribed and paid-up equity share capital of the company by Rs. 1,21,23,425 by cancelling the paid-up ordinary share capital of the company which is lost and unrepresented by available assets to the extent of 95% per share, upon each of the 12,76,150 equity shares of Rs. 10 each, and consequent to such reduction (ii) by issue of 63,808 new equity shares of Rs. 10 each credited at par to the holders of existing 12,76,150 shares of Rs. 10 each in the proportion of one new equity share of Rs. 10 each for 20 existing ordinary shares of Rs. 10 each.

Resolved further that share capital be further reduced to the extent as may be required consequential to the issue of debentures to the shareholders as per the proposed amalgamation scheme and also for cancellation of 1,52,700 shares of Rs. 15,27,000/- held by Dabur (Dr. S.K. Burman) (P) Ltd. as investment in the company.

Resolved further that any fractional entitlement resulting from issue of shares aforesaid shall be allowed to person to be nominated by the Board, who shall dispose of such shares and distribute the net proceeds among the shareholders entitled to the fractional entitlement in proportion in which they would be so entitled.

Further Resolved that the Board of Directors be and are hereby authorised to make suitable modifications in the extent of reduction/consolidation to settle any practical difficulty in implementing the above Resolution."

PART III

(Form of Minute)

The paid-up capital of M/s Vidogum & Chemicals Ltd. is henceforth Rs. 25,200/- divided into 2520 equity shares of Rs. 10 each, reduced from Rs. 1,27,61,500/-. At the date of the registration of this minute 2520 equity shares have been issued and are deemed to be fully paid, and the remaining 19,47,480 equity shares of Rs. 10/- each, and 5000 9.5% redeemable cumulative preference shares of Rs. 100/- each are unissued.

SCHEDULE II

PART I

FREEHOLD PROPERTY OF THE TRANSFEROR COMPANY AS AT 30.6.1985.

1. Factory and office buildings constructed on land situated at Netaji Subhash Chander Bose Road (Leading to Baruipur from Calcutta) Narenderpur, 24 Parganas Distt. West Bengal, measuring 13,159 acres.

2. Factory buildings, residential quarters and office buildings constructed on land measuring covered area of 3.5 acres situated at an important suburb of Calcutta having its frontage on the main Raja S.C. Mullick Road, P.O. Garia, Calcutta-700 084.
3. Vacant land measuring 2.47 acres situated at 47/A, S.N. Ghosh Avenue Elaichi, 24 Parganas Distt. West Bengal falling in Rajpur Municipality Area.
4. Office Flat No. A-1, 14th Floor, 33-A, Jawaharlal Nehru Road, Chowranghee, Calcutta-700 907 having total plinth area of 1600 sq. feet.
5. Factory building, office building and guest house constructed on land measuring 8.3 acres situated at Deoghar, P.O. Deoghar Santhal Paraganas, Railway Station Baidanathdham, Jasidih, Eastern Railway, Bihar.
6. Office and godown building constructed on land measuring 1,472 sq. yd. situated at Mohalla Kaharan (in residential area within Municipality limits of the town Hathras Distt. Aligarh, U.P.)
7. Temporary sheds and herbal farms on the land measuring 38,418 sq. yd. situated in front of Dabur Factory at 22, Site IV, Sahibabad, Ghaziabad.
8. Off ice-cum-residential flat situated at Flat No. G-9, 7th Floor, Commerce Centre, 78, Tardeo Road, Bombay-400 034.
9. A residential flat situated at 3-4, Sagar Apartment, 2nd Floor, 6, Tilak Marg, New Delhi - 110 001.
10. A basement No.-23-A situated at Sagar Apartment, 6, Tilak Marg, New Delhi - 110 001.
11. Plant and Machinery installed in the factory buildings.
12. Furniture, fixtures and office equipment lying in or installed in the factory building, office building or residential buildings.
13. Capital-work-in-progress at factory building and other premises.
14. Vehicles owned by the transferor company.
15. Library books and live stock owned by the transferor company.

PART II

LEASE HOLD PROPERTY OF TRANSFEROR COMPANY AS AT 30.6.1985

1. Factory and office building constructed on land measuring 95,679 sq. yd. situated at Plot No. 22, Site No. IV, Sahibabad, U.P. The land is on 90 years lease from UPSIDC, on yearly rent@ Rs. 100/- per acre during the first 30 years and Rs. 150/- per acre during the next 30 years and Rs. 225/- per acre after the expiry of the first 60 years.
2. Factory building constructed at land measuring 2.8 acres situated at Kusum Kanan, Raja, S.C. Mullick Road, P.O. Garia, 24 Paraganas Distt. West Bengal. The land is on 30 years lease w.e.f. October, 1960 from Deb Kumar Bannerjee.

3. Land measuring 0.917 acres at Rajpur situated behind Garia factory of Dabur at S.C. Mullick, Road, P.O. Garia, 24 Parganas Distt. West Bengal.
4. Plant and Machinery installed in the factory building.
5. Furniture, fixture and office equipment lying in or installed in the factory buildings, office buildings or residential buildings.
6. Capital work-in-progress at factory buildings and other premises.

PART III
STOCK, SHARES, DEBENTURES AND OTHER CHOSSES IN ACTION AS AT
30TH JUNE, 1985

1. Stock of raw material.
2. Stock of finished goods.
3. Stock of goods in progress.
4. Stock of consumable stores and spares.
5. Stock of packing materials.
6. Sundry debtors.
7. Amount recoverable from banks and other institutions, in current account and fixed deposit.
8. Investment in shares.
9. Cash in hand.
10. Other current assets, loans and advances.

Dated this 12th day of September, 1986.
(By the Court)

Sd/-
USHA MEHRA
REGISTRAR

17.10.2003

Present: Mr. Rajiv Nayar, Senior Advocate, with Mr. Sandeep Mittal and Mr. Ashish Jha for the petitioners.
Mr. S.K.Sharma, Dy.ROC, for the Regional Director, Northern Region, Department of Company Affairs, Kanpur.

CP Nos. 324/2003 & 325/2003.

This petitions have been filed by the petitioners under Sections 391 to 394 of the Companies Act praying for sanction of the Scheme of Arrangement between Dabur India Limited (the transferor Company) and Dabur Pharma Limited (the transferee company).

The registered offices of the transferor as well as the transferee companies are located at New Delhi which are within the territorial jurisdiction of this Court.

The Board of Directors of the transferor as well as the transferee company had passed resolutions approving the proposed Scheme of Arrangement.

The transferor as well as transferee companies filed applications under Section 391(1) to 394 of the Companies Act, 1956, which were registered as C.A. (M) 116/2003 & 117/2003, respectively, praying for directions regarding the convening of the meetings of the shareholders and creditors of the said company for the purpose of considering and approving the Scheme of Arrangement. The said applications were disposed of by this Court by order dated May 21, 2003 directing dispensing with the holding of meeting of secured creditors of the transferor company and further directing for convening the meetings of the unsecured creditors and the shareholders of the transferor company. However, in the case of the transferee company the requirement of convening and holding of separate meetings of the equity shareholders and creditors was dispensed with. Accordingly, the meetings of the unsecured creditors and shareholders of the transferor company were held and the report of the Chairman has been filed on record. Thereafter, the transferor as well as the transferee company have filed the present petitions for sanction of the Scheme of Arrangement under sections 391 to 394 of the Companies Act.

Notices of these petitions were issued and duly served on the Regional Director, Department of Company Affairs, Kanpur. Notice was also advertised in the newspapers in compliance with this court's order dated August 11, 2003.

The Regional Director has submitted a report wherein two observations have been made. The first observation pertains to the fact that 46 shareholders holding 3961 equity shares voted against the proposed scheme of arrangement and votes of 89 shareholders were found invalid. It, however, cannot be disputed that the aforesaid scheme of arrangement was approved by 3/4th majority in terms of the provisions of the section 391(2) of the Companies Act as is indicated from the report of the Chairman of the meeting. The 46 shareholders who had voted against the proposed scheme of arrangement constitute about 12% only, whereas 99.88% of the shareholders have voted in favour of the claim. Since the majority in number representing 3/4th in value of the members present and voting agreed to the scheme of arrangement, therefore, the provisions of section 391 of the Companies Act stand satisfied.

The other observation that is made by the Regional Director is that the transferee company, namely, M/s. Dabur Pharma Ltd. is stated to be a wholly owned subsidiary of the transferee company, whereas from the reply dated September 1, 2003 it transpires that the transferor company holds 99.88% of the shares of the transferee company. In respect of this observation made by the Regional Director the petitioner has filed a short affidavit contending inter alia that at the time of incorporation it was necessary to ensure compliance with the provisions relating to minimum number of shareholders contained in section 12(1) of the Companies Act. In that view of the

matter, minimum number of shareholders of a public company which was seven had to be maintained. It is contended by the counsel appearing for the petitioner before me that in order to keep parity with the aforesaid provisions nominal number of shares, i.e., 100 equity shares of Re. 1/- each, were allowed to each of the six persons who were closely associated with the petitioner company in their capacity as promoter/employees in order to meet the technical requirement of the aforesaid section. It is, however, reiterated in the affidavit that the relationship between the transferor and the transferee company is that of a company and its wholly owned subsidiary. Be that as it may, the records clearly prove and establish that the transferee company is a subsidiary company of the transferor company and, therefore, the observation made by the Regional Director cannot be accepted as a ground to reject the scheme of arrangement which is propounded by the petitioner.

In spite of advertisement of the notice of these petitions in the newspapers, none else has filed any objection to the grant of sanction to the Scheme of Arrangement.

In the aforesaid circumstances and having regard to the averments made in these petitions and the materials placed on record and the reports filed by the Regional Director, Department of Company Affairs, Kanpur, I am satisfied that the prayers made in the petitions deserve to be allowed. I also do not find any legal impediment to the grant of sanction to the Scheme of Arrangement. Hence, sanction is hereby granted to the above-mentioned scheme of arrangement under Sections 391 to 394 of the Companies Act, 1956.

Both the petitions stand disposed of in terms of the above order.

A copy of this order be given *dasli* to the counsel for the the petitioners.

October 17, 2003

Sd / -
Dr. Mukundakam Sharma, J.

THE HIGH COURT OF DELHI AT NEW DELHI
 (ORIGINAL JURISDICTION)
 IN THE MATTER OF THE COMPANIES ACT, 1956
 AND
 IN THE MATTER OF SCHEME OF ARRANGEMENT
 BETWEEN
 COMPANY PETITION NO. 324/2003 -
 CONNECTED WITH
 COMPANY APPLICATION NO. (M) 116/2003
 IN THE MATTER OF DABUR INDIA LTD.
 having its regd. office at 8/3, Asaf Ali Road, New Delhi - 110002

..... Petitioner/Transferor Company

AND
 COMPANY PETITION NO. 325/2003
 CONNECTED WITH
 COMPANY APPLICATION NO. 117/2003
 IN THE MATTER OF DABUR PHARMA LTD.,
 having its regd. office at 3, Factory Road, New Delhi-110029

..... Petitioner/Transferee Company

BEFORE HON'BLE DR. JUSTICE MUKUNDKAM SHARMA
DATED THIS 17TH DAY OF OCTOBER, 2003
ORDER UNDER SECTION 394 OF THE COMPANIES ACT, 1956

The above petitions coming up for hearing on 17.10.2003 for sanction of the Scheme of Arrangement proposed to be made between Dabur India Ltd., (hereinafter referred to as the transferor company) and Dabur Pharma Ltd., (hereinafter referred to as the transferee company) upon reading the said petition, the orders dt. 21/5/2003, 28.5.2003 whereby the requirement of convening the meeting of secured creditors of the transferor company and meeting of shareholders and creditors of transferee company was dispensed with and transferor company was ordered to convene a meeting of its unsecured creditors and shareholders for the purpose of considering, and if thought fit, approving, with or without modification the scheme of arrangement and annexed to the affidavit of Secretary/Director of the Companies, filed on the 19th day of May, 2003, and the publication in the Newspapers namely (1) The Indian Express (English) (2) Jansatta (Hindi) both dated 3.7.2003 each containing the advertisement of the said notice of convening the said meetings directed to be held by the said order dated 21/5/2003 and 28/5/2003, the affidavit of Chairman filed on 25/7/2003 showing the publication and despatch of the notices convening the said meetings, the reports of Chairman of the said meetings, as to the result of said meetings and upon hearing Mr. Rajiv Nayar, Senior Advocate, with Mr. Sandeep Mittal and Mr. Ashish Jha Adv., for the petitioners Mr. S.K. Sharma, Deputy Registrar of Companies, for the Regional Director, Northern Region, Department of Company Affairs, Kanpur, and it appearing from the reports that the proposed scheme of arrangement has been approved by 3/4th majority without any modification by the said shareholders and unsecured creditors of the Transferor Company present and voting either in person or by proxy and upon reading the affidavit dated 24.9.2003 of Sh. U.C. Nahta, Regional Director, Northern Region, Department of Company Affairs, Kanpur on behalf of Central Government and observation made by the Regional Director in his report having been rejected and there being no investigation proceedings pending in relation to the petitioner companies under Section 235 to 251 of the Companies Act, 1956.

THIS COURT DOETH HEREBY SANCTION THE SCHEME OF ARRANGEMENT setforth in Schedule-I annexed hereto and DOETH HEREBY DECLARE the same to be binding on all the shareholders and creditors of Pharmaceutical Division/Undertaking of the transferor company and transferee company and all concerned and doth approve the said scheme from the appointed date i.e. 1.4.2003.

AND THIS COURT DOETH FURTHER ORDER;

1. That all the property, rights and powers of Pharmaceuticals undertaking or division of the Transferor Company as per Clause 1, para (c) of the scheme of arrangement relating to Demerged undertaking and also as specified in the First, Second and Third Part of the Schedule- II hereto and all other property, rights and powers of Pharmaceutical Division of the Transferor company be transferred without further act or deed to the transferee company and accordingly the same shall pursuant to Section 394(2) of the Companies Act, 1956 be transferred to and vest in the transferee company for all the estate and interest of the Pharmaceuticals Division of transferor company therein but subject nevertheless to all charges now affecting the same; and
2. That all the liabilities and duties of the Pharmaceutical Division of the Transferor Company be transferred without further act or deed to the Transferee Company and accordingly the same shall pursuant to Section 394 (2) of the Companies Act, 1956, be transferred to and become the liabilities and duties of the Transferee Company ; and
3. That all the proceedings now pending by or against the Pharmaceutical division of the Transferor Company be continued by or against the Transferee Company ; and
4. That the Transferee Company do without further application allot to such members of the Pharmaceutical Division of the Transferor Company as have not given such notice of dissent as is required by Clause 9 of Part III given in the Scheme of Arrangement herein the shares in transferee company do which they are entitled under said Arrangement; and
5. That the Pharmaceuticals Division of the Transferor Company do within 30 days after the date of this order cause a certified copy of this order to be delivered to the Registrar of Companies for registration.
6. That any person interested shall be at liberty to apply to the Court in the above matter for any directions that may be necessary.

SCHEDULE - I
SCHEME OF ARRANGEMENT
BETWEEN

Dabur India Limited

Transferor Company

AND

Dabur Pharma Limited

Resulting Company

UNDER SECTION 391 READ WITH SECTION 394 OF THE COMPANIES ACT, 1956 AND THEIR RESPECTIVE SHAREHOLDERS AND CREDITORS IN RESPECT OF THE PHARMACEUTICALS UNDERTAKING OF DABUR INDIA LIMITED

PART I - GENERAL

- A. Dabur India Limited ("DIL") is a listed company presently engaged in the businesses of Pharmaceuticals, Ayurvedic Specialities, Family Products and Healthcare Products.
- B. The present Scheme of Arrangement (hereinafter referred to as "this Scheme") would involve transfer on a going concern basis of the Pharmaceuticals Undertaking ("Demerged Undertaking" as defined later in this Scheme) into Dabur Pharma Limited ("DPL", a wholly owned subsidiary of DIL), with DIL focusing on the Remaining Business (as defined later in this Scheme) and in consideration thereof, issue of equity shares by DPL to the shareholders of DIL on a proportionate basis, pursuant to section 394 and other relevant provisions of the Companies Act, 1956 and in compliance with the norms laid down under section 2(19AA) of the Income Tax Act, 1961. This restructuring is intended to provide greater business focus both in DIL and DPL.
- C. The Board of Directors of both the Demerged Company and the Resulting Company are of the opinion that the demerger would result in benefit to the shareholders, creditors, employees of both the companies and the general public.

1. DEFINITIONS

In this Scheme, unless repugnant to the meaning or context thereof, the following expressions shall have the following meaning:

- (a) "Act" means the Companies Act, 1956 or any statutory modification or re-enactment thereof.
- (b) "Appointed Date" means the First day of April, 2003 or such other date as may be fixed by the High Court of Judicature at New Delhi, or by such other authority having jurisdiction under law.
- (c) "Demerged Undertaking" means the Pharmaceuticals Undertaking or division of DIL largely comprising, inter alia, of the business activity of Pharmaceuticals being carried on by DIL on a going concern basis, including the manufacturing and/ or allied activities at the following units (hereinafter referred to as Pharmaceuticals Units), as on the Appointed Date:
- Injunctibles Unit' at 19, HPSIDC Industrial Area, Baddi 173 205, Distt. Solan, Himachal Pradesh
 - Kalyani Unit' at D35, Industrial Area, Kalyani, Distt. Nadia 741 235, West Bengal
 - Trading branch at Lion Court, Farnham Road, Bordon, Hampshire, GU35 ONF, United Kingdom
 - Non-trading Office at Barikovsky PCR, 4, Part 2, Room 212, 213, Moscow 119034, Russia
 - Non-trading office in Thailand

and shall include (without limitation):

- all assets wherever situated, whether movable or immovable, leasehold or freehold, tangible or intangible, including all plant and machinery, buildings, offices, roads and culverts, tubewell installations, capital work-in-progress, vehicles, furniture, fixtures, office equipment, computer installations, electricals, appliances, accessories, investments including investment specified in **Schedule A**, stocks pertaining to or relating to the Demerged Undertaking;
- all liabilities present and future (including the liabilities allocable as per Clause 4.8 of this Scheme) and the specific contingent liabilities pertaining to or relating to the Demerged Undertaking;
- all rights and licences, all assignments and grants thereof, all permits, registrations, quota rights, import quotas, rights (including rights under any agreement, contracts, applications, letters of intent, or any other contracts), subsidies, grants, tax credits, incentives or schemes of central/state governments, quality certifications and approvals, drug approvals (both Indian and foreign), product registrations (both Indian and foreign), regulatory approvals, entitlements, industrial and other licenses, municipal permissions, goodwill, approvals, consents, tenancies, if any in relation to the office and/or residential properties for the employees, investments and/or interest (whether vested, contingent or otherwise) in projects undertaken by the Demerged Undertaking, either solely or jointly with other parties, cash balances, bank balances, bank accounts, deposits, advances, recoverables, receivables, easements, advantages, financial assets, hire purchase and lease arrangements, the benefits of bank guarantees issued by Transferor Company in relation to the Demerged Undertaking, funds belonging to or proposed to be utilised for the Pharmaceuticals Units, privileges, all other claims, rights and benefits (including under any powers of attorney issued by the Transferor Company in relation to the Demerged Undertaking or any powers of attorney issued in favour of the Transferor Company or from or by virtue of any proceeding before a legal, quasi judicial authority or any other statutory authority to which the Transferor Company was a party), powers and facilities of every kind, nature and description whatsoever, rights to use and avail of telephones, telexes, facsimile connections and installations, utilities, electricity, water and other services, provisions, funds, benefits of all agreements, contracts and arrangements and all other interests in connection with or relating to the Demerged Undertaking;
- all permanent employees of Dabur India Limited substantially engaged in the Demerged Undertaking and those permanent employees that are determined by the Board of Directors of the Transferor Company, to be substantially engaged in or in relation to the Demerged Undertaking;
- all deposits and balances with Government, Semi-Government, local and other authorities and bodies, customers and other persons, earnest moneys and/ or security deposits paid or received by the Transferor Company, directly or indirectly in connection with or in relation to the Demerged Undertaking;
- all books, records, files, papers, product specifications and process information, records of standard operating procedures, computer programmes along with their licenses, manuals and back up copies, drawings, other manuals, data catalogues, quotations, sales and advertising materials, lists of present and former customers and suppliers, customer credit information, customer pricing information, and other records whether in physical or electronic form, directly or indirectly in connection with or relating to the Demerged Undertaking;
- all trademarks, tradenames, patents and domain names, copyrights, industrial designs, trade secrets, product registrations and other intellectual property and all other interests exclusively relating to the goods or services being dealt with by the Demerged Undertaking, including

those illustratively listed in Schedule B; but shall not include any assets or liabilities relating to the Remaining Business of the Transferor Company.

It is intended that the definition of Pharmaceuticals Undertaking under this clause would enable the transfer of all property, assets and liabilities of the Pharmaceuticals Undertaking to DPL pursuant to this Scheme.

It is hereby clarified that the Pharmaceuticals Undertaking shall include without limitation the immovable properties illustratively listed in Schedule C of this Scheme of Arrangement.

- (d) "Effective Date" means the last of the dates on which all the conditions and matters referred to in Clause 14 hereof have been fulfilled. References in this Scheme to the date of "coming into effect of this Scheme" or "effectiveness of the Scheme" shall mean the Effective Date.
- (e) "Housemark" shall mean the trademark and tradename DABUR, irrespective of the goods or services in respect of which it is used or is proposed to be used in the immediate or distant future.
- (f) "Remaining Business" means all other businesses, divisions, assets and liabilities of the Transferor Company other than the Demerged Undertaking as defined in sub clause (c).
- (g) "Resulting Company" or "Dabur Pharma Limited" or "DPL" means Dabur Pharma Limited, a company incorporated under the Act and having its registered office at 3 Factory Road, New Delhi.
- (h) "Scheme of Demerger" or "this Scheme" or "the Scheme" means this Scheme of Arrangement in its present form or with any modifications made under Clause 12 of the Scheme.
- (i) "Specified Date" means the date to be fixed by the Board of Directors or a committee thereof of the Transferor Company for the purpose of determining the members of the Transferor Company to whom shares will be allotted pursuant to Clause 9.1 of this Scheme.
- (j) "Transferor Company" or "Demerged Company" or "Dabur India Limited" or "DIL" means Dabur India Limited, a Company incorporated under the Act and having its registered office at 8/3 Asaf Ali Road, New Delhi-110002.

2. DATE OF COMING INTO EFFECT

The Scheme shall come into legal operation from the Appointed Date, though it shall be effective from the Effective Date.

3. SHARE CAPITAL

- (a) The authorised, issued, subscribed and paid up capital of the Transferor Company as on March 31, 2003 was as follow :

Particulars	Amount (Rs.)
Authorised Capital	
500,000,000 Equity Shares of Re 1/- each	500,000,000
Issued, Subscribed and Paid-Up Capital	
285,749,934 Equity Shares of Re 1/- each	285,749,934

- (b) The authorised, issued, subscribed and paid up capital of DPL as on March 31, 2003 was as follows:

Particulars	Amount (Rs.)
Authorised Capital	
150,000,000 Equity Shares of Re 1/- each	150,000,000
Issued, Subscribed and Paid-Up Capital	
500,000 Equity Shares of Re 1/- each	500,000

- (c) This Scheme has been drawn up to comply with the conditions relating to "Demerger" as specified under section 2(19AA) of the Income Tax Act, 1961. If any terms or provisions of the Scheme are found or interpreted to be inconsistent with the said provisions at a later date including resulting from an amendment of law or for any other reason whatsoever, the provisions of the said section of the Income Tax Act, 1961 shall prevail and the Scheme shall stand modified to the extent determined necessary to comply with section 2(19AA) of the Income Tax Act, 1961. Such modification will however not affect other parts of the Scheme.

PART II - DEMERGED UNDERTAKING

4. TRANSFER OF UNDERTAKING

- 4.1 With effect from the Appointed Date, the Demerged Undertaking shall, pursuant to the provisions contained in Section 394(2) of the Act and other provisions of law for the time being in force and without any further act or deed, be demerged from the Transferor Company, and be transferred to and vested in or be deemed to have been transferred to and vested in DPL on the Appointed Date, on a going concern basis, so as to become as and from the Appointed Date, the undertaking of DPL.
- 4.2 All assets acquired by the Transferor Company after the Appointed Date and prior to the Effective Date for operation of the Demerged Undertaking or pertaining to the Demerged Undertaking, shall also stand transferred to and vested in the Resulting Company upon the coming into effect of the Scheme, at their book values.
- 4.3 In respect of such of the assets of the Demerged Undertaking (mentioned in Clause 4.1 and Clause 4.2 above) as are movable in nature or are otherwise capable of transfer by manual delivery, by paying over or by endorsement and delivery, the same may be so delivered, paid over, or endorsed and delivered, by the Transferor Company and shall become the property of the Resulting Company as an integral part of the Demerged Undertaking transferred to it. Such delivery shall be made on a date mutually agreed upon between the Board of Directors of the Transferor Company and the Board of Directors of the Resulting Company within thirty days from the Effective Date.
- 4.4 In respect of such of the assets of the Demerged Undertaking other than those referred to in Clause 4.3 above, the same shall, as more particularly provided in Clause 4.1 above, without any further act, instrument or deed, be transferred to and vested in and/or be deemed to be transferred to and vested in the Resulting Company on the Appointed Date pursuant to the provisions of Section 394 of the Act or other provisions of law as applicable.
- 4.5 It is hereby clarified that the rest of the assets and liabilities (other than those forming part of the Demerged Undertaking or otherwise specified in this Scheme), if any, of the Transferor Company shall continue to vest in the Transferor Company.
- 4.6 Upon the coming into effect of the Scheme, as regards the future usage of the Housemark by the Resulting Company, it is clarified that the Transferor Company and the Resulting Company shall enter into a licensing arrangement on the basis of such terms and conditions as are mutually agreed.
- 4.7 For the avoidance of doubt and without prejudice to the generality of the foregoing, it is clarified that upon the coming into effect of this Scheme, in accordance with the provisions of relevant laws, consents, permissions, licenses, certificates, authorities (including for the operation of bank accounts), powers of attorneys given by, issued to or executed in favour of the Transferor Company, and the rights and benefits under the same shall, in so far as they relate to the Demerged Undertaking and all quality certifications and approvals, trademarks, patents and domain names, copyrights, industrial designs, trade secrets, product registrations and other intellectual property and all other interests relating to the goods or services being dealt with by the Demerged Undertaking, be transferred to and vested in the Resulting Company.

In so far as the various incentives, sales tax deferral benefits, subsidies (including applications for subsidies), rehabilitation schemes, grants, special status and other benefits or privileges enjoyed, granted by any Government body, local authority or by any other person, or availed of by the Transferor Company are concerned, the same shall, without any further act or deed, in so far as they relate to the Demerged Undertaking, vest with and be available to the Resulting Company on the same terms and conditions.

- 4.8 It is clarified that, upon the coming into effect of the Scheme, the following liabilities and obligations of the Transferor Company as on the Appointed Date and being a part of the Demerged Undertaking shall, without any further act or deed be and shall stand transferred to the Resulting Company, and all rights, powers, duties and obligations in relation thereto shall be and stand transferred to and vested in and shall be exercised by or against the Resulting Company as if it had entered into such loans or incurred such borrowings and the Resulting Company undertakes to meet, discharge and satisfy the same:
- (a) the liabilities which directly and specifically arose out of the activities or operations of the Demerged Undertaking;
 - (b) specific loans or borrowings raised, if any, and incurred and utilized solely for the activities or operations of the Demerged Undertaking;
 - (c) in cases other than those referred to in sub-clauses (a) and (b) above, proportionate part of the general or multipurpose borrowings and liabilities of the Transferor Company allocable to the Demerged Undertaking in the same proportion in which the value of the assets transferred under this Scheme bears to the total value of the assets of the Transferor Company immediately before the demerger. It is hereby clarified that upon the coming into effect of this Scheme, where any regulatory approvals are required for the purposes of apportioning the general or multipurpose borrowings as provided herein, the same shall be obtained by the Transferor Company and/ or the Resulting Company by way of specific applications in this behalf.
- 4.9 Where any of the liabilities and obligations of the Transferor Company as on the Appointed Date deemed to be transferred to the Resulting Company have been discharged by the Transferor Company after the Appointed Date and prior to the Effective Date, such discharge shall be deemed to have been for and on account of the Resulting Company, and all loans raised and used and all liabilities and obligations incurred by the Transferor Company for the operations of the Demerged Undertaking after the Appointed Date and prior to the Effective Date shall be deemed to have been raised, used or incurred for and on behalf of the Resulting Company and to the extent they are outstanding on the Effective Date, shall also without any further act or deed be and stand transferred to the Resulting Company and shall become its liabilities and obligations.
- 4.10 Upon the coming into effect of this Scheme, the balances as on the Appointed Date of general or multipurpose borrowings shall be transferred to and assumed by DPL in the proportion provided in Clause 4.8 (c) above. Thus, the primary obligation to redeem or repay such transferred liabilities shall be that of the Resulting Company. However, without prejudice to such transfer of proportionate liability amount, where considered necessary for the sake of convenience and towards facilitating single point creditor discharge, the Resulting Company may discharge such liability (including accretions thereto) by making payments on the respective due dates to the Transferor Company, which in turn shall make payments to the respective creditors.
- 4.11 Upon the coming into effect of this Scheme, in so far as the security in respect of the liabilities of the Transferor Company as on the Appointed Date is concerned, it is hereby clarified that the Transferor Company and the Resulting Company shall, subject to confirmation by the concerned creditor(s), mutually agree upon and arrange for such security as may be considered necessary to secure such liabilities, and obtain such consents under law as may be prescribed.

- 4.12 Upon the coming into effect of this Scheme, the borrowing limits of the Resulting Company in terms of Section 293 (1) (d) of the Act shall be deemed without any further act or deed to have been enhanced by the aggregate liabilities of the Transferor Company which are being transferred to the Resulting Company pursuant to the Scheme, such limits being incremental to the existing limits of the Resulting Company, with effect from the Appointed Date.
- 4.13 The provisions of this Clause insofar as they relate to the transfer of liabilities to the Resulting Company shall operate notwithstanding anything to the contrary contained in any deed or writing or the terms of sanction or issue or any security document, all of which instruments shall stand modified and/or superseded by the foregoing provisions.
- 4.14 It is hereby clarified that all assets and liabilities of the Demerged Undertaking shall be transferred at values appearing in the books of account of the Transferor Company as on the Appointed Date which are set forth in the closing balance sheet of the Transferor Company as of the close of business hours on the date immediately preceding the Appointed Date.
- 4.15 It is clarified that since the Transferor Company beneficially owns over 90% of the issued share capital of the Resulting Company as on the Appointed Date, the transfer of the Demerged Undertaking in pursuance of this Scheme shall be eligible to the benefit under Notification No 1, dated January 16, 1937 issued under Section 9(a) of the Indian Stamp Act, 1899.

5. CONTRACTS AND DEEDS

- 5.1 Upon the coming into effect of this Scheme and subject to other provisions of this Scheme, all contracts, deeds, bonds, agreements, schemes, arrangements and other instruments of whatsoever nature in relation to the Demerged Undertaking to which the Transferor Company is a party or to the benefit of which the Transferor Company may be eligible, and which are subsisting or having effect immediately before the Effective Date, shall be in full force and effect on or against or in favour, as the case may be, of the Resulting Company and may be enforced as fully and effectually as if, instead of the Transferor Company, the Resulting Company had been a party or beneficiary or obligee thereto.
- 5.2 Without prejudice to other provisions of the Scheme and notwithstanding that vesting of the Demerged Undertaking with the Resulting Company occurs by virtue of this Scheme itself, the Resulting Company may, at any time after the coming into effect of this Scheme in accordance with the provisions hereof, if so required under any law or if it is otherwise considered necessary or expedient, execute deeds, confirmations or other writings or tripartite arrangements with any party to any contract or arrangement to which the Transferor Company is a party or any writings as may be necessary to be executed merely in order to give formal effect to the above provisions. The Transferor Company will, if necessary, also be a party to the above.

6. LEGAL PROCEEDINGS

- 6.1 Upon the coming into effect of the Scheme, all legal or other proceedings (including before any statutory or quasi-judicial authority or tribunal) by or against the Transferor Company under any statute, whether pending on the Appointed Date, or which may be instituted any time in the future and in each case relating to the Demerged Undertaking shall be continued and enforced by or against the Resulting Company after the Effective Date. In the event that the legal proceedings referred to herein require the Transferor Company and the Resulting Company to be jointly treated as parties thereto, the Resulting Company shall be added as party to such proceedings and shall prosecute or defend such proceedings in co-operation with the Transferor Company. In the event of any difference or difficulty in determining whether any specific legal or other proceeding relates to the Demerged Undertaking or not, the decision of the Board of Directors of the Transferor Company as to whether such proceeding relates to the Demerged Undertaking or not, shall be conclusive evidence of the relationship with Demerged Undertaking.

- 6.2. The Resulting Company undertakes to have all legal proceedings initiated by or against the Transferor Company referred to in Clause 6.1 above transferred into its name and to have the same continued, prosecuted and enforced by or against the Resulting Company to the exclusion of the Transferor Company. Both companies shall make relevant applications in that behalf.
- 6.3. Notwithstanding the above, in case the proceedings referred to in Clause 6.1 above cannot be transferred for any reason, the Transferor Company shall defend the same in accordance with the advice of the Resulting Company and at the cost of the Resulting Company, and the Resulting Company shall reimburse, indemnify and hold harmless the Transferor Company against all liabilities and obligations incurred by the Transferor Company in respect thereof.

7. BUSINESS AND PROPERTY IN TRUST FOR RESULTING COMPANY/ CONDUCT OF BUSINESS

- 7.1 With effect from the Appointed Date and up to and including the Effective Date, the Transferor Company:
- (a) shall be deemed to have been carrying on all business and activities relating to the Demerged Undertaking and stand possessed of all assets, rights, title, interest and authorities of the Demerged Undertaking for and on account of, and in trust for, the Resulting Company; and
 - (b) all profits accruing to the Transferor Company, or losses arising or incurred by it (including the effect of taxes if any thereon), relating to the Demerged Undertaking shall for all purposes, be treated as the profits, taxes or losses, as the case may be, of the Resulting Company.
- 7.2 The Transferor Company undertakes that it will from the date of approval of the Scheme by the Board of Directors of the Transferor Company and the Resulting Company, or the Appointed Date, whichever is earlier, and up to and including the Effective Date preserve and carry on the Demerged Undertaking with diligence and prudence and agrees that it will not, in any material respect, without the prior written consent of the Resulting Company, alienate, charge or otherwise deal with or dispose of the Demerged Undertaking or any part thereof except in the ordinary course of business or undertake substantial expansion of the Demerged Undertaking, other than expansions which have already been commenced.
- 7.3 The Resulting Company undertakes to engage such of the permanent employees of the Transferor Company as are determined under Clause 1(c) of this Scheme of Arrangement, as being substantially engaged in the Demerged Undertaking and who are in the employment of the Transferor Company as on the Effective Date, on terms and conditions not less favourable than those on which they are engaged by the Transferor Company, without any interruption of service as a result of the transfer of Demerged Undertaking to the Resulting Company. The Resulting Company undertakes to continue to abide by any agreement/ settlement entered into by the Transferor Company in respect of the Demerged Undertaking. The Resulting Company agrees that for the purpose of payment of any compensation, gratuity and other terminal benefits, the past services of such employees with the Transferor Company shall also be taken into account, and agrees and undertakes to pay the same as and when payable.
- 7.4 Upon the Scheme coming into effect, the accounts of the employees, who are employed by the Transferor Company and who fall under Clause 7.3 above, relating to the Provident Fund, Gratuity Fund and Pension and/or Superannuation Fund and any other Fund, shall be identified, determined and transferred to the respective funds of the Resulting Company and the employees shall be deemed to have become members of such trusts/ funds of the Resulting Company. Upon the Scheme coming into effect, until such time that the Resulting Company creates its own funds, the Resulting Company may, subject to necessary approvals and permissions, if any, continue to make contributions pertaining to the employees of the Demerged Undertaking to the relevant funds of the Transferor Company and such contributions pertaining to the employees of the Demerged Undertaking shall be transferred by the Transferor Company to the funds of the Resulting Company as and when created.

The Transferor Company shall take all steps necessary for the transfer of the Provident Fund, Gratuity Fund and Pension and/or Superannuation Fund and any other Fund of employees, pursuant to the Scheme, to the Resulting Company.

8. SAVING OF CONCLUDED TRANSACTIONS

Transfer and vesting of the assets, liabilities and obligations of the Demerged Undertaking and continuance of the proceedings by or against the Resulting Company shall not in any manner affect any transaction or proceedings already completed by the Transferor Company (in respect of the Demerged Undertaking) on or before the Appointed Date to the end and intent that the Resulting Company accepts all such acts, deeds and things done and executed by and/or on behalf of the Transferor Company as acts, deeds and things done and executed by and on behalf of the Resulting Company.

PART III - ISSUE OF SHARES

9. ISSUE OF SHARES

- 9.1 Upon the coming into effect of the Scheme and in consideration of the demerger of the Demerged Undertaking in the Resulting Company pursuant to Part II of the Scheme, the Resulting Company shall, without any further act or deed and without any further payment, issue and allot equity shares (hereinafter also referred to as the "New Equity Shares") at par on a proportionate basis to each member of the Transferor Company whose name is recorded in the register of members of the Transferor Company as holding equity shares on the Specified Date in the ratio of 1:2 i.e. one equity share of the Resulting Company to be issued for every two equity shares of the Transferor Company, held by the member.
- 9.2 In case any member's holding in the Transferor Company is such that the member becomes entitled to a fraction of an equity share in the Resulting Company, the Resulting Company shall not issue fractional share certificates to such member but shall consolidate such fractions and issue consolidated equity shares to separate trustees nominated by the Resulting Company in that behalf, who shall sell such shares and distribute the net sale proceeds (after deduction of the expenses incurred) to the members respectively entitled to the same in proportion to their fractional entitlements.
- 9.3 The New Equity Shares to be issued and allotted pursuant to Clause 9.1 shall in all respects, rank *pari passu* with the existing equity shares of the Resulting Company, save and except in relation to dividends, if any, to which they may be entitled to, as and from the Appointed Date.
- 9.4 The New Equity Shares to be issued and allotted in terms hereof will be subject to the Memorandum and Articles of Association of the Resulting Company.
- 9.5 The Resulting Company shall, if and to the extent required, apply for and obtain any approvals from the concerned regulatory authorities for the issue and allotment by the Resulting Company of New Equity Shares to the members of the Transferor Company.
- 9.6 The New Equity Shares of the Resulting Company issued in terms of Clause 9.1 shall, subject to the execution of the listing agreement and payment of the appropriate fee, be listed on the National Stock Exchange, the Mumbai Stock Exchange and on such other recognised stock exchange(s) in India as is desired by the Resulting Company, considering factors such as the trading turnover, floating stock, etc. The Resulting Company would obtain such approvals as may be necessary for the aforesaid listing on recognised stock exchange(s) by making suitable applications in this behalf.
- 9.7 In so far as the issue of shares pursuant to Clause 9.1 is concerned, each member of the Transferor Company shall have the option to be exercised, by way of giving a notice (with prescribed details) to Resulting Company, on or before such date as may be determined by the Board of Directors of the Resulting Company, to receive the shares either in certificate form or in dematerialised form. In the event that such notice or requisite details have not been received by the Resulting Company in

respect of any member, the shares shall be issued by them to such members in certificate form. In respect of those members exercising the option to receive the shares in dematerialised form, such members shall have opened and maintained an account with a depository participant, and shall provide such other confirmation, information and details as may be required.

- 9.8 Equity shares to be issued by the Resulting Company pursuant to Clause 9.1 of this Scheme, in respect of any equity shares of DIL which are held in abeyance under the provisions of section 206A of the Act or otherwise, shall pending allotment or settlement of dispute by order of Court or otherwise be held by the trustees appointed by the Resulting Company.
- 9.9 In the event of there being any pending and valid share transfers, whether lodged or outstanding, of any shareholder of the Transferor Company, the Board of Directors or any committee thereof of the Transferor Company shall be empowered in appropriate cases, even subsequent to the Specified Date or the Effective Date, as the case may be, to effectuate such a transfer in the Transferor Company, as if such changes in registered holder were operative as on the Specified Date, in order to remove any difficulties arising to the Transferor/ Resulting Company of such shares.

PART IV - GENERAL TERMS AND CONDITIONS

10. ACCOUNTING TREATMENT

10.1 Treatment in the books of the Transferor Company

- (a) Upon the coming into effect of this Scheme, with effect from the Appointed Date, the accounts representing the assets and liabilities of the Demerged Undertaking shall stand closed on transfer to the Resulting Company. Insofar as the accounts representing common or multipurpose borrowings referred to in Clause 4.8 are concerned, they shall stand reduced by the amounts transferred to DPL in accordance with the provisions of this Scheme.
- (b) Further, the balance of the Debenture Redemption Reserve of DIL as on the Appointed Date will stand reduced by a proportionate amount based on the amounts of 14.75% Secured Redeemable Non-convertible Debentures of DIL that are transferred to DPL as per Clause 4.8 and shall stand transferred to DPL accordingly.
- (c) The difference between the amount of assets and liabilities so transferred shall be written off against/ added to the General Reserve account in the books of account of the Transferor Company after considering the reduction of the Debenture Redemption Reserve account as provided in sub-clause (b) above.

10.2 Treatment in the books of the Resulting Company

Upon the coming into effect of this Scheme, the Resulting Company shall record all the assets and liabilities of the Demerged Undertaking transferred to it in pursuance of this Scheme at their respective book values thereof appearing in the books of account of the Transferor Company immediately before the Appointed Date including the amount of Debenture Redemption Reserve transferred as per provisions of sub-clause 10.1(b). It is clarified that insofar as the amounts of common or multipurpose borrowings referred to in Clause 4.8 and sub-Clause 10.1(a) are concerned, the Resulting Company shall record the same under the same account caption as that used by DIL.

Further, the amount arising as an accounting differential for the Resulting Company, an account of the difference between:

- (a) the amount representing the surplus of assets over liabilities of the Demerged Undertaking recorded in its books of account after considering the amount of Debenture Redemption Reserve transferred to the Resulting Company as per sub-clause 10.1(b); and

(b) the aggregate of the face value of equity share capital issued by the Resulting Company in terms of Clause 9.1 above,

shall be debited/ credited to the General Reserve of the Resulting Company. This amount shall be free for distribution as dividend, and shall for all purposes constitute a part of the Free Reserves of the Resulting Company.

10.3 It is hereby clarified that pursuant to the provisions of Clause 4, all transactions during the period between the Appointed Date and Effective Date relating to the Demerged Undertaking would be duly reflected in the financial statements of the Resulting Company, upon the Scheme coming into effect.

11. APPLICATIONS TO HIGH COURT/OTHER AUTHORITY

11.1 The Transferor Company and the Resulting Company shall, with all reasonable dispatch, make applications to the High Court of Judicature at New Delhi where the registered offices of the Transferor Company and the Resulting Company are situated or such other authority having jurisdiction under law, under Section 391 of the Act, seeking orders for dispensing with or convening, holding and conducting of the meetings of the respective classes of the members and/or creditors of the Transferor Company and the Resulting Company as may be directed by the High Court or such other authority having jurisdiction under law.

11.2 On the Scheme being agreed to by the requisite majorities of the classes of the members and/or creditors of the Transferor Company and the Resulting Company as directed by the High Court of Judicature at New Delhi or such other authority having jurisdiction under law, the Transferor Company and the Resulting Company shall, with all reasonable dispatch, apply to the High Court of Judicature at New Delhi or such other authority having jurisdiction under law, for sanctioning the Scheme under Sections 391 and 394 of the Act, and for such other order or orders, as the said High Court or such other authority having jurisdiction under law may deem fit for carrying this Scheme into effect.

12. MODIFICATION OR CLARIFICATION

12.1 The Transferor Company (by its Directors or their committee thereof) and the Resulting Company (by their Directors or their committee thereof) may assent to any modification(s) or amendment(s) in this Scheme which the Court and/or any other authorities may deem fit to direct or impose or which may otherwise be considered necessary or desirable for implementing and/or carrying out the Scheme or which may be considered necessary due to any change in law and the Transferor Company (by its Directors or their committee thereof) and the Resulting Company (by their Directors) be and is hereby authorised to take such steps and do all acts, deeds and things as may be necessary, desirable or proper to give effect to this Scheme and to resolve any doubts, difficulties or questions whether by reason of any orders of the Court or of any directive or orders of any other authorities or otherwise howsoever arising out of, under or by virtue of this Scheme and/or any matters concerning or connected therewith.

12.2 Any issue as to whether any asset or liability or incentives/ subsidies etc (more specifically mentioned in Clause 4.7 and Clause 4.8 hereof) pertains to or is relatable to the Demerged Undertaking or not shall be solely decided by the Board of Directors of the Transferor Company, on the basis of evidence that they may deem relevant for the purpose (including the books or records of the Transferor Company).

12.3 If any part of this Scheme is found to be unworkable for any reason whatsoever, the same shall not, subject to the decision of the respective Boards of Directors of the Transferor Company and the Resulting Company, affect the adoption or validity or interpretation of the other parts and/or provisions of this Scheme. It is hereby clarified that the Board of Directors of the Transferor Company and the Resultant Company may in their absolute discretion, adopt any part of this Scheme or declare the entire Scheme to be null and void and in that event no rights and liabilities whatsoever shall accrue

to or be incurred inter se by the parties or their shareholders or creditors or employees or any other person. In such case each Company shall bear its own cost or bear costs as may be mutually agreed.

13. GENERAL TERMS

13.1 It is clarified that all taxes payable by the Transferor Company, relating to the Demerged Undertaking, from the Appointed Date onwards including all or any refunds and claims shall, for all purposes, be treated as the tax liabilities or refunds and claims of the Resulting Company. Accordingly, upon the Scheme becoming effective, the Resulting Company is expressly permitted to revise its Sales tax returns, Excise & Modvat/ Cenvat returns, other tax returns, and to claim refunds/ credits, pursuant to the provisions of this Scheme.

Upon the Scheme becoming effective, the Resulting Company is also expressly permitted to revise its income tax returns and to claim refunds, advance tax and withholding tax credits, etc. pursuant to the provisions of this Scheme.

13.2 In accordance with the Modvat/ Cenvat Rules framed under the Central Excise Act, 1944, as are prevalent on the Effective Date, the unutilized credits relating to excise duties paid on inputs/ capital goods lying to the account of the Demerged Undertaking shall be permitted to be transferred to the credit of the Resulting Company, as if all such unutilized credits were lying to the account of the Resulting Company. The Resulting Company shall accordingly be entitled to set off all such unutilized credits against the excise duty payable by it.

14. CONDITIONALITY OF SCHEME

The Scheme is conditional upon and subject to:

- (a) the Scheme being agreed to by the respective requisite majorities of the various classes of members and creditors (where applicable) of the Transferor Company and the Resulting Company as required under the Act and the requisite sanction and orders of the High Court of Judicature at New Delhi or of such other authority having jurisdiction under law, being obtained; and
- (b) the certified copies of the above orders of the High Court or of such other authority having jurisdiction under law being filed with the Registrar of Companies, Delhi & Haryana.

15. COSTS, CHARGES AND EXPENSES

All past, present and future costs, charges, levies, duties, and expenses (save and except stamp duty payable pursuant to transfer of Demerged Undertaking, if any, which shall be borne by the Resulting Company) in relation to or in connection with or incidental to the Scheme or the implementation thereof shall be borne by the Transferor Company and all of the above costs (including stamp duty) shall be treated as costs relating to the demerger.

16. EFFECT OF NON-APPROVALS

In the event of this Scheme failing to take effect finally by December 31, 2003 or by such later date as may be agreed upon by the respective Boards of Directors of the Transferor Company and the Resulting Company, this Scheme shall become null and void and in that event no rights and liabilities whatsoever shall accrue to or be incurred inter se by the parties or their shareholders or creditors or employees or any other person. In such case each Company shall bear its own cost or as may be mutually agreed.

SCHEDULE 'A'

111,400,000 Equity Shares of 10p each fully paid up of Dabur Oncology Pte representing 100% of the paid up equity Share Capital (share certificate numbers 9, 10 and 11).

SCHEDULE 'B'

LIST OF PHARMA TRADE MARKS
REGISTERED IN FOREIGN COUNTRIES

Sl.No.	Trade Mark	Country	Regn. No.	Class	Regn.Date	Valid up to
1	Intaxel	Nepal	11435/052	5	25.03.1996	25.03.2010
2	Intaxel	Thailand	294543	5	26.04.1995	26.04.2005
3	Intaxel	Indonesia	356843	5	07.04.1995	07.04.2005
4	Intaxel	South Korea	338783	10	30.04.1996	30.04.2005
5	Intaxel	Sri Lanka	75240	5	07.08.1995	07.08.2005
6	Intaxel	China	1002846	5	14.05.1997	14.05.2007
7	Intaxel	Czech Republic	198762	5	25.08.1995	25.08.2005
8	Intaxel	Slovak Republic	197047	5	28.08.1995	28.08.2005
9	Intaxel	Turkey	165442	5	06.12.1995	06.12.2005
10	Intaxel	Israel	102497	5	22.12.1995	22.12.2016
11	Intaxel	South Africa	96/00206	5	08.01.1998	08.01.2005
12	Intaxel	Kenya	43739	5	11.01.1996	11.01.2003
13	Intaxel	Russia	161240	5	08.08.1997	08.08.2007
14	Dabilax	South Africa	098/08507	5	20.05.1998	20.05.2008
15	Kemocarb	Thailand	Kor 101041	5	11.09.1998	11.09.2008
16	Ledoxan	Thailand	Kor 92219	5	11.09.1998	11.09.2008
17	Adrim	Thailand	Kor 92220	5	11.09.1998	11.09.2008
18	Fytosid	Thailand	Kor 92221	5	11.09.1998	11.09.2008
19	Fivoflu	Thailand	Kor 92222	5	11.09.1998	11.09.2008
20	Hydab	Thailand	Kor 148279	5	29.03.2001	29.03.2011
21	Topotel	Thailand	Kor 148280	5	29.03.2001	29.03.2011
22	Gynatam	Thailand	Kor 148281	5	29.03.2001	29.03.2011
23	Ipamide	Thailand	Kor 148282	5	29.03.2001	29.03.2011
24	Innotel	Thailand	Kor 148283	5	29.03.2001	29.03.2011
25	Empurine	Thailand	Kor 149094	5	29.03.2001	29.03.2011
26	Zexate - 50 Dabur	Thailand	Kor 152691	5	24.03.2000	24.03.2010
27	Emetra	Thailand	Kor 166287	5	24.01.2002	24.01.2012
28	Kemoplat	Brazil	820745910	5	11.09.2001	11.09.2011

LIST OF PHARMA TRADE MARKS PENDING
FOR REGISTRATION IN FOREIGN COUNTRIES

Sl.No.	Trade Mark	Country	App. No.	Class	App Date
1	Intaxel	Malaysia	95/01640	5	24.02.1995
2	Intaxel	Philippines	105116	5	-
3	Intaxel	Brazil	820745901	5	15.05.1998
4	Fytosid	Brazil	820745928	5	15.05.1998
5	Kemoplat	Thailand	Kor 101142	5	11.09.1998
6	Zexate	Thailand	369492	5	11.09.1998
7	Kemoplat	Philippines	4-1998-06630	5	02.09.1998
8	Kemocarb	Philippines	4-1998-06635	5	02.09.1998
9	Ledoxan	Philippines	4-1998-06636	5	02.09.1998
10	Adrim	Philippines	4-1998-06634	5	02.09.1998
11	Fytosid	Philippines	4-1998-06633	5	02.09.1998
12	Fivoflu	Philippines	4-1998-06631	5	02.09.1998
13	Zexate	Philippines	4-1998-06632	5	02.09.1998
14	Gynatam	Philippines	4-1999-04399	5	21.06.1999
15	Intaxel	Bangladesh	61306	5	19.08.1999
16	Fivoflu	Costa Rica	114260	5	07.06.1999
17	Zexate	Costa Rica	114443	5	22.06.1999

Sl.No.	Trade Mark	Country	App. No.	Class	App Date
18	Kemoplal	Costa Rica	114446	5	22.06.1999
19	Gynelam	Costa Rica	114445	5	22.06.1999
20	Daxotel	Thailand	449833	5	29.03.2001
21	Zexate	Brazil	—	—	—
22	Emetra	Philippines	4-2002-00572	5	—
23	Emetra	Malaysia	2002/01669	5	11.02.2002
24	Emetra	Singapore	T02/00059B	5	03.01.2002
25	Emetra	Sri Lanka	105327	5	07.01.2002
26	Cytarine	Philippines	4-2002-02977	5	15.04.2002
27	Empurine	Philippines	4-2002-02976	5	15.04.2002
28	Hydab	Philippines	4-2002-02979	5	15.04.2002
29	Daburex	Mexico	—	5	—
30	Daxotel	Mexico	—	5	—
31	Kemocarb	Mexico	—	5	—
32	Kemocarb	Peru	—	5	—
33	Kemoplal	Peru	—	5	—
34	Ledoxan	Peru	—	5	—
35	Adrim	Peru	—	5	—
36	Fylosid	Peru	—	5	—
37	Zexate	Peru	—	5	—
38	Intaxel	Peru	—	5	—
39	Gynatam	Peru	—	5	—
40	Topotel	Peru	—	5	—
41	Fivoflu	Peru	—	5	—
42	Daxotel	Colombia	03017492	5	28.02.2003
43	Daxotel	Trinidad & Tobago	—	5	—
44	Daxotel	Belarus	20030105	5	22.01.2003
45	Daxotel	Macau	NI10932	5	27.01.2003
46	Daxotel	Costa Rica	—	5	—
47	Daxotel	Hong Kong	01376/2003	5	27.01.2003
48	Daxotel	Myanmar	—	5	—
49	Daxotel	Russia	2003701220	5	22.01.2003
50	Daxotel	Sri Lanka	110804	5	17.12.2002
51	Daxotel	Turkey	—	5	—
52	Daxotel	Ukraine	200221211178/T	5	26.12.2002
53	Daxotel	Venezuela	—	5	—
54	Daxotel	Vietnam	4-2003-01175	5	25.02.2003
55	Daxotel	Chile	—	5	—
56	Docotel	Peru	—	5	—
57	Adenex	Brazil	—	5	—
58	Adrim	El Salvador	—	5	—
59	Daxotel	El Salvador	—	5	—
60	Intaxel	El Salvador	—	5	—
61	Vinibine	El Salvador	—	5	—
62	Kemocarb	El Salvador	—	5	—
63	Fylosid	El Salvador	—	5	—
64	Kemocarb	Vietnam	—	5	—
65	Kemoplal	Vietnam	—	5	—
66	Ledoxan	Vietnam	—	5	—
67	Cytarine	Vietnam	—	5	—
68	Fylosid	Vietnam	—	5	—
70	Fivoflu	Vietnam	—	5	—
71	Ipamide	Vietnam	—	5	—
73	Zexate	Vietnam	—	5	—
74	Intaxel	Vietnam	—	5	—
75	Gynatam	Vietnam	—	5	—

LIST OF PHARMA INDIAN REGISTERED TRADE MARKS

Sl. No.	Trade Mark	Regn. No.	Class	Regn. Date	Valid up to
1	Oryza	475434	5	17.07.1987	17.07.2008
2	Tinavale	479546	5	07.10.1987	07.10.2008
3	Atecard	479547	5	07.10.1987	07.10.2008
4	Damox	479548	5	07.10.1987	07.10.2008
5	Dabcilin	479557	5	07.10.1987	07.10.2008
6	Strox	481403	5	20.11.1987	20.11.2008
7	Greeneam	494418	5	15.07.1988	15.07.2009
8	Nuren	498444	6	27.09.1988	27.09.2009
9	Cetamil	428974	5	25.10.1984	25.10.2005
10	Rheumatil	437392	5	06.05.1985	06.05.2006
11	Zened	563852	5	16.12.1991	16.12.2005
12	Groinate	475431	5	17.07.1987	17.07.2008
13	Cameron	475435	5	17.07.1987	17.07.2008
14	Magalidid	475436	5	17.07.1987	17.07.2008
15	Damox	475438	5	17.07.1987	17.07.2008
16	Dabox	475439	5	17.07.1987	17.07.2008
17	Buspar	477816	5	03.09.1987	03.09.2004
18	Enkaid	477817	5	03.09.1987	03.09.2008
19	Seovin	479545	5	07.10.1987	07.10.2008
20	Frontic	479549	5	07.10.1987	07.10.2008
21	Boncid	479551	5	07.10.1987	07.10.2008
22	Gescape	479552	5	07.10.1987	07.10.2008
23	Gescote	479553	5	07.10.1987	07.10.2008
24	Oinate	479554	5	07.10.1987	07.10.2008
25	Dabexin	479555	5	07.10.1987	07.10.2008
26	Ultracel	479558	5	07.10.1987	07.10.2008
27	Gritinea	479639	5	09.10.1987	09.10.2008
28	Do - Do	487217	5	10.03.1988	10.03.2009
29	Daxcel	487219	5	10.03.1988	10.03.2009
30	Panaleve	487219	5	10.03.1988	10.03.2009
31	Varta	490495	5	04.05.1988	04.05.2009
32	Grogain	490496	5	04.05.1988	04.05.2009
33	Rantaid	495915	5	12.08.1988	12.08.2002
34	Okedo	496672	5	26.08.1988	26.08.2009
35	Bupernax	498453	5	27.09.1988	27.09.2002
36	Nefidip	511809	5	13.08.1989	13.08.2003
37	Vytee	515919	5	29.08.1989	29.08.2003
38	Quinostat	518269	5	12.10.1989	12.10.2003
39	Microneg	519046	5	27.10.1989	27.10.2003
40	Danizol	519047	5	27.10.1989	27.10.2003
41	Cesadroxil	519048	5	27.10.1989	27.10.2003
42	Frutral	531498	5	14.06.1990	14.06.2004
43	Whotral	573954	5	25.05.1992	25.05.2006
44	Wycide	579051	5	11.08.1992	11.08.2006
45	Vidistat	579052	5	11.08.1992	11.08.2006
46	Gynosep	579053	5	11.08.1992	11.08.2006
47	Biljing	590740	5	12.02.1993	12.02.2007
48	Kelodab	602118	5	20.07.1993	20.07.2007
49	V - Uracll	630390	5	08.06.1994	08.06.2008
50	Ranfaz	632800	5	04.07.1994	04.07.2008
51	Kemoptal	632803	5	04.07.1994	04.07.2008
52	Gentus	641445	5	28.09.1994	28.09.2008
53	Rusimid	641446	5	28.09.1994	28.09.2008
54	Toxyfyl	641448	5	28.09.1994	28.09.2008
55	Adlam	641449	5	28.09.1994	28.09.2008

LIST OF PHARMA INDIAN PENDING TRADE MARK APPLICATIONS

Sl. No.	Trade Mark	Application No.	Class	App. Date
1	Livfit	454537	5	22.05.1986
2	Ulgel	475433	5	17.07.1987
3	Alexin	488651	5	31.03.1988
4	Ecoprin	519044	5	27.10.1989
5	Livfit - Label	547687	5	13.03.1991
6	So Low	556239	5	09.08.1991
7	So Low	556238	30	09.08.1991
8	Colestran	555731	5	02.08.1991
9	Mazinal	574081	5	25.07.1992
10	Yestor	574082	5	27.05.1992
11	Honitus	577232	5	17.07.1992
12	Septidina	579054	5	11.08.1992
13	Taxol	606182	5	07.09.1993
14	Stresscom	608200	5	-
15	Fe Chew	613284	5	03.12.1993
16	Ultraquin	613285	5	03.12.1993
17	Intaxel	644195	5	27.10.1994
18	Indaxel	617521	5	24.01.1994
19	Hintaxel	617522	5	24.01.1994
20	Hindaxel	617520	5	24.01.1994
21	Intaxol	644196	5	27.10.1994
22	Inloxat	644194	5	27.10.1994
23	Lactonic	621814	5	11.03.1994
24	Lactonic - Label	638152	5	25.08.1994
25	Lipistol	626080	5	27.04.1994
26	Diamet	626088	5	22.04.1994
27	Tricawin	624057	5	31.03.1994
28	Ulcinorm	624056	5	31.03.1994
29	Acrim	630392	5	08.06.1994
30	Ipamide	630396	5	08.06.1994
31	Alenod	630394	5	08.06.1994
32	Retinod	630395	5	08.06.1994
33	Bemocin	630393	5	08.06.1994
34	Zexale	632805	5	04.07.1994
35	Adoxim	632806	5	04.07.1994
36	Ledoxan	632802	5	04.07.1994
37	Fytosid	632804	5	04.07.1994
38	Daboxan	632801	5	04.07.1994
39	Fivoflu	636130	5	05.08.1994
40	Wotam	636131	5	05.08.1994
41	Seredal	641447	5	28.09.1994
42	Precon	647672	5	02.12.1994
43	Dexasone	647667	5	02.12.1994
44	Betnal	647671	5	02.12.1994
45	Betnal - S	647661	5	02.12.1994
46	Relelab	647670	5	02.12.1994
47	Keloten	647668	5	02.12.1994
48	Colrizol	647666	5	02.12.1994
49	Cimetol	647665	5	02.12.1994
50	Oxytron	647669	5	02.12.1994
51	Povisepl	648315	5	09.12.1994
52	Migratan	649543	5	22.12.1994
53	Serobrip	649545	5	22.12.1994
54	Dabsprin	649544	5	22.12.1994
55	Curamig	653931	5	31.01.1995
56	Migranorm	653930	5	31.01.1995
57	Inacticol	670547	5	26.06.1995
58	Camptotel	829746	5	27.11.1996

Sl. No.	Trade Mark	Application No.	Class	App. Date
59	Immusol	679518	5	08.09.1995
60	Meganeg	684750	5	27.10.1995
61	Aleracel	691041	5	18.12.1995
62	Radiopaque	702538	5	21.03.1996
63	Clonizol	718454	5	10.06.1996
64	Daxotel	718455	5	10.06.1996
65	Eskinase	720032	5	27.06.1996
66	Contrastin	762104	5	10.06.1997
67	Magniscan	762105	5	10.06.1997
68	Resyic	765787	5	05.08.1997
69	Gynatam	792436	5	23.02.1998
70	Kemocarb	792437	5	23.02.1998
71	Topotel	794071	5	10.06.1998
72	Eternax	805505	5	10.06.1998
73	Hydab	800312	5	28.04.1998
74	Cylarine	802926	5	20.05.1998
75	Empurine	802927	5	20.05.1998
76	Dabitax	802925	5	20.05.1998
77	Aternax	835889	5	08.01.1999
78	Nasarel	864171	5	06.07.1999
79	Cycloset	860151	5	08.06.1999
80	Aniphos	860764	5	11.06.1999
81	Mitodab	867333	5	22.07.1999
82	Roxisole	877656	5	22.09.1999
83	Flucostat	879136	5	30.09.1999
84	Irinotel	907545	5	03.03.2000
85	Amlocan	926787	5	23.05.2000
86	Pamfos	926788	5	23.05.2000
87	Ulzol	938875	5	12.07.2000
88	Vineltbine	948126	5	16.08.2000
89	Osofit	1001608	5	04.04.2001
90	Harmoni	1001610	5	04.04.2001
91	Ferorich	1001611	5	04.04.2001
92	Richglow	1001609	5	04.04.2001
93	Osteotone	986977	5	30.01.2001
94	Dabfit	986978	5	30.01.2001
95	Dipilp	986976	5	30.01.2001
96	Lestrol	986975	5	30.01.2001
97	Dabrol	986974	5	30.01.2001
98	Sirox TZ	995266	5	08.03.2001
99	Phylotac	1003192	5	12.04.2001
100	Immunolit	1003193	5	12.04.2001
101	Ocuflit	1003194	5	12.04.2001
102	Gastrofit	1003195	5	12.04.2001
103	Cardiolit	1003196	5	12.04.2001
104	Ioscan	1018787	5	26.06.2001
105	Menopin	1020442	5	26.06.2001
106	Gynacor	1020443	5	26.06.2001
107	Mifeprel	1020444	5	26.06.2001
108	Ovupin	1020445	5	26.06.2001
109	Artrex	705491	5	02.05.1996
110	Artrex - Carton	800641	5	30.04.1998
111	Fencite	1033950	5	02.08.2001
112	Gynatrop	1035316	5	08.08.2001
113	Buserel	1051482	5	11.10.2001
114	Isolit	1051480	5	11.10.2001
115	Fylosoy	1051481	5	11.10.2001
116	Ernetra	1057273	5	07.11.2001
117	Ramil	1066385	5	12.12.2001

Sl. No.	Trade Mark	Application No.	Class	App. Date
118	Surviv	1066386	5	12.12.2001
119	Prace	1066387	5	12.12.2001
120	Sinclit	1066384	5	12.12.2001
121	Sinocure	1066383	5	12.12.2001
122	Tiborel	1068008	5	19.12.2001
123	Estrolit	1068009	5	19.12.2001
124	Osteofil	1068389	5	20.12.2001
125	Trozel	1069417	5	26.12.2001
126	Alemex Distab	1069722	5	27.12.2001
127	Gingiva	1069721	5	27.12.2001
128	Cetorgel	1078046	5	04.02.2002
129	Voflox	1078114	5	04.02.2002
130	Revas	1078115	5	04.02.2002
131	Anthracin	1097432	5	22.04.2002
132	Gesiofil	1103597	5	09.05.2002
133	Thalix	1103596	5	09.05.2002
134	Osteoset	1103880	5	10.05.2002
135	Oxitan	1141164	5	04.10.2002
136	Echoscan	1141166	5	04.10.2002
137	OncQuest	1157457	5	11.12.2002
138	Flutrox	1165805	5	10.01.2003
139	Temozam	—	5	—
140	Cladrim	—	5	—
141	Zyloss	—	5	—
142	Gemita	—	5	—
143	Femizet	—	5	—
144	Bypro	—	5	—
145	Osteolin	—	5	—
146	Tumotran	—	5	—
147	Ovigyn	1195776	5	01.05.2003
148	Foliripe	1195777	5	01.05.2003
149	PMS Free	—	5	—

DETAILS OF GRANTED PATENTS

Sl. No.	Title	Country	Patent No.	Date of grant
1	Hepatoprotective compositions and composition for Treatment of conditions related to Hepatitis B and E infection	USA	6-136316	24.10.2001
2	A Combined plant Coagulate Composition, Process for manufacture thereof and uses thereof	South Africa	2001/2491	24.12.2001
3	A Combined plant Coagulate Composition, Process for manufacture thereof and uses thereof	Sri Lanka	12390	27.11.2001
4	Novel compositions of Taxane and Taxane Derivative and Process for manufacturing thereof	Sri-Lanka	11999	21.07.2000
5	Use of Betulinic Acid and its Derivatives for inhibiting cancer growth and a method of monitoring this	USA	6048847	11.04.2000
6	Anti Angiogenic Activity of Betulinic Acid and its Derivatives	USA	6228850	08.05.2001
7	Use of Betulinic Acid Derivatives for inhibiting Cancer growth	USA	6214814	10.04.2001
8	Anti Angiogenic Activity, of betulinic acid and its derivatives	USA	6403816	11.06.2002
9	Extracting Betulinic Acid from Zizi Plus Jajuba	USA	6264998	24.07.2001
10	Process for isolating 10-Deacetyl Baccatin-III	USA	6214482	26.09.2000
11	Process for the isolation of 14-B-Hydroxy-10-Deacetyl Baccatin-III	EPO	1010697 B1	31.10.2001
12	Process for the isolation of 14-B-Hydroxy-10-Deacetyl Baccatin-III	USA	6002024	14.12.1999
13	Novel Paclitaxel Analogues having Anti Cancer activity	USA	6395771 B1	28.05.2002
14	Vasoactive Intestinal Peptide Analogs	USA	6489287	03.12.2002
15	Somatostatin Analogs for the treatment of Cancer	USA	6316414	13.11.2001
16	A novel process for preparing Herbal Galactagogue composition	Sri Lanka	12497	14.12.2001

Sl. No.	Title	Country	Patent No.	Date of grant
17	A novel composition for treatment of Drug Resistant Bacterial Infection and a method of treating Drug Bacterial Infections	Sri Lanka	12434	21.11.2001
18	An antiangiogenic drug	USA	6492330	10.12.2002
19	Formulations of Docitaxel, its derivatives or its analogs entrapped in to nano particles of polymeric micelles, process for preparing same and use thereof	USA	6365191	21.09.2000
20	Novel Betulinic acid derivatives, processes for preparing such derivatives and its use as cancer growth inhibitors	South Africa	2001/3616	24.04.2002
21	Formulations of Docitaxel, its derivatives or its analogs entrapped in to nano particles of polymeric micelles, process for preparing same and use thereof	USA	6322817	27.11.2001
22	A process for isolation of 10-deacetyllobococcin III from recoverable part of a plant taxus species	Australia	753086	23.01.2003

DETAILS OF PENDING PATENTS

Sl.No.	Title	Country	App. No.	Date of Appl.
1	Hepatoprotective compositions and composition for Treatment of conditions related to Hepatitis B and E Infection	European Patent	EP0990360 A1	13.01.1999
2	Herbal composition for the treatment of Bone Metabolic Disorders and a process for its preparation	India	574/DEL/2001	15.05.2001
3	A process for the preparation of a Synergistic Herbal Composition in the treatment of Bone Metabolic Disorders	India	573/DEL/2001	15.05.2001
4	A Combined plant Coagulate Composition, Process for manufacture thereof and uses thereof	India	340/DEL/2000	28.03.2000
5	A Combined plant Coagulate Composition, Process for manufacture thereof and uses thereof	Malaysia	PI 20011403	27.03.2001
6	A Herbal composition and process for the manufacturing of such composition for Gynecological Disorders	India	344/DEL/2000	28.03.2000
7	A Herbal composition and process for the manufacturing of such composition for Gynecological Disorders	Malaysia	PI20011404	27.03.2001
8	A Herbal composition and process for the manufacturing of such composition for Gynecological Disorders	Russia	2001108465	27.03.2001
9	A Herbal composition and process for the manufacturing of such composition for Gynecological Disorders	USA	09/819828	23.03.2001
10	A Novel process for preparing Herbal Galactogogue composition	India	702/DEL/2001	25.06.2001
11	A Novel composition for treatment of Drug Resistant Bacterial Infection and a method of treating Drug Resistant Bacterial Infections	India	1260/DEL/1999	17.09.1999
12	A Novel composition for treatment of Drug Resistant Bacterial Infection and a method of treating Drug Resistant Bacterial Infections	USA	9/882809	15.09.2001
13	A Novel composition for treatment of Drug Resistant Bacterial Infection and a method of treating Drug Resistant Bacterial Infections	PCT	PCT/NOO/00095	04.10.2000
14	A Novel composition to treat Hepatitis B virus infection	India	797/DEL/1996	15.04.1996
15	A process for production of Taxus Plants through tissue culture invitro	India	708/DEL/2001	26.06.2001
16	Method for Agrobacterium mediated Transformation of Taxus SP. Callus Culture	India	709/DEL/2001	26.06.2001
17	A process for purifying Polyethoxylated Castor Oil	India	29/Del/2002	16.01.2002
18	A formulation containing improved Polyethoxylated Castor Oil	India	30/Del/2002	16.01.2002
19	Novel composition of Taxane Derivative and process for manufacturing thereof	India	931/Del/1999	30.06.1999
20	Novel composition of Taxane Derivative and process for manufacturing thereof	WTO	934/Del/1999	30.06.1999
21	Use of Betulinic Acid and its Derivatives for inhibiting Cancer growth and a method of monitoring this	India	2801/Del/1997	18.03.1998
22	Use of Betulinic Acid and its Derivatives for inhibiting Cancer growth and a method of monitoring this	EPO	9530/593.8-2103	18.03.1998
23	Use of Betulinic Acid and its Derivatives for inhibiting Cancer growth and a method of monitoring this	Israel	126346	18.03.1998

Sl. No.	Title	Country	App. No.	Date of Appl.
24	Anti Angiogenic activity of Betulinic Acid and its derivatives	India	2195/Del/1998	09.09.1999
25	Anti Angiogenic activity of Betulinic Acid and its derivatives	Canada	19990816940 T	09.09.1999
26	Anti Angiogenic activity of Betulinic Acid and its derivatives	UK	19990017495	09.09.1999
27	Use of Betulinic Acid and its derivatives for inhibiting Cancer Growth	India	3458/Del/1998	17.11.1999
28	Novel Betulinic Acid Derivatives, Processes for preparing such derivatives and its use for Cancer growth inhibitors	India	932/Del/1999	30.06.1999
29	Novel Betulinic Acid Derivatives, Processes for preparing such derivatives and its use for Cancer growth inhibitors	USA	03/431905	03.11.1999
30	Novel Betulinic Acid Derivatives, Processes for preparing such derivatives and its use for Cancer growth inhibitors	PCT	PCT/IN99/0085	17.11.1999
31	Novel Betulinic Acid Derivatives, Processes for preparing such derivatives and its use for Cancer growth inhibitors	EP	999647596	18.03.1998
32	Novel Betulinic Acid having Anti Angiogenic activity, processes for producing such derivatives and their use for treating Tumor associated Angiogenesis	India	N.A.	18.03.1998
33	Novel Betulinic Acid having Anti Angiogenic activity, processes for producing such derivatives and their use for treating Tumor associated Angiogenesis	PCT	PCT/IN99/0043	09.09.1999
34	Novel Process for the isolation of Betulinic Acid from Ziziphus Jujuba	PCT	IN00/00019	29.02.2000
35	Process for isolating 10-Deacetyl Baccatin-III	India	2193/Del/1998	07.09.1999
36	Process for isolating 10-Deacetyl Baccatin-III	PCT	PCT/IN99/00041	07.09.1999
37	Process for the isolation of 14-B-Hydroxy-10-Deacetyl Baccatin-III	India	2194/Del/1998	15.12.1998
38	Process for the isolation of 14-B-Hydroxy-10-Deacetyl Baccatin-III	EPO	99890/2613	15.12.1998
39	Novel Paclitaxel Analogues having Anti Cancer Activity	WTO	522/Del/2000	19.05.2000
40	Novel Paclitaxel Analogues having Anti Cancer Activity	PCT	PCT/IN00/00074	03.08.2000
41	Radiolabeled Vasoactive Intestinal Peptide Analogs for Diagnosis and therapy	USA	09/629632	31.07.2000
42	Radiolabeled Vasoactive Intestinal Peptide Analogs for Diagnosis and therapy	PCT	US00/20874	18.02.2000
43	Vasoactive Intestinal Peptide Analogs	Malaysia	P120012467	18.02.2000
44	Vasoactive Intestinal Peptide Analogs	PCT	US00/630335	18.02.2000
45	Vasoactive Intestinal Peptide Analogs	Argentina	PO10102426	18.02.2000
46	Bombesin Analogs for the treatment of Cancer	Argentina	PO0102428	24.02.2000
47	Bombesin Analogs for the treatment of Cancer	USA	09/630333	31.07.2000
48	Bombesin Analogs for the treatment of Cancer	PCT	US00/20873	24.02.2000
49	Substance P Analogs for the treatment of Cancer	Malaysia	P120012471	31.07.2000
50	Substance P Analogs for the treatment of Cancer	Argentina	PO10102429	31.07.2000
51	Substance P Analogs for the treatment of Cancer	USA	09/629642	31.07.2000
52	Radiolabeled Vasoactive Intestinal Peptide Analogs for diagnosis and therapy	Malaysia	P120012468	18.02.2000
53	Radiolabeled Vasoactive Intestinal Peptide Analogs for diagnosis and therapy	Argentina	PO10102425	18.02.2000
54	Substance P Analogs for the treatment of Cancer	PCT	US00/20875	31.07.2000
55	Somatostatin Analogs for the treatment of Cancer	Malaysia	P120012467	31.07.2000
56	Somatostatin Analogs for the treatment of Cancer	Canada	2385910	31.07.2000
57	Somatostatin Analogs for the treatment of Cancer	Argentina	PO10102424	31.07.2000
58	Somatostatin Analogs for the treatment of Cancer	PCT	US00/20872	31.07.2000
59	Somatostatin Analogs for the treatment of Cancer	Philippines	1-2001-01294	31.07.2000
60	Novel peptides for the treatment of Cancer	India	N.A.	N.A.
61	Novel peptides for the treatment of Cancer	USA	09/630345	31.07.2000
62	Novel peptides for the treatment of Cancer	Malaysia	P120012468	31.07.2000
63	Novel peptides for the treatment of Cancer	PCT	US00/20876	31.07.2000
64	Novel peptides analogs for the treatment of Cancer	PCT	US00/03	10.02.1999
65	Method and composition for Solubilization of Pentacyclic Terpenes, particularly Betulinic Acid and its derivatives	USA	09/802293	08.03.2001
66	Method and composition for Solubilization of Pentacyclic Terpenes, particularly Betulinic Acid and its derivatives	PCT	US2002/0091091	11.05.2000
67	Prodrug approach to a mixture of Bio active peptide	India	1022/Dec/2002	08.10.2002
68	Method for treating Cancer using betulinic acid rich herbal extract	PCT	N.A.	13.12.2002
69	A drug comprising peptide analogs for the treatment of Cancer	PCT	PCT/IN03/00040	23.12.2002

Sl. No.	Title	Country	App. No.	Date of Appl.
70	Anti Cancer activity of Carvediol and its Isomers	USA	10/238992	10.09.2002
71	Anti Cancer activity of Carvediol and its Isomers	PCT	PCT/US02/28794	10.09.2002
72	Multivalent Synthetic vaccine for Cancer	USA	10/211994	02.08.2002
73	Multivalent Synthetic vaccine for Cancer	PCT	US02/24561	03.08.2001
74	Peptide Combination for the treatment of Cancer	EPO	EPO835662	29.06.2001
75	Peptide Combination for the treatment of Cancer	PCT	PCT/US01/120775	29.06.2001
76	Anti Cancer activity of Methylglyoxal and its Imino Acid Conjugates	USA	60/302637	02.07.2001
77	Anti Cancer activity of Methylglyoxal and its Imino Acid Conjugates	PCT	PCT/US02/20753	02.07.2001
78	An oral formulation of Alpha-Ketoaldehyde for Human use	USA	10/187422	01.07.2002
79	An oral formulation of Alpha-Ketoaldehyde for Human use	PCT	US02/20656	02.07.2001
80	Cyclopentenone derivatives for Cancer Therapy	USA	10/309754	04.12.2002
81	Cyclopentenone derivatives for Cancer Therapy	PCT	IN/02/004239	N.A.
82	Prodrug approach to a Mixture of Bio active Peptides	USA	10/186226	28.06.2002
83	Method for treating Cancer using Betulinic Acid rich Herbal Extract	USA	10/319374	13.12.2002
84	A Drug Comprising Peptide Analogs for the treatment of Cancer	USA	10/329321	23.12.2002
85	A pharmaceutical composition for the treatment of pathological conditions arising out of excessive proliferation of cells and a process for the preparation of thereof	India	64/1/01/2000	11.07.2000
86	A new drug for the treatment of Cancer	Canada	2197130	08.10.1996
87	A new drug for the treatment of Cancer	EPO	96309012-2107	08.10.1996
88	A new drug for the treatment of Cancer	USA	6156725	08.10.1996
89	A new method for establishing cell lines from tumor biopsies	Canada	2193752	16.08.1996
90	A new method for establishing cell lines from tumor biopsies	USA	5744363	13.12.1996
91	An antiangiogenic drug	EPO	EP1150700	11.02.1999
92	An antiangiogenic drug	PCT	US00/03559	11.02.1999
93	An antiangiogenic drug	Australia	AU 2991200	11.02.1999
94	An antiangiogenic drug	USA	64892330	11.02.1999
95	A process for the preparation of Pharmaceutical formulation of into polymeric micelles nanoparticles for the treatment of Cancer Paclitaxel	PCT	US00/25914	17.02.1999
96	A process for the preparation of Pharmaceutical formulation of into polymeric micelles nanoparticles for the treatment of Cancer Paclitaxel	India	263/01/1999	17.02.1999
97	Vasoactive Intestinal Peptide analogs	USA	6489297	31.07.2000
98	Novel peptide analogs for the treatment of Cancer	USA	09/248382	11.02.1998
99	Process for the preparation of Paclitaxel Tri Hydrate & Docetaxel Tri Hydrate	Thailand	80554	03.03.2003
100	A process for preparing (4s, 5R)-3-[3 substituted prop-2-Ynyloxy]-2, 2 Distributed -4-(substituted Phenyl)-5-Oxazolidine Carboxylic Acid	India	552/Cal/2000	25.09.2002
101	Method of preparation of Paclitaxel (Taxol) using 3-ALK-2-Ynyloxy Carbonyl-5-Oxazolidine Carboxylic Acid	PCT	PCT/IN01/00020	20.02.2001
102	Method of preparation of Paclitaxel (Taxol) using 3-ALK-2-Ynyloxy Carbonyl-5-Oxazolidine Carboxylic Acid	USA	09/870942	01.06.2001
103	Process for Paclitaxel Purification	India	305/Cal/2001	24.05.2001
104	Method of preparation of Anti Cancer Taxane using 3-(substituted-2-Trialkylsilyl) Ethoxy-Carbonyl)-5-Oxazolidine (Carboxylic Acid)	India	269/Cal/2002	07.05.2002
105	Method of preparation of Anti Cancer Taxanes using 3-Trihaloacetyl-5-Oxazolidine Carboxylic Acid	India	268/Cal/2002	07.05.2002
106	Anti Cancer Taxanes such as Paclitaxel, Docetaxel and their structural analogs and a method for the preparation thereof	India	294/Cal/2002	10.05.2002
107	Process for the preparation of Paclitaxel Tri Hydrate & Docetaxel Tri Hydrate	India	697/Cal/2002	16.12.2002
108	A process for the preparation of Taxane Baccatin III and 7-O protected Baccatin	India	392/Cal/2001	13.07.2001
109	Process for the preparation of Taxanes such as Paclitaxel, Docetaxel and structurally similar Analogs	USA	60/311077	10.08.2001
110	Process for purification of Paclitaxel and Docetaxel	USA	60/353995	05.02.2002

PHARMACEUTICAL PRODUCTS LIST - REGISTRATION STATUS
FROM 1992 TO JANUARY 2002

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
ALBANIA	—	Uizol	Non-Onco	—	Submitted
BANGLADESH	17.05.1998	Intaxel 30 mg	Onco	11.05.1998	Registered
BANGLADESH	22.12.1997	Daxotel 20	Onco	—	Registered
BANGLADESH	22.12.1997	Daxotel 80	Onco	—	Registered
BANGLADESH	22.12.1997	Kemocarb 15 ml	Onco	28.04.1998	Registered
BANGLADESH	22.12.1997	Kemocarb 45 ml	Onco	28.04.1998	Registered
BANGLADESH	08.05.1998	Zexate Tab. 2.5 mg	Onco	04.08.1998	Submitted
BANGLADESH	08.05.1998	Zexate Inj. 50 mg	Onco	04.08.1998	Submitted
BANGLADESH	08.05.1998	Zexate Inj. 15 mg	Onco	04.08.1998	Submitted
BANGLADESH	08.05.1998	Fivoflu 250	Onco	04.08.1998	Submitted
BANGLADESH	08.05.1998	Fivoflu 500 mg	Onco	04.08.1998	Submitted
BANGLADESH	08.05.1998	Fylosid 100 mg	Onco	04.08.1998	Submitted
BARBADOS	13.06.1997	Oncology Products	Onco	—	Registered
BARBADOS	13.06.1997	Antibiotic	Non-Onco	—	Registered
BARBADOS	30.09.1998	Ledoxan, Gattwell Pharmaceuticals	Onco	10.05.1999	Submitted
BARBADOS	07.01.1999	BHPL	Non-Onco	—	Submitted
BARBADOS	01.04.1999	Fylosid (USP)	Onco	24.05.1999	Submitted
BELARUS	08.01.1998	Adrim 10	Onco	—	Submitted
BELARUS	08.01.1998	Adrim 50	Onco	—	Submitted
BELARUS	08.01.1998	Zexate Tablet	Onco	03.09.1998	Submitted
BELARUS	08.02.2000	Intaxel 30	Onco	17.02.2000	Submitted
BELARUS	08.02.2000	Intaxel 100 mg	Onco	17.02.2000	Submitted
BELARUS	03.02.2000	Kemocarb 150	Onco	07.04.2000	Submitted
BELARUS	03.02.2000	Kemocarb 450	Onco	07.04.2000	Submitted
BELARUS	03.02.2000	Kemoplat 10	Onco	07.04.2000	Submitted
BELARUS	03.02.2000	Kemoplat 50	Onco	07.04.2000	Submitted
BELARUS	03.02.2000	Fylosid	Onco	07.04.2000	Submitted
BELARUS	03.02.2000	Zexate 15	Onco	07.04.2000	Submitted
BELARUS	03.02.2000	Zexate 50	Onco	07.04.2000	Submitted
BELARUS	03.02.2000	Fivoflu 250	Onco	07.04.2000	Submitted
BELARUS	03.02.2000	Fivoflu 500	Onco	07.04.2000	Submitted
BELARUS	03.03.2001	Daxotel Injection 20 mg	Onco	28.06.2001	Submitted
BELARUS	03.03.2001	Daxotel Injection 80 mg	Onco	28.06.2001	Submitted
BELARUS	03.03.2001	Vinorelbine Injection 10 mg	Onco	20.09.2001	Submitted
BELARUS	03.03.2001	Vinorelbine Injection 50 mg	Onco	20.09.2001	Submitted
BOTSWANA	—	Supplier Registration Form 1998	—	24.07.1999	Submitted
BOTSWANA	—	Adrim 10	Onco	09.08.1999	Submitted
BOTSWANA	—	Adrim 50	Onco	09.08.1999	Submitted
BOTSWANA	—	Zexate 50	Onco	09.08.1999	Submitted
BRAZIL	06.08.1996	Adrim 10 mg	Onco	19.09.1996	Registered
BRAZIL	06.08.1996	Adrim 50 mg	Onco	19.09.1996	Registered
BRAZIL	06.08.1996	Kemoplat 10 mg	Onco	19.09.1996	Registered
BRAZIL	06.08.1996	Kemoplat 50 mg	Onco	19.09.1996	Registered
BRAZIL	06.08.1996	Fylosid 100 mg	Onco	19.09.1996	Registered
BRAZIL	06.08.1996	Zexate 50 mg & 500	Onco	19.09.1996	Registered
BRAZIL	06.08.1996	Tamoxifen Tabs 10 mg	Onco	19.09.1996	Registered
BRAZIL	06.08.1996	Tamoxifen Tabs 20 mg	Onco	19.09.1996	Registered
BRAZIL	06.08.1996	Intaxel 30 mg & 100mg	Onco	19.09.1996	Registered
BRAZIL	06.08.1996	Zexate 15 mg	Onco	19.09.1996	Submitted
BRAZIL	18.02.1997	Cellaxone Inj. 1 g	Non-onco	—	Submitted
BRAZIL	13.06.1997	lohexol	Non-onco	24.06.1997	Submitted
BRAZIL	30.09.1999	lohexol 350	Non-onco	05.10.1999	Submitted
BRAZIL	13.06.1997	Ciprofloxacin Tablets 500 mg	Non-Onco	24.06.1997	Submitted
BRAZIL	13.06.1997	Fluconazole	Non-Onco	—	Submitted
BRAZIL 2	21.04.1998	Zexate Tabs 2.5 mg	Onco	11.08.1998	Submitted
BRAZIL 2	21.04.1998	Fivoflu Inj. 250 & 500 mg	Onco	11.08.1998	Submitted

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
BRAZIL 2	21.04.1998	Ledoxan Tabs 50 mg	Onco	11.08.1998	Submitted
BRAZIL 2	21.04.1998	Ledoxan Inj. 200, 500, 1 g	Onco	11.08.1998	Submitted
BRAZIL	08.11.2000	Kemocarb 150 & 450 mg	Onco	29.03.2001	Submitted
BRAZIL	08.11.2000	Daxotef 20 & 80 mg	Onco	29.03.2001	Submitted
BRAZIL	08.11.2000	Cytarin BP 500mg	Onco	12.04.2001	Submitted
CANADA	21.04.1998	Intaxel	Onco	—	Submitted
CHILE	05.06.1997	Mesna	Adjuvant	—	Submitted
CHILE	05.06.1997	Tamoxifen 10	Onco	—	Submitted
CHILE	04.01.2000	Cisplatin 10 mg/20ml	Onco	30.09.2000	Submitted
CHILE	04.01.2000	Cisplatin 50 mg	Onco	30.09.2000	Submitted
CHILE	04.01.2000	Adrim 10 mg	Onco	17.02.2001	Submitted
CHILE	04.01.2000	Adrim 50 mg	Onco	17.02.2001	Submitted
CHILE	04.01.2000	Fytosid 100 mg	Onco	08.05.2000	Submitted
CHILE	04.01.2000	Fivoflu 250 mg	Onco	30.09.2000	Submitted
CHILE	04.01.2000	Fivoflu 500mg	Onco	30.09.2000	Submitted
CHILE	04.01.2000	Gynatam 20 mg	Onco	08.05.2000	Submitted
CHILE	04.01.2000	Intaxel 30	Onco	08.05.2000	Submitted
CHILE	04.01.2000	Docetaxel 20	Onco	08.05.2000	Submitted
CHILE	04.01.2000	Docetaxel 80 mg	Onco	08.05.2000	Submitted
CHILE	04.01.2000	Ipamide inj. 1 gm	Onco	08.05.2000	Submitted
CHILE	04.01.2000	Leucovorin 3, 15 & 50 mg	Adjuvant	08.05.2000	Submitted
CHILE	04.01.2000	Empurine Tab 50 mg	Onco	08.05.2000	Submitted
CHILE	04.01.2000	Zexate inj 50 & 500 mg	Onco	08.05.2000	Submitted
CHILE	04.01.2000	Zexate Tab 2.5 mg	Onco	08.05.2000	Submitted
CHILE	04.01.2000	Topotel 4 mg	Onco	17.02.2001	Submitted
COLOMBIA	23.04.1999	Adrim 10 mg	Onco	12.05.1999	Registered
COLOMBIA	23.04.1999	Adrim 50 mg	Onco	12.05.1999	Registered
COLOMBIA	23.04.1999	Fivoflu 250 mg	Onco	12.05.1999	Registered
COLOMBIA	23.04.1999	Fivoflu 500 mg	Onco	12.05.1999	Registered
COLOMBIA	23.04.1999	Zexate 15 mg	Onco	20.05.1999	Registered
COLOMBIA	23.04.1999	Fytosid 100	Onco	20.05.1999	Registered
COLOMBIA	23.04.1999	Kemopat 10 mg	Onco	20.05.1999	Registered
COLOMBIA	23.04.1999	Kemoplat 50 mg	Onco	20.05.1999	Registered
COLOMBIA	23.04.1999	Gynatam 10	Onco	14.06.1999	Registered
COLOMBIA	23.04.1999	Kemocarb 150	Onco	20.05.1999	Registered
COLOMBIA	23.04.1999	Kemocarb 450 mg	Onco	20.05.1999	Registered
COLOMBIA	23.04.1999	Intaxel 30 mg & 100 mg	Onco	12.05.1999	Submitted
COLOMBIA	23.04.1999	Zexate 50 mg	Onco	20.05.1999	Submitted
COLOMBIA	23.04.1999	Daxotef 20 mg & 80 mg	Onco	20.05.1999	Submitted
COLOMBIA	23.04.1999	Zexate 2.5 mg	Onco	14.06.1999	Submitted
COLOMBIA	23.04.1999	Ledoxan 50 mg	Onco	14.06.1999	Submitted
COLOMBIA	23.04.1999	Gynatam 20	Onco	14.06.1999	Submitted
COLOMBIA	23.04.1999	Ledoxan 200, 500 mg & 1 gm	Onco	08.07.1999	Submitted
COLOMBIA	23.04.1999	Hydab 500mg	Onco	17.08.1999	Submitted
COLOMBIA	23.04.1999	Empurin 50 mg	Onco	17.09.1999	Submitted
COSTA RICA	11.10.1999	Fytosid 100	Onco	14.12.1999	Registered
COSTA RICA	11.10.1999	Zexate inj. 50 mg	Onco	14.12.1999	Registered
COSTA RICA	11.10.1999	Zexate Tablet 2.5	Onco	14.12.1999	Registered
COSTA RICA	11.10.1999	Intaxel 30 mg	Onco	14.12.1999	Registered
COSTA RICA	11.10.1999	Intaxel 100 mg	Onco	14.12.1999	Registered
COSTA RICA	11.10.1999	Fivoflu 500	Onco	14.12.1999	Registered
COSTA RICA	11.10.1999	Ledoxan Tablet 50	Onco	14.12.1999	Registered
COSTA RICA	12.09.2000	Kemoplat Injection 10mg	Onco	—	Registered
COSTA RICA	01.08.2001	Kemocarb 150	Onco	22.08.2001	Submitted
COSTA RICA	01.08.2001	Kemocarb 450	Onco	22.08.2001	Submitted
COSTA RICA	11.10.1999	Gynatam 20	Onco	14.12.1999	Submitted
COSTA RICA	30.01.1998	Fivoflu 750	Onco	31.07.1998	Submitted
COSTA RICA	25.05.1998	Ledoxan Inj 200	Onco	31.07.1998	Submitted

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
COSTA RICA	25.05.1998	Ledoxan Inj 500	Onco	31.07.1998	Submitted
COSTA RICA	25.05.1998	Ledoxan Inj 1g	Onco	31.07.1998	Submitted
COSTA RICA	12.09.2000	Cytarin Inj 100 mg	Onco	13.04.2001	Submitted
COSTA RICA	12.09.2000	Leucovorin Injection 50mg	Adjuvant	13.04.2001	Submitted
CZECHOSLOVAKIA	—	Inilaxel	Onco	—	Submitted
DUBAI	—	Gold Lowcal (Aspartame Tablet)	Non-Onco	—	Registered
DUBAI	—	Diet Salt	Non-Onco	—	Registered
DUBAI	—	O-lyte	Non-Onco	—	Registered
ECDS (Eastern caribbean)	15.02.1999	Fivoflu 250 mg	Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Zexale 50 mg	Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Ledoxan 50 mg	Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Tamoxifen tab 20 mg	Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Hydab 500 mg	Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Alexin 250 mg	Non-Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Alexin 500 mg	Non-Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Atecard 50 mg	Non-Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Atecard 100 mg	Non-Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Strox 250 mg	Non-Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Strox 500 mg	Non-Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Norfloraxine tab 400 mg	Non-Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Ultal 20 mg	Non-Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Empurine 50 mg	Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Tinavate Cream	Non-Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Tinavate Solution	Non-Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Ranitidine 150 mg	Non-Onco	—	Provided samples
ECDS (Eastern caribbean)	06.05.1998	Ledoxan 50 tab	Onco	—	Provided samples
EL SALVADOR	02.05.1998	Kemacarb 150 mg	Onco	24.09.1998	Submitted
EL SALVADOR	02.05.1998	Kemoplat 10 mg	Onco	24.09.1998	Submitted
EL SALVADOR	02.05.1998	Ledoxan Inj. 500 mg	Onco	24.09.1998	Submitted
EL SALVADOR	02.05.1998	Ledoxan Tab. 50	Onco	24.09.1998	Submitted
EL SALVADOR	02.05.1998	Daxolief 20 mg	Onco	24.09.1998	Submitted
EL SALVADOR	02.05.1998	Adrim 10 mg	Onco	24.09.1998	Submitted
EL SALVADOR	02.05.1998	Fytosid 100	Onco	24.09.1998	Submitted
EL SALVADOR	02.05.1998	Fivoflu 500 mg	Onco	24.09.1998	Submitted
EL SALVADOR	02.05.1998	Zexale Inj. 50 mg	Onco	24.09.1998	Submitted
EL SALVADOR	02.05.1998	Zexale Tab.	Onco	24.09.1998	Submitted
EL SALVADOR	02.05.1998	Inilaxel 30 mg	Onco	24.09.1998	Submitted
EL SALVADOR	02.05.1998	Gynatam 10 mg	Onco	24.09.1998	Submitted
ESTONIA/ FINLAND	27.03.1997	Ampicilin Capsules 500 mg	Non-Onco	22.4.97, 4.8.97	Submitted
ESTONIA/ FINLAND	27.03.1997	Cephalexin Capsules 250 mg	Non-Onco	24.09.1998	Submitted
ESTONIA/ FINLAND	May 1997	Norfloraxin Tablets 400 mg	Non-Onco	24.09.1998	Submitted
ESTONIA/ FINLAND	May 1997	Amoxycillin Cap. 250 mg	Non-Onco	16.06.1997	Submitted
ESTONIA/ FINLAND	May 1997	Amoxycillin Cap. 500 mg	Non-Onco	16.06.1997	Submitted
ESTONIA/ FINLAND	May 1997	Ampicilin Capsules 250 mg	Non-Onco	04.08.1997	Submitted
ESTONIA/ FINLAND	May 1997	Omeprazole Capsules 20 mg	Non-Onco	04.08.1997	Submitted
ESTONIA/ FINLAND	May 1997	Metronidazole tablets 400 mg	Non-Onco	04.08.1997	Submitted
ESTONIA/ FINLAND	May 1997	Metronidazole tablets 200	Non-Onco	04.08.1997	Submitted
ESTONIA/ FINLAND	May 1997	Ciprofloraxin tablets 500 mg	Non-Onco	04.08.1997	Submitted
ESTONIA/ FINLAND	May 1997	Ciprofloraxin tablets 250	Non-Onco	04.08.1997	Submitted
ETHIOPIA	30.05.2000	Company Profile	—	30.08.2000	Submitted
GHANA	—	Demoxy 250 Capsules	Non-Onco	—	Registered
GHANA	—	Alexin 125mg/5ml	Non-Onco	—	Registered
GHANA	—	Alexin 250	Non-Onco	—	Registered
GHANA	—	Alexin 500	Non-Onco	—	Registered
GHANA	—	Nuren 200	Non-Onco	—	Registered
GHANA	—	Nuren 400	Non-Onco	—	Registered
GHANA	—	Tinavate cream 1% w/w	Non-Onco	—	Registered
GHANA	—	Ulgel liquid	Non-Onco	—	Registered

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
GHANA	—	Ulgel tablet	Non-Onco	—	Registered
GHANA	—	Atecard 100	Non-Onco	—	Registered
GHANA	—	Atecard 50	Non-Onco	—	Registered
GHANA	—	Damoxy 500	Non-Onco	—	Registered
GHANA	—	Damoxy syrup 125mg/ 5ml	Non-Onco	—	Registered
GHANA	—	Tinavate Solution	Non-Onco	—	Registered
GHANA	09.11.1999	Fivoflu 250	Onco	01.03.2000	Registered
GHANA	06.03.2000	Fylosid inj. 100 mg	Onco	15.07.2000	Registered
HONG KONG	04.01.1996	Intaxel	Onco	08.01.1996	Submitted
HONG KONG	04.01.1996	Fylosid	Onco	08.01.1996	Submitted
HONG KONG	27.07.1996	Ledoxan	Onco	24.07.1996	Submitted
HUNGARY	—	Intaxel	Onco	—	Submitted
IRAN 1	07.04.1998	Intaxel inj. 30 mg&100 mg	Onco	—	Submitted
IRAN 1	15.02.1999	Fylosid inj.	Onco	—	Submitted
IRAN 2	12.06.2000	Ledoxan inj. 200 mg	Onco	18.12.2000	Submitted
IRAN 2	12.06.2000	Ledoxan inj. 500 mg	Onco	18.12.2000	Submitted
IRAN 2	12.06.2000	Ledoxan inj. 1 gm	Onco	18.12.2000	Submitted
IRAN 3	21.09.2001	Intaxel 260mg	Onco	31.12.2001	Submitted
IRAN 3	21.09.2001	Kemocarb 150 mg	Onco	31.12.2001	Submitted
IRAN 3	21.09.2001	Kemocarb 450 mg	Onco	31.12.2001	Submitted
IRAN 3	21.09.2001	Kemoplat 10 mg	Onco	31.12.2001	Submitted
IRAN 3	21.09.2001	Kemoplat 50 mg	Onco	31.12.2001	Submitted
IRAN 3	21.09.2001	Adrim 10	Onco	31.12.2001	Submitted
IRAN 3	21.09.2001	Adrim 50	Onco	31.12.2001	Submitted
IRAN 3	21.09.2001	Fivoflu 250	Onco	31.12.2001	Submitted
IRAN 3	21.09.2001	Fivoflu 500	Onco	31.12.2001	Submitted
IRAN 3	21.09.2001	Cytarine 100 mg	Onco	31.12.2001	Submitted
IRAN 3	21.09.2001	Cytarine 500 mg	Onco	31.12.2001	Submitted
IRAN 3	21.09.2001	Cytarine 1g	Onco	31.12.2001	Submitted
IRAN 3	21.09.2001	Zexate 15	Onco	31.12.2001	Submitted
IRAN 3	21.09.2001	Zexate 50	Onco	31.12.2001	Submitted
IRAN 3	21.09.2001	Daxotel-20mg	Onco	21.01.2002	Submitted
IRAN 3	21.09.2001	Daxotel-80mg	Onco	21.01.2002	Submitted
IRAN 3	21.09.2001	Leuco-Ca inj. USP 3mg	Adjuvant	21.01.2002	Submitted
IRAN 3	21.09.2001	Leuco-Ca inj. USP 15mg	Adjuvant	21.01.2002	Submitted
IRAN 3	21.09.2001	Leuco-Ca inj. USP 50mg	Adjuvant	21.01.2002	Submitted
IRAN 3	21.09.2001	Mesna Injection	Adjuvant	21.01.2002	Submitted
IRAN 3	21.09.2001	Irinotel Injection 40mg	Onco	21.01.2002	Submitted
IRAN 3	21.09.2001	Irinotel Injection 100mg	Onco	21.01.2002	Submitted
IRAN 3	21.09.2001	Vineltine Injection 10mg	Onco	21.01.2002	Submitted
IRAN 3	21.09.2001	Vineltine Injection 50mg	Onco	21.01.2002	Submitted
IRAN 3	21.09.2001	Topotel Injection 2.5mg	Onco	21.01.2002	Submitted
IRAN 3	21.09.2001	Topotel Injection 4mg	Onco	21.01.2002	Submitted
IRAN 3	21.09.2001	Empurine Tabs.	Onco	21.01.2002	Submitted
IRAN 3	21.09.2001	Gynatam-10 Tabs	Onco	21.01.2002	Submitted
IRAN 3	21.09.2001	Gynatam-20 Tabs	Onco	21.01.2002	Submitted
IRAN 3	21.09.2001	Ledoxan Tabs	Onco	21.01.2002	Submitted
IRAN 3	21.09.2001	Zexate Tabs	Onco	21.01.2002	Submitted
IRAQ	Dec 1997	Company Profile	—	—	Registered
IRAQ	15.12.1997	Atecard 50	Non-Onco	08.01.1998	Submitted
IRAQ	15.12.1997	Atecard 100	Non-Onco	08.01.1998	Submitted
IRAQ	15.12.1997	Damoxy 250	Non-Onco	08.01.1998	Submitted
IRAQ	15.12.1997	Damoxy 500	Non-Onco	08.01.1998	Submitted
IRAQ	15.12.1997	Damoxy DS	Non-Onco	08.01.1998	Submitted
IRAQ	15.12.1997	Nuren 200	Non-Onco	08.01.1998	Submitted
IRAQ	15.12.1997	Nuren 400	Non-Onco	08.01.1998	Submitted
IRAQ	15.12.1997	Alexin 250	Non-Onco	08.01.1998	Submitted
IRAQ	15.12.1997	Alexin 500	Non-Onco	08.01.1998	Submitted

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
IRAQ	15.12.1997	Dabcofax 500	Non-Onco	08.01.1998	Submitted
IRAQ	18.12.1997	Dabcofax DS	Non-Onco	08.01.1998	Submitted
IRAQ	24.07.1998	Strox 250	Non-Onco	—	Submitted
IRAQ	24.07.1998	Strox 500	Non-Onco	—	Submitted
IRAQ	24.07.1998	Tamoxifen 10	Onco	—	Submitted
IRAQ	24.07.1998	Tamoxifen 20	Onco	—	Submitted
IRAQ	24.07.1998	Kemoplat 20 ml	Onco	—	Submitted
IRAQ	24.07.1998	Kemoplat 100ml	Onco	—	Submitted
IRAQ	24.07.1998	Adrim 10	Onco	—	Submitted
IRAQ	24.07.1998	Adrim 20	Onco	—	Submitted
IRAQ	24.07.1998	Fytosid	Onco	—	Submitted
IRAQ	24.07.1998	Fivoflu 250 mg	Onco	—	Submitted
IRAQ	24.07.1998	Zexate Injection 50 mg	Onco	—	Submitted
IRAQ	24.07.1998	Zexate Tablet 2.5 mg	Onco	—	Submitted
ISRAEL	—	Intaxel	Onco	06.09.1999	Registered
JAMAICA	June 1997	Adrim 10 mg	Onco	—	Registered
JAMAICA	June 1997	Adrim 50 mg	Onco	—	Registered
JAMAICA	June 1997	Fytosid 100	Onco	—	Registered
JAMAICA	June 1997	Kemoplat 50 mg	Onco	—	Registered
JAMAICA	June 1997	Intaxel 30 mg	Onco	—	Registered
JAMAICA	June 1997	Fivoflu 5 ml	Onco	—	Registered
JAMAICA	June 1997	Fivoflu 10 ml	Onco	—	Registered
JAMAICA	June 1997	Zexate 50 mg	Onco	—	Registered
JAMAICA	June 1997	Gynatam 10	Onco	—	Submitted
JAMAICA	June 1997	Kemocarb 150 mg	Onco	—	Submitted
JAMAICA	02.05.1998	Ledoxan Tab.	Onco	—	Submitted
JAMAICA	09.05.1998	Ledoxan 200, 500 mg & 1 g	Onco	—	Submitted
JORDAN	08.03.1999	Intaxel inj. 30mg	Onco	04.10.1999	Registered
JORDAN	08.03.1999	Intaxel inj. 100mg	Onco	04.10.1999	Registered
JORDAN	08.03.1999	Fivoflu inj. 250mg	Onco	04.10.1999	Registered
JORDAN	08.03.1999	Fivoflu inj. 500mg	Onco	04.10.1999	Registered
JORDAN	06.03.2000	Adrim inj. 10 mg	Onco	10.2001	Submitted
JORDAN	06.03.2000	Adrim inj. 50 mg	Onco	10.2001	Submitted
JORDAN	06.03.2000	Fytosid 100 mg	Onco	10.2001	Submitted
KAZAKHSTAN	Nov. 1997	Docetaxel inj. 20 & 80	Onco	—	Submitted
KAZAKHSTAN	Nov. 1997	Intaxel inj. 30 mg & 100 mg	Onco	—	Submitted
KAZAKHSTAN	Nov. 1997	Fytosid inj. 100	Onco	—	Submitted
KAZAKHSTAN	Nov. 1997	Cisplatin inj. 10 & 50	Onco	—	Submitted
KAZAKHSTAN	Nov. 1997	Adrim inj. 10 & 50	Onco	—	Submitted
KAZAKHSTAN	Nov. 1997	Carboplatin inj. 150 & 450	Onco	—	Submitted
KENYA	11.11.1993	Nuren Gel	Non-Onco	—	Registered
KENYA	—	Zenad 60 Tablets	Non-Onco	—	Registered
KENYA	—	Zenad 120 Tablets	Non-Onco	—	Registered
KENYA	—	Ulgel tab	Non-Onco	—	Registered
KENYA	—	Ulgel liquid	Non-Onco	—	Registered
KENYA	—	Atecard 25	Non-Onco	—	Registered
KENYA	—	Atecard 50	Non-Onco	—	Registered
KENYA	—	Atecard 100	Non-Onco	—	Registered
KENYA	—	Atecard D	Non-Onco	—	Registered
KENYA	—	Zenad Suspension	Non-Onco	—	Registered
KENYA	—	Oryza-SF Expectoant	Non-Onco	—	Registered
KENYA	—	Cefadroxil Tabs 250 mg (Kid tabs)	Non-Onco	—	Registered
KENYA	—	Cefadroxil Caps 500 mg	Non-Onco	—	Registered
KENYA	—	Alexin 250, 500 & DS	Non-Onco	—	Registered
KENYA	—	Unilyte Oral rehydration salt	Non-Onco	—	Registered
KENYA	—	Durox Caps 20 mg	Non-Onco	—	Registered
KENYA	24.07.1996	Tamoxifen tab 10 & 20	Onco	27.11.1996	Registered
KENYA	24.07.1996	Intaxel 30 & 100	Onco	—	Registered

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
KENYA	24.07.1998	Kemoplat Inj	Onco	27.11.1998	Registered
KENYA	09.01.1998	Adrim Inj 2mg/ml	Onco	18.03.1998	Registered
KENYA	15.02.1999	Zexate Injection 50	Onco	20.07.1999	Registered
KENYA	15.02.1999	Kemocarb	Onco	20.07.1999	Registered
KENYA	11.11.1993	Dabcin Caps	Non-Onco	—	Submitted
KENYA	11.11.1993	Dabotin Dry Syrup	Non-Onco	—	Submitted
KENYA	11.11.1993	Damoxy Caps 250 mg	Non-Onco	—	Submitted
KENYA	11.11.1993	Damoxy Dry Syrup	Non-Onco	—	Submitted
KENYA	11.11.1993	Co-trimoxazole Tablets	Non-Onco	—	Submitted
KENYA	11.11.1993	Paediatric Co-trimoxazole Suspension	Non-Onco	—	Submitted
KENYA	—	Dabcof Caps	Non-Onco	—	Submitted
KENYA	—	Dabcof Injection	Non-Onco	—	Submitted
KENYA	—	Dabcof Dry Syrup	Non-Onco	—	Submitted
KENYA	—	Sirox 250 Tabs	Non-Onco	—	Submitted
KENYA	—	Sirox 500 Tabs	Non-Onco	—	Submitted
KENYA	—	Celadroxil Tabs 500 mg	Non-Onco	—	Submitted
KENYA	—	Celadroxil Dry Syrup DS250 mg/ 5ml	Non-Onco	—	Submitted
KENYA	09.01.1998	Daxotel 20 580	Onco	—	Submitted
KENYA	15.02.1999	Fivoflu 750 8500	Onco	20.07.1999	Submitted
KOREA	—	Intaxel	Onco	—	Submitted
LITHUANIA	26.03.1999	Ulzol	Non-Onco	—	Submitted
MACAO	08.10.2001	Intaxel 30	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Intaxel 100	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Intaxel 200 mg	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Daxotel 20	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Daxotel 80mg	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Adrim 10	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Adrim 50	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Contrastin (60 %) 20ml	Non Onco	17.01.2002	Submitted
MACAO	08.10.2001	Contrastin 76% inj. 20ml	Non Onco	17.01.2002	Submitted
MACAO	08.10.2001	Contrastin 76% inj. 50 ml	Non Onco	17.01.2002	Submitted
MACAO	08.10.2001	Contrastin 76% inj. 100 ml	Non Onco	17.01.2002	Submitted
MACAO	08.10.2001	Cytarabine BP100mg	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Cytarabine BP 500 mg	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Cytarabine BP 1g	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Fivoflu 250 vial	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Fivoflu 500 vial	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Fytosid 100	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Ifinotel 40 & 100 mg	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Kemocarb 150	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Kemoplat 10mg/20ml & 50mg/100ml	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Leucovorine 15 mg	Adjuvant	17.01.2002	Submitted
MACAO	08.10.2001	Leucovorine 3 mg	Adjuvant	17.01.2002	Submitted
MACAO	08.10.2001	Leucovorine 50 mg	Adjuvant	17.01.2002	Submitted
MACAO	08.10.2001	Mesna 200	Adjuvant	17.01.2002	Submitted
MACAO	08.10.2001	Radiopaque inj. 240mg/ml, 10 ml	Non Onco	17.01.2002	Submitted
MACAO	08.10.2001	Radiopaque inj. 300mg/ml, 10ml, 20ml, 50ml & 100ml	Non Onco	17.01.2002	Submitted
MACAO	08.10.2001	Radiopaque inj. 350mg/ml, 20ml, 50ml & 100ml	Non Onco	17.01.2002	Submitted
MACAO	08.10.2001	Topotel 2.5 & 4 mg	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Vinorelbine 10 & 50 mg	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Zexate 15	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Zexate 50	Onco	17.01.2002	Submitted
MADAGASCAR	18.05.1996	Dabcof 250mg, 500mg	Non-Onco	—	Submitted
MADAGASCAR	18.05.1996	Damoxy 250mg, 500 mg	Non-Onco	—	Submitted
MADAGASCAR	18.05.1996	Uligel Tab orange	Non-Onco	—	Submitted
MADAGASCAR	18.05.1996	Coltri 480 mg	Non-Onco	—	Submitted

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
MADAGASCAR	18.05.1996	Paracetamol 500 mg	Non-Onco	—	Submitted
MADAGASCAR	18.05.1996	Tetracyclin 250 mg	Non-Onco	—	Submitted
MADAGASCAR	18.05.1996	Indomethacin 25 mg	Non-Onco	—	Submitted
MADAGASCAR	18.05.1996	Metronidazole 200 mg Tabs	Non-Onco	—	Submitted
MADAGASCAR	18.05.1996	Vitamin C 500 mg 1000 Tabs	Non-Onco	—	Submitted
MADAGASCAR	18.05.1996	C.P.M 4 mg Tabs	Non-Onco	—	Submitted
MALAWI	10.05.1995	Dabcolin Caps 250 mg	Non-Onco	19.07.1995	Registered
MALAWI	10.05.1995	Dabcolin Dry syrup	Non-Onco	19.07.1995	Registered
MALAWI	10.05.1995	Damoxy Dry Syrup	Non-Onco	19.07.1995	Registered
MALAWI	10.05.1995	Damoxy (250 mg)	Non-Onco	19.07.1995	Registered
MALAWI	10.05.1995	Atecard 50 mg	Non-Onco	19.07.1995	Registered
MALAWI	10.05.1995	Ulgel tablet orange flavour	Non-Onco	19.07.1995	Registered
MALAWI	—	Metronidazole	Non-Onco	—	Registered
MALAWI	—	Indomethacin	Non-Onco	—	Registered
MALAWI	10.05.1995	Dabcolin Caps 500 mg	Non-Onco	19.07.1995	Submitted
MALAWI	10.05.1995	Dabcolox (500 mg)	Non-Onco	19.07.1995	Submitted
MALAWI	10.05.1995	Dabcolox Dry Syrup	Non-Onco	19.07.1995	Submitted
MALAWI	10.05.1995	Damoxy (500 mg)	Non-Onco	19.07.1995	Submitted
MALAWI	10.05.1995	Atecard 25 mg	Non-Onco	19.07.1995	Submitted
MALAWI	10.05.1995	Atecard 100 mg	Non-Onco	19.07.1995	Submitted
MALAWI	10.05.1995	Oryza Expectorant	Non-Onco	19.07.1995	Submitted
MALAWI	10.05.1995	Alexin (500mg)	Non-Onco	19.07.1995	Submitted
MALAWI	10.05.1995	Alexin (250 mg)	Non-Onco	19.07.1995	Submitted
MALAWI	10.05.1995	Alexin Dispersible	Non-Onco	19.07.1995	Submitted
MALAWI	10.05.1995	Strox 250	Non-Onco	19.07.1995	Submitted
MALAWI	10.05.1995	Strox 500	Non-Onco	19.07.1995	Submitted
MALAWI	10.05.1995	Tinavate cream	Non-Onco	19.07.1995	Submitted
MALAWI	10.05.1995	Ulgel liquid	Non-Onco	19.07.1995	Submitted
ALAYSIA	29.12.1999	Adrim10 mg & 50 mg	Onco	25.01.2000	Registered
ALAYSIA	29.12.1999	Fytosid	Onco	25.01.2000	Registered
MALAYSIA	29.12.1999	Intaxel 30	Onco	25.01.2000	Registered
MALAYSIA	29.12.1999	Intaxel 100	Onco	25.01.2000	Registered
MALAYSIA	04.01.2000	Kemoplat 10mg/20ml	Onco	29.02.2000	Registered
MALAYSIA	04.01.2000	Kemoplat 50mg/100ml	Onco	29.02.2000	Registered
MALAYSIA	09.08.1997	Gynatam 10 mg & 20 mg	Onco	28.01.1998	Submitted
MALAYSIA	04.01.2000	Zexate 15ml/3ml	Onco	29.02.2000	Submitted
MALAYSIA	04.01.2000	Zexate 50ml/2ml	Onco	29.02.2000	Submitted
MALAYSIA	20.04.2000	Zexate Tablet I.P. 2.5 mg	Onco	16.06.2000	Submitted
MALAYSIA	20.04.2000	Ledoxan Tablet I.P.	Onco	16.06.2000	Submitted
MALAYSIA	11.12.2000	Kemocarb Injection 150 mg	Onco	09.04.2001	Submitted
MALAYSIA	11.12.2000	Kemocarb Injection 450 mg	Onco	09.04.2001	Submitted
MALAYSIA	11.12.2000	Cytarabin injection 100 mg	Onco	09.04.2001	Submitted
MALAYSIA	11.12.2000	Cytarabin injection 500 mg	Onco	09.04.2001	Submitted
MALAYSIA	11.12.2000	Cytarabin injection 1 gm	Onco	09.04.2001	Submitted
MALAYSIA	11.12.2000	Fivoflu Injection 250 mg	Onco	09.04.2001	Submitted
MALAYSIA	11.12.2000	Fivoflu Injection 500 mg	Onco	09.04.2001	Submitted
MALAYSIA	11.12.2000	Empurine Tabs. 50 mg	Onco	09.04.2001	Submitted
MALAYSIA	11.12.2000	Leucovorin Injection, 3 mg	Adjuvant	09.04.2001	Submitted
MALAYSIA	11.12.2000	Leucovorin Injection15 mg	Adjuvant	09.04.2001	Submitted
MALAYSIA	11.12.2000	Leucovorin Injection 50 mg	Adjuvant	09.04.2001	Submitted
MALAYSIA	11.12.2000	Mesna Injection 200mg	Adjuvant	09.04.2001	Submitted
MALAYSIA	07.2001	Intaxel 260mg	Onco	22.11.2001	Submitted
MALAYSIA	07.2001	Kemoplat 1mg/ml (10mg)	Onco	22.11.2001	Submitted
MALAYSIA	07.2001	Kemoplat 1mg/ml (50mg)	Onco	22.11.2001	Submitted
MALAYSIA	07.2001	Zexate 500mg	Onco	22.11.2001	Submitted
MALAYSIA	07.2001	Vinelbine 10mg	Onco	22.11.2001	Submitted
MALAYSIA	07.2001	Vinelbine 50mg	Onco	22.11.2001	Submitted
MALDIVES	02.1999	Company Profile	—	—	Submitted

Name Of the Country	Date of request	Name of the Products	Category	Date of submission	Status
MEXICO	13.12.2000	Daxotel 80 mg	Onco	23.02.2001	Registered
MEXICO	13.12.2000	Intaxel 30 mg	Onco	23.02.2001	Submitted
MEXICO	13.12.2000	Kemocarb 150 mg	Onco	23.02.2001	Submitted
MONGOLIA	09.05.1999	Adrim 10	Onco	18.05.1999	Registered
MONGOLIA	09.05.1999	Kemoplat 10	Onco	18.05.1999	Registered
MONGOLIA	09.05.1999	Tamoxifen Citrate tablet 10	Onco	18.05.1999	Registered
MONGOLIA	09.05.1999	Leucovorin 3	Adjuvant	18.05.1999	Registered
MONGOLIA	09.05.1999	Leucovorin 15	Adjuvant	18.05.1999	Registered
MONGOLIA	09.05.1999	Leucovorin 50mg	Adjuvant	18.05.1999	Registered
MONGOLIA	09.05.1999	Adrim 50	Onco	18.05.1999	Submitted
MONGOLIA	09.05.1999	Kemoplat 50	Onco	18.05.1999	Submitted
MONGOLIA	09.05.1999	Tamoxifen Citrate Tab 20 mg	Onco	18.05.1999	Submitted
MONGOLIA	24.12.1999	Ledoxan inj. 200	Onco	28.02.2000	Submitted
MONGOLIA	24.12.1999	Ledoxan inj. 500	Onco	28.02.2000	Submitted
MONGOLIA	24.12.1999	Fivoflu Inj. 250 mg	Onco	28.02.2000	Submitted
MONGOLIA	10.02.2000	Zexale 15 mg	Onco	28.02.2000	Submitted
MONGOLIA	10.02.2000	Zexale 50 mg	Onco	28.02.2000	Submitted
MONGOLIA	10.02.2000	Intaxel 30	Onco	28.02.2000	Submitted
MONGOLIA	10.02.2000	Intaxel 100	Onco	28.02.2000	Submitted
MAURITIUS	14.05.2001	Intaxel 30 mg	Onco	11.06.2001	Registered
MAURITIUS	14.05.2001	Intaxel 100 mg	Onco	11.06.2001	Registered
MAURITIUS	14.05.2001	Daxotel 20 mg	Onco	11.06.2001	Registered
MAURITIUS	14.05.2001	Daxotel 80 mg	Onco	11.06.2001	Registered
MAURITIUS	14.05.2001	Kemoplat 10 mg	Onco	11.06.2001	Registered
MAURITIUS	14.05.2001	Kemoplat 50 mg	Onco	11.06.2001	Registered
MAURITIUS	14.05.2001	Kemocarb 150 mg	Onco	11.06.2001	Registered
MAURITIUS	14.05.2001	Kemocarb 450 mg	Onco	11.06.2001	Registered
MAURITIUS	09.12.1995	Dabcollin 250	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Dabcollin 500	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Dabcollin DS	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Damoxoy 250	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Damoxoy 500	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Damoxoy DS	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Alexin 250, 500, DS	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Atecard 50	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Atecard 100	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Nuren 200	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Nuren 400	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Ulgei Tab	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Tinavate Cream	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Tinavate Solution	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Q-Lyte 35 gm	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Ampicillin Inj. 500 mg	Non-Onco	26.02.1996	Submitted
MYANMAR	11.02.1997	Strox Tabs 250 mg	Non-Onco	16.01.1998	Submitted
MYANMAR	11.02.1997	Strox Tabs 500 mg	Non-Onco	16.01.1998	Submitted
MYANMAR	11.02.1997	Nuren Tabs 200 mg	Non-Onco	16.01.1998	Submitted
MYANMAR	11.02.1997	Nuren Tabs 400 mg	Non-Onco	16.01.1998	Submitted
MYANMAR	11.02.1997	Olzol Capsules 10 mg	Non-Onco	16.01.1998	Submitted
MYANMAR	11.02.1997	Ranfaz Tabs 150 mg	Non-Onco	16.01.1998	Submitted
MYANMAR	11.02.1997	Ranfaz Tabs 300 mg	Non-Onco	16.01.1998	Submitted
MYANMAR	11.02.1997	Tinavate Cream	Non-Onco	16.01.1998	Submitted
MYANMAR	13.02.2001	Intaxel Injection 30 mg	Onco	31.10.2001	Submitted
MYANMAR	13.02.2001	Intaxel Injection 100 mg	Onco	31.10.2001	Submitted
MYANMAR	13.02.2001	Intaxel Injection 200 mg	Onco	31.10.2001	Submitted
MYANMAR	13.02.2001	Daxotel Injection 20 mg	Onco	31.10.2001	Submitted
MYANMAR	13.02.2001	Daxotel Injection 80 mg	Onco	31.10.2001	Submitted
MYANMAR	13.02.2001	Kemocarb Injection 150 mg	Onco	31.10.2001	Submitted
MYANMAR	13.02.2001	Kemocarb Injection 450 mg	Onco	31.10.2001	Submitted

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
MYANMAR	31.02.2001	Kemoplat Injection 10 mg (0.5mg/ml)	Onco	31.10.2001	Submitted
MYANMAR	31.02.2001	Kemoplat Injection 50 mg (0.5mg/ml)	Onco	31.10.2001	Submitted
MYANMAR	31.02.2001	Cytarin Injection 100 mg	Onco	31.10.2001	Submitted
MYANMAR	31.02.2001	Cytarin Injection 500 mg	Onco	31.10.2001	Submitted
MYANMAR	31.02.2001	Cytarin Injection 1 gm	Onco	31.10.2001	Submitted
MYANMAR	31.02.2001	Adrim Injection 10 mg	Onco	31.10.2001	Submitted
MYANMAR	31.02.2001	Adrim Injection 50 mg	Onco	31.10.2001	Submitted
MYANMAR	31.02.2001	Fytosid Injection 20 mg	Onco	31.10.2001	Submitted
MYANMAR	31.02.2001	Zexale Injection 15mg	Onco	31.10.2001	Submitted
MYANMAR	31.02.2001	Zexale Injection 50mg	Onco	31.10.2001	Submitted
MYANMAR	31.02.2001	Fivoflu Injection 250 mg, 500 mg	Onco	31.10.2001	Submitted
MYANMAR	31.02.2001	Leucovorin Injection 3 mg	Adjuvant	31.10.2001	Submitted
MYANMAR	31.02.2001	Leucovorin Injection 15 mg	Adjuvant	31.10.2001	Submitted
MYANMAR	31.02.2001	Leucovorin Injection 50 mg	Adjuvant	31.10.2001	Submitted
MYANMAR	31.02.2001	Mesna Injection 200 mg	Adjuvant	31.10.2001	Submitted
NEPAL	09.08.1996	Intaxel Injection 30, 100 & 260 mg	Onco	21.08.1996	Registered
NEPAL	09.08.1996	Tamoxifen tab 10 & 20 mg	Onco	21.08.1996	Registered
NEPAL	09.08.1996	Kemoplat inj. 10 & 50 mg	Onco	21.08.1996	Registered
NEPAL	09.08.1996	Fytosid inj.	Onco	21.08.1996	Registered
NEPAL	09.08.1996	Zexale Injection 15 & 50 mg	Onco	19.09.1996	Registered
NEPAL	09.08.1996	Kemocarb inj. 150 & 450 mg	Onco	19.09.1996	Registered
NEPAL	09.08.1996	Ledoxan inj. 200, 500mg & 1g	Onco	21.08.1996	Registered
NEPAL	09.08.1996	Ledoxan Tablet	Onco	21.08.1996	Registered
NEPAL	09.08.1996	Fivoflu inj. 250 & 500	Onco	21.08.1996	Registered
NEPAL	09.08.1996	Adrim inj. 10&50	Onco	21.08.1996	Registered
NEPAL	02.07.1997	Strox 250 & 500 mg	Non-Onco	—	Registered
NEPAL	02.07.1997	Uigel Tabs	Non-Onco	—	Registered
NEPAL	02.07.1997	Uigel Liquid	Non-Onco	—	Registered
NEPAL	02.07.1997	Atocard 25, 50, 100 & D	Non-Onco	—	Registered
NEPAL	02.07.1997	Livlit Tabs	Non-Onco	—	Registered
NEPAL	02.07.1997	Livlit Liquid	Non-Onco	—	Registered
NEPAL	02.07.1997	Honitus	Non-Onco	—	Registered
NEPAL	02.07.1997	Damoxy	Non-Onco	—	Registered
NEPAL	02.07.1997	Uizol 20	Non-Onco	—	Registered
NEPAL	02.07.1997	Uizol 10	Non-Onco	—	Registered
NEPAL	02.07.1997	Alexin	Non-Onco	—	Registered
NEPAL	02.07.1997	Nuren Ace	Non-Onco	—	Registered
NEPAL	02.07.1997	Zenad 60 Tablet USP	Non-Onco	—	Registered
NEPAL	02.07.1997	LoNa 150/500	Non-Onco	—	Registered
NEPAL	02.06.1998	Contrastin Injection 60 %, 76% (20 & 50 ml)	Non-Onco	—	Registered
NEPAL	01.08.1998	Leucovorin inj. 3 mg, 15 mg & 50 mg	Adjuvant	—	Registered
NEPAL	01.08.1998	Daxotel inj. 20 & 80	Onco	—	Registered
NEPAL	—	Amiphos inj. 500 mg/vial	Adjuvant	—	Registered
NEPAL	—	Cytarin inj. 100 mg/ml USP	Onco	—	Registered
NEPAL	—	Cytarin inj. 1gm/10ml USP	Onco	—	Registered
NEPAL	—	Cytarin inj. 500mg USP	Onco	—	Registered
NEPAL	—	Empurine tab. IP 50 mg	Onco	—	Registered
NEPAL	—	Hydsb Cap 500mg USP	Onco	—	Registered
NEPAL	—	Ipamide inj. USP 1gm/vial	Onco	—	Registered
NEPAL	—	Irinotel inj. 100mg/5ml	Onco	—	Registered
NEPAL	—	Irinotel inj. 40 mg/2 ml	Onco	—	Registered
NEPAL	—	Mesna inj. 200mg/2ml	Adjuvant	—	Registered
NEPAL	—	Topotel inj. 2.5 mg/2.5 ml	Onco	—	Registered
NEPAL	—	Topotel inj. 4 mg/4 ml	Onco	—	Registered
NEPAL	—	Zexale Tab. 2.5 mg IP	Onco	—	Registered
NEPAL	—	Radiopaque inj. 300 mg (10 ml) USP	Non-Onco	—	Registered
NEPAL	—	Radiopaque inj. 300 mg (20 ml) USP	Non-Onco	—	Registered

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
NEPAL	—	Radiopaque Inj 300 mg (50 ml) USP	Non-Onco	—	Registered
NEPAL	—	Radiopaque Inj 350 mg (20 ml) USP	Non-Onco	—	Registered
NEPAL	—	Radiopaque Inj 350 mg (50 ml) USP	Non-Onco	—	Registered
NEPAL	—	Alornex 120	Non-Onco	27.06.2001	Registered
NEPAL	—	Alornex 180	Non-Onco	27.06.2001	Registered
NEPAL	—	Alecard M	Non-Onco	17.11.2001	Registered
NEPAL	—	Specific information given for marketing	—	—	Submitted
NEPAL	29.03.1997	Livfil Tabliq	Non-Onco	—	Submitted
NEPAL	29.03.1997	Radiopaque	Non-Onco	—	Submitted
NEPAL	29.03.1997	Chlorizok	Non-Onco	—	Submitted
NEPAL	29.03.1997	Uzor 10	Non-Onco	—	Submitted
NEPAL	29.03.1997	Dexamethasone Inj. 2 ml & 10 ml vial	Non-Onco	—	Submitted
NEPAL	29.03.1997	Gentamicin Inj. 2 ml & 10 ml vial	Non-Onco	12.05.1997	Submitted
NEPAL	29.03.1997	Ranitidine Injection 2 ml	Non-Onco	12.05.1997	Submitted
NEPAL	29.03.1997	Diclofenac Inj. 15 ml vial	Non-Onco	12.05.1997	Submitted
NEPAL	29.03.1997	Amikacin Inj. 100, 250 & 500 mg vial	Non-Onco	12.05.1997	Submitted
NEPAL	29.03.1997	Co-trimoxazole suspension 60	Non-Onco	12.05.1997	Submitted
NEPAL	02.07.1997	Radiopaque Inj. 240 ml	Non-Onco	—	Submitted
NEPAL	02.07.1997	Maxim Hp (Choc)	Non-Onco	—	Submitted
NEPAL	02.07.1997	Cetaniil Syrup	Non-Onco	—	Submitted
NEPAL	02.07.1997	Cetaniil Tabs	Non-Onco	—	Submitted
NEPAL	02.07.1997	New Livfil Tabs	Non-Onco	—	Submitted
NEPAL	02.07.1997	New Livfil Syrup	Non-Onco	—	Submitted
NEPAL	25.03.1998	Cetirizine tablet 10 mg	Non-Onco	—	Submitted
NEPAL	02.05.1998	Roxithromycin Tablets	Non-Onco	—	Submitted
NEPAL	09.01.2001	Pamifos 30 & 60 mg	Adjuvant	29.01.2001	Submitted
NEPAL	26.04.2001	Pamifos 90 mg	Adjuvant	17.05.2001	Submitted
NEPAL	26.04.2001	Vincelbine 10 & 50	Onco	17.05.2001	Submitted
NEPAL	24.02.2000	Flutrox 50 mg	Non-Onco	27.06.2001	Submitted
NEPAL	24.02.2000	Flutrox 150 mg	Non-Onco	27.06.2001	Submitted
NEPAL	—	Nasarel - 60	Non-Onco	29.08.2001	Submitted
NEPAL	—	Nasarel - 20	Non-Onco	10.11.2001	Submitted
NEPAL	05.10.2001	Amifocan 50 mg	Adjuvant	05.10.2001	Submitted
NIGERIA	27.03.1997	Ampicillin Caps 250	Non-Onco	16.06.1997	Submitted
NIGERIA	27.03.1997	Ampicillin Caps 500	Non-Onco	16.06.1997	Submitted
NIGERIA	27.03.1997	Ampicillin Caps DS	Non-Onco	16.06.1997	Submitted
NIGERIA	27.03.1997	Amoxycillin Caps 250	Non-Onco	16.06.1997	Submitted
NIGERIA	27.03.1997	Amoxycillin Caps 500	Non-Onco	16.06.1997	Submitted
NIGERIA	27.03.1997	Amoxycillin Caps DS	Non-Onco	16.06.1997	Submitted
NIGERIA	27.03.1997	Ibuprofen Tablets 200	Non-Onco	16.06.1997	Submitted
NIGERIA	27.03.1997	Ibuprofen Tablets 400mg	Non-Onco	16.06.1997	Submitted
NIGERIA	27.03.1997	Stresssok	Veterinary	16.06.1997	Submitted
NIGERIA	27.03.1997	Livfil Vet Premix	Veterinary	16.06.1997	Submitted
NIGERIA	27.03.1997	Dimpro Premix	Veterinary	16.06.1997	Submitted
NIGERIA	27.03.1997	Stimulex Capsules	Ayuurvedic	—	Submitted
NIGERIA	28.04.1998	Dabur Balm	Ayuurvedic	—	Submitted
NIGERIA	28.04.1998	Daburub	Ayuurvedic	—	Submitted
NIGERIA	14.05.1998	Alecard Tab.	Non-Onco	—	Submitted
NIGERIA	15.07.1998	Strox 250 & 500	Non-Onco	—	Submitted
OMAN	14.06.2001	Company Registration	—	18.08.2001	Submitted
PANAMA	13.06.1997	Fluconazole	Non-Onco	—	Submitted
PANAMA	13.06.1997	Carboplatin Injection 150 & 450	Onco	—	Submitted
PANAMA	13.06.1997	Methotrexate Inj. & Tablets	Onco	—	Submitted
PANAMA	13.06.1997	Intaxel Injection	Onco	—	Submitted
PANAMA	13.06.1997	Fytosid Injection	Onco	—	Submitted
PANAMA	13.06.1997	Diclofenac Sodium Tablets	Non-Onco	—	Submitted
PANAMA	09.05.1998	Gynalam Tablet 10 & 20 mg	Onco	—	Submitted

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
PERU	—	Intaxel 100	Onco	—	Registered
PERU	—	Intaxel 30	Onco	23.12.1998	Registered
PERU	05.05.1998	Kemocarb 150 mg	Onco	—	Registered
PERU	06.05.1998	Kemocarb 450 mg	Onco	23.12.1998	Registered
PERU	06.05.1998	Kemoplat 10mg/20 ml	Onco	23.12.1998	Registered
PERU	06.05.1998	Adrim 50 mg	Onco	23.12.1998	Registered
PERU	06.05.1998	Fivoflu 250 mg	Onco	23.12.1998	Registered
PERU	06.05.1998	Zexate Inj 15 mg	Onco	—	Registered
PERU	06.05.1998	Zexate Tab.	Onco	23.12.1998	Registered
PERU	01.04.1999	Fytosid U.S.P.	Onco	23.12.1998	Registered
PERU	15.09.2000	Topotel 4	Onco	24.01.2001	Registered
PERU	15.09.2000	Daxotel 80	Onco	24.01.2001	Registered
PERU	06.05.1998	Kemoplat 50	Onco	—	Submitted
PERU	06.05.1998	Ledoxan Tab. 50 mg	Onco	—	Submitted
PERU	06.05.1998	Adrim 10 mg	Onco	23.12.1998	Submitted
PERU	06.05.1998	Fivoflu 500 mg	Onco	23.12.1998	Submitted
PERU	06.05.1998	Gynalam 10 mg	Onco	—	Submitted
PERU	06.05.1998	Gynalam 20 mg	Onco	23.12.1998	Submitted
PERU	15.02.1999	Empurin Tab.	Onco	03.12.1999	Submitted
PERU	15.02.1999	Hydab Capsules	Onco	03.12.1999	Submitted
PERU	15.09.2000	Daxotel 20	Onco	24.01.2001	Submitted
PERU	15.09.2000	Zexate 50	Onco	24.01.2001	Submitted
PERU	26.04.2001	Irinotel 40	Onco	21.06.2001	Submitted
PERU	26.04.2001	Irinotel 100	Onco	21.06.2001	Submitted
PHILIPPINES	28.01.1995	Intaxel	Onco	20.05.1995	Registered
PHILIPPINES	Aug 1996	Ledoxan Tablets 50 mg	Onco	—	Registered
PHILIPPINES	Aug 1996	Gynalam Tablets USP 10mg	Onco	—	Registered
PHILIPPINES	Aug 1996	Gynalam Tablets USP 20mg	Onco	—	Registered
PHILIPPINES	Aug 1996	Zexate Tablets USP 2.5mg/tab	Onco	—	Registered
PHILIPPINES	Aug 1996	Zexate Inj. USP 50 & 15 mg	Onco	—	Registered
PHILIPPINES	Aug 1996	Mesna Injection 100mg/ampoule	Adjuvant	—	Registered
PHILIPPINES	Aug 1996	Fivoflu 250mg/ampoule	Onco	—	Registered
PHILIPPINES	Aug 1996	Fivoflu 500mg/ampoule	Onco	—	Registered
PHILIPPINES	Aug 1996	Adrim 10 mg/vial	Onco	—	Registered
PHILIPPINES	Aug 1996	Adrim 50 mg/vial	Onco	—	Registered
PHILIPPINES	Aug 1996	Fytosid Injection 100 mg/vial	Onco	—	Registered
PHILIPPINES	24.04.1998	Ledoxan Inj. 200, 500 & 1 g	Onco	—	Registered
PHILIPPINES	16.09.1999	Kemocarb injection	Onco	18.03.2000	Submitted
PHILIPPINES	16.09.1999	Hydab Capsule 500 mg	Onco	18.03.2000	Submitted
PHILIPPINES	16.09.1999	Empurin Tablets 50 mg	Onco	18.03.2000	Submitted
PHILIPPINES	16.09.1999	Leucovorin Inj. 3mg, 15mg & 50 mg	Adjuvant	02.05.2000	Submitted
PHILIPPINES	16.09.1999	Cytarin Inj. 100mg, 300mg 1g	Onco	18.03.2000	Submitted
PHILIPPINES	16.09.1999	Kemoplat Inj. 10mg/20, 50mg/100ml	Onco	18.03.2000	Submitted
PHILIPPINES	24.05.2000	Intaxel 100 mg	Onco	16.07.2001	Submitted
PHILIPPINES	30.05.2000	Intaxel 250 mg	Onco	16.07.2001	Submitted
PHILIPPINES	—	Fivoflu 250 & 500 vials	Onco	14.01.2002	Submitted
POLAND	Dec 1997	Intaxel	Onco	—	Submitted
ROMANIA	—	Intaxel	Onco	—	Submitted
RUSSIA	—	Levodopa Tablets 500	Non-Onco	—	Registered
RUSSIA	—	Multivitamin Multimineral Tab	Non-Onco	—	Registered
RUSSIA	—	Levodopa Carbidopa Tablets	Non-Onco	—	Registered
RUSSIA	—	Paracetamol Syrup	Non-Onco	—	Registered
RUSSIA	—	Ascorbic Acid Tablets 250mg	Non-Onco	—	Registered
RUSSIA	—	Ascorbic Acid Tablets 500 mg	Non-Onco	—	Registered
RUSSIA	—	Ascorbic Acid Tab. 1000 mg	Non-Onco	—	Registered
RUSSIA	—	Intaxel injection 5 ml	Onco	—	Registered
RUSSIA	—	Intaxel injection 17 ml	Onco	—	Registered
RUSSIA	18.02.1997	Zexate Tab 2.5 mg/tablet	Onco	—	Registered

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
RUSSIA	18.02.1997	Zexate Inj USP 50 mg/vial	Onco	—	Registered
RUSSIA	18.02.1997	Zexate Inj USP 15 mg/vial	Onco	—	Registered
RUSSIA	18.02.1997	Fivoflu Injection 5 ml	Onco	—	Registered
RUSSIA	18.02.1997	Fivoflu Inj 10ml	Onco	—	Registered
RUSSIA	18.02.1997	Kemoplat Injection 10 mg/20ml	Onco	—	Registered
RUSSIA	18.02.1997	Kemoplat Injection 50 mg/100 ml	Onco	—	Registered
RUSSIA	18.02.1997	Kemocarb Inj 15	Onco	—	Registered
RUSSIA	18.02.1997	Kemocarb Inj 45ml	Onco	—	Registered
RUSSIA	03.2000	Fytosid 100 mg	Onco	25.07.2000	Registered
RUSSIA	—	Bromhexine Elixir	Non-Onco	—	Submitted
RUSSIA	—	DUROX DiSTAB 20 mg	Non-Onco	—	Submitted
RUSSIA	—	DUROX Capsule 20 mg	Non-Onco	—	Submitted
RUSSIA	—	Paracetamol Tablets 500 mg (for M/S J R Sharma)	Non-Onco	—	Submitted
RUSSIA	—	Analgin Tab 500 mg (M/S J RSharma)	Non-Onco	—	Submitted
RUSSIA	—	Vitamin B complex Tablets	Non-Onco	—	Submitted
RUSSIA	—	Naproxen Sodium Tablets	Non-Onco	—	Submitted
RUSSIA	—	Ketolifen Tablets 1mg	Non-Onco	—	Submitted
RUSSIA	—	Ketolifen Elixir 1mg/5ml	Non-Onco	—	Submitted
RUSSIA	—	Atecard	Non-Onco	—	Submitted
RUSSIA	18.02.1997	Adrim Injection 10 mg/vial	Onco	—	Submitted
RUSSIA	18.02.1997	Adrim Injection 50 mg/vial	Onco	—	Submitted
RUSSIA	18.02.1997	Docetaxel Inj 20 & 80 mg	Onco	—	Submitted
RUSSIA	21.10.2000	Leucovorin Inj 3, 15 & 50mg	Adjuvant	15.12.2000	Submitted
RUSSIA	03.03.2001	Vinebline Injection 10 & 50 mg	Onco	24.08.2001	Submitted
SIERRA LEONE	—	Honilus Cough Syrup 100 ml	Ayur	—	Submitted
SIERRA LEONE	—	Nature Care 100 g	Ayur	—	Submitted
SIERRA LEONE	—	Tolnaftale Cream 10 gm	Non-Onco	—	Submitted
SIERRA LEONE	—	Sarbyna tablets 10x10 Strip	Non-Onco	—	Submitted
SIERRA LEONE	—	Ampicillin syrup 60 ml	Non-Onco	—	Submitted
SIERRA LEONE	—	Ulgel liquid 170 ml-Saunf flavour	Non-Onco	—	Submitted
SIERRA LEONE	—	Ulgel tabs 10x25-Saunf flavour	Non-Onco	—	Submitted
SIERRA LEONE	—	Clean & Clear Capsules 75 caps	Ayur	—	Submitted
SIERRA LEONE	15.10.2001	Sarbyna Strong	Non-Onco	05.11.2001	Submitted
SINGAPORE	07.04.1998	Company Profile	—	—	Submitted
SINGAPORE	15.02.2001	Intaxel Injection 30 mg	Onco	30.09.2001	Submitted
SINGAPORE	15.02.2001	Kemocarb Inj 150 & 450 mg	Onco	30.09.2001	Submitted
SINGAPORE	15.02.2001	Kemoplat Injection 10 mg, 50 mg	Onco	30.09.2001	Submitted
SINGAPORE	15.02.2001	Cytarin Inj. BP100, 500 mg, 1 gm	Onco	30.09.2001	Submitted
SINGAPORE	15.02.2001	Adrim Injection 10 mg, 50 mg	Onco	30.09.2001	Submitted
SINGAPORE	15.02.2001	Fytosid Injection 20 mg	Onco	30.09.2001	Submitted
SINGAPORE	15.02.2001	Zexate Injection, 15mg, 50mg	Onco	30.09.2001	Submitted
SINGAPORE	15.02.2001	Fivoflu Injection 250 mg, 500 mg	Onco	30.09.2001	Submitted
SINGAPORE	15.02.2001	Leucovorin Injection 3 mg, 15 mg, 50 mg	Adjuvant	30.09.2001	Submitted
SOUTH AFRICA	—	Paclitaxel Inj	Onco	—	Submitted
SRI LANKA	—	Alexin Capsules 250 mg	Non-Onco	—	Registered
SRI LANKA	—	Alexin Capsules 500 mg	Non-Onco	—	Registered
SRI LANKA	—	Alexin Dry Syrup 125 mg/ml	Non-Onco	—	Registered
SRI LANKA	—	Ampicillin 1000's	Non-Onco	—	Registered
SRI LANKA	—	Nuren 200	Non-Onco	—	Registered
SRI LANKA	—	Nuren 400	Non-Onco	—	Registered
SRI LANKA	—	Damoxy Dry Syrup 125 mg/ml	Non-Onco	—	Registered
SRI LANKA	—	Tolnaftale Cream (Tinavale)	Non-Onco	—	Registered
SRI LANKA	—	Tolnaftale Solution	Non-Onco	—	Registered
SRI LANKA	—	Ulgel Tablet	Non-Onco	—	Registered
SRI LANKA	—	Ulgel Liquid	Non-Onco	—	Registered
SRI LANKA	—	Cetani Suspension 120 mg/5 ml	Non-Onco	—	Registered

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
SRI LANKA	—	Cetani Tablet 500 mg	Non-Onco	—	Registered
SRI LANKA	—	Atecard 25	Non-Onco	—	Registered
SRI LANKA	—	Atecard 50 Partial Inf	Non-Onco	—	Registered
SRI LANKA	—	Atecard 100 Partial Inf.	Non-Onco	—	Registered
SRI LANKA	13.06.1997	Fluorouracil 250-8500	Non-Onco	—	Registered
SRI LANKA	13.06.1997	Adrim 10	Onco	—	Registered
SRI LANKA	13.06.1997	Adrim 50	Onco	—	Registered
SRI LANKA	13.06.1997	Cisplatin 10 & 50	Onco	—	Registered
SRI LANKA	13.06.1997	Zexate 50 mg	Onco	—	Registered
SRI LANKA	13.06.1997	Zexate Tab	Onco	—	Registered
SRI LANKA	13.06.1997	Intaxel 30	Onco	—	Registered
SRI LANKA	19.06.2000	Empurine tablet 50 mg USP	Onco	07.09.2000	Registered
SRI LANKA	13.06.1997	Fylasid	Onco	—	Registered
SRI LANKA	—	Dabciin Dry Syrup 125 mg/ml	Non-Onco	—	Submitted
SRI LANKA	—	Ulzol capsule	Non-Onco	—	Submitted
SRI LANKA	10.10.2000	Cytarabin injection 100 mg	Onco	30.07.2001	Submitted
SRI LANKA	10.10.2000	Cytarabin injection 500 mg	Onco	30.07.2001	Submitted
SRI LANKA	10.10.2000	Cytarabin injection 1g	Onco	30.07.2001	Submitted
SRI LANKA	10.10.2000	Kemocarb Injection 150 mg	Onco	30.07.2001	Submitted
SRI LANKA	10.10.2000	Kemocarb Injection 450	Onco	30.07.2001	Submitted
SRI LANKA	10.10.2000	Mesna Injection 100 mg	Adjuvant	30.07.2001	Submitted
SRI LANKA	10.10.2000	Leucovorin Injection 3 mg	Adjuvant	30.07.2001	Submitted
SRI LANKA	10.10.2000	Leucovorin Injection 15 mg	Adjuvant	30.07.2001	Submitted
SRI LANKA	10.10.2000	Leucovorin Injection 50 mg	Adjuvant	30.07.2001	Submitted
SRI LANKA	10.10.2000	Radiopaque Inj 240 mg/ml, 10 ml	Non-Onco	10.09.2001	Submitted
SRI LANKA	10.10.2000	Radiopaque Inj 240 mg/ml, 20 ml	Non-Onco	10.09.2001	Submitted
SRI LANKA	10.10.2000	Radiopaque Inj 300 mg/ml, 10 ml	Non-Onco	10.09.2001	Submitted
SRI LANKA	10.10.2000	Radiopaque Inj 300 mg/ml, 20 ml	Non-Onco	10.09.2001	Submitted
SRI LANKA	10.10.2000	Radiopaque Inj 300 mg/ml, 50 ml	Non-Onco	10.09.2001	Submitted
SRI LANKA	10.10.2000	Radiopaque Inj 300 mg/ml, 100ml	Non-Onco	10.09.2001	Submitted
SRI LANKA	10.10.2000	Radiopaque Inj 350 mg/ml, 20 ml	Non-Onco	10.09.2001	Submitted
SRI LANKA	10.10.2000	Radiopaque Inj 350 mg/ml, 50 ml	Non-Onco	10.09.2001	Submitted
SRI LANKA	10.10.2000	Radiopaque Inj 350 mg/ml, 100 ml	Non-Onco	10.09.2001	Submitted
SRI LANKA	10.10.2000	Constrastin (60%) Inj., 20 ml	Non-Onco	16.11.2001	Submitted
SRI LANKA	10.10.2000	Constrastin (60%) Inj., 50 ml	Non-Onco	16.11.2001	Submitted
SRI LANKA	10.10.2000	Constrastin (76%) Inj., 20 ml	Non-Onco	16.11.2001	Submitted
SRI LANKA	10.10.2000	Constrastin (76%) Inj., 50 ml	Non-Onco	16.11.2001	Submitted
SRI LANKA	10.10.2000	Constrastin (76%) Inj., 100 ml	Non-Onco	16.11.2001	Submitted
SRI LANKA	10.01.2001	Intaxel 100 mg	Onco	01.08.2001	Submitted
SRI LANKA	10.01.2001	Intaxel 200 mg	Onco	01.08.2001	Submitted
SRI LANKA	12.06.2001	Daxotel 20	Onco	24.12.2001	Submitted
SRI LANKA	12.06.2001	Daxotel 80	Onco	24.12.2001	Submitted
SRI LANKA	12.06.2001	Zexate 15	Onco	02.12.2001	Submitted
SRI LANKA	12.06.2001	Zexate 500	Onco	02.12.2001	Submitted
SRI LANKA	12.06.2001	Irinotel 40mg	Onco	09.01.2002	Submitted
SRI LANKA	12.06.2001	Irinotel 100mg	Onco	09.01.2002	Submitted
SRI LANKA	25.07.2001	Vinorelbine 10	Onco	16.10.2001	Submitted
SRI LANKA	25.07.2001	Vinorelbine 50	Onco	16.10.2001	Submitted
SRI LANKA	10.10.2000	Ledoxan tab. 50 mg	Onco	16.01.2002	Submitted
SRI LANKA	10.10.2000	Tamoxifen 10 mg	Onco	16.01.2002	Submitted
SRI LANKA	10.10.2000	Tamoxifen 20 mg	Onco	16.01.2002	Submitted
SUDAN	—	Damoxy 250 mg	Non-Onco	—	Submitted
SUDAN	—	Damoxy 500 mg	Non-Onco	—	Submitted
SUDAN	—	Damoxy DS	Non-Onco	—	Submitted
SUDAN	—	Alexin 250 mg	Non-Onco	—	Submitted
SUDAN	—	Alexin 500 mg	Non-Onco	—	Submitted
SUDAN	—	Atecard 50 mg	Non-Onco	—	Submitted
SUDAN	—	Atecard 100 mg	Non-Onco	—	Submitted

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
SUDAN	—	Zenad 60	Onco	—	Submitted
SUDAN	—	Zenad 120	Onco	—	Submitted
SUDAN	—	Diclofenac 25 mg	Non-Onco	—	Submitted
SUDAN	—	Cefadroxil 250 mg	Non-Onco	—	Submitted
SUDAN	—	Cefadroxil 500 mg	Non-Onco	—	Submitted
SUDAN	—	Cefadroxil Dry Syrup	Non-Onco	—	Submitted
SUDAN	—	Muren 200	Non-Onco	—	Submitted
SUDAN	—	Muren 400	Non-Onco	—	Submitted
SUDAN	24.04.1998	Adrim Injection 5 ml vial	Onco	—	Submitted
SUDAN	24.04.1998	Cisplatin Inj. 10 mg	Onco	—	Submitted
SUDAN	24.04.1998	Intaxel 5 ml	Onco	—	Submitted
SUDAN	24.04.1998	Zexate 50 mg	Onco	—	Submitted
SUDAN	24.04.1998	Tamoxifen Tabs 10 mg	Onco	—	Submitted
SUDAN	Feb. 1999	Fivoflu 250, 500 mg	Onco	—	Submitted
SYRIA	29.05.1998	Intaxel	Onco	—	Submitted
TAIWAN	Feb. 1999	Terfenadine	Non-Onco	08.11.1996	Submitted
TAIWAN	01.10.1996	Fluconazole	Non-Onco	17.09.1996	Submitted
TAIWAN	30.01.1997	Melatonin Tablet 3 mg	Non-Onco	14.11.1996	Submitted
THAILAND	09.08.1999	Intaxel Injection	Onco	30.01.1997	Submitted
THAILAND	17.08.1999	Kemocarb Inj 150 & 450 mg	Onco	09.08.1999	Registered
THAILAND	25.03.1997	Kemoplat 20ml & 100ml	Onco	18.05.1999	Registered
THAILAND	25.03.1997	Zexate 50 (Methotrexate inj.)	Onco	—	Registered
THAILAND	25.03.1997	Fivoflu 250 mg & 500 mg ampoule	Onco	—	Registered
THAILAND	25.03.1997	Fivoflu 250 mg & 500 mg vial	Onco	—	Registered
THAILAND	25.03.1997	Ledoxan Tabs 50 mg	Onco	—	Registered
THAILAND	25.03.1997	Adrim	Onco	—	Registered
THAILAND	25.03.1997	Zexate Tablet 2.5 mg	Onco	—	Registered
THAILAND	25.03.1997	Fylosid 100 mg	Onco	—	Registered
THAILAND	25.03.1997	Gynalam Tabs 10 mg	Onco	—	Registered
THAILAND	25.03.1997	Gynalam Tabs 20 mg	Onco	—	Registered
THAILAND	15.02.1999	Cytarin Inj 100 mg, 500 mg & 1 g	Onco	18.08.1999	Registered
THAILAND	15.02.1999	Leucovorin Inj 3, 50 mg	Non-Onco	07.05.1999	Registered
THAILAND	15.02.1999	Mesna Inj. 200 mg	Non-Onco	07.05.1999	Registered
THAILAND	16.09.1999	Daxosiel inj. 20 & 80	Onco	15.02.2000	Registered
THAILAND	15.02.1999	Empurin Tab. 50 mg	Onco	18.08.1999	Registered
THAILAND	15.02.1998	Ipamide Inj. 1 gm	Onco	18.08.1999	Registered
THAILAND	02.05.1998	Ledoxan Inj 200 mg	Onco	10.05.1999	Submitted
THAILAND	02.05.1998	Ledoxan Inj 500 mg	Onco	10.05.1999	Submitted
THAILAND	02.05.1998	Ledoxan Inj 1 gm	Onco	10.05.1999	Submitted
THAILAND	03.05.2000	Irinotel 40 & 100 mg	Onco	30.01.2001	Submitted
THAILAND	30.05.2000	Intaxel 260 mg	Onco	06.09.2000	Submitted
TRINIDAD & TOBAGO	13.06.1997	Fivoflu Inj. 250 mg	Onco	17.07.1997	Registered
TRINIDAD & TOBAGO	—	Gynalam 10 mg	Onco	04.04.1998	Registered
TRINIDAD & TOBAGO	—	Gynalam 20 mg	Onco	04.04.1998	Registered
TRINIDAD & TOBAGO	21.07.1998	Fylosid 100	Onco	14.02.1998	Registered
TRINIDAD & TOBAGO	21.07.1998	Zexate Tab	Onco	14.02.1998	Registered
TRINIDAD & TOBAGO	—	Kemoplat 50 mg	Onco	04.04.1998	Registered
TRINIDAD & TOBAGO	21.07.1998	Intaxel Injection 30 mg	Onco	14.02.1998	Registered
TRINIDAD & TOBAGO	21.07.1998	Kemocarb 150	Onco	14.02.1998	Registered
TRINIDAD & TOBAGO	02.05.1998	Ledoxan Tablet	Onco	25.05.1998	Registered
TRINIDAD & TOBAGO	17.11.1998	Ledoxan Injection 200 mg	Onco	31.07.1999	Registered
TRINIDAD & TOBAGO	13.06.1997	Kemoplat Inj. 10 mg	Onco	17.07.1997	Submitted
TRINIDAD & TOBAGO	13.06.1997	Fivoflu Inj. 500 mg	Onco	17.07.1997	Submitted
TRINIDAD & TOBAGO	13.06.1997	Urizol 20 mg Caps	Non-Onco	17.07.1997	Submitted
TRINIDAD & TOBAGO	13.06.1997	Ranitaz Tabs 150 mg	Non-Onco	17.07.1997	Submitted
TRINIDAD & TOBAGO	13.06.1997	Ranitidine Inj. 25 mg/ml	Non-Onco	02.08.1997	Submitted
TRINIDAD & TOBAGO	13.06.1997	Fluconazole Caps 150 mg	Non-Onco	02.08.1997	Submitted
TRINIDAD & TOBAGO	—	Adrim 10 mg, 50 mg	Onco	04.04.1998	Submitted

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
TRINIDAD & TOBAGO	21.07.1998	Ledoxan Inj. 500 & 1000 mg	Onco	—	Submitted
TRINIDAD & TOBAGO	21.07.1998	Kemocarb 450 mg	Onco	14.02.1998	Submitted
TRINIDAD & TOBAGO	02.09.2000	Cytarin Inj. 100 mg	Onco	21.07.2001	Submitted
TRINIDAD & TOBAGO	02.09.2000	Daxotel Inj. 20 mg, 80 mg	Onco	21.04.2001	Submitted
TRINIDAD & TOBAGO	02.09.2000	Leucovorin Injection 50mg	Adjuvant	21.04.2001	Submitted
TRINIDAD & TOBAGO	02.09.2000	Empurine Tablets 50 mg	Onco	21.04.2001	Submitted
TRINIDAD & TOBAGO	02.09.2000	Zexate 50 mg	Onco	21.04.2001	Submitted
TRINIDAD & TOBAGO	02.09.2000	Topotel Injection 4 mg	Onco	21.07.2001	Submitted
TRINIDAD & TOBAGO	21.05.2001	Intaxel Injection 100 mg	Onco	21.07.2001	Submitted
TURKEY	Oct 1997	Fytosid Injection 100 mg	Onco	29.12.1997	Submitted
TURKEY	Oct 1997	5-Fluorouracil Inj. 250 & 500 mg	Onco	30.12.1997	Submitted
TURKEY	Oct 1997	Cisplatin Injection 10 & 50 mg	Onco	26.12.1997	Submitted
TURKEY	Oct 1997	Gynalam Tablets 10 & 20 mg	Onco	—	Submitted
TURKEY	Oct 1997	Adrian 5 ml & 25 ml	Onco	26.12.1997	Submitted
TURKEY	Oct 1997	Methotrexate (PF) Inj 15 mg & 50 mg	Onco	26.12.1997	Submitted
TURKEY	Oct 1997	Cyclophosphamide Tabs 50 mg	Onco	—	Submitted
TURKEY	24.04.1998	Docetaxel 20 mg & 80 mg	Onco	—	Submitted
TURKEY	24.04.1998	Intaxel 30 mg & 100 mg	Onco	—	Submitted
TURKEY	24.04.1998	Zexate 2.5 mg, 100's pack	Onco	—	Submitted
TURKEY	26.06.1998	Zexate 5 mg/1 ml vial	Onco	—	Submitted
TURKEY	26.06.1998	Mesna 200	Adjuvant	—	Submitted
TURKEY	26.06.1998	Leucovorin 50 mg	Adjuvant	—	Submitted
TURKEY	15.02.1999	Ledoxan Inj. 200, 500mg & 1g	Onco	12.06.1999	Submitted
UGANDA	06.10.1997	Ulgel Tabs 75X10	Non-Onco	—	Submitted
UGANDA	06.10.1997	Ulgel Liquid 170 ml	Non-Onco	—	Submitted
UGANDA	06.10.1997	Tinavale Cream/Solution	Non-Onco	—	Submitted
UGANDA	06.10.1997	Flutrox	Non-Onco	—	Submitted
UGANDA	06.10.1997	Atecard 100 mg/D	Non-Onco	—	Submitted
UGANDA	06.10.1997	Dabcilin 250 mg/Dry Syrup	Non-Onco	—	Submitted
UGANDA	06.10.1997	Damox 250 mg/Dry Syrup	Non-Onco	—	Submitted
UGANDA	06.10.1997	Alexin Cap 250	Non-Onco	—	Submitted
UGANDA	06.10.1997	Alexin Cap 500	Non-Onco	—	Submitted
UGANDA	06.10.1997	Strox 250	Non-Onco	—	Submitted
UGANDA	06.10.1997	Strox 500	Non-Onco	—	Submitted
UKRAINE	10.11.1995	Gentus 20	Non-Onco	12.12.1995	Submitted
UKRAINE	10.11.1995	Gentus 60	Non-Onco	12.12.1995	Submitted
UKRAINE	10.11.1995	Gentus 80	Non-Onco	12.12.1995	Submitted
UKRAINE	10.11.1995	Gentus eye drop	Non-Onco	12.12.1995	Submitted
UKRAINE	10.11.1995	Gentus eardrops	Non-Onco	12.12.1995	Submitted
UKRAINE	10.11.1995	Seredal 2	Non-Onco	12.12.1995	Submitted
UKRAINE	10.11.1995	Seredal 5	Non-Onco	12.12.1995	Submitted
UKRAINE	10.11.1995	Seredal 10	Non-Onco	12.12.1995	Submitted
UKRAINE	10.11.1995	Seredal Injection	Non-Onco	12.12.1995	Submitted
UKRAINE	10.11.1995	Seredal Suspension	Non-Onco	12.12.1995	Submitted
UKRAINE	10.11.1995	Alexin 250 mg (reregistration)	Non-Onco	12.12.1995	Registered
UKRAINE	10.11.1995	Cifocin 500,1(reregistration)	Non-Onco	18.12.1995	Registered
UKRAINE	10.11.1995	Dabcilor Cap. (reregistration)	Non-Onco	23.12.1995	Registered
UKRAINE	10.11.1995	Dabcilor Inj. (reregistration)	Non-Onco	18.12.1995	Registered
UKRAINE	10.11.1995	Strox 250,500 (reregistration)	Non-Onco	12.12.1995	Registered
UKRAINE	13.06.2000	Kemoplat 20 & 100ml (0.5mg)	Onco	13.12.2000	Registered
UKRAINE	13.06.2000	Kemocarb 150 & 450mg	Onco	13.12.2000	Registered
UKRAINE	13.06.2000	Fytoside 100mg	Onco	13.12.2000	Registered
UKRAINE	15.06.2000	Zexate 15 & 50 mg	Onco	13.12.2000	Registered
UKRAINE	11.09.2000	Intaxel 30 & 100 mg	Onco	12.02.2001	Registered
UKRAINE	29.11.1997	Docetaxel Inj 20 & 80	Onco	17.01.1998	Submitted
UKRAINE	29.11.1997	Adrian Inj. 10 & 50	Onco	12.03.1998	Submitted
UKRAINE	30.10.2000	Zexate 2.5	Onco	12.02.2001	Submitted
UKRAINE	06.04.2001	Vinelbine Injection 10 & 50 mg	Onco	28.09.2001	Submitted

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
URUGUAY	17.05.2000	Zexale 50	Onco	12.12.2000	Submitted
URUGUAY	20.06.2000	Ledoxan tab. 50 mg	Onco	12.12.2000	Submitted
URUGUAY	28.10.2000	Zexale Tablet 2.5 mg	Onco	12.12.2000	Submitted
VENEZUELA	15.10.1999	Kemocarb 150 mg (Bioplatinex)	Onco	24.02.2000	Registered
VENEZUELA	15.10.1999	Kemocarb 450 mg (Bioplatinex)	Onco	24.02.2000	Registered
VENEZUELA	15.10.1999	Ledoxan 50 mg (Biodoxan)	Onco	04.09.2000	Registered
VENEZUELA	15.10.1999	Adrim 10 mg	Onco	24.02.2000	Registered
VENEZUELA	15.10.1999	Adrim 50 mg	Onco	24.02.2000	Registered
VENEZUELA	15.10.1999	Fivoftu 250 mg	Onco	24.02.2000	Registered
VENEZUELA	15.10.1999	Fivoftu 500 mg	Onco	24.02.2000	Registered
VENEZUELA	15.10.1999	Zexale 50 mg	Onco	24.02.2000	Registered
VENEZUELA	15.10.1999	Zexale 2.5 mg	Onco	04.09.2000	Registered
VENEZUELA	15.10.1999	Intaxel 30 mg, 100 mg	Onco	24.02.2000	Registered
VENEZUELA	15.10.1999	Gynatam 10 mg	Onco	04.09.2000	Registered
VENEZUELA	15.10.1999	Gynatam 20 mg	Onco	04.09.2000	Registered
VENEZUELA	15.10.1999	Fytosid 100 mg	Onco	24.02.2000	Registered
VENEZUELA	17.04.1998	Docetaxel inj. 20 & 80 mg	Onco	04.06.1998	Submitted
VENEZUELA	15.10.1999	Empurine 50 mg	Onco	04.09.2000	Submitted
VIETNAM	24.04.1998	Uizat Capsule	Non-Onco	—	Submitted
VIETNAM	24.04.1998	Zenad 60	Non-Onco	—	Submitted
VIETNAM	24.04.1998	Zenad 120	Non-Onco	—	Submitted
VIETNAM	24.04.1998	Zenad Suspension	Non-Onco	—	Submitted
VIETNAM	24.04.1998	Strox 250	Non-Onco	—	Submitted
VIETNAM	24.04.1998	Strox 500	Non-Onco	—	Submitted
VIETNAM	24.04.1998	Alexin 250	Non-Onco	—	Submitted
VIETNAM	24.04.1998	Alexin 500	Non-Onco	—	Submitted
VIETNAM	24.04.1998	Alexin Dry Syrup 125	Non-Onco	—	Submitted
VIETNAM	24.04.1998	Ulgel Tablets	Non-Onco	—	Submitted
VIETNAM	24.04.1998	Ulgel Liquid	Non-Onco	—	Submitted
VIETNAM	08.09.2000	Adrim 10mg & 50mg	Onco	19.03.2001	Submitted
VIETNAM	08.09.2000	Kemoplat 10mg, 50mg (0.5mg/ml)	Onco	19.03.2001	Submitted
VIETNAM	08.09.2000	Kemocarb 150mg, 450mg(10mg/ml)	Onco	19.03.2001	Submitted
VIETNAM	08.09.2000	Fytosid USP	Onco	19.03.2001	Submitted
VIETNAM	08.09.2000	Gynatam 10	Onco	19.03.2001	Submitted
VIETNAM	08.09.2000	Gynatam 20	Onco	19.03.2001	Submitted
VIETNAM	08.09.2000	Ledoxan tab. USP, 50 mg	Onco	19.03.2001	Submitted
VIETNAM	08.09.2000	Empurine tab. USP 50 mg	Onco	19.03.2001	Submitted
VIETNAM	08.09.2000	Ledoxan inj. 200mg	Onco	19.03.2001	Submitted
VIETNAM	08.09.2000	Ledoxan 500 mg	Onco	19.03.2001	Submitted
VIETNAM	08.09.2000	Ledoxan 1gm	Onco	19.03.2001	Submitted
VIETNAM	08.09.2000	Ipamide 1gm	Onco	19.03.2001	Submitted
VIETNAM	08.09.2000	Leucovorine Calcium Inj. 3mg	Adjuvant	19.03.2001	Submitted
VIETNAM	08.09.2000	Leucovorine Calcium Inj. 15 mg	Adjuvant	19.03.2001	Submitted
VIETNAM	08.09.2000	Leucovorine Calcium Inj. 50 mg	Adjuvant	19.03.2001	Submitted
VIETNAM	08.09.2000	Intaxel 30 & 100 mg	Onco	19.03.2001	Submitted
VIETNAM	08.09.2000	Cytarin Inj. 100mg	Onco	30.04.2001	Submitted
VIETNAM	08.09.2000	Cytarin Inj. 500mg	Onco	30.04.2001	Submitted
VIETNAM	08.09.2000	Cytarin Inj. 1 g	Onco	30.04.2001	Submitted
VIETNAM	06.09.2000	Dasopiel 20 & 80 mg	Onco	30.04.2001	Submitted
VIETNAM	08.09.2000	Fivoftu 250 m&500 mg	Onco	30.04.2001	Submitted
VIETNAM	08.09.2000	Zexale inj. 15mg	Onco	30.04.2001	Submitted
VIETNAM	08.09.2000	Zexale inj. 50 & 500 mg	Onco	30.04.2001	Submitted
VIETNAM	08.09.2000	Zexale Tab.	Onco	30.04.2001	Submitted
YEMEN	26.12.1995	Alexin 250	Non-Onco	—	Registered
YEMEN	26.12.1995	Alexin 500	Non-Onco	—	Registered
YEMEN	26.12.1995	Atecard 50	Non-Onco	—	Registered
YEMEN	26.12.1995	Atecard 100	Non-Onco	—	Registered
YEMEN	26.12.1995	Damoxu 250	Non-Onco	—	Registered

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
YEMEN	26.12.1995	Damoxy 500	Non-Onco	—	Registered
YEMEN	26.12.1995	Damoxy DS 125 mg/ml, 60 ml	Non-Onco	—	Registered
YEMEN	26.12.1995	Dabcofax Capsules 500 mg	Non-Onco	—	Registered
YEMEN	26.12.1995	Nuten 200	Non-Onco	—	Registered
YEMEN	26.12.1995	Nuten 400	Non-Onco	—	Registered
YEMEN	26.12.1995	Q-Lyte 27.9 gm sachet	Non-Onco	—	Registered
YEMEN	26.12.1995	Kemoplat Injection 10 mg	Onco	—	Registered
YEMEN	26.12.1995	Fluorouracil Injection 250	Onco	—	Registered
YEMEN	26.12.1995	Dabcofax Dry Syrup	Non-Onco	—	Submitted
YEMEN	26.12.1995	Ulzol Capsule 20 mg	Non-Onco	—	Submitted
YEMEN	26.12.1995	Ulzel Liquid	Non-Onco	—	Submitted
YEMEN	26.12.1995	Komoplat Injection 50 mg	Onco	—	Submitted
YEMEN	26.12.1995	Adrim Injection 10	Onco	—	Submitted
YEMEN	26.12.1995	Adrim Injection 50	Onco	—	Submitted
YEMEN	26.12.1995	Cyclosporin Oral Liquid	Non-Onco	—	Submitted
YEMEN	26.12.1995	Ledoxan inj. 200, 500 mg & 1g	Onco	—	Submitted
YEMEN	26.12.1995	Ciprofloxacin Tablets 250 & 500 mg	Non-Onco	—	Submitted
YEMEN	26.12.1995	Zexate inj. 50	Onco	—	Submitted
YEMEN	26.12.1995	Fluorouracil inj. 500	Onco	—	Submitted
YEMEN	26.12.1995	Bleomycin Injection 15 units	Onco	—	Submitted
YEMEN	09.10.1997	Strox 250 & 500	Non-Onco	17.10.1997	Submitted
YUGOSLAVIA	29.03.1996	Methotrexate inj.	Onco	—	Submitted
YUGOSLAVIA	29.03.1996	Adrim inj. 5ml	Onco	—	Submitted
YUGOSLAVIA	29.03.1996	Adrim inj. 25ml	Onco	—	Submitted
YUGOSLAVIA	29.03.1996	Cyclophosphamide inj. 200 mg	Onco	—	Submitted
YUGOSLAVIA	29.03.1996	Cyclophosphamide inj. 500 mg	Onco	—	Submitted
YUGOSLAVIA	29.03.1996	Cyclophosphamide inj. 1 g	Onco	—	Submitted
YUGOSLAVIA	29.03.1996	Fytoxid inj. 20mg/ml	Onco	—	Submitted
YUGOSLAVIA	29.03.1996	Cisplatin inj. 10 mg	Onco	—	Submitted
YUGOSLAVIA	29.03.1996	Cisplatin inj. 50 mg	Onco	—	Submitted
YUGOSLAVIA	29.03.1996	Fivoflu inj. 250 mg	Onco	—	Submitted
YUGOSLAVIA	29.03.1996	Fivoflu inj. 500 mg	Onco	—	Submitted
YUGOSLAVIA	29.03.1996	Mesna inj. 100 mg/ml	Adjuvant	—	Submitted
ZAMBIA	03.05.1995	Dabcofax 250 mg	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Dabcofax 500 mg	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Dabcofax Dry syrup	Non-Onco	26.08.1995	Registered
ZAMBIA	—	Dabcofax Distab	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Alexin 250 mg	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Alexin 500 mg	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Alexin Dispersible 125 mg	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Alexin Dry syrup	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Atecard 25 mg	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Atecard 50 mg	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Atecard 100 mg	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Ulzel Liquids Orange flavour	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Ulzel Tablets Orange flavour	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Tinavate Cream	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Tinavate lotion	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Dabcofax 500 mg	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Dabcofax Dry syrup	Non-Onco	26.08.1995	Registered
ZAMBIA	—	Dabcofax Distab	Non-Onco	26.08.1995	Registered
ZAMBIA	—	Damoxy 250 mg	Non-Onco	—	Registered
ZAMBIA	03.05.1995	Damoxy 500 mg	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Damoxy Dry syrup	Non-Onco	26.08.1995	Registered
ZAMBIA	—	Damoxy Distab 125 mg	Non-Onco	26.08.1995	Registered
ZAMBIA	—	Damoxy Distab 250 mg	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Oryza Expecto-rant	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Frufal	Non-Onco	26.08.1995	Registered

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
ZIMBABWE	07.10.1999	Kemoplat 10 mg	Onco	20.01.2000	Registered
ZIMBABWE	07.10.1999	Fytosid	Onco	20.01.2000	Registered
ZIMBABWE	07.10.1999	Adrim 10 mg & 50 mg	Onco	20.01.2000	Submitted
ZIMBABWE	06.03.2000	Fivoflu 500 mg	Onco	29.09.2000	Submitted
ZIMBABWE	06.03.2000	Zexate inj 50 mg	Onco	29.09.2000	Submitted

TENDER'S

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
BANGLADESH	05.10.1995	Adrim 50 (tender papers)	Onco	22.11.1995	Registered
BANGLADESH	05.10.1995	Kemoplat 20 ml (tender papers)	Onco	22.11.1995	Registered
BANGLADESH	05.10.1995	Kemoplat 10mg (tender papers)	Onco	22.11.1995	Submitted
BANGLADESH	05.10.1995	Adrim 10 mg (tender papers)	Onco	22.11.1995	Submitted
BANGLADESH	05.10.1995	Zexate Inj. 50 mg (tender papers)	Onco	22.11.1995	Submitted
BANGLADESH	05.10.1995	Fivoflu 250 & 500 mg (tender papers)	Onco	22.11.1995	Submitted
BANGLADESH	05.10.1995	Fytosid 100 mg (tender papers)	Onco	22.11.1995	Submitted
COLOMBIA	04.10.2000	Adrim 10 mg (for tender)	Onco	17.10.2000	Submitted
COLOMBIA	04.10.2000	Adrim 50 mg (for tender)	Onco	17.10.2000	Submitted
COLOMBIA	04.10.2000	Fivoflu 500 mg (for tender)	Onco	17.10.2000	Submitted
COLOMBIA	04.10.2000	Fytosid 100 (for tender)	Onco	17.10.2000	Submitted
COLOMBIA	04.10.2000	Kemoplat 10 mg (for tender)	Onco	17.10.2000	Submitted
COLOMBIA	04.10.2000	Gynalam 10 (for tender)	Onco	17.10.2000	Submitted
HONDURAS & COSTA RICA	—	Intaxel	Onco	—	Submitted
ECUADOR	29.08.2000	Adrim 10/50 (for tender)	Onco	31.08.2000	Submitted
ECUADOR	29.08.2000	Fytosid 100 mg (for tender)	Onco	31.08.2000	Submitted
ECUADOR	29.08.2000	Fivoflu 250 (for tender)	Onco	31.08.2000	Submitted
ECUADOR	29.08.2000	Zexate inj 50 mg (for tender)	Onco	31.08.2000	Submitted
ECUADOR	29.08.2000	Zexate 2.5 mg Tab (for tender)	Onco	31.08.2000	Submitted
ECUADOR	29.08.2000	Intaxel 30 mg (for tender)	Onco	31.08.2000	Submitted
ECUADOR	29.08.2000	Cytarabine 100mg (for tender)	Onco	31.08.2000	Submitted
ECUADOR	29.08.2000	Cytarabine 500mg (for tender)	Onco	31.08.2000	Submitted
ECUADOR	29.08.2000	Cytarabine 1g (for tender)	Onco	31.08.2000	Submitted
ECUADOR	29.08.2000	Empurine tab. (for tender)	Onco	31.08.2000	Submitted
ECUADOR	29.08.2000	Kemocarb 150 (for tender)	Onco	31.08.2000	Submitted
ECUADOR	29.08.2000	Kemoplat 10 (for tender)	Onco	31.08.2000	Submitted
ECUADOR	29.08.2000	Ledoxan Tab 50 mg (for tender)	Onco	31.08.2000	Submitted
PAPUA NEW GUINEA	25.09.1998	Cetaniil tablet (tender papers)	Non-Onco	29.09.1998	Submitted
PAPUA NEW GUINEA	25.09.1998	Damoxy Capsules (tender papers)	Non-Onco	29.09.1998	Submitted
PERU	21.04.2001	Irinotei 40 & 100 (For tender)	Onco	24.04.2001	Submitted
PERU	21.04.2001	Kemocarb 150 & 450 (tender)	Onco	24.04.2001	Submitted
PERU	21.04.2001	Kemoplat 10mg/20ml (tender)	Onco	24.04.2001	Submitted
PERU	21.04.2001	Docetaxel 20 & 80 (For tender)	Onco	24.04.2001	Submitted
PERU	21.04.2001	Adrim 10 & 50 (For tender)	Onco	24.04.2001	Submitted
PERU	21.04.2001	Fytosid 100 (For tender)	Onco	24.04.2001	Submitted
PERU	21.04.2001	Fivoflu 250 mg (For tender)	Onco	24.04.2001	Submitted
PERU	21.04.2001	Zexate 15 (For tender)	Onco	24.04.2001	Submitted
PERU	21.04.2001	Intaxel 30 (For tender)	Onco	24.04.2001	Submitted
PERU	21.04.2001	Topotec 4 (For tender)	Onco	24.04.2001	Submitted
PERU	21.04.2001	Ledoxan 50 (For tender)	Onco	24.04.2001	Submitted
PERU	21.04.2001	Gynalam 20 (For tender)	Onco	24.04.2001	Submitted
URUGUAY	13.07.2000	Ledoxan 50 mg (tender)	Onco	11.08.2000	Submitted
URUGUAY	13.07.2000	Zexate Tab 2.5(tender)	Onco	11.08.2000	Submitted

DOSSIERS SUBMITTED, FROM FEBRUARY 2002 TO APRIL 2003

SINo	Country	Products	No. of dossiers	No. of products	Dossier sent on
1.	Thailand	Topotel 4	1	1	18.02.2002
2.	Jamaica	Kemocarb 450	1	1	04.02.2002
3.	Philippines	Vinorelbine 10 & 50	1	2	28.02.2002
4.	Liberia	Damoxoy BP 250 Damoxoy BP500 Nuren BP200 Nuren BP400	4	4	06.03.2002
5.	Nepal	Contrastin 76% 100 ml Radiopaque 300mg/ml (100ml)	6	6	08.02.2002
		Radiopaque 350mg/ml (100ml)			
		adiopaque 300mg/ml (40ml)			11.03.2002
		Magniscan 10 & 20 ml			25.03.2002
		Back Aid 5g & 25 g			27.03.2001
6.	T&T	Vinlbine-10	6	6	18.03.2002
		Vinlbine -50 Irinotel - 40 Irinotel -100			
		Cytarine B.P. 500 mg Cytarine B.P. 1g			
7.	Macao	Kemocarb 450 Radiopaque 300 (40 ml)	2	2	25.03.2002
8.	Peru	Irinotel-100	5	5	29.03.2002
		Cytarine -100 Vinlbine-10 Vinlbine-50 Intaxel -260			
9.	Iraq	ADRIUM 10 mg ADRIUM 50 mg FYTOSID 100 mg	8	8	15.03.2002
		FIVOFU 250 mg (amp.) KEMOPLAT 10 mg			
		KEMOPLAT 50 mg ZEXATE 2.5 mg tablets ZEXATE 50 mg			
10.	T&T	KEMOPLAT 10mg/20 ml FIVOFU 500 mg(Amp.)	3	3	18.03.2002
		KEMOCARB 450 mg			
11.	Venezuela & Badan	DAXOTEL 20 & 80	1	2	02.03.2002
12.	Brazil	Pamifos 90	1	1	28.06.2002
13.	Brazil	Topotel 4 Irinotel 100 mg Daxotel 20 & 80 mg	3	4	19.07.2002
14.	Brazil	Intaxel 30	1	1	12.08.2002
15.	Brazil	Intaxel 100	1	1	13.09.2002
16.	Brazil	Intaxel 100	1	1	13.09.2002
17.	Burkina Faso	Adrim 10	7	10	08.05.2002
		Cytarine BP 100, 500 & 1g Fivofu 250 & 500 mg ampoule			
		Fytosid 100 mg Leucovorin inj.50 Zexate 50			
		Zexate tablet 2.5 mg			
18.	Burkina Faso	Alocard 50	8	8	10.05.2002
		Alocard 100 Damoxoy caps 500 Damoxoy dry syrup			
		Nuren 200 Nuren 400 Strox 250 Strox 500			
19.	Costa Rica	Daxotel 20	6	6	12.04.2002
		Daxotel 80 Irinotel 40 Irinotel 100 Topotel 4 Empurine 50			
20.	Hong Kong	CytarineBP 100, 500 & 1 gm	14	23	12.07.2002
		Fivofu 250mg & 500mg amp. Leucovorin Calcium Inj.3mg			
		Leucovorin Calcium Inj. 15mg Leucovorin Calcium Inj. 50mg			
		Fytosid 100mg Adrim 10mg and 50mg Zexate 50mg			
		Zexate 15mg Vinorelbine Inj. 10mg & 50mg			
		Mesna Injection 200mg Kemoplat (0.5mg)20 & 100ml			
		Intaxel Inj.30,100mg& 260mg Kemocarb 150mg and 450mg			
21.	Jordan	Kemocarb 150 Kemocarb 450	2	2	26.04.2002
22.	Jordan	Kemoplat 10mg/20ml	4	4	18.07.2002
		Kemoplat 50mg/100ml Zexate 50mg Zexate 500mg			
23.	Jordan	Intaxel 260	1	1	18.07.2002
24.	Kazakhstan	Zexate 50	1	1	26.04.2002
25.	Kazakhstan	Adrim 10 & 50	6	12	03.08.2002
		Fytosid 100 Intaxel 30, 100 & 260 Kemocarb 150 & 450			
		Kemoplat 20 ml&100ml Zexate 50 & 15			
26.	Kazakhstan	Adrim 10 & 50	6	12	21.09.2002
		Fytosid 100 Intaxel 30, 100 & 260 Kemocarb 150 & 450			
		Kemoplat 20 ml&100ml Zexate 50 & 15			
27.	Malaysia	Fivofu 250mg & 500mg (Vials)	1	2	19.06.2002
28.	Malaysia	Stage 3	4	6	16.04.2002
		INTAXEL 260MG VINOIRELBINE 10MG AND 50MG			
		ZEXATE-500MG			24.04.2002
		KEMOPLAT 1MG/ML (10 & 50 MG)			30.04.2002

S/No	Country	Products	No. of dossiers	No. of products	Dossier sent on
29	Malaysia	Part II of stage 3 Kemoplat Injection 1mg/ml	1	1	17.07.2002
30	Morocco	Kemoplat 50mg/50ml	1	1	03.06.2002
31	Nepal	Emetra 4 & Bmg Bismocycin for inj. 15 units	2	3	12.07.2002
32	Nepal	Trozol 2.5 mg	1	1	25.09.2002
33	Singapore	Zexate -500	1	1	31.05.2002
34	Sri Lanka	Nasarel 20 & 60	1	2	27.05.2002
35	Sri Lanka	For Re-registration Tinavate Solution USP Demoxy Dry Syrup BP Alexin Dry Syrup BP Alexin 250 Alexin 500	5	6	12.08.2002
36	Sudan	ADRIUM 10MG FIVOFU 250MG ampoule KEMOPLAT 10MG/20ml	3	3	18.04.2002
37	Thailand	Vinorelbine 10 & 50	1	2	26.04.2002
38	Thailand	Zexate 500	1	1	Oct 2002
39	Sri Lanka	Strox 250 Strox 500	2	2	09.10.2002
40	Singapore	Kemoplat 10 & 50 (1mg/ml)	1	2	-
41	Venezuela	Cytarabine 100/500/1 g	1	3	26.10.2002
42	Afghanistan	Fivofu Vials 250 & 500 Fylosid 100mg Kemocarb 150 & 450	9	12	02.11.2002
43	Sri Lanka	Kemoplat 10/20 & 50/100ml Zexate 50 Gynatam 10 Gynatam 20 Ledoxan Tab 50 mg Zexate Tab. 2.5 mg Atocard 25, 50& 100(re-registration) Aternex 120 & Aternex 180 Aternex	4	6	Nov. 2002
44	Burkina Faso	Zexate 2.5 Ledoxan 50	2	2	21.11.2002
45	Maldives	Tinavate Cream	5	5	22.11.2002
46	Nepal	Tinavate Solution Atocard 25 Atocard 50 Atocard 100	1	4	27.11.2002
47	Malaysia	Ioscan 300 & 370 (50 & 100 ml for both strength)	1	2	10.12.2002
48	Maldives	Stage 3 Fivofu Injection 250 & 500 (Vials)	3	3	11.12.2002
49	Philippines	Alexin dry syrup Alexin 250 Alexin 500	1	2	13.12.2002
50	Philippines	Daxotel 20 & 80 Re-registration	5	8	16.12.2002
51	IRAQ	Gynatam Tablets 10 & 20 mg Mesna Injection 200 Adrim Injection 10 & 50 mg Fylosid Injection 100 mg Fivofu Injection 250 & 500 mg (Ampoules) Ledoxan Injection 200 Ledoxan Injection 500 Ledoxan Tabs 50 mg Cytarin 100 Ipamide Injection	5	5	27.12.2002
52	IRAQ	Empurine Tablets Mesna Injection Leucovorin Calcium Injection USP 3mg Leucovorin Calcium Injection USP 15mg Leucovorin Calcium Injection USP 50mg	5	5	27.12.2002
53	Myanmar	Vinorelbine -10 Vinorelbine - 50	2	2	23.12.2002
54	Malaysia	Docetaxel Injection 20mg and 80mg Topotel Injection 4mg and 2.5mg	2	4	27.12.2002
55	Peru	Leucovorin Calcium Injection USP 50mg Mesna Injection 200mg	2	2	30.12.2002
56	Jamaica	Irinotel 40& 100 Zexate 15 & 500 Empurine Gynatam 10 & 20 mg	4	7	15.01.2003
57	Venezuela	Kemoplat 10 and 50 (1 mg/ml) Irinotel 40 & 100 Topotel 2.5 & 4	3	6	27.01.2003
58	Mexico	Vinorelbine 10 & 50 Irinotel 40 & 100 Fivofu 5ml amp., 5ml vial, 10ml amp. and 10ml vial Cytarabine 100 mg, 500 mg and 1 g Kemoplat 20 ml, 100ml, 10ml and 50ml	5	15	03.02.2003

Sl No	Country	Products	No. of dossiers	No. of products	Dossier sent on
59	Kazakhstan	Intaxel 30, 100 & 260 Fytosid 100 Kemocarb 150 & 450 Zexale 15 & 50 Kemoplat 10 & 50 Adrim 10 & 50	6	12	07.02.2003
60	Colombia	Vineltine 10 & 50 Fivoflu Vials 250 & 500 Cytarabine 100 mg, 500 mg & 1g Irinotel 40 & 100 Leucovorin Calcium Injection 3, 15 and 50mg mesna	6	13	02.2003
61	El Salvador	Vineltine 10 & 50 Zexale 50 Gynatem 10 Adrim 10mg & 50mg Cytarabine 100mg, 500mg & 1g Kemocarb 150mg & 450mg Fivoflu 5ml Amp. & 10ml Amp. Fivoflu 5ml Vial & 10ml Vial Intaxel 30mg, 100mg & 260mg Fytosid Injection	10	19	10.03.2003
62	Zimbabwe	Cytarabine 100 mg	1	1	27.03.2003
63	Russia	Daxotel 20 & 80	1	2	27.03.2003
64	Lithuania	Fytosid 100 Intaxel 30, 100 & 260 Kemoplat 20 & 100 ml Kemocarb 150 & 450	4	8	11.04.2002
65	Ukraine	Daxotel 20 & 80 Irinotel 40 & 100	2	4	18.04.2003
66	El Salvador	Daxotel 20 & 80	1	2	02.04.2003
67	Cuba	Eripurine Tablet Ledoxan Tablet	2	2	23.04.2003
68	Sri Lanka	Ulgel Tablet -Cardamom flavour Ulzol Capsule IP	2	2	23.04.2003

SCHEDULE 'C'

Schedule of immovable property of Demerged Undertaking

Sl No	Particulars
1.	Injectible unit 19, HPSIDC Industrial Area, Baddi 173 205 Distt Solan, Himachal Pradesh
2.	D-35, Industrial Area, Kalyani, Distt Nadia 741 235, West Bengal All that land admeasuring 18.9439 acres lying and bearing Plot No. 35 in Block O, in the township of Kalyani Sub-Division, Kalyani, Thane Kalyani, Sub-registration Office Kalyani in the District of Nadia and bulited and bounded in the manner following that is to say: On the North: By 60 ft wide Road On the East: By Plot No. 36/D On the South: By 60 ft. wide Road On the West: By 60 ft. wide Road
3.	Plot No 11, Echelon Institutional, Sector 32, Gurgaon, Haryana
4.	3 Factory Road, New Delhi Bounded by the North by proposed 30' wide road Bounded by the South by plot of Mrs Gunwanti Devi Bounded on the East by 75' wide road Bounded on the West by S. Gurcharan Singh's Plot No. 4
5.	Flat No 321, Petit Hall, Mumbai

* Omitted vide Court order dt: 22-09-08

SCHEDULE II

SCHEDULE OF ASSETS OF M/S DABUR INDIA LIMITED (The Transferor Company) to be transferred to
and vested in M/S DABUR PHARMA LIMITED (The Transferee Company)

PART - I

A short description of the freehold property of the Transferor Company

1. Injectible unit - 19, HPSIDC Industrial Area, Baddi 173 205, Distt Solan, Himachal Pradesh
2. Plot No. 11, Echelon Institutional, Sector 32, Gurgaon, Haryana

PART - II

A short description of the leasehold property of the Transferor Company

1. D-35, Industrial Area, Kalyani, Distt Nadia 741 235, West Bengal - All that land admeasuring 16.9439 acres lying and bearing Plot No. 35 in Block D, in the township of Kalyani Sub-Division, Kalyani, Thana Kalyani, Sub-registration Office Kalyani in the District of Nadia and butted and bounded in the manner following that is to say :
On the North By 80 ft wide Road
On the East By Plot No. 36/D
On the South By 60 ft. wide Road
On the West: By 60 ft. wide Road
2. 3 Factory Road, New Delhi - 110029
Bounded by the North by proposed 30' wide road
Bounded by the South by plot of Mrs. Gunwanti Devi
Bounded on the East by 75' wide road
Bounded on the West by S. Gurcharan Singh's Plot No.4
3. Flat No 321, Petit Hall, Mumbai

PART - III

A short description of all stocks, shares, debentures and other charges in action of the Transferor Company:

Illustrative list of movable assets

111, 400, 000 Equity shares of 10p each fully paid up of Dabur Oncology Plc representing 100% of the paid up equity share capital (share certificate No. 9, 10 and 11)

S. No.	Particulars	Net Book Value as on March 31, 2003 (Rs in crores)
1	Inventories	47.17
2	Sundry Debtors	24.74
3	Cash and Bank Balances	16.63
4	Loans and Advances	6.31
	Total	94.85

Illustrative list of movable assets

LIST OF PHARMA TRADE MARKS
REGISTERED IN FOREIGN COUNTRIES

Sl.No.	Trade Mark	Country	Regn. No.	Class	Regn. Date	Valid up to
1	Intaxel	Nepal	11435/052	5	25.03.1996	25.03.2010
2	Intaxel	Thailand	284543	5	26.04.1995	26.04.2005
3	Intaxel	Indonesia	356643	5	07.04.1995	07.04.2005
4	Intaxel	South Korea	338783	10	30.04.1996	30.04.2005
5	Intaxel	Sri Lanka	75240	5	07.08.1995	07.08.2005
6	Intaxel	China	1002846	5	14.05.1997	14.05.2007
7	Intaxel	Czech Republic	198762	5	25.08.1995	25.08.2005
8	Intaxel	Slovak Republic	197047	5	28.08.1995	28.08.2005
9	Intaxel	Turkey	105442	5	06.12.1995	06.12.2005
10	Intaxel	Israel	102497	5	22.12.1995	22.12.2016
11	Intaxel	South Africa	98/00206	5	08.01.1996	08.01.2006
12	Intaxel	Kenya	43739	5	11.01.1996	11.01.2003
13	Intaxel	Russia	161240	5	08.08.1997	08.08.2007
14	Dabitas	South Africa	098/08507	5	20.05.1998	20.05.2008
15	Kemocarb	Thailand	Kor 101041	5	11.09.1998	11.09.2008
16	Ledoxan	Thailand	Kor 92219	5	11.09.1998	11.09.2008
17	Adrim	Thailand	Kor 92220	5	11.09.1998	11.09.2008
18	Fytosid	Thailand	Kor 92221	5	11.09.1998	11.09.2008
19	Fivoflu	Thailand	Kor 92222	5	11.09.1998	11.09.2008
20	Hydab	Thailand	Kor 148279	5	29.03.2001	29.03.2011
21	Topotel	Thailand	Kor 148280	5	29.03.2001	29.03.2011
22	Gynatam	Thailand	Kor 148281	5	29.03.2001	29.03.2011
23	Igamide	Thailand	Kor 148282	5	29.03.2001	29.03.2011
24	Ininotel	Thailand	Kor 148283	5	29.03.2001	29.03.2011
25	Empurine	Thailand	Kor 149094	5	29.03.2001	29.03.2011
26	Zexale - 50 Daber	Thailand	Kor 152091	5	24.03.2000	24.03.2010
27	Emetra	Thailand	Kor 166287	5	24.01.2002	24.01.2012
28	Kemoplat	Brazil	820745910	5	11.09.2001	11.09.2011

LIST OF PHARMA TRADE MARKS PENDING
FOR REGISTRATION IN FOREIGN COUNTRIES

Sl.No.	Trade Mark	Country	App. No.	Class	App Date
1	Intaxel	Malaysia	95/01640	5	24.02.1995
2	Intaxel	Philippines	105116	5	—
3	Intaxel	Brazil	820745901	5	15.05.1998
4	Fytosid	Brazil	820745928	5	15.05.1998
5	Kemoplat	Thailand	Kor 101142	5	11.09.1998
6	Zexale	Thailand	369492	5	11.09.1998
7	Kemoplat	Philippines	4-1998-06630	5	02.09.1998
8	Kemocarb	Philippines	4-1998-06635	5	02.09.1998
9	Ledoxan	Philippines	4-1998-06636	5	02.09.1998
10	Adrim	Philippines	4-1998-06634	5	02.09.1998
11	Fytosid	Philippines	4-1998-06633	5	02.09.1998
12	Fivoflu	Philippines	4-1998-06631	5	02.09.1998
13	Zexale	Philippines	4-1998-06632	5	02.09.1998
14	Gynatam	Philippines	4-1999-04399	5	21.06.1999
15	Intaxel	Bangladesh	61306	5	19.08.1999
16	Fivoflu	Costa Rica	114266	5	07.06.1999
17	Zexale	Costa Rica	114443	5	22.06.1999

Sl.No.	Trade Mark	Country	App. No.	Class	App Date
18	Kemoplai	Costa Rica	114446	5	22.06.1999
19	Gynatam	Costa Rica	114445	5	22.06.1999
20	Daxotel	Thailand	449833	5	29.03.2001
21	Zexate	Brazil	—	—	—
22	Emetra	Philippines	4-2002-00572	5	—
23	Emetra	Malaysia	2002/01669	5	11.02.2002
24	Erjetra	Singapore	T02/000598	5	03.01.2002
25	Emetra	Sri Lanka	106327	5	07.01.2002
26	Cytarine	Philippines	4-2002-02977	5	15.04.2002
27	Empurine	Philippines	4-2002-02978	5	15.04.2002
28	Hydab	Philippines	4-2002-02979	5	15.04.2002
29	Daburex	Mexico	—	5	—
30	Daxotel	Mexico	—	5	—
31	Kemocarb	Mexico	—	5	—
32	Kemocarb	Peru	—	5	—
33	Kemoplai	Peru	—	5	—
34	Ledoxan	Peru	—	5	—
35	Adrim	Peru	—	5	—
36	Fytosid	Peru	—	5	—
37	Zexate	Peru	—	5	—
38	Intaxel	Peru	—	5	—
39	Gynatam	Peru	—	5	—
40	Topotel	Peru	—	5	—
41	Fivoflu	Peru	—	5	—
42	Daxotel	Colombia	03017492	5	28.02.2003
43	Daxotel	Trinidad & Tobago	—	5	—
44	Daxotel	Belarus	20030105	5	22.01.2003
45	Daxotel	Macau	M/10932	5	27.01.2003
46	Daxotel	Costa Rica	—	5	—
47	Daxotel	Hong Kong	01376/2003	5	27.01.2003
48	Daxotel	Myanmar	—	5	—
49	Daxotel	Russia	2003701220	5	22.01.2003
50	Daxotel	Sri Lanka	110804	5	17.12.2002
51	Daxotel	Turkey	—	5	—
52	Daxotel	Ukraine	200221211178/T	5	26.12.2002
53	Daxotel	Venezuela	—	5	—
54	Daxotel	Vietnam	4-2003-01175	5	25.02.2003
55	Daxotel	Chile	—	5	—
56	Docetal	Peru	—	5	—
57	Adenex	Brazil	—	5	—
58	Adrim	El Salvador	—	5	—
59	Daxotel	El Salvador	—	5	—
60	Intaxel	El Salvador	—	5	—
61	Vineibine	El Salvador	—	5	—
62	Kemocarb	El Salvador	—	5	—
63	Fytosid	El Salvador	—	5	—
64	Kemocarb	Vietnam	—	5	—
65	Kemoplai	Vietnam	—	5	—
66	Ledoxan	Vietnam	—	5	—
67	Cytarine	Vietnam	—	5	—
69	Fytosid	Vietnam	—	5	—
70	Fivoflu	Vietnam	—	5	—
71	Ipamide	Vietnam	—	5	—
73	Zexate	Vietnam	—	5	—
74	Intaxel	Vietnam	—	5	—
75	Gynatam	Vietnam	—	5	—

LIST OF PHARMA INDIAN REGISTERED TRADE MARKS

Sl. No.	Trade Mark	Regn. No.	Class	Regn. Date	Valid up to
1	Oryza	475434	5	17.07.1987	17.07.2008
2	Tinavate	479548	5	07.10.1987	07.10.2008
3	Alecard	479547	5	07.10.1987	07.10.2008
4	Damoxy	479548	5	07.10.1987	07.10.2008
5	Dabcilin	479557	5	07.10.1987	07.10.2008
6	Strox	481403	5	20.11.1987	20.11.2008
7	Grencem	494418	5	15.07.1988	15.07.2009
8	Nuren	498444	5	27.09.1988	27.09.2009
9	Cetanil	428974	5	25.10.1984	25.10.2005
10	Rheumatil	437392	5	06.05.1985	06.05.2006
11	Zened	563852	5	16.12.1991	16.12.2005
12	Groinate	475431	5	17.07.1987	17.07.2008
13	Cameron	475435	5	17.07.1987	17.07.2008
14	Magaldid	475436	5	17.07.1987	17.07.2008
15	Damox	475438	5	17.07.1987	17.07.2008
16	Dabox	475439	5	17.07.1987	17.07.2008
17	Buspar	477816	5	03.09.1987	03.09.2008
18	Enkaid	477817	5	03.09.1987	03.09.2008
19	Seovin	479545	5	07.10.1987	07.10.2008
20	Frontic	479549	5	07.10.1987	07.10.2008
21	Boncid	479551	5	07.10.1987	07.10.2008
22	Gescape	479552	5	07.10.1987	07.10.2008
23	Gescole	479553	5	07.10.1987	07.10.2008
24	Oinate	479554	5	07.10.1987	07.10.2008
25	Dabexin	479555	5	07.10.1987	07.10.2008
26	Ultracel	479556	5	07.10.1987	07.10.2008
27	Gritinea	479639	5	09.10.1987	09.10.2008
28	Do - Do	487217	5	10.03.1988	10.03.2009
29	Daxcel	487219	5	10.03.1988	10.03.2009
30	Panalova	487219	5	10.03.1988	10.03.2009
31	Vanta	490495	5	04.05.1988	04.05.2009
32	Grogam	490496	5	04.05.1988	04.05.2009
33	Rantaid	495915	5	12.08.1988	12.08.2002
34	Okedo	496672	5	26.08.1988	26.08.2009
35	Bopernex	498453	5	27.09.1988	27.09.2002
36	Netidip	511809	5	13.06.1989	13.06.2003
37	Vytee	515919	5	29.08.1989	29.08.2003
38	Quinosiat	518269	5	12.10.1989	12.10.2003
39	Microneg	519046	5	27.10.1989	27.10.2003
40	Danizol	519047	5	27.10.1989	27.10.2003
41	Cesadroxil	519048	5	27.10.1989	27.10.2003
42	Futral	531498	5	14.06.1990	14.06.2004
43	Whotral	573954	5	25.05.1992	25.05.2006
44	Wycide	579051	5	11.08.1992	11.08.2006
45	Vidistal	579052	5	11.08.1992	11.08.2006
46	Gynosep	579053	5	11.08.1992	11.08.2006
47	Biljing	590740	5	12.02.1993	12.02.2007
48	Kevodab	602118	5	20.07.1993	20.07.2007
49	V - Uracl	630390	5	08.06.1994	08.06.2008
50	Ranfaz	632800	5	04.07.1994	04.07.2008
51	Kemoplat	632803	5	04.07.1994	04.07.2008
52	Gentus	641445	5	28.09.1994	28.09.2008
53	Rusimid	641446	5	28.09.1994	28.09.2008
54	Tosylfi	641448	5	28.09.1994	28.09.2008
55	Adlam	641449	5	28.09.1994	28.09.2008

LIST OF PHARMA INDIAN PENDING TRADE MARK APPLICATIONS

Sl. No.	Trade Mark	Application No.	Class	App. Date
1	Livfit	454537	5	22.05.1986
2	Ulgei	475433	5	17.07.1987
3	Alexin	488851	5	31.03.1988
4	Ecoprin	519044	5	27.10.1989
5	Livfit - Label	547087	5	13.03.1991
6	So Low	556238	5	09.08.1991
7	So Low	556238	30	09.08.1991
8	Colestron	555731	5	02.08.1991
9	Mazinal	574081	5	25.07.1992
10	Yestel	574082	5	27.05.1992
11	Honilus	577232	5	17.07.1992
12	Septidine	579054	5	11.08.1992
13	Taxol	606182	5	07.09.1993
14	Stresscom	609200	5	—
15	Fechew	613284	5	03.12.1993
16	Ultraquin	613285	5	03.12.1993
17	Intaxel	644195	5	27.10.1994
18	Indaxel	617521	5	24.01.1994
19	Hintaxel	617522	5	24.01.1994
20	Hindaxel	617520	5	24.01.1994
21	Intaxol	644196	5	27.10.1994
22	Inloxal	644194	5	27.10.1994
23	Lactonic	621814	5	11.03.1994
24	Lactonic - Label	638152	5	25.08.1994
25	Lipisal	626089	5	27.04.1994
26	Diamet	626088	5	22.04.1994
27	Tricawin	624057	5	31.03.1994
28	Ulcinorm	624058	5	31.03.1994
29	Adrim	630392	5	08.06.1994
30	ipamide	630396	5	08.06.1994
31	Alenod	630394	5	08.06.1994
32	Retinod	630395	5	08.06.1994
33	Bemocin	630393	5	08.06.1994
34	Zexale	632805	5	04.07.1994
35	Adoxim	632806	5	04.07.1994
36	Ledoxan	632802	5	04.07.1994
37	Fytosid	632804	5	04.07.1994
38	Daboxan	632801	5	04.07.1994
39	Fivoflu	636130	5	05.08.1994
40	Wotam	636131	5	05.08.1994
41	Saredal	641447	5	28.09.1994
42	Precorl	647672	5	02.12.1994
43	Dexasone	647667	5	02.12.1994
44	Betnal	647671	5	02.12.1994
45	Betnal - S	647661	5	02.12.1994
46	Rafetab	647670	5	02.12.1994
47	Keloten	647668	5	02.12.1994
48	Coltrizol	647666	5	02.12.1994
49	Cimetol	647665	5	02.12.1994
50	Oxytron	647669	5	02.12.1994
51	Povisept	648315	5	09.12.1994
52	Migratan	649543	5	22.12.1994
53	Serotrip	649545	5	22.12.1994
54	Dabaprin	649544	5	22.12.1994
55	Curamig	653931	5	31.01.1995
56	Migranorm	653930	5	31.01.1995
57	Inactical	670547	5	26.06.1995
58	Camptotel	829746	5	27.11.1998

Sl. No.	Trade Mark	Application No.	Class	App. Date
59	Immusol	679518	5	08.09.1995
60	Meganeg	684750	5	27.10.1995
61	Aleract	691041	5	18.12.1995
62	Radlopaque	702538	5	21.03.1996
63	Clorzok	718454	5	10.06.1996
64	Daxotel	718455	5	10.06.1996
65	Eskinase	720032	5	27.06.1996
66	Contrastin	762104	5	10.06.1997
67	Magniscan	762105	5	10.06.1997
68	Resync	765787	5	05.08.1997
69	Gynatam	792436	5	23.02.1998
70	Kemocarb	792437	5	23.02.1998
71	Topotel	794071	5	10.06.1998
72	Elamex	805505	5	10.06.1998
73	Hydab	800312	5	28.04.1998
74	Cytarine	802926	5	20.05.1998
75	Empurine	802927	5	20.05.1998
76	Dabitax	802925	5	20.05.1998
77	Alamax	835889	5	08.01.1999
78	Nasarel	864171	5	06.07.1999
79	Cycloset	860151	5	08.06.1999
80	Amiphos	860764	5	11.06.1999
81	Mitodab	867333	5	22.07.1999
82	Roxisole	877656	5	22.09.1999
83	Flucostat	879136	5	30.09.1999
84	Irinotel	907545	5	03.03.2000
85	Amifocan	926787	5	23.05.2000
86	Pamifos	926788	5	23.05.2000
87	Utzol	938875	5	12.07.2000
88	Vinabine	948125	5	16.08.2000
89	Osofit	1001608	5	04.04.2001
90	Harmoni	1001610	5	04.04.2001
91	Feronich	1001811	5	04.04.2001
92	Richglow	1001609	5	04.04.2001
93	Osteolone	988977	5	30.01.2001
94	Dablit	988978	5	30.01.2001
95	Diptip	988976	5	30.01.2001
96	Lestrol	988975	5	30.01.2001
97	Dabrol	988974	5	30.01.2001
98	Sirox T2	995266	5	08.03.2001
99	Phytolac	1003192	5	12.04.2001
100	Immunofit	1003193	5	12.04.2001
101	Ocuflit	1003194	5	12.04.2001
102	Gastrofit	1003195	5	12.04.2001
103	Cardiofit	1003196	5	12.04.2001
104	Ioscan	1018787	5	20.06.2001
105	Menopin	1020442	5	26.06.2001
106	Gynacor	1020443	5	26.06.2001
107	Mifeprel	1020444	5	26.06.2001
108	Ovupin	1020445	5	26.06.2001
109	Artrex	705491	5	02.05.1998
110	Artrex - Carton	800641	5	30.04.1998
111	Fencile	1033950	5	02.08.2001
112	Gynatrop	1035316	5	08.08.2001
113	Buserel	1051482	5	11.10.2001
114	Isofil	1051480	5	11.10.2001
115	Fylosoy	1051481	5	11.10.2001
116	Emetra	1057273	5	07.11.2001
117	Ramil	1068385	5	12.12.2001

Sl. No.	Trade Mark	Application No.	Class	App. Date
118	Surviv	1066386	5	12.12.2001
119	Praca	1066387	5	12.12.2001
120	Sinofit	1066384	5	12.12.2001
121	Sinocure	1066383	5	12.12.2001
122	Tiboral	1068008	5	19.12.2001
123	Estrofit	1068009	5	19.12.2001
124	Osteofit	1068369	5	20.12.2001
125	Trozal	1069417	5	26.12.2001
126	Aternex Distab	1069722	5	27.12.2001
127	Gingiva	1069721	5	27.12.2001
128	Celoral	1078048	5	04.02.2002
129	Volox	1078114	5	04.02.2002
130	Revas	1078115	5	04.02.2002
131	Anthracin	1097432	5	27.04.2002
132	Gestofit	1103597	5	09.05.2002
133	Thalix	1103596	5	09.05.2002
134	Osteosel	1103880	5	10.05.2002
135	Oxitan	1141164	5	04.10.2002
136	Echoscan	1141166	5	04.10.2002
137	OncQuest	1157457	5	11.12.2002
138	Flutrox	1165805	5	10.01.2003
139	Temozam	—	5	—
140	Cladrim	—	5	—
141	Zyfos	—	5	—
142	Gemita	—	5	—
143	Femizel	—	5	—
144	Bypro	—	5	—
145	Osteoin	—	5	—
146	Tumotran	—	5	—
147	Ovigny	1195776	5	01.05.2003
148	Folripe	1195777	5	01.05.2003
149	PMS Free	—	5	—

DETAILS OF GRANTED PATENTS

Sl. No.	Title	Country	Patent No.	Date of grant
1	Hepatoprotective compositions and composition for Treatment of conditions related to Hepatitis B and E Infection	USA	6-136316	24.10.2001
2	A Combined plant Coagulate Composition, Process for manufacture thereof and uses thereof	South Africa	2001/2491	24.12.2001
3	A Combined plant Coagulate Composition, Process for manufacture thereof and uses thereof	Sri Lanka	12390	27.11.2001
4	Novel compositions of Taxane and Taxane Derivative and Process for manufacturing thereof	Sri Lanka	11999	21.07.2000
5	Use of Betulinic Acid and its Derivatives for inhibiting cancer growth and a method of monitoring this	USA	6048847	11.04.2000
6	Anti Angiogenic Activity of Betulinic Acid and its Derivatives	USA	6226850	08.05.2001
7	Use of Betulinic Acid Derivatives for inhibiting Cancer growth	USA	6214814	10.04.2001
8	Anti Angiogenic Activity, of betulinic acid and its derivatives	USA	6403816	11.06.2002
9	Extracting Betulinic Acid from Zizi Plus Jujuba	USA	6264998	24.07.2001
10	Process for Isolating 10-Deacetyl Baccatin-III	USA	6214482	26.09.2000
11	Process for the Isolation of 14-B-Hydroxy-10-Deacetyl Baccatin-III	EPO	1010697 B1	31.10.2001
12	Process for the Isolation of 14-B-Hydroxy-10-Deacetyl Baccatin-III	USA	6002024	14.12.1999
13	Novel Paclitaxel Analogues having Anti Cancer activity	USA	6395771 B1	28.05.2002
14	Vasoactive intestinal Peptide Analogs	USA	6489297	03.12.2002
15	Somatostatin Analogs for the treatment of Cancer	USA	6316414	13.11.2001
16	A novel process for preparing Herbal Galactagogue composition	Sri Lanka	12497	14.12.2001

Sl. No.	Title	Country	Patent No.	Date of grant
17	A novel composition for treatment of Drug Resistant Bacterial Infection and a method of treating Drug Bacterial Infections	Sri Lanka	12434	21.11.2001
18	An antiangiogenic drug	USA	6492330	10.12.2002
19	Formulations of Paclitaxel, its derivatives or its analogs entrapped in to nano particles of polymeric micelles, process for preparing same and use thereof	USA	6365191	21.09.2000
20	Novel Betulinic acid derivatives, processes for preparing such derivatives and its use as cancer growth inhibitors	South Africa	2001/3616	24.04.2002
21	Formulations of Paclitaxel, its derivatives or its analogs entrapped in to nano particles of polymeric micelles, process for preparing same and use thereof	USA	6322817	27.11.2001
22	A process for isolation of 10-deacetylbaicalonin III from recoverable part of a plant taxus species	Australia	753086	23.01.2003

DETAILS OF PENDING PATENTS

Sl.No.	Title	Country	App. No.	Date of Appl.
1	Hepatoprotective compositions and composition for Treatment of conditions related to Hepatitis B and E Infection	European Patent	EP0890360 A1	13.01.1999
2	Herbal composition for the treatment of Bone Metabolic Disorders and a process for its preparation	India	574/DEL/2001	15.05.2001
3	A process for the preparation of a Synergistic Herbal Composition in the treatment of Bone Metabolic Disorders	India	573/DEL/2001	15.05.2001
4	A Combined plant Coagulate Composition, Process for manufacture thereof and uses thereof	India	340/DEL/2000	28.03.2000
5	A Combined plant Coagulate Composition, Process for manufacture thereof and uses thereof	Malaysia	PI 20011403	27.03.2001
6	A Herbal composition and process for the manufacturing of such composition for Gynecological Disorders	India	344/DEL/2000	28.03.2000
7	A Herbal composition and process for the manufacturing of such composition for Gynecological Disorders	Malaysia	PI20011404	27.03.2001
8	A Herbal composition and process for the manufacturing of such composition for Gynecological Disorders	Russia	2001108465	27.03.2001
9	A Herbal composition and process for the manufacturing of such composition for Gynecological Disorders	USA	09/819828	23.03.2001
10	A Novel process for preparing Herbal Galactogogue composition	India	702/DEL/2001	25.06.2001
11	A Novel composition for treatment of Drug Resistant Bacterial Infection and a method of treating Drug Resistant Bacterial Infections	India	1260/DEL/1999	17.09.1999
12	A Novel composition for treatment of Drug Resistant Bacterial Infection and a method of treating Drug Resistant Bacterial Infections	USA	9/662609	15.09.2001
13	A Novel composition for treatment of Drug Resistant Bacterial Infection and a method of treating Drug Resistant Bacterial Infections	PCT	PCT/INOO/00095	04.10.2000
14	A Novel composition to treat Hepatitis B virus infection	India	797/DEL/1996	15.04.1996
15	A process for production of Taxus Plants through tissue culture invitro	India	708/DEL/2001	26.06.2001
16	Method for Agrobacterium mediated Transformation of Taxus SP. Callus Culture	India	709/DEL/2001	26.06.2001
17	A process for purifying Polyethoxylated Castor Oil	India	29/Del/2002	16.01.2002
18	A formulation containing improved Polyethoxylated Castor Oil	India	30/Del/2002	16.01.2002
19	Novel composition of Taxane Derivative and process for manufacturing thereof	India	931/Del/1999	30.06.1999
20	Novel composition of Taxane Derivative and process for manufacturing thereof	WTO	934/Del/1999	30.06.1999
21	Use of Betulinic Acid and its Derivatives for inhibiting Cancer growth and a method of monitoring this	India	2801/Del/1997	18.03.1998
22	Use of Betulinic Acid and its Derivatives for inhibiting Cancer growth and a method of monitoring this	EPO	98307593.8-2103	18.03.1998
23	Use of Betulinic Acid and its Derivatives for inhibiting Cancer growth and a method of monitoring this	Israel	126345	18.03.1998

Sl. No.	Title	Country	App. No.	Date of Appl.
24	Anti Angiogenic activity of Betulinic Acid and its derivatives	India	2195/Del/1998	09.09.1999
25	Anti Angiogenic activity of Betulinic Acid and its derivatives	Canada	19990110340-1	09.09.1999
26	Anti Angiogenic activity of Betulinic Acid and its derivatives	UK	19990017495	09.09.1999
27	Use of Betulinic Acid and its derivatives for inhibiting Cancer Growth	India	3458/Del/1998	17.11.1999
28	Novel Betulinic Acid Derivatives, Processes for preparing such derivatives and its use for Cancer growth inhibitors	India	932/Del/1998	30.06.1999
29	Novel Betulinic Acid Derivatives, Processes for preparing such derivatives and its use for Cancer growth inhibitors	USA	09/431905	02.11.1999
30	Novel Betulinic Acid Derivatives, Processes for preparing such derivatives and its use for Cancer growth inhibitors	PCT	PCT/IN99/0065	17.11.1999
31	Novel Betulinic Acid Derivatives, Processes for preparing such derivatives and its use for Cancer growth inhibitors	EP	999847696	18.03.1998
32	Novel Betulinic Acid having Anti Angiogenic activity, processes for producing such derivatives and their use for treating Tumor associated Angiogenesis	India	N.A.	18.03.1998
33	Novel Betulinic Acid having Anti Angiogenic activity, processes for producing such derivatives and their use for treating Tumor associated Angiogenesis	PCT	PCT/IN99/0043	09.09.1999
34	Novel Process for the isolation of Betulinic Acid from Ziziphus Jujuba	PCT	INOO/00019	29.02.2000
35	Process for isolating 10-Deacetyl Baccatin-III	India	2193/Del/1998	07.09.1999
36	Process for isolating 10-Deacetyl Baccatin-III	PCT	PCT/IN99/00041	07.09.1999
37	Process for the isolation of 14-B-Hydroxy-10-Deacetyl Baccatin-III	India	2194/Del/1998	15.12.1998
38	Process for the isolation of 14-B-Hydroxy-10-Deacetyl Baccatin-III	EPO	99890/2613	15.12.1998
39	Novel Paclitaxel Analogues having Anti Cancer Activity	WTO	522/Del/2000	19.05.2000
40	Novel Paclitaxel Analogues having Anti Cancer Activity	PCT	PCT/INOO/00074	03.08.2000
41	Radiolabeled Vasoactive Intestinal Peptide Analogs for Diagnosis and therapy	USA	09/629632	31.07.2000
42	Radiolabeled Vasoactive Intestinal Peptide Analogs for Diagnosis and therapy	PCT	USOO/20874	18.02.2000
43	Vasoactive Intestinal Peptide Analogs	Malaysia	PI20012467	18.02.2000
44	Vasoactive Intestinal Peptide Analogs	PCT	USOO/630335	18.02.2000
45	Vasoactive Intestinal Peptide Analogs	Argentina	PO10102426	18.02.2000
46	Bombesin Analogs for the treatment of Cancer	Argentina	PO102426	24.02.2000
47	Bombesin Analogs for the treatment of Cancer	USA	09/630333	31.07.2000
48	Bombesin Analogs for the treatment of Cancer	PCT	USOO/20873	24.02.2000
49	Substance P Analogs for the treatment of Cancer	Malaysia	PI20012471	31.07.2000
50	Substance P Analogs for the treatment of Cancer	Argentina	PO10102429	31.07.2000
51	Substance P Analogs for the treatment of Cancer	USA	09/629642	31.07.2000
52	Radiolabeled Vasoactive Intestinal Peptide Analogs for diagnosis and therapy	Malaysia	PI20012468	18.02.2000
53	Radiolabeled Vasoactive Intestinal Peptide Analogs for diagnosis and therapy	Argentina	PO101012425	18.02.2000
54	Substance P Analogs for the treatment of Cancer	PCT	USOO/20875	31.07.2000
55	Somatostatin Analogs for the treatment of Cancer	Malaysia	PI20012467	31.07.2000
56	Somatostatin Analogs for the treatment of Cancer	Canada	2385910	31.07.2000
57	Somatostatin Analogs for the treatment of Cancer	Argentina	PO10102424	31.07.2000
58	Somatostatin Analogs for the treatment of Cancer	PCT	USOO/20872	31.07.2000
59	Somatostatin Analogs for the treatment of Cancer	Philippines	1-2001-01294	31.07.2000
60	Novel peptides for the treatment of Cancer	India	N.A.	N.A.
61	Novel peptides for the treatment of Cancer	USA	09/630345	31.07.2000
62	Novel peptides for the treatment of Cancer	Malaysia	PI20012468	31.07.2000
63	Novel peptides for the treatment of Cancer	PCT	USOO/20876	31.07.2000
64	Novel peptides analogs for the treatment of Cancer	PCT	USOO/03	10.02.1998
65	Method and composition for Solubilization of Pentacyclic triterpenes, particularly Betulinic Acid and its derivatives	USA	09/602293	08.03.2001
66	Method and composition for Solubilization of Pentacyclic triterpenes, particularly Betulinic Acid and its derivatives	PCT	US2002/0091091	11.05.2000
67	Prodrug approach to a mixture of Bio active peptide	India	1022/Dec/2002	08.10.2002
68	Method for treating Cancer using betulinic acid rich herbal extract	PCT	N.A.	13.12.2002
69	A drug comprising peptide analogs for the treatment of Cancer	PCT	PCT/IN03/00040	23.12.2002

Sl. No.	Title	Country	App. No.	Date of Appl.
70	Anti Cancer activity of Carvedilol and its Isomers	USA	10/238992	10.09.2002
71	Anti Cancer activity, of Carvedilol and its Isomers	PCT	PCT/US02/28794	10.09.2002
72	Multivalent Synthetic vaccine for Cancer	USA	10/211994	02.08.2002
73	Multivalent Synthetic vaccine for Cancer	PCT	US02/24561	03.08.2001
74	Peptide Combination for the treatment of Cancer	EPO	EPO835662	29.06.2001
75	Peptide Combination for the treatment of Cancer	PCT	PCT/US01/120775	29.06.2001
76	Anti Cancer activity of Methylglyoxal and its Imino Acid Conjugates	USA	60/302637	02.07.2001
77	Anti Cancer activity of Methylglyoxal and its Imino Acid Conjugates	PCT	PCT/US02/20753	02.07.2001
78	An oral formulation of Alpha-Ketoaldehyde for Human use	USA	10/187422	01.07.2002
79	An oral formulation of Alpha-Ketoaldehyde for Human use	PCT	US02/20656	02.07.2001
80	Cyclopentenone derivatives for Cancer Therapy	USA	10/309754	04.12.2002
81	Cyclopentenone derivatives for Cancer Therapy	PCT	IN/02/004239	N.A
82	Prodrug approach to a Mixture of Bio active Peptides	USA	10/186226	28.06.2002
83	Method for treating Cancer using Betulinic Acid rich Herbal Extract	USA	10/119374	13.12.2002
84	A Drug Comprising Peptide Analogs for the treatment of Cancer	USA	10/328321	23.12.2002
85	A pharmaceutical composition for the treatment of pathological conditions arising out of excessive proliferation of cells and a process for the preparation of thereof	India	641/Del/2000	11.07.2000
86	A new drug for the treatment of Cancer	Canada	2157139	08.10.1996
87	A new drug for the treatment of Cancer	EPO	96309012-2107	08.10.1996
88	A new drug for the treatment of Cancer	USA	6156725	08.10.1996
89	A new method for establishing cell lines from tumor biopsies	Canada	2193752	16.08.1996
90	A new method for establishing cell lines from tumor biopsies	USA	5744363	13.12.1996
91	An antiangiogenic drug	EPO	EP1150700	11.02.1999
92	An antiangiogenic drug	PCT	US00/03559	11.02.1999
93	An antiangiogenic drug	Australia	AU 2991200	11.02.1999
94	An antiangiogenic drug	USA	64992330	11.02.1999
95	A process for the preparation of Pharmaceutical formulation of into polymeric micelles nanoparticles for the treatment of Cancer Paclitaxel	PCT	US00/25914	17.02.1999
96	A process for the preparation of Pharmaceutical formulation of into polymeric micelles nanoparticles for the treatment of Cancer Paclitaxel	India	263/Del/1999	17.02.1999
97	Vasoactive Intestinal Peptide analogs	USA	6489297	31.07.2000
98	Novel peptide analogs for the treatment of Cancer	USA	09/248382	11.02.1998
99	Process for the preparation of Paclitaxel Tri Hydrate & Docetaxel Tri Hydrate	Thailand	80554	03.03.2003
100	A process for preparing (4s, 5R)-3-(3-substituted prop-2-Ynyloxy)-2, 2-Distributed -4-(substituted Phenyl)-5-Oxazolidine Carboxylic Acid	India	562/Cal/2000	25.09.2002
101	Method of preparation of Paclitaxel (Taxol) using 3-ALK-2-Ynyloxy Carbonyl-5-Oxazolidine Carboxylic Acid	PCT	PCT/IN01/00020	20.02.2001
102	Method of preparation of Paclitaxel (Taxol) using 3-ALK-2-Ynyloxy Carbonyl-5-Oxazolidine Carboxylic Acid	USA	09/670942	01.06.2001
103	Process for Paclitaxel Purification	India	309/Cal/2001	24.05.2001
104	Method of preparation of Anti Cancer Taxane using 3-(substituted-2-Tralkylsilyl) Ethoxy-Carbonyl-5-Oxazolidine (Carboxylic Acid)	India	269/Cal/2002	07.05.2002
105	Method of preparation of Anti Cancer Taxanes using-3-Trihaloacetyl-5-Oxazolidine Carboxylic Acid	India	268/Cal/2002	07.05.2002
106	Anti Cancer Taxanes such as Paclitaxel, Docetaxel and their structural analogs and a method for the preparation thereof	India	294/Cal/2002	10.05.2002
107	Process for the preparation of Paclitaxel Tri Hydrate & Docetaxel Tri Hydrate	India	697/Cal/2002	16.12.2002
108	A process for the preparation of Taxane Baccatin III and 7-O protected Baccatin	India	392/Cal/2001	13.07.2001
109	Process for the preparation of Taxanes such as Paclitaxel, Docetaxel and structurally similar Analogs	USA	60/311077	10.08.2001
110	Process for purification of Paclitaxel and Docetaxel	USA	60/353995	05.02.2002

PHARMACEUTICAL PRODUCTS LIST - REGISTRATION STATUS
FROM 1992 TO JANUARY 2002

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
ALBANIA	—	Ulzol	Non-Onco	—	Submitted
BANGLADESH	17.05.1996	Intaxel 30 mg	Onco	11.06.1996	Registered
BANGLADESH	22.12.1997	Daxotel 20	Onco	—	Registered
BANGLADESH	22.12.1997	Daxotel 80	Onco	—	Registered
BANGLADESH	22.12.1997	Kemocarb 15 ml	Onco	28.04.1998	Registered
BANGLADESH	22.12.1997	Kemocarb 45 ml	Onco	28.04.1998	Registered
BANGLADESH	08.05.1998	Zexale Tab. 2.5 mg	Onco	04.08.1998	Submitted
BANGLADESH	08.05.1998	Zexale Inj 50 mg	Onco	04.08.1998	Submitted
BANGLADESH	08.05.1998	Zexale Inj 15 mg	Onco	04.08.1998	Submitted
BANGLADESH	08.05.1998	Fivoflu 250	Onco	04.08.1998	Submitted
BANGLADESH	08.05.1998	Fivoflu 500 mg	Onco	04.08.1998	Submitted
BANGLADESH	08.05.1998	Fytosid 100 mg	Onco	04.08.1998	Submitted
BARBADOS	13.06.1997	Oncology Products	Onco	—	Registered
BARBADOS	13.06.1997	Antibiotics	Non-Onco	—	Registered
BARBADOS	30.09.1999	Ledoxan, Getwell Pharmaceuticals	Onco	10.05.1999	Submitted
BARBADOS	07.01.1999	BHPL	Non-Onco	—	Submitted
BARBADOS	01.04.1999	Fytosid (USP)	Onco	24.05.1999	Submitted
BELARUS	08.01.1998	Adrim 10	Onco	—	Submitted
BELARUS	08.01.1998	Adrim 50	Onco	—	Submitted
BELARUS	08.01.1998	Zexale Tablet	Onco	03.09.1998	Submitted
BELARUS	08.02.2000	Intaxel 30	Onco	17.02.2000	Submitted
BELARUS	08.02.2000	Intaxel 100 mg	Onco	17.02.2000	Submitted
BELARUS	03.02.2000	Kemocarb 150	Onco	07.04.2000	Submitted
BELARUS	03.02.2000	Kemocarb 450	Onco	07.04.2000	Submitted
BELARUS	03.02.2000	Kemoplat 10	Onco	07.04.2000	Submitted
BELARUS	03.02.2000	Kemoplat 50	Onco	07.04.2000	Submitted
BELARUS	03.02.2000	Fytosid	Onco	07.04.2000	Submitted
BELARUS	03.02.2000	Zexale 15	Onco	07.04.2000	Submitted
BELARUS	03.02.2000	Zexale 50	Onco	07.04.2000	Submitted
BELARUS	03.02.2000	Fivoflu 250	Onco	07.04.2000	Submitted
BELARUS	03.02.2000	Fivoflu 500	Onco	07.04.2000	Submitted
BELARUS	03.03.2001	Daxotel Injection 20 mg	Onco	28.06.2001	Submitted
BELARUS	03.03.2001	Daxotel Injection 80 mg	Onco	28.06.2001	Submitted
BELARUS	03.03.2001	Vineltine Injection 10 mg	Onco	20.09.2001	Submitted
BELARUS	03.03.2001	Vineltine Injection 50 mg	Onco	20.09.2001	Submitted
BOTSWANA	—	Supplier Registration Form 1999	—	24.07.1999	Submitted
BOTSWANA	—	Adrim 10	Onco	09.08.1999	Submitted
BOTSWANA	—	Adrim 50	Onco	09.08.1999	Submitted
BOTSWANA	—	Zexale 50	Onco	09.08.1999	Submitted
BRAZIL	06.08.1996	Adrim 10 mg	Onco	19.09.1996	Registered
BRAZIL	06.08.1996	Adrim 50 mg	Onco	19.09.1996	Registered
BRAZIL	06.08.1996	Kemoplat 10 mg	Onco	19.09.1996	Registered
BRAZIL	06.08.1996	Kemoplat 50 mg	Onco	19.09.1996	Registered
BRAZIL	06.08.1996	Fytosid 100 mg	Onco	19.09.1996	Registered
BRAZIL	06.08.1996	Zexale 50 mg 8.500	Onco	19.09.1996	Registered
BRAZIL	06.08.1996	Tamoxifen Tabs 10 mg	Onco	19.09.1996	Registered
BRAZIL	06.08.1996	Tamoxifen Tabs 20 mg	Onco	19.09.1996	Registered
BRAZIL	06.08.1996	Intaxel 30 mg & 100mg	Onco	19.09.1996	Registered
BRAZIL	06.08.1996	Zexale 15 mg	Onco	19.09.1996	Submitted
BRAZIL	18.02.1997	Ceftiozone Inj. 1 g	Non-onco	—	Submitted
BRAZIL	13.06.1997	Iohexol	Non-onco	24.06.1997	Submitted
BRAZIL	30.09.1999	Iohexol 350	Non-onco	05.10.1999	Submitted
BRAZIL	13.06.1997	Ciprofloxacin Tablets 500 mg	Non-Onco	24.06.1997	Submitted
BRAZIL	13.06.1997	Fluconazole	Non-Onco	—	Submitted
BRAZIL 2	21.04.1998	Zexale Tabs 2.5 mg	Onco	11.08.1998	Submitted
BRAZIL 2	21.04.1998	Fivoflu Inj. 250 & 500 mg	Onco	11.08.1998	Submitted

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
BRAZIL 2	21.04.1998	Ledoxan Tabs 50 mg	Onco	11.08.1998	Submitted
BRAZIL 2	21.04.1998	Ledoxan Inj. 200, 500, 1 g	Onco	11.08.1998	Submitted
BRAZIL	08.11.2000	Kemocarb 150 & 450 mg	Onco	29.03.2001	Submitted
BRAZIL	08.11.2000	Daxotel 20 & 80 mg	Onco	29.03.2001	Submitted
BRAZIL	06.11.2000	Cytarin BP 500mg	Onco	12.04.2001	Submitted
CANADA	21.04.1998	Intaxel	Onco	—	Submitted
CHILE	05.06.1997	Mesna	Adjuvant	—	Submitted
CHILE	05.06.1997	Tamoxifen 10	Onco	—	Submitted
CHILE	04.01.2000	Cisplatin 10 mg/20ml	Onco	30.09.2000	Submitted
CHILE	04.01.2000	Cisplatin 50 mg	Onco	30.09.2000	Submitted
CHILE	04.01.2000	Adrim 10 mg	Onco	17.02.2001	Submitted
CHILE	04.01.2000	Adrim 50 mg	Onco	17.02.2001	Submitted
CHILE	04.01.2000	Fytosid 100 mg	Onco	08.05.2000	Submitted
CHILE	04.01.2000	Fivoflu 250 mg	Onco	30.09.2000	Submitted
CHILE	04.01.2000	Fivoflu 500mg	Onco	30.09.2000	Submitted
CHILE	04.01.2000	Gynatam 20 mg	Onco	08.05.2000	Submitted
CHILE	04.01.2000	Intaxel 30	Onco	08.05.2000	Submitted
CHILE	04.01.2000	Docetaxel 20	Onco	08.05.2000	Submitted
CHILE	04.01.2000	Docetaxel 80 mg	Onco	08.05.2000	Submitted
CHILE	04.01.2000	Ipamide Inj. 1 gm	Onco	08.05.2000	Submitted
CHILE	04.01.2000	Leucovorin 3, 15 & 50 mg	Adjuvant	08.05.2000	Submitted
CHILE	04.01.2000	Empurine Tab 50 mg	Onco	08.05.2000	Submitted
CHILE	04.01.2000	Zexale inj 50 & 500 mg	Onco	08.05.2000	Submitted
CHILE	04.01.2000	Zexale Tab 2.5 mg	Onco	08.05.2000	Submitted
CHILE	04.01.2000	Topotel 4 mg	Onco	17.02.2001	Submitted
COLOMBIA	23.04.1999	Adrim 10 mg	Onco	12.05.1999	Registered
COLOMBIA	23.04.1999	Adrim 50 mg	Onco	12.05.1999	Registered
COLOMBIA	23.04.1999	Fivoflu 250 mg	Onco	12.05.1999	Registered
COLOMBIA	23.04.1999	Fivoflu 500 mg	Onco	12.05.1999	Registered
COLOMBIA	23.04.1999	Zexale 15 mg	Onco	20.05.1999	Registered
COLOMBIA	23.04.1999	Fytosid 100	Onco	20.05.1999	Registered
COLOMBIA	23.04.1999	Kemoplat 10 mg	Onco	20.05.1999	Registered
COLOMBIA	23.04.1999	Kemoplat 50 mg	Onco	20.05.1999	Registered
COLOMBIA	23.04.1999	Gynatam 10	Onco	14.06.1999	Registered
COLOMBIA	23.04.1999	Kemocarb 150	Onco	20.05.1999	Registered
COLOMBIA	23.04.1999	Kemocarb 450 mg	Onco	20.05.1999	Registered
COLOMBIA	23.04.1999	Intaxel 30 mg & 100 mg	Onco	12.05.1999	Submitted
COLOMBIA	23.04.1999	Zexale 50 mg	Onco	20.05.1999	Submitted
COLOMBIA	23.04.1999	Daxotel 20 mg & 80 mg	Onco	20.05.1999	Submitted
COLOMBIA	23.04.1999	Zexale 2.5 mg	Onco	14.06.1999	Submitted
COLOMBIA	23.04.1999	Ledoxan 50 mg	Onco	14.06.1999	Submitted
COLOMBIA	23.04.1999	Gynatam 20	Onco	14.06.1999	Submitted
COLOMBIA	23.04.1999	Ledoxan 200, 500 mg & 1 gm	Onco	08.07.1999	Submitted
COLOMBIA	23.04.1999	Hydab 500mg	Onco	17.09.1999	Submitted
COLOMBIA	23.04.1999	Empurin 50 mg	Onco	17.05.1999	Submitted
COSTA RICA	11.10.1999	Fytosid 100	Onco	14.12.1999	Registered
COSTA RICA	11.10.1999	Zexale Inj. 50 mg	Onco	14.12.1999	Registered
COSTA RICA	11.10.1999	Zexale Tablet 2.5	Onco	14.12.1999	Registered
COSTA RICA	11.10.1999	Intaxel 30 mg	Onco	14.12.1999	Registered
COSTA RICA	11.10.1999	Intaxel 100 mg	Onco	14.12.1999	Registered
COSTA RICA	11.10.1999	Fivoflu 500	Onco	14.12.1999	Registered
COSTA RICA	11.10.1999	Ledoxan Tablet 50	Onco	14.12.1999	Registered
COSTA RICA	12.09.2000	Kemoplat Injection 10mg	Onco	—	Registered
COSTA RICA	01.08.2001	Kemocarb 150	Onco	22.08.2001	Submitted
COSTA RICA	01.08.2001	Kemocarb 450	Onco	22.08.2001	Submitted
COSTA RICA	11.10.1999	Gynatam 20	Onco	14.12.1999	Submitted
COSTA RICA	30.01.1998	Fivoflu 250	Onco	31.07.1998	Submitted
COSTA RICA	25.05.1998	Ledoxan Inj 200	Onco	31.07.1998	Submitted

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
COSTA RICA	25.05.1998	Ledoxan Inj 500	Onco	31.07.1998	Submitted
COSTA RICA	25.05.1998	Ledoxan Inj 1g	Onco	31.07.1998	Submitted
COSTA RICA	12.09.2000	Cytarin Inj. 100 mg	Onco	13.04.2001	Submitted
COSTA RICA	12.09.2000	Leucovorin Injection 50mg	Adjuvant	13.04.2001	Submitted
CZECHOSLOVAKIA	—	Intaxel	Onco	—	Submitted
DUBAI	—	Gold Lowcal (Aspartame Tablet)	Non-Onco	—	Registered
DUBAI	—	Diet Salt	Non-Onco	—	Registered
DUBAI	—	Q-lyle	Non-Onco	—	Registered
ECDS (Eastern caribbean)	15.02.1999	Fivoflu 250 mg	Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Zexale 50 mg	Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Ledoxan 50 mg	Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Tamoxifen tab 20 mg	Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Hydab 500 mg	Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Alexin 250 mg	Non-Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Alexin 500 mg	Non-Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Atecard 50 mg	Non-Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Atecard 100 mg	Non-Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Strox 250 mg	Non-Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Strox 500 mg	Non-Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Norfloxacin tab 400 mg	Non-Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Ulzol 20 mg	Non-Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Empurine 50 mg	Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Tinavate Cream	Non-Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Tinavate Solution	Non-Onco	—	Provided samples
ECDS (Eastern caribbean)	15.02.1999	Ranitidine 150 mg	Non-Onco	—	Provided samples
ECDS (Eastern caribbean)	06.05.1999	Ledoxan 50 tab	Onco	—	Provided samples
EL SALVADOR	02.05.1998	Kemocarb 150 mg	Onco	24.09.1998	Submitted
EL SALVADOR	02.05.1998	Kemoplat 10 mg	Onco	24.09.1998	Submitted
EL SALVADOR	02.05.1998	Ledoxan Inj. 500 mg	Onco	24.09.1998	Submitted
EL SALVADOR	02.05.1998	Ledoxan Tab. 50	Onco	24.09.1998	Submitted
EL SALVADOR	02.05.1998	Daxotel 20 mg	Onco	24.09.1998	Submitted
EL SALVADOR	02.05.1998	Adrim 10 mg	Onco	24.09.1998	Submitted
EL SALVADOR	02.05.1998	Fylosid 100	Onco	24.09.1998	Submitted
EL SALVADOR	02.05.1998	Fivoflu 500 mg	Onco	24.09.1998	Submitted
EL SALVADOR	02.05.1998	Zexale Inj. 50 mg	Onco	24.09.1998	Submitted
EL SALVADOR	02.05.1998	Zexale Tab.	Onco	24.09.1998	Submitted
EL SALVADOR	02.05.1998	Intaxel 30 mg	Onco	24.09.1998	Submitted
EL SALVADOR	02.05.1998	Gynatam 10 mg	Onco	24.09.1998	Submitted
ESTONIA/ FINLAND	27.03.1997	Ampicilin Capsules 500 mg	Non-Onco	22.4.97, 4.8.97	Submitted
ESTONIA/ FINLAND	27.03.1997	Cephalexin Capsules 250 mg	Non-Onco	24.09.1998	Submitted
ESTONIA/ FINLAND	May 1997	Norfloxacin Tablets 400 mg	Non-Onco	24.09.1998	Submitted
ESTONIA/ FINLAND	May 1997	Amoxycilin Cap. 250 mg	Non-Onco	16.06.1997	Submitted
ESTONIA/ FINLAND	May 1997	Amoxycilin Cap. 500 mg	Non-Onco	16.06.1997	Submitted
ESTONIA/ FINLAND	May 1997	Ampicilin Capsules 250 mg	Non-Onco	04.08.1997	Submitted
ESTONIA/ FINLAND	May 1997	Omeprazole Capsules 20 mg	Non-Onco	04.08.1997	Submitted
ESTONIA/ FINLAND	May 1997	Metronidazole tablets 400 mg	Non-Onco	04.08.1997	Submitted
ESTONIA/ FINLAND	May 1997	Metronidazole tablets 200	Non-Onco	04.08.1997	Submitted
ESTONIA/ FINLAND	May 1997	Ciprofloxacin tablets 500 mg	Non-Onco	04.08.1997	Submitted
ESTONIA/ FINLAND	May 1997	Ciprofloxacin tablets 250	Non-Onco	04.08.1997	Submitted
ETHIOPIA	30.05.2000	Company Profile	—	30.08.2000	Submitted
GHANA	—	Damoxy 250 Capsules	Non-Onco	—	Registered
GHANA	—	Alexin 125mg/5ml	Non-Onco	—	Registered
GHANA	—	Alexin 250	Non-Onco	—	Registered
GHANA	—	Alexin 500	Non-Onco	—	Registered
GHANA	—	Nuren 200	Non-Onco	—	Registered
GHANA	—	Nuren 400	Non-Onco	—	Registered
GHANA	—	Tinavate cream 1% w/w	Non-Onco	—	Registered
GHANA	—	Ulgel liquid	Non-Onco	—	Registered

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
GHANA	—	Ulger tablet	Non-Onco	—	Registered
GHANA	—	Alecard 100	Non-Onco	—	Registered
GHANA	—	Alecard 50	Non-Onco	—	Registered
GHANA	—	Damoxy 500	Non-Onco	—	Registered
GHANA	—	Damoxy syrup 125mg/ 5ml	Non-Onco	—	Registered
GHANA	—	Tinavate Solution	Non-Onco	—	Registered
GHANA	09.11.1999	Fivoflu 250	Onco	01.03.2000	Registered
GHANA	06.03.2000	Fytosid Inj. 100 mg	Onco	15.07.2000	Registered
HONG KONG	04.01.1996	Intaxel	Onco	08.01.1996	Submitted
HONG KONG	04.01.1996	Fytosid	Onco	08.01.1996	Submitted
HONG KONG	22.07.1996	Ledoxan	Onco	24.07.1996	Submitted
HUNGARY	—	Intaxel	Onco	—	Submitted
IRAN 1	07.04.1998	Intaxel Inj 30 mg&100 mg	Onco	—	Submitted
IRAN 1	15.02.1999	Fytosid inj	Onco	—	Submitted
IRAN 2	12.06.2000	Ledoxan inj. 200 mg	Onco	18.12.2000	Submitted
IRAN 2	12.06.2000	Ledoxan inj. 500 mg	Onco	18.12.2000	Submitted
IRAN 2	12.06.2000	Ledoxan inj. 1 gm	Onco	18.12.2000	Submitted
IRAN 3	21.09.2001	Intaxel 280mg	Onco	31.12.2001	Submitted
IRAN 3	21.09.2001	Kemocarb 150 mg	Onco	31.12.2001	Submitted
IRAN 3	21.09.2001	Kemocarb 450 mg	Onco	31.12.2001	Submitted
IRAN 3	21.09.2001	Kemoplat 10 mg	Onco	31.12.2001	Submitted
IRAN 3	21.09.2001	Kemoplat 50 mg	Onco	31.12.2001	Submitted
IRAN 3	21.09.2001	Adrim 10	Onco	31.12.2001	Submitted
IRAN 3	21.09.2001	Adrim 50	Onco	31.12.2001	Submitted
IRAN 3	21.09.2001	Fivoflu 250	Onco	31.12.2001	Submitted
IRAN 3	21.09.2001	Fivoflu 500	Onco	31.12.2001	Submitted
IRAN 3	21.09.2001	Cytarine 100 mg	Onco	31.12.2001	Submitted
IRAN 3	21.09.2001	Cytarine 500 mg	Onco	31.12.2001	Submitted
IRAN 3	21.09.2001	Cytarine 1g	Onco	31.12.2001	Submitted
IRAN 3	21.09.2001	Zexale 15	Onco	31.12.2001	Submitted
IRAN 3	21.09.2001	Zexale 50	Onco	31.12.2001	Submitted
IRAN 3	21.09.2001	Daxotel-20mg	Onco	21.01.2002	Submitted
IRAN 3	21.09.2001	Daxotel-80mg	Onco	21.01.2002	Submitted
IRAN 3	21.09.2001	Leuco-Ca Inj. USP 3mg	Adjuvant	21.01.2002	Submitted
IRAN 3	21.09.2001	Le co-Ca Inj. USP 15mg	Adjuvant	21.01.2002	Submitted
IRAN 3	21.09.2001	Leuco-Ca Inj. USP 50mg	Adjuvant	21.01.2002	Submitted
IRAN 3	21.09.2001	Mesna Injection	Adjuvant	21.01.2002	Submitted
IRAN 3	21.09.2001	Innotel Injection 40mg	Onco	21.01.2002	Submitted
IRAN 3	21.09.2001	Innotel Injection 100mg	Onco	21.01.2002	Submitted
IRAN 3	21.09.2001	Vinelbine Injection 10mg	Onco	21.01.2002	Submitted
IRAN 3	21.09.2001	Vinelbine Injection 50mg	Onco	21.01.2002	Submitted
IRAN 3	21.09.2001	Topotel Injection 2.5mg	Onco	21.01.2002	Submitted
IRAN 3	21.09.2001	Topotel Injection 4mg	Onco	21.01.2002	Submitted
IRAN 3	21.09.2001	Empurine Tabs	Onco	21.01.2002	Submitted
IRAN 3	21.09.2001	Gynalam-10 Tabs	Onco	21.01.2002	Submitted
IRAN 3	21.09.2001	Gynalam-20 Tabs	Onco	21.01.2002	Submitted
IRAN 3	21.09.2001	Ledoxan Tabs	Onco	21.01.2002	Submitted
IRAN 3	21.09.2001	Zexale Tabs	Onco	21.01.2002	Submitted
IRAQ	Dec 1997	Company Profile	—	—	Registered
IRAQ	15.12.1997	Alecard 50	Non-Onco	08.01.1998	Submitted
IRAQ	15.12.1997	Alecard 100	Non-Onco	08.01.1998	Submitted
IRAQ	15.12.1997	Damoxy 250	Non-Onco	08.01.1998	Submitted
IRAQ	15.12.1997	Damoxy 500	Non-Onco	08.01.1998	Submitted
IRAQ	15.12.1997	Damoxy DS	Non-Onco	08.01.1998	Submitted
IRAQ	15.12.1997	Nuren 200	Non-Onco	08.01.1998	Submitted
IRAQ	15.12.1997	Nuren 400	Non-Onco	08.01.1998	Submitted
IRAQ	15.12.1997	Alexin 250	Non-Onco	08.01.1998	Submitted
IRAQ	15.12.1997	Alexin 500	Non-Onco	08.01.1998	Submitted

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
IRAQ	15.12.1997	Dabcofox 500	Non-Onco	08.01.1998	Submitted
IRAQ	15.12.1997	Dabcofox DS	Non-Onco	08.01.1998	Submitted
IRAQ	24.07.1998	Strox 250	Non-Onco	—	Submitted
IRAQ	24.07.1998	Strox 500	Non-Onco	—	Submitted
IRAQ	24.07.1998	Tamoxifen 10	Onco	—	Submitted
IRAQ	24.07.1998	Tamoxifen 20	Onco	—	Submitted
IRAQ	24.07.1998	Kemoplat 20 ml	Onco	—	Submitted
IRAQ	24.07.1998	Kemoplat 100ml	Onco	—	Submitted
IRAQ	24.07.1998	Adrim 10	Onco	—	Submitted
IRAQ	24.07.1998	Adrim 20	Onco	—	Submitted
IRAQ	24.07.1998	Fytosid	Onco	—	Submitted
IRAQ	24.07.1998	Fivoflu 250 mg	Onco	—	Submitted
IRAQ	24.07.1998	Zexale Injection 50 mg	Onco	—	Submitted
IRAQ	24.07.1998	Zexale Tablet 2.5 mg	Onco	—	Submitted
ISRAEL	—	Intaxel	Onco	08.09.1999	Registered
JAMAICA	June 1997	Adrim 10 mg	Onco	—	Registered
JAMAICA	June 1997	Adrim 50 mg	Onco	—	Registered
JAMAICA	June 1997	Fytosid 100	Onco	—	Registered
JAMAICA	June 1997	Kemoplat 50 mg	Onco	—	Registered
JAMAICA	June 1997	Intaxel 30 mg	Onco	—	Registered
JAMAICA	June 1997	Fivoflu 5 ml	Onco	—	Registered
JAMAICA	June 1997	Fivoflu 10 ml	Onco	—	Registered
JAMAICA	June 1997	Zexale 50 mg	Onco	—	Registered
JAMAICA	June 1997	Gynatam 10	Onco	—	Submitted
JAMAICA	June 1997	Kemocarb 150 mg	Onco	—	Submitted
JAMAICA	02.05.1998	Ledoxan Tab	Onco	—	Submitted
JAMAICA	09.05.1998	Ledoxan 200, 500 mg & 1 g	Onco	—	Submitted
JORDAN	08.03.1999	Intaxel inj. 30mg	Onco	04.10.1999	Registered
JORDAN	08.03.1999	Intaxel inj. 100mg	Onco	04.10.1999	Registered
JORDAN	08.03.1999	Fivoflu inj.250mg	Onco	04.10.1999	Registered
JORDAN	08.03.1999	Fivoflu inj.500mg	Onco	04.10.1999	Registered
JORDAN	06.03.2000	Adrim Inj 10 mg	Onco	10.2001	Submitted
JORDAN	06.03.2000	Adrim Inj 50 mg	Onco	10.2001	Submitted
JORDAN	06.03.2000	Fytosid 100 mg	Onco	10.2001	Submitted
KAZAKHSTAN	Nov. 1997	Docetaxel Inj. 20 & 80	Onco	—	Submitted
KAZAKHSTAN	Nov. 1997	Intaxel inj. 30 mg & 100 mg	Onco	—	Submitted
KAZAKHSTAN	Nov. 1997	Fytosid Inj. 100	Onco	—	Submitted
KAZAKHSTAN	Nov. 1997	Cisplatin Inj. 10 & 50	Onco	—	Submitted
KAZAKHSTAN	Nov. 1997	Adrim Inj. 10 & 50	Onco	—	Submitted
KAZAKHSTAN	Nov. 1997	Carboplatin Inj. 150 & 450	Onco	—	Submitted
KENYA	11.11.1993	Nuren Gel	Non-Onco	—	Registered
KENYA	—	Zenad 60 Tablets	Non-Onco	—	Registered
KENYA	—	Zenad 120 Tablets	Non-Onco	—	Registered
KENYA	—	Ulgel tab	Non-Onco	—	Registered
KENYA	—	Ulgel liquid	Non-Onco	—	Registered
KENYA	—	Alecard 25	Non-Onco	—	Registered
KENYA	—	Alecard 50	Non-Onco	—	Registered
KENYA	—	Alecard 100	Non-Onco	—	Registered
KENYA	—	Alecard D	Non-Onco	—	Registered
KENYA	—	Zenad Suspension	Non-Onco	—	Registered
KENYA	—	Oryza-SF Expectorant	Non-Onco	—	Registered
KENYA	—	Cefadroxil Tabs 250 mg (Kid tabs)	Non-Onco	—	Registered
KENYA	—	Cefadroxil Caps 500 mg	Non-Onco	—	Registered
KENYA	—	Alexin 250, 500 & DS	Non-Onco	—	Registered
KENYA	—	Unilyte Oral rehydration salt	Non-Onco	—	Registered
KENYA	—	Durox Caps 20 mg	Non-Onco	—	Registered
KENYA	24.07.1998	Tamoxifen tab 10 & 20	Onco	27.11.1998	Registered
KENYA	24.07.1998	Intaxel 30 & 100	Onco	—	Registered

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
KENYA	24.07.1996	Kemoplat inj	Onco	27.11.1996	Registered
KENYA	09.01.1998	Adnre inj 2mg/ml	Onco	18.03.1998	Registered
KENYA	15.02.1999	Zexate Injection 50	Onco	20.07.1999	Registered
KENYA	15.02.1999	Kemocarb	Onco	20.07.1999	Registered
KENYA	11.11.1993	Dabclin Caps	Non-Onco	—	Submitted
KENYA	11.11.1993	Dabclin Dry syrup	Non-Onco	—	Submitted
KENYA	11.11.1993	Damoxy Caps 250 mg	Non-Onco	—	Submitted
KENYA	11.11.1993	Damoxy Dry Syrup	Non-Onco	—	Submitted
KENYA	11.11.1993	Co-trimoxazole Tablets	Non-Onco	—	Submitted
KENYA	11.11.1993	Paediatric Co-trimoxazole Suspension	Non-Onco	—	Submitted
KENYA	—	Dabclox Caps	Non-Onco	—	Submitted
KENYA	—	Dabclox Injection	Non-Onco	—	Submitted
KENYA	—	Dabclox Dry Syrup	Non-Onco	—	Submitted
KENYA	—	Strax 250 Tabs	Non-Onco	—	Submitted
KENYA	—	Strax 500 Tabs	Non-Onco	—	Submitted
KENYA	—	Cefadroxil Tabs 500 mg	Non-Onco	—	Submitted
KENYA	—	Cefadroxil Dry Syrup DS250 mg/ 5ml	Non-Onco	—	Submitted
KENYA	09.01.1998	Daxotel 20 580	Onco	—	Submitted
KENYA	15.02.1999	Fivoftu 250 & 500	Onco	20.07.1999	Submitted
KOREA	—	Intaxel	Onco	—	Submitted
LITHUANIA	26.03.1999	Utzol	Non-Onco	—	Submitted
MACAO	08.10.2001	Intaxel 30	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Intaxel 100	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Intaxel 260 mg	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Daxotel 20	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Daxotel 80mg	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Adrim 10	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Adrim 50	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Contrastin (60 %) 20ml	Non Onco	17.01.2002	Submitted
MACAO	08.10.2001	Contrastin 76% inj. 20ml	Non Onco	17.01.2002	Submitted
MACAO	08.10.2001	Contrastin 76% inj. 50 ml	Non Onco	17.01.2002	Submitted
MACAO	08.10.2001	Contrastin 76% inj. 100 ml	Non Onco	17.01.2002	Submitted
MACAO	08.10.2001	Cytarabine BP100mg	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Cytarabine BP 500 mg	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Cytarabine BP 1g	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Fivoftu 250 vial	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Fivoftu 500 vial	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Fylosid 100	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Intaxel 40 & 100 mg	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Kemocarb 150	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Kemoplat 10mg/20ml & 50mg/100ml	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Leucovorine 15 mg	Adjuvant	17.01.2002	Submitted
MACAO	08.10.2001	Leucovorine 3 mg	Adjuvant	17.01.2002	Submitted
MACAO	08.10.2001	Leucovorine 50 mg	Adjuvant	17.01.2002	Submitted
MACAO	08.10.2001	Mesna 200	Adjuvant	17.01.2002	Submitted
MACAO	08.10.2001	Radiopaque inj. 240mg/ml, 10 ml	Non Onco	17.01.2002	Submitted
MACAO	08.10.2001	Radiopaque inj. 300mg/ml, 10ml, 20ml, 50ml & 100ml	Non Onco	17.01.2002	Submitted
MACAO	08.10.2001	Radiopaque inj. 350mg/ml, 20ml, 50ml & 100ml	Non Onco	17.01.2002	Submitted
MACAO	08.10.2001	Topotel 2.5 & 4 mg	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Vinorelbine 10 & 50 mg	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Zexate 15	Onco	17.01.2002	Submitted
MACAO	08.10.2001	Zexate 50	Onco	17.01.2002	Submitted
MADAGASCAR	18.05.1996	Dabclitin 250mg, 500mg	Non-Onco	—	Submitted
MADAGASCAR	18.05.1996	Damoxy 250mg, 500 mg	Non-Onco	—	Submitted
MADAGASCAR	18.05.1996	Utzol Tab orange	Non-Onco	—	Submitted
MADAGASCAR	18.05.1996	Coti 480 mg	Non-Onco	—	Submitted

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
MADAGASCAR	18.05.1996	Paracetamol 500 mg	Non-Onco	—	Submitted
MADAGASCAR	18.05.1996	Tetracyclin 250 mg	Non-Onco	—	Submitted
MADAGASCAR	18.05.1996	Indomethacin 25 mg	Non-Onco	—	Submitted
MADAGASCAR	18.05.1996	Metronidazole 200 mg Tabs	Non-Onco	—	Submitted
MADAGASCAR	18.05.1996	Vitamin C 500 mg 1000 Tabs	Non-Onco	—	Submitted
MADAGASCAR	18.05.1996	C.P.M. 4-mg Tabs	Non-Onco	—	Submitted
MALAWI	10.05.1995	Dabcofin Caps 250 mg	Non-Onco	19.07.1995	Registered
MALAWI	10.05.1995	Dabcofin Dry syrup	Non-Onco	19.07.1995	Registered
MALAWI	10.05.1995	Damoxy Dry Syrup	Non-Onco	19.07.1995	Registered
MALAWI	10.05.1995	Damoxy (250 mg)	Non-Onco	19.07.1995	Registered
MALAWI	10.05.1995	Alecard 50 mg	Non-Onco	19.07.1995	Registered
MALAWI	10.05.1995	Uligel tablet orange flavour	Non-Onco	19.07.1995	Registered
MALAWI	—	Metronidazole	Non-Onco	—	Registered
MALAWI	—	Indomethacin	Non-Onco	—	Registered
MALAWI	10.05.1995	Dabcofin Caps 500 mg	Non-Onco	19.07.1995	Submitted
MALAWI	10.05.1995	Dabcofin (500 mg)	Non-Onco	19.07.1995	Submitted
MALAWI	10.05.1995	Dabcofin Dry Syrup	Non-Onco	19.07.1995	Submitted
MALAWI	10.05.1995	Damoxy (500 mg)	Non-Onco	19.07.1995	Submitted
MALAWI	10.05.1995	Alecard 25 mg	Non-Onco	19.07.1995	Submitted
MALAWI	10.05.1995	Alecard 100 mg	Non-Onco	19.07.1995	Submitted
MALAWI	10.05.1995	Oryze Expectorant	Non-Onco	19.07.1995	Submitted
MALAWI	10.05.1995	Alexin (500mg)	Non-Onco	19.07.1995	Submitted
MALAWI	10.05.1995	Alexin (250 mg)	Non-Onco	19.07.1995	Submitted
MALAWI	10.05.1995	Alexin Dispersible	Non-Onco	19.07.1995	Submitted
MALAWI	10.05.1995	Sirox 250	Non-Onco	19.07.1995	Submitted
MALAWI	10.05.1995	Sirox 500	Non-Onco	19.07.1995	Submitted
MALAWI	10.05.1995	Tinavale cream	Non-Onco	19.07.1995	Submitted
MALAWI	10.05.1995	Uligel liquid	Non-Onco	19.07.1995	Submitted
ALAYSIA	29.12.1999	Adrim 10 mg & 50 mg	Onco	25.01.2000	Registered
MALAYSIA	29.12.1999	Fytosid	Onco	25.01.2000	Registered
MALAYSIA	29.12.1999	Intaxel 30	Onco	25.01.2000	Registered
MALAYSIA	29.12.1999	Intaxel 100	Onco	25.01.2000	Registered
MALAYSIA	04.01.2000	Kemoplat 10mg/20ml	Onco	29.02.2000	Registered
MALAYSIA	04.01.2000	Kemoplat 50mg/100ml	Onco	29.02.2000	Registered
MALAYSIA	09.08.1997	Gynalam 10 mg & 20 mg	Onco	28.01.1998	Submitted
MALAYSIA	04.01.2000	Zexate 15ml/3ml	Onco	29.02.2000	Submitted
MALAYSIA	04.01.2000	Zexate 50ml/2ml	Onco	29.02.2000	Submitted
MALAYSIA	20.04.2000	Zexate Tablet I.P. 2.5 mg	Onco	16.06.2000	Submitted
MALAYSIA	20.04.2000	Ledosan Tablet I.P.	Onco	16.06.2000	Submitted
MALAYSIA	11.12.2000	Kemocarb Injection 150 mg	Onco	09.04.2001	Submitted
MALAYSIA	11.12.2000	Kemocarb Injection 450 mg	Onco	09.04.2001	Submitted
MALAYSIA	11.12.2000	Cytarabin injection 100 mg	Onco	09.04.2001	Submitted
MALAYSIA	11.12.2000	Cytarabin injection 500 mg	Onco	09.04.2001	Submitted
MALAYSIA	11.12.2000	Cytarabin injection 1 gm	Onco	09.04.2001	Submitted
MALAYSIA	11.12.2000	Fivoflu Injection 250 mg	Onco	09.04.2001	Submitted
MALAYSIA	11.12.2000	Fivoflu Injection 500 mg	Onco	09.04.2001	Submitted
MALAYSIA	11.12.2000	Empurine Tabs. 50 mg	Onco	09.04.2001	Submitted
MALAYSIA	11.12.2000	Leucovorin Injection, 3 mg	Adjuvant	09.04.2001	Submitted
MALAYSIA	11.12.2000	Leucovorin Injection 15 mg	Adjuvant	09.04.2001	Submitted
MALAYSIA	11.12.2000	Leucovorin Injection 50 mg	Adjuvant	09.04.2001	Submitted
MALAYSIA	11.12.2000	Mesna Injection 200mg	Adjuvant	09.04.2001	Submitted
MALAYSIA	07.2001	Intaxel 250mg	Onco	22.11.2001	Submitted
MALAYSIA	07.2001	Kemoplat 1mg/ml (10mg)	Onco	22.11.2001	Submitted
MALAYSIA	07.2001	Kemoplat 1mg/ml (50mg)	Onco	22.11.2001	Submitted
MALAYSIA	07.2001	Zexate 500mg	Onco	22.11.2001	Submitted
MALAYSIA	07.2001	Vinorelbine 10mg	Onco	22.11.2001	Submitted
MALAYSIA	07.2001	Vinorelbine 50mg	Onco	22.11.2001	Submitted
MALDIVES	02.1999	Company Profile	—	—	Submitted

Name Of the Country	Date of request	Name of the Products	Category	Date of submission	Status
MEXICO	13.12.2000	Daxotel 80 mg	Onco	23.02.2001	Registered
MEXICO	13.12.2000	Intaxel 30 mg	Onco	23.02.2001	Submitted
MEXICO	13.12.2000	Kemocarb 150 mg	Onco	23.02.2001	Submitted
MONGOLIA	09.05.1999	Adrim 10	Onco	18.05.1999	Registered
MONGOLIA	09.05.1999	Kemoplat 10	Onco	18.05.1999	Registered
MONGOLIA	09.05.1999	Tamoxifen Citrate tablet 10	Onco	18.05.1999	Registered
MONGOLIA	09.05.1999	Leucovorin 3	Adjuvant	18.05.1999	Registered
MONGOLIA	09.05.1999	Leucovorin 15	Adjuvant	18.05.1999	Registered
MONGOLIA	09.05.1999	Leucovorin 50mg	Adjuvant	18.05.1999	Registered
MONGOLIA	09.05.1999	Adrim 50	Onco	18.05.1999	Submitted
MONGOLIA	09.05.1999	Kemoplat 50	Onco	18.05.1999	Submitted
MONGOLIA	09.05.1999	Tamoxifen Citrate Tab 20 mg	Onco	18.05.1999	Submitted
MONGOLIA	24.12.1999	Ledoxan inj. 200	Onco	28.02.2000	Submitted
MONGOLIA	24.12.1999	Ledoxan inj. 500	Onco	28.02.2000	Submitted
MONGOLIA	24.12.1999	Fivoflu inj. 250 mg	Onco	28.02.2000	Submitted
MONGOLIA	10.02.2000	Zexate 15 mg	Onco	28.02.2000	Submitted
MONGOLIA	10.02.2000	Zexate 50 mg	Onco	28.02.2000	Submitted
MONGOLIA	10.02.2000	Intaxel 30	Onco	28.02.2000	Submitted
MONGOLIA	10.02.2000	Intaxel 100	Onco	28.02.2000	Submitted
MAURITIUS	14.05.2001	Intaxel 30 mg	Onco	11.06.2001	Registered
MAURITIUS	14.05.2001	Intaxel 100 mg	Onco	11.06.2001	Registered
MAURITIUS	14.05.2001	Daxotel 20 mg	Onco	11.06.2001	Registered
MAURITIUS	14.05.2001	Daxotel 80 mg	Onco	11.06.2001	Registered
MAURITIUS	14.05.2001	Kemoplat 10 mg	Onco	11.06.2001	Registered
MAURITIUS	14.05.2001	Kemoplat 50 mg	Onco	11.06.2001	Registered
MAURITIUS	14.05.2001	Kemocarb 150 mg	Onco	11.06.2001	Registered
MAURITIUS	14.05.2001	Kemocarb 450 mg	Onco	11.06.2001	Registered
MAURITIUS	09.12.1995	Dabcollin 250	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Dabcollin 500	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Dabcollin DS	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Damoxy 250	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Damoxy 500	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Damoxy OS	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Alexin 250, 500, DS	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Atecard 50	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Atecard 100	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Nuren 200	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Nuren 400	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Ulgel Tab	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Tinavate Cream	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Tinavate Solution	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Q-Lyte 35 gm	Non-Onco	26.02.1996	Submitted
MAURITIUS	09.12.1995	Ampicillin inj. 500 mg	Non-Onco	26.02.1996	Submitted
MYANMAR	11.02.1997	Sivok Tabs 250 mg	Non-Onco	16.01.1998	Submitted
MYANMAR	11.02.1997	Sivok Tabs 500 mg	Non-Onco	16.01.1998	Submitted
MYANMAR	11.02.1997	Nuren Tabs 200 mg	Non-Onco	16.01.1998	Submitted
MYANMAR	11.02.1997	Nuren Tabs 400 mg	Non-Onco	16.01.1998	Submitted
MYANMAR	11.02.1997	Olzol Capsules 10 mg	Non-Onco	16.01.1998	Submitted
MYANMAR	11.02.1997	Ranfaz Tabs 150 mg	Non-Onco	16.01.1998	Submitted
MYANMAR	11.02.1997	Ranfaz Tabs 300 mg	Non-Onco	16.01.1998	Submitted
MYANMAR	11.02.1997	Tinavate Cream	Non-Onco	16.01.1998	Submitted
MYANMAR	13.02.2001	Intaxel Injection 30 mg	Onco	31.10.2001	Submitted
MYANMAR	13.02.2001	Intaxel Injection 100 mg	Onco	31.10.2001	Submitted
MYANMAR	13.02.2001	Intaxel Injection 250 mg	Onco	31.10.2001	Submitted
MYANMAR	13.02.2001	Daxotel Injection 20 mg	Onco	31.10.2001	Submitted
MYANMAR	13.02.2001	Daxotel Injection 80 mg	Onco	31.10.2001	Submitted
MYANMAR	13.02.2001	Kemocarb Injection 150 mg	Onco	31.10.2001	Submitted
MYANMAR	13.02.2001	Kemocarb Injection 450 mg	Onco	31.10.2001	Submitted

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
MYANMAR	31.02.2001	Kemoplat Injection 10 mg (0.5mg/ml)	Onco	31.10.2001	Submitted
MYANMAR	31.02.2001	Kemoplat Injection 50 mg (0.5mg/ml)	Onco	31.10.2001	Submitted
MYANMAR	31.02.2001	Cytarin Injection 100 mg	Onco	31.10.2001	Submitted
MYANMAR	31.02.2001	Cytarin Injection 500 mg	Onco	31.10.2001	Submitted
MYANMAR	31.02.2001	Cytarin Injection 1 gm	Onco	31.10.2001	Submitted
MYANMAR	31.02.2001	Adrim Injection 10 mg	Onco	31.10.2001	Submitted
MYANMAR	31.02.2001	Adrim Injection 50 mg	Onco	31.10.2001	Submitted
MYANMAR	31.02.2001	Fylosid Injection 20 mg	Onco	31.10.2001	Submitted
MYANMAR	31.02.2001	Zexate Injection 15mg	Onco	31.10.2001	Submitted
MYANMAR	31.02.2001	Zexate Injection 50mg	Onco	31.10.2001	Submitted
MYANMAR	31.02.2001	Fivoflu Injection 250 mg, 500 mg	Onco	31.10.2001	Submitted
MYANMAR	31.02.2001	Leucovorin Injection 3 mg	Adjuvant	31.10.2001	Submitted
MYANMAR	31.02.2001	Leucovorin Injection 15 mg	Adjuvant	31.10.2001	Submitted
MYANMAR	31.02.2001	Leucovorin Injection 50 mg	Adjuvant	31.10.2001	Submitted
MYANMAR	31.02.2001	Mesna Injection 200 mg	Adjuvant	31.10.2001	Submitted
NEPAL	09.08.1996	Inflaxel Injection 30, 100 & 260 mg	Onco	21.08.1996	Registered
NEPAL	09.08.1996	Tamoxifen tab, 10 & 20 mg	Onco	21.08.1996	Registered
NEPAL	09.08.1996	Kemoplat inj, 10 & 50 mg	Onco	21.08.1996	Registered
NEPAL	09.08.1996	Fylosid inj.	Onco	21.08.1996	Registered
NEPAL	09.08.1996	Zexate Injection 15 & 50 mg	Onco	19.09.1996	Registered
NEPAL	09.08.1996	Kemcarb inj, 150 & 450 mg	Onco	19.09.1996	Registered
NEPAL	09.08.1996	Ledoxan inj, 200, 500mg & 1g	Onco	21.08.1996	Registered
NEPAL	09.08.1996	Ledoxan Tablet	Onco	21.08.1996	Registered
NEPAL	09.08.1996	Fivoflu inj, 250 & 500	Onco	21.08.1996	Registered
NEPAL	09.08.1996	Adrim inj, 10&50	Onco	21.08.1996	Registered
NEPAL	02.07.1997	Sirox 250 & 500 mg	Non-Onco	—	Registered
NEPAL	02.07.1997	Uigel Tabs	Non-Onco	—	Registered
NEPAL	02.07.1997	Uigel Liquid	Non-Onco	—	Registered
NEPAL	02.07.1997	Alocard 25, 50, 100 & D	Non-Onco	—	Registered
NEPAL	02.07.1997	Livlit Tabs	Non-Onco	—	Registered
NEPAL	02.07.1997	Livlit Liquid	Non-Onco	—	Registered
NEPAL	02.07.1997	Honitus	Non-Onco	—	Registered
NEPAL	02.07.1997	Damoxy	Non-Onco	—	Registered
NEPAL	02.07.1997	Ulzol 20	Non-Onco	—	Registered
NEPAL	02.07.1997	Ulzol 10	Non-Onco	—	Registered
NEPAL	02.07.1997	Alexin	Non-Onco	—	Registered
NEPAL	02.07.1997	Nuren Ace	Non-Onco	—	Registered
NEPAL	02.07.1997	Zened 60 Tablet USP	Non-Onco	—	Registered
NEPAL	02.07.1997	LoNa 150/500	Non-Onco	—	Registered
NEPAL	02.08.1998	Contrastin Injection 60 %, 76% (20 & 50 ml)	Non-Onco	—	Registered
NEPAL	01.08.1998	Leucovorin inj, 3 mg, 15 mg & 50 mg	Adjuvant	—	Registered
NEPAL	01.08.1998	Daxotel inj, 20 & 80	Onco	—	Registered
NEPAL	—	Amiphos inj, 500 mg/vial	Adjuvant	—	Registered
NEPAL	—	Cytarin inj, 100 mg/ml USP	Onco	—	Registered
NEPAL	—	Cytarin inj, 1gm/10ml USP	Onco	—	Registered
NEPAL	—	Cytarin inj, 500mg USP	Onco	—	Registered
NEPAL	—	Empurine tab, IP, 50 mg	Onco	—	Registered
NEPAL	—	Hydab Cap 500mg USP	Onco	—	Registered
NEPAL	—	Ipamide inj, USP 1gm/vial	Onco	—	Registered
NEPAL	—	Irinotel inj, 100mg/2ml	Onco	—	Registered
NEPAL	—	Irinotel inj, 40 mg/2 ml	Onco	—	Registered
NEPAL	—	Mesna inj, 200mg/2ml	Adjuvant	—	Registered
NEPAL	—	Topotel inj, 2.5 mg/2.5 ml	Onco	—	Registered
NEPAL	—	Topotel inj, 4 mg/4 ml	Onco	—	Registered
NEPAL	—	Zexate Tab, 2.5 mg IP	Onco	—	Registered
NEPAL	—	Radiopaque inj, 300 mg (10 ml) USP	Non-Onco	—	Registered
NEPAL	—	Radiopaque inj, 300 mg (20 ml) USP	Non-Onco	—	Registered

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
NEPAL	—	Radiopaque Inj 300 mg (50 ml) USP	Non-Onco	—	Registered
NEPAL	—	Radiopaque Inj 350 mg (20 ml) USP	Non-Onco	—	Registered
NEPAL	—	Radiopaque Inj 350 mg (50 ml) USP	Non-Onco	—	Registered
NEPAL	—	Alemex 120	Non-Onco	27.06.2001	Registered
NEPAL	—	Alemex 180	Non-Onco	27.06.2001	Registered
NEPAL	—	Atecard M	Non-Onco	17.11.2001	Registered
NEPAL	—	Specific information given for marketing	—	—	Submitted
NEPAL	29.03.1997	Livlit Tab/Inj	Non-Onco	—	Submitted
NEPAL	29.03.1997	Radiopaque	Non-Onco	—	Submitted
NEPAL	29.03.1997	Chlorzox	Non-Onco	—	Submitted
NEPAL	29.03.1997	Utzol 10	Non-Onco	—	Submitted
NEPAL	29.03.1997	Dexamethasone Inj 2 ml & 10 ml vial	Non-Onco	—	Submitted
NEPAL	29.03.1997	Gentamicin Inj 2 ml & 10 ml vial	Non-Onco	12.05.1997	Submitted
NEPAL	29.03.1997	Ranitidine Injection 2 ml	Non-Onco	12.05.1997	Submitted
NEPAL	29.03.1997	Diclofenac Inj 15 ml vial	Non-Onco	12.05.1997	Submitted
NEPAL	29.03.1997	Amikacin Inj 100, 250 & 500 mg vial	Non-Onco	12.05.1997	Submitted
NEPAL	29.03.1997	Co-Trimoxazole suspension 60	Non-Onco	12.05.1997	Submitted
NEPAL	02.07.1997	Radiopaque inj, 240 ml	Non-Onco	—	Submitted
NEPAL	02.07.1997	Maxim Hp (Choc)	Non-Onco	—	Submitted
NEPAL	02.07.1997	Cetanil Syrup	Non-Onco	—	Submitted
NEPAL	02.07.1997	Cetanil Tabs	Non-Onco	—	Submitted
NEPAL	02.07.1997	New Livlit Tabs	Non-Onco	—	Submitted
NEPAL	02.07.1997	New Livlit Syrup	Non-Onco	—	Submitted
NEPAL	25.03.1998	Cetirizine tablet 10 mg	Non-Onco	—	Submitted
NEPAL	02.05.1998	Roxithromycin Tablets	Non-Onco	—	Submitted
NEPAL	09.01.2001	Pamifos 30 & 60 mg	Adjuvant	29.01.2001	Submitted
NEPAL	26.04.2001	Pamifos 90 mg	Adjuvant	17.05.2001	Submitted
NEPAL	26.04.2001	Vinorelbine 10 & 50	Onco	17.05.2001	Submitted
NEPAL	24.02.2000	Flutrox 50 mg	Non-Onco	27.06.2001	Submitted
NEPAL	24.02.2000	Flutrox 150 mg	Non-Onco	27.06.2001	Submitted
NEPAL	—	Nasarel - 60	Non-Onco	29.08.2001	Submitted
NEPAL	—	Nasarel - 20	Non-Onco	10.11.2001	Submitted
NEPAL	05.10.2001	Amfocan 50 mg	Adjuvant	06.10.2001	Submitted
NIGERIA	27.03.1997	Ampicillin Caps 250	Non-Onco	16.06.1997	Submitted
NIGERIA	27.03.1997	Ampicillin Caps 500	Non-Onco	16.06.1997	Submitted
NIGERIA	27.03.1997	Ampicillin Caps DS	Non-Onco	16.06.1997	Submitted
NIGERIA	27.03.1997	Amoxycillin Caps 250	Non-Onco	16.06.1997	Submitted
NIGERIA	27.03.1997	Amoxycillin Caps 500	Non-Onco	16.06.1997	Submitted
NIGERIA	27.03.1997	Amoxycillin Caps DS	Non-Onco	16.06.1997	Submitted
NIGERIA	27.03.1997	Ibuprofen Tablets 200	Non-Onco	16.06.1997	Submitted
NIGERIA	27.03.1997	Ibuprofen Tablets 400mg	Non-Onco	16.06.1997	Submitted
NIGERIA	27.03.1997	Stressoak	Veterinary	16.06.1997	Submitted
NIGERIA	27.03.1997	Livlit Vet Premix	Veterinary	16.06.1997	Submitted
NIGERIA	27.03.1997	Dimpro Premix	Veterinary	16.06.1997	Submitted
NIGERIA	27.03.1997	Stimulex Capsules	Ayurvedic	—	Submitted
NIGERIA	28.04.1998	Dabur Balm	Ayurvedic	—	Submitted
NIGERIA	28.04.1998	Daburub	Ayurvedic	—	Submitted
NIGERIA	14.05.1998	Atecard Tab	Non-Onco	—	Submitted
NIGERIA	15.07.1998	Strox 250 & 500	Non-Onco	—	Submitted
OMAN	14.06.2001	Company Registration	—	18.08.2001	Submitted
PANAMA	13.06.1997	Fluconazole	Non-Onco	—	Submitted
PANAMA	13.06.1997	Carboplatin Injection 150 & 450	Onco	—	Submitted
PANAMA	13.06.1997	Methotrexate Inj & Tablets	Onco	—	Submitted
PANAMA	13.06.1997	Intaxel Injection	Onco	—	Submitted
PANAMA	13.06.1997	Fytosid Injection	Onco	—	Submitted
PANAMA	13.06.1997	Diclofenac Sodium Tablets	Non-Onco	—	Submitted
PANAMA	09.05.1998	Gyratam Tablet 10 & 20 mg	Onco	—	Submitted

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
PERU	—	Intaxel 100	Onco	—	Registered
PERU	—	Intaxel 30	Onco	23.12.1998	Registered
PERU	06.05.1998	Kemocarb 150 mg	Onco	—	Registered
PERU	06.05.1998	Kemocarb 450 mg	Onco	23.12.1998	Registered
PERU	06.05.1998	Kemoplat 10mg/20 ml	Onco	23.12.1998	Registered
PERU	06.05.1998	Adrim 50 mg	Onco	23.12.1998	Registered
PERU	06.05.1998	Fivoflu 250 mg	Onco	23.12.1998	Registered
PERU	06.05.1998	Zexale Inj 15 mg	Onco	—	Registered
PERU	06.05.1998	Zexale Tab	Onco	23.12.1998	Registered
PERU	01.04.1999	Fytosid U S P	Onco	23.12.1998	Registered
PERU	15.09.2000	Topotel -4	Onco	24.01.2001	Registered
PERU	15.09.2000	Daxotel 80	Onco	24.01.2001	Registered
PERU	06.05.1998	Kemoplat 50	Onco	—	Submitted
PERU	06.05.1998	Ledoxan Tab 50 mg	Onco	—	Submitted
PERU	06.05.1998	Adrim 10 mg	Onco	23.12.1998	Submitted
PERU	06.05.1998	Fivoflu 500 mg	Onco	23.12.1998	Submitted
PERU	06.05.1998	Gynatam 10 mg	Onco	—	Submitted
PERU	06.05.1998	Gynatam 20 mg	Onco	23.12.1998	Submitted
PERU	15.02.1999	Empurin Tab	Onco	03.12.1999	Submitted
PERU	15.02.1999	Hydab Capsules	Onco	03.12.1999	Submitted
PERU	15.09.2000	Daxotel 20	Onco	24.01.2001	Submitted
PERU	15.09.2000	Zexale 50	Onco	24.01.2001	Submitted
PERU	26.04.2001	Irinotel 40	Onco	21.06.2001	Submitted
PERU	26.04.2001	Irinotel 100	Onco	21.06.2001	Submitted
PHILIPPINES	28.01.1995	Intaxel	Onco	20.05.1995	Registered
PHILIPPINES	Aug 1996	Ledoxan Tablets 50 mg	Onco	—	Registered
PHILIPPINES	Aug 1996	Gynatam Tablets USP 10mg	Onco	—	Registered
PHILIPPINES	Aug 1996	Gynatam Tablets USP 20mg	Onco	—	Registered
PHILIPPINES	Aug 1996	Zexale Tablets USP 2.5mg/tab	Onco	—	Registered
PHILIPPINES	Aug 1996	Zexale Inj. USP 50 & 15 mg	Onco	—	Registered
PHILIPPINES	Aug 1996	Mesns Injection 100mg/ampoule	Adjuvant	—	Registered
PHILIPPINES	Aug 1996	Fivoflu 250mg/ampoule	Onco	—	Registered
PHILIPPINES	Aug 1996	Fivoflu 500mg/ampoule	Onco	—	Registered
PHILIPPINES	Aug 1996	Adrim 10 mg/vial	Onco	—	Registered
PHILIPPINES	Aug 1996	Adrim 50 mg/vial	Onco	—	Registered
PHILIPPINES	Aug 1996	Fytosid Injection 100 mg/vial	Onco	—	Registered
PHILIPPINES	24.04.1998	Ledoxan Inj. 200, 500 & 1 g	Onco	—	Registered
PHILIPPINES	16.09.1999	Kemocarb injection	Onco	18.03.2000	Submitted
PHILIPPINES	16.09.1999	Hydab Capsule 500 mg	Onco	18.03.2000	Submitted
PHILIPPINES	16.09.1999	Empurin Tablets 50 mg	Onco	18.03.2000	Submitted
PHILIPPINES	16.09.1999	Leucovorin Inj. 3mg, 15mg & 50 mg	Adjuvant	02.05.2000	Submitted
PHILIPPINES	16.09.1999	Cytarin Inj. 100mg,500mg 1g	Onco	18.03.2000	Submitted
PHILIPPINES	16.09.1999	Kemoplat Inj. 10mg/20,50mg/100ml	Onco	18.03.2000	Submitted
PHILIPPINES	24.05.2000	Intaxel 100 mg	Onco	16.07.2001	Submitted
PHILIPPINES	30.05.2000	Intaxel 250 mg	Onco	16.07.2001	Submitted
PHILIPPINES	—	Fivoflu 250 & 500 vials	Onco	14.01.2002	Submitted
POLAND	Dec 1997	Intaxel	Onco	—	Submitted
ROMANIA	—	Intaxel	Onco	—	Submitted
RUSSIA	—	Levodopa Tablets 500	Non-Onco	—	Registered
RUSSIA	—	Multivitamin Multimineral Tab	Non-Onco	—	Registered
RUSSIA	—	Levodopa Carbidopa Tablets	Non-Onco	—	Registered
RUSSIA	—	Paracetamol Syrup	Non-Onco	—	Registered
RUSSIA	—	Ascorbic Acid Tablets 250mg	Non-Onco	—	Registered
RUSSIA	—	Ascorbic Acid Tablets 500 mg	Non-Onco	—	Registered
RUSSIA	—	Ascorbic Acid Tab. 1000 mg	Non-Onco	—	Registered
RUSSIA	—	Intaxel injection 5 ml	Onco	—	Registered
RUSSIA	—	Intaxel injection 17 ml	Onco	—	Registered
RUSSIA	18.02.1997	Zexale Tab 2.5 mg/tablet	Onco	—	Registered

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
RUSSIA	18.02.1997	Zexale Inj USP 50 mg/vial	Onco	—	Registered
RUSSIA	18.02.1997	Zexale Inj USP15 mg/vial	Onco	—	Registered
RUSSIA	18.02.1997	Fivoflu Injection 5 ml	Onco	—	Registered
RUSSIA	18.02.1997	Fivoflu Inj, 10ml	Onco	—	Registered
RUSSIA	18.02.1997	Kemoplat Injection 10 mg/20ml	Onco	—	Registered
RUSSIA	18.02.1997	Kemoplat Injection 50 mg/100 ml	Onco	—	Registered
RUSSIA	18.02.1997	Kemocarb Inj 15	Onco	—	Registered
RUSSIA	18.02.1997	Kemocarb Inj 45ml	Onco	—	Registered
RUSSIA	03.2000	Fytosid 100 mg	Onco	25.07.2000	Registered
RUSSIA	—	Bromhexine Elixir	Non-Onco	—	Submitted
RUSSIA	—	DUROX DISTAB 20 mg	Non-Onco	—	Submitted
RUSSIA	—	DUROX Capsule 20 mg	Non-Onco	—	Submitted
RUSSIA	—	Paracetamol Tablets 500 mg (for M/S J R Sharma)	Non-Onco	—	Submitted
RUSSIA	—	Analgin Tab 500 mg (M/S J R Sharma)	Non-Onco	—	Submitted
RUSSIA	—	Vitamin B complex Tablets	Non-Onco	—	Submitted
RUSSIA	—	Naproxen Sodium Tablets	Non-Onco	—	Submitted
RUSSIA	—	Ketolifen Tablets 1mg	Non-Onco	—	Submitted
RUSSIA	—	Ketolifen Elixir 1mg/5ml	Non-Onco	—	Submitted
RUSSIA	—	Alecard	Non-Onco	—	Submitted
RUSSIA	18.02.1997	Adrim Injection 10 mg/vial	Onco	—	Submitted
RUSSIA	18.02.1997	Adrim Injection 50 mg/vial	Onco	—	Submitted
RUSSIA	18.02.1997	Dacelaxel Inj 20 & 80 mg	Onco	—	Submitted
RUSSIA	21.10.2000	Leucovorin Inj. 3, 15 & 50mg	Adjuvant	15.12.2000	Submitted
RUSSIA	03.03.2001	Vinorelbine injection 10 & 50 mg	Onco	24.08.2001	Submitted
SIERRA LEONE	—	Honitus Cough Syrup 100 ml	Ayur	—	Submitted
SIERRA LEONE	—	Nature Care 100 g	Ayur	—	Submitted
SIERRA LEONE	—	Tolnaftate Cream 10 gm	Non-Onco	—	Submitted
SIERRA LEONE	—	Sarbyna tablets 10x10 Strip	Non-Onco	—	Submitted
SIERRA LEONE	—	Ampicillin syrup 60 ml	Non-Onco	—	Submitted
SIERRA LEONE	—	Uigel liquid 170 ml-Saunt flavour	Non-Onco	—	Submitted
SIERRA LEONE	—	Uigel tabs 10x25-Saunt flavour	Non-Onco	—	Submitted
SIERRA LEONE	—	Clean & Clear Capsules 75 caps	Ayur	—	Submitted
SIERRA LEONE	15.10.2001	Sarbyna Strong	Non-Onco	05.11.2001	Submitted
SINGAPORE	07.04.1998	Company Profile	—	—	Submitted
SINGAPORE	15.02.2001	Intaxel Injection 30 mg	Onco	30.09.2001	Submitted
SINGAPORE	15.02.2001	Kemocarb Inj 150 & 450 mg	Onco	30.09.2001	Submitted
SINGAPORE	15.02.2001	Kemoplat Injection 10 mg, 50 mg	Onco	30.09.2001	Submitted
SINGAPORE	15.02.2001	Cytarin Inj. BP100, 500 mg, 1 gm	Onco	30.09.2001	Submitted
SINGAPORE	15.02.2001	Adrim Injection 10 mg, 50 mg	Onco	30.09.2001	Submitted
SINGAPORE	15.02.2001	Fytosid Injection 20 mg	Onco	30.09.2001	Submitted
SINGAPORE	15.02.2001	Zexale Injection, 15mg, 50mg	Onco	30.09.2001	Submitted
SINGAPORE	15.02.2001	Froflu Injection 250 mg, 500 mg	Onco	30.09.2001	Submitted
SINGAPORE	15.02.2001	Leucovorin Injection 3 mg, 15 mg, 50 mg	Adjuvant	30.09.2001	Submitted
SOUTH AFRICA	—	Paclitaxel Inj.	Onco	—	Submitted
SRI LANKA	—	Alexin Capsules 250 mg	Non-Onco	—	Registered
SRI LANKA	—	Alexin Capsules 500 mg	Non-Onco	—	Registered
SRI LANKA	—	Alexin Dry Syrup 125 mg/ml	Non-Onco	—	Registered
SRI LANKA	—	Ampicillin 1000's	Non-Onco	—	Registered
SRI LANKA	—	Nuren 200	Non-Onco	—	Registered
SRI LANKA	—	Nuren 400	Non-Onco	—	Registered
SRI LANKA	—	Damoxy Dry Syrup 125 mg/ml	Non-Onco	—	Registered
SRI LANKA	—	Tolnaftate Cream (Tinavate)	Non-Onco	—	Registered
SRI LANKA	—	Tolnaftate Solution	Non-Onco	—	Registered
SRI LANKA	—	Uigel Tablet	Non-Onco	—	Registered
SRI LANKA	—	Uigel Liquid	Non-Onco	—	Registered
SRI LANKA	—	Cetani Suspension 120 mg/5 ml	Non-Onco	—	Registered

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
SRI LANKA	-	Celarin Tablet 500 mg	Non-Onco	-	Registered
SRI LANKA	-	Atocard 25	Non-Onco	-	Registered
SRI LANKA	-	Atocard 50 Partial Inf.	Non-Onco	-	Registered
SRI LANKA	-	Atocard 100 Partial Inf.	Non-Onco	-	Registered
SRI LANKA	13.06.1997	Fluorouracil 250 & 500	Non-Onco	-	Registered
SRI LANKA	13.06.1997	Adrim 10	Onco	-	Registered
SRI LANKA	13.06.1997	Adrim 50	Onco	-	Registered
SRI LANKA	13.06.1997	Cisplatin 10 & 50	Onco	-	Registered
SRI LANKA	13.06.1997	Zexale 50 mg	Onco	-	Registered
SRI LANKA	13.06.1997	Zexale Tab	Onco	-	Registered
SRI LANKA	13.06.1997	Intaxel 30	Onco	-	Registered
SRI LANKA	19.06.2000	Empurine tablet 50 mg USP	Onco	07.09.2000	Registered
SRI LANKA	13.06.1997	Fytosid	Onco	-	Registered
SRI LANKA	-	Dabolin Dry Syrup 125 mg/ml	Non-Onco	-	Submitted
SRI LANKA	-	Utzol capsule	Non-Onco	-	Submitted
SRI LANKA	10.10.2000	Cytarabin injection 100 mg	Onco	30.07.2001	Submitted
SRI LANKA	10.10.2000	Cytarabin injection 500 mg	Onco	30.07.2001	Submitted
SRI LANKA	10.10.2000	Cytarabin injection 1g	Onco	30.07.2001	Submitted
SRI LANKA	10.10.2000	Kemocarb Injection 150 mg	Onco	30.07.2001	Submitted
SRI LANKA	10.10.2000	Kemocarb Injection 450	Onco	30.07.2001	Submitted
SRI LANKA	10.10.2000	Mesna Injection 100 mg	Adjuvant	30.07.2001	Submitted
SRI LANKA	10.10.2000	Leucovorin Injection 3 mg	Adjuvant	30.07.2001	Submitted
SRI LANKA	10.10.2000	Leucovorin Injection 15 mg	Adjuvant	30.07.2001	Submitted
SRI LANKA	10.10.2000	Leucovorin Injection 50 mg	Adjuvant	30.07.2001	Submitted
SRI LANKA	10.10.2000	Radiopaque Inj 240 mg/ml, 10 ml	Non-Onco	10.09.2001	Submitted
SRI LANKA	10.10.2000	Radiopaque Inj 240 mg/ml, 20 ml	Non-Onco	10.09.2001	Submitted
SRI LANKA	10.10.2000	Radiopaque Inj 300 mg/ml, 10 ml	Non-Onco	10.09.2001	Submitted
SRI LANKA	10.10.2000	Radiopaque Inj 300 mg/ml, 20 ml	Non-Onco	10.09.2001	Submitted
SRI LANKA	10.10.2000	Radiopaque Inj 300 mg/ml, 50 ml	Non-Onco	10.09.2001	Submitted
SRI LANKA	10.10.2000	Radiopaque Inj 300 mg/ml, 100ml	Non-Onco	10.09.2001	Submitted
SRI LANKA	10.10.2000	Radiopaque Inj 350 mg/ml, 20 ml	Non-Onco	10.09.2001	Submitted
SRI LANKA	10.10.2000	Radiopaque Inj 350 mg/ml, 50 ml	Non-Onco	10.09.2001	Submitted
SRI LANKA	10.10.2000	Radiopaque Inj 350 mg/ml, 100 ml	Non-Onco	10.09.2001	Submitted
SRI LANKA	10.10.2000	Constrastin (60%) Inj., 20 ml	Non-Onco	16.11.2001	Submitted
SRI LANKA	10.10.2000	Constrastin (60%) Inj., 50 ml	Non-Onco	16.11.2001	Submitted
SRI LANKA	10.10.2000	Constrastin (75%) Inj., 20 ml	Non-Onco	16.11.2001	Submitted
SRI LANKA	10.10.2000	Constrastin (75%) Inj., 50 ml	Non-Onco	16.11.2001	Submitted
SRI LANKA	10.10.2000	Constrastin (75%) Inj., 100 ml	Non-Onco	16.11.2001	Submitted
SRI LANKA	10.01.2001	Iritaxel 100 mg	Onco	01.08.2001	Submitted
SRI LANKA	10.01.2001	Iritaxel 260 mg	Onco	01.08.2001	Submitted
SRI LANKA	12.06.2001	Daxotel 20	Onco	24.12.2001	Submitted
SRI LANKA	12.06.2001	Daxotel 80	Onco	24.12.2001	Submitted
SRI LANKA	12.06.2001	Zexale 15	Onco	02.12.2001	Submitted
SRI LANKA	12.06.2001	Zexale 500	Onco	02.12.2001	Submitted
SRI LANKA	12.06.2001	Irinotel 40mg	Onco	09.01.2002	Submitted
SRI LANKA	12.06.2001	Irinotel 100mg	Onco	09.01.2002	Submitted
SRI LANKA	25.07.2001	Vinorelbine 10	Onco	16.10.2001	Submitted
SRI LANKA	25.07.2001	Vinorelbine 50	Onco	16.10.2001	Submitted
SRI LANKA	10.10.2000	Ledoxan tab. 50 mg	Onco	16.01.2002	Submitted
SRI LANKA	10.10.2000	Tamoxifen 10 mg	Onco	16.01.2002	Submitted
SRI LANKA	10.10.2000	Tamoxifen 20 mg	Onco	16.01.2002	Submitted
SUDAN	-	Damoxxy 250 mg	Non-Onco	-	Submitted
SUDAN	-	Damoxxy 500 mg	Non-Onco	-	Submitted
SUDAN	-	Damoxxy DS	Non-Onco	-	Submitted
SUDAN	-	Alexin 250 mg	Non-Onco	-	Submitted
SUDAN	-	Alexin 500 mg	Non-Onco	-	Submitted
SUDAN	-	Atocard 50 mg	Non-Onco	-	Submitted
SUDAN	-	Atocard 100 mg	Non-Onco	-	Submitted

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
SUDAN	—	Zenad 80	Onco	—	Submitted
SUDAN	—	Zenad 120	Onco	—	Submitted
SUDAN	—	Diclofenac 25 mg	Non-Onco	—	Submitted
SUDAN	—	Cefadroxil 250 mg	Non-Onco	—	Submitted
SUDAN	—	Cefadroxil 500 mg	Non-Onco	—	Submitted
SUDAN	—	Cefadroxil Dry Syrup	Non-Onco	—	Submitted
SUDAN	—	Nuren 200	Non-Onco	—	Submitted
SUDAN	—	Nuren 400	Non-Onco	—	Submitted
SUDAN	24.04.1998	Adrim Injection 5 ml vial	Onco	—	Submitted
SUDAN	24.04.1998	Cisplatin Inj. 10 mg	Onco	—	Submitted
SUDAN	24.04.1998	Intaxel 5 ml	Onco	—	Submitted
SUDAN	24.04.1998	Zexale 50 mg	Onco	—	Submitted
SUDAN	24.04.1998	Tamoxifen Tabs 10 mg	Onco	—	Submitted
SUDAN	Feb. 1999	Fivoflu 250, 500 mg	Onco	—	Submitted
SYRIA	29.05.1996	Intaxel	Onco	08.11.1996	Submitted
TAIWAN	Feb. 1999	Terfenadine	Non-Onco	17.09.1996	Submitted
TAIWAN	01.10.1998	Fluconazole	Non-Onco	14.11.1996	Submitted
TAIWAN	30.01.1997	Melatonin Tablet 3 mg	Non-Onco	30.01.1997	Submitted
THAILAND	09.08.1999	Intaxel Injection	Onco	09.08.1999	Registered
THAILAND	17.08.1999	Kemocarb Inj 150 & 450 mg	Onco	18.08.1999	Registered
THAILAND	25.03.1997	Kemoplat 20ml & 100ml	Onco	—	Registered
THAILAND	25.03.1997	Zexale 50 (Methotrexate inj.)	Onco	—	Registered
THAILAND	25.03.1997	Fivoflu 250 mg & 500 mg ampoule	Onco	—	Registered
THAILAND	25.03.1997	Fivoflu 250 mg & 500 mg vial	Onco	—	Registered
THAILAND	25.03.1997	Ledoxan Tabs 50 mg	Onco	—	Registered
THAILAND	25.03.1997	Adrim	Onco	—	Registered
THAILAND	25.03.1997	Zexale Tablet 2.5 mg	Onco	—	Registered
THAILAND	25.03.1997	Fytosid 100 mg	Onco	—	Registered
THAILAND	25.03.1997	Gynatam Tabs 10 mg	Onco	—	Registered
THAILAND	25.03.1997	Gynatam Tabs 20 mg	Onco	—	Registered
THAILAND	15.02.1999	Cytarin Inj 100 mg, 500 mg & 1 g	Onco	18.08.1999	Registered
THAILAND	15.02.1999	Leucovorin Inj. 3, 50 mg	Non-Onco	07.05.1999	Registered
THAILAND	15.02.1999	Mesna Inj. 200 mg	Non-Onco	07.05.1999	Registered
THAILAND	16.09.1999	Daxotel inj 20 & 80	Onco	15.02.2000	Registered
THAILAND	15.02.1999	Empurin Tab. 50 mg	Onco	18.08.1999	Registered
THAILAND	15.02.1999	Ipanide Inj. 1 gm	Onco	18.08.1999	Registered
THAILAND	02.05.1998	Ledoxan Inj 200 mg	Onco	10.05.1999	Submitted
THAILAND	02.05.1998	Ledoxan Inj 500 mg	Onco	10.05.1999	Submitted
THAILAND	02.05.1998	Ledoxan Inj 1 gm	Onco	10.05.1999	Submitted
THAILAND	03.05.2000	Irinotecan 40 & 100 mg	Onco	30.01.2001	Submitted
THAILAND	30.05.2000	Intaxel 250 mg	Onco	08.09.2000	Submitted
TRINIDAD & TOBAGO	13.06.1997	Fivoflu Inj. 250 mg	Onco	17.07.1997	Registered
TRINIDAD & TOBAGO	—	Gynatam 10 mg	Onco	04.04.1998	Registered
TRINIDAD & TOBAGO	—	Gynatam 20 mg	Onco	04.04.1998	Registered
TRINIDAD & TOBAGO	21.07.1998	Fytosid 100	Onco	14.02.1998	Registered
TRINIDAD & TOBAGO	21.07.1998	Zexale Tab.	Onco	14.02.1998	Registered
TRINIDAD & TOBAGO	—	Kemoplat 50 mg	Onco	04.04.1998	Registered
TRINIDAD & TOBAGO	21.07.1998	Intaxel Injection 30 mg	Onco	14.02.1998	Registered
TRINIDAD & TOBAGO	21.07.1998	Kemocarb 150	Onco	14.02.1998	Registered
TRINIDAD & TOBAGO	02.05.1998	Ledoxan Tablet	Onco	25.05.1998	Registered
TRINIDAD & TOBAGO	17.11.1998	Ledoxan Injection 200 mg	Onco	31.07.1999	Registered
TRINIDAD & TOBAGO	13.06.1997	Kemoplat Inj. 10 mg	Onco	17.07.1997	Submitted
TRINIDAD & TOBAGO	13.06.1997	Fivoflu Inj. 500 mg	Onco	17.07.1997	Submitted
TRINIDAD & TOBAGO	13.06.1997	Utzol 20 mg Caps	Non-Onco	17.07.1997	Submitted
TRINIDAD & TOBAGO	13.06.1997	Ranfaz Tabs 150 mg	Non-Onco	17.07.1997	Submitted
TRINIDAD & TOBAGO	13.06.1997	Ranitidine Inj. 25 mg/ml	Non-Onco	02.08.1997	Submitted
TRINIDAD & TOBAGO	13.06.1997	Fluconazole Caps 150 mg	Non-Onco	02.08.1997	Submitted
TRINIDAD & TOBAGO	—	Adrim 10 mg, 50 mg	Onco	04.04.1998	Submitted

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
TRINIDAD & TOBAGO	21.07.1998	Ledoxan Inj. 500 & 1000 mg	Onco	—	Submitted
TRINIDAD & TOBAGO	21.07.1998	Kemocarb 450 mg	Onco	14.02.1998	Submitted
TRINIDAD & TOBAGO	02.09.2000	Cylarin Inj. 100 mg	Onco	21.07.2001	Submitted
TRINIDAD & TOBAGO	02.09.2000	Daxotel Inj. 20 mg, 80 mg	Onco	21.04.2001	Submitted
TRINIDAD & TOBAGO	02.09.2000	Leocovorin Injection 50mg	Adjuvant	21.04.2001	Submitted
TRINIDAD & TOBAGO	02.09.2000	Empurine Tablets 50 mg	Onco	21.04.2001	Submitted
TRINIDAD & TOBAGO	02.09.2000	Zexale 50 mg	Onco	21.04.2001	Submitted
TRINIDAD & TOBAGO	02.09.2000	Topotel Injection 4 mg	Onco	21.07.2001	Submitted
TRINIDAD & TOBAGO	21.05.2001	Intaxel Injection 100 mg	Onco	21.07.2001	Submitted
TURKEY	Oct 1997	Fytosid Injection 100 mg	Onco	29.12.1997	Submitted
TURKEY	Oct 1997	5-Fluorouracil Inj. 250 & 500 mg	Onco	30.12.1997	Submitted
TURKEY	Oct 1997	Cisplatin Injection 10 & 50 mg	Onco	26.12.1997	Submitted
TURKEY	Oct 1997	Gynatam Tablets 10 & 20 mg	Onco	—	Submitted
TURKEY	Oct 1997	Adrim 5 ml & 25 ml	Onco	26.12.1997	Submitted
TURKEY	Oct 1997	Methotrexate (PF) Inj 10 mg & 50 mg	Onco	26.12.1997	Submitted
TURKEY	Oct 1997	Cyclophosphamide Tabs 50 mg	Onco	—	Submitted
TURKEY	24.04.1998	Docetaxel 20 mg & 80 mg	Onco	—	Submitted
TURKEY	24.04.1998	Intaxel 30 mg & 100 mg	Onco	—	Submitted
TURKEY	24.04.1998	Zexale 2.5 mg, 100's pack	Onco	—	Submitted
TURKEY	26.06.1998	Zexale 5 mg/1 ml vial	Onco	—	Submitted
TURKEY	26.06.1998	Mesna 200	Adjuvant	—	Submitted
TURKEY	26.06.1998	Leucovorin 50 mg	Adjuvant	—	Submitted
TURKEY	15.02.1999	Ledoxan Inj. 200, 500mg & 1g	Onco	12.06.1999	Submitted
UGANDA	06.10.1997	Ulgel Tabs 25X10	Non-Onco	—	Submitted
UGANDA	06.10.1997	Ulgel Liquid 170 ml	Non-Onco	—	Submitted
UGANDA	06.10.1997	Tinavate Cream/Solution	Non-Onco	—	Submitted
UGANDA	06.10.1997	Flutrox	Non-Onco	—	Submitted
UGANDA	06.10.1997	Alecard 100 mg/D	Non-Onco	—	Submitted
UGANDA	06.10.1997	Dabcilin 250 mg/Dry Syrup	Non-Onco	—	Submitted
UGANDA	06.10.1997	Damoxy 250 mg/Dry Syrup	Non-Onco	—	Submitted
UGANDA	06.10.1997	Alexin Cap 250	Non-Onco	—	Submitted
UGANDA	06.10.1997	Alexin Cap 500	Non-Onco	—	Submitted
UGANDA	06.10.1997	Strox 250	Non-Onco	—	Submitted
UGANDA	06.10.1997	Strox 500	Non-Onco	—	Submitted
UKRAINE	10.11.1995	Gentus 20	Non-Onco	12.12.1995	Submitted
UKRAINE	10.11.1995	Gentus 60	Non-Onco	12.12.1995	Submitted
UKRAINE	10.11.1995	Gentus 80	Non-Onco	12.12.1995	Submitted
UKRAINE	10.11.1995	Gentus eye drop	Non-Onco	12.12.1995	Submitted
UKRAINE	10.11.1995	Gentus eardrops	Non-Onco	12.12.1995	Submitted
UKRAINE	10.11.1995	Seredal 2	Non-Onco	12.12.1995	Submitted
UKRAINE	10.11.1995	Seredal 5	Non-Onco	12.12.1995	Submitted
UKRAINE	10.11.1995	Seredal 10	Non-Onco	12.12.1995	Submitted
UKRAINE	10.11.1995	Seredal Injection	Non-Onco	12.12.1995	Submitted
UKRAINE	10.11.1995	Seredal Suspension	Non-Onco	12.12.1995	Submitted
UKRAINE	10.11.1995	Alexin 250 mg (reregistration)	Non-Onco	12.12.1995	Registered
UKRAINE	10.11.1995	Cifocin 500,1(reregistration)	Non-Onco	16.12.1995	Registered
UKRAINE	10.11.1995	Dabciox Cap. (reregistration)	Non-Onco	23.12.1995	Registered
UKRAINE	10.11.1995	Dabciox inj. (reregistration)	Non-Onco	15.12.1995	Registered
UKRAINE	10.11.1995	Strox 250,500 (reregistration)	Non-Onco	12.12.1995	Registered
UKRAINE	13.06.2000	Kemoplat 20 & 100ml (0.5mg)	Onco	13.12.2000	Registered
UKRAINE	13.06.2000	Kemocarb 150 & 450mg	Onco	13.12.2000	Registered
UKRAINE	13.06.2000	Fytoside 100mg	Onco	13.12.2000	Registered
UKRAINE	15.06.2000	Zexale 15 & 50 mg	Onco	13.12.2000	Registered
UKRAINE	11.09.2000	Intaxel 30 & 100 mg	Onco	12.02.2001	Registered
UKRAINE	29.11.1997	Docetaxel Inj. 20&80	Onco	12.03.1998	Submitted
UKRAINE	29.11.1997	Adrim Inj. 10 & 50	Onco	12.03.1998	Submitted
UKRAINE	30.10.2000	Zexale 2.5	Onco	12.02.2001	Submitted
UKRAINE	05.04.2001	Vinorelbine Injection 10&50 mg	Onco	28.09.2001	Submitted

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
URUGUAY	12.05.2000	Zexale 50	Onco	12.12.2000	Submitted
URUGUAY	20.06.2000	Ledoxan tab. 50 mg	Onco	12.12.2000	Submitted
URUGUAY	28.10.2000	Zexale Tablet 2.5 mg	Onco	12.12.2000	Submitted
VENEZUELA	15.10.1999	Kemocarb 150 mg (Bioplatinex)	Onco	24.02.2000	Registered
VENEZUELA	15.10.1999	Kemocarb 450 mg (Bioplatinex)	Onco	24.02.2000	Registered
VENEZUELA	15.10.1999	Ledoxan 50 mg (Biodoxan)	Onco	04.09.2000	Registered
VENEZUELA	15.10.1999	Adrim 10 mg	Onco	24.02.2000	Registered
VENEZUELA	15.10.1999	Adrim 50 mg	Onco	24.02.2000	Registered
VENEZUELA	15.10.1999	Fivoflu 250 mg	Onco	24.02.2000	Registered
VENEZUELA	15.10.1999	Fivoflu 500 mg	Onco	24.02.2000	Registered
VENEZUELA	15.10.1999	Zexale 50 mg	Onco	24.02.2000	Registered
VENEZUELA	15.10.1999	Zexale 2.5 mg	Onco	04.09.2000	Registered
VENEZUELA	15.10.1999	Intaxel 30 mg,100 mg	Onco	24.02.2000	Registered
VENEZUELA	15.10.1999	Gynalam 10 mg	Onco	04.09.2000	Registered
VENEZUELA	15.10.1999	Gynalam 20 mg	Onco	04.09.2000	Registered
VENEZUELA	15.10.1999	Fytosid 100 mg	Onco	24.02.2000	Registered
VENEZUELA	17.04.1998	Docetaxel inj. 20 & 80 mg	Onco	04.08.1998	Submitted
VENEZUELA	15.10.1999	Empurine 50 mg	Onco	04.09.2000	Submitted
VIETNAM	24.04.1998	Utzol Capsule	Non-Onco	—	Submitted
VIETNAM	24.04.1998	Zenad 60	Non-Onco	—	Submitted
VIETNAM	24.04.1998	Zenad 120	Non-Onco	—	Submitted
VIETNAM	24.04.1998	Zenad Suspension	Non-Onco	—	Submitted
VIETNAM	24.04.1998	Sirox 250	Non-Onco	—	Submitted
VIETNAM	24.04.1998	Sirox 500	Non-Onco	—	Submitted
VIETNAM	24.04.1998	Alexin 250	Non-Onco	—	Submitted
VIETNAM	24.04.1998	Alexin 500	Non-Onco	—	Submitted
VIETNAM	24.04.1998	Alexin Dry Syrup 125	Non-Onco	—	Submitted
VIETNAM	24.04.1998	Ulgel Tablets	Non-Onco	—	Submitted
VIETNAM	24.04.1998	Ulgel Liquid	Non-Onco	—	Submitted
VIETNAM	08.09.2000	Adrim 10mg &50mg	Onco	19.03.2001	Submitted
VIETNAM	08.09.2000	Kemoplat 10mg .50mg (0.5mg/ml)	Onco	19.03.2001	Submitted
VIETNAM	08.09.2000	Kemocarb 150mg, 450mg(10mg/ml)	Onco	19.03.2001	Submitted
VIETNAM	08.09.2000	Fytosid USP	Onco	19.03.2001	Submitted
VIETNAM	08.09.2000	Gynalam 10	Onco	19.03.2001	Submitted
VIETNAM	08.09.2000	Gynalam 20	Onco	19.03.2001	Submitted
VIETNAM	08.09.2000	Ledoxan tab. USP 50 mg	Onco	19.03.2001	Submitted
VIETNAM	08.09.2000	Empurine tab. USP 50 mg	Onco	19.03.2001	Submitted
VIETNAM	08.09.2000	Ledoxan inj. 200mg	Onco	19.03.2001	Submitted
VIETNAM	08.09.2000	Ledoxan 500 mg	Onco	19.03.2001	Submitted
VIETNAM	08.09.2000	Ledoxan 1gm	Onco	19.03.2001	Submitted
VIETNAM	08.09.2000	Ipamide 1gm	Onco	19.03.2001	Submitted
VIETNAM	08.09.2000	Leucovorine Calcium Inj. 3mg	Adjuvant	19.03.2001	Submitted
VIETNAM	08.09.2000	Leucovorine Calcium Inj. 15 mg	Adjuvant	19.03.2001	Submitted
VIETNAM	08.09.2000	Leucovorine Calcium Inj.50 mg	Adjuvant	19.03.2001	Submitted
VIETNAM	08.09.2000	Intaxel 30 &100 mg	Onco	19.03.2001	Submitted
VIETNAM	08.09.2000	Cytarin inj. 100mg	Onco	30.04.2001	Submitted
VIETNAM	08.09.2000	Cytarin inj. 500mg	Onco	30.04.2001	Submitted
VIETNAM	08.09.2000	Cytarin inj. 1 g	Onco	30.04.2001	Submitted
VIETNAM	08.09.2000	Daxotel 20 &80 mg	Onco	30.04.2001	Submitted
VIETNAM	08.09.2000	Fivoflu 250 m&500 mg	Onco	30.04.2001	Submitted
VIETNAM	08.09.2000	Zexale inj.15mg	Onco	30.04.2001	Submitted
VIETNAM	08.09.2000	Zexale inj.50 &500 mg	Onco	30.04.2001	Submitted
VIETNAM	08.09.2000	Zexale Tab.	Onco	30.04.2001	Submitted
YEMEN	26.12.1995	Alexin 250	Non-Onco	—	Registered
YEMEN	26.12.1995	Alexin 500	Non-Onco	—	Registered
YEMEN	26.12.1995	Alecard 50	Non-Onco	—	Registered
YEMEN	26.12.1995	Alecard 100	Non-Onco	—	Registered
YEMEN	26.12.1995	Damoxy 250	Non-Onco	—	Registered

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
YEMEN	26.12.1995	Damoxy 500	Non-Onco	—	Registered
YEMEN	26.12.1995	Damoxy DS 125 mg/ml, 60 ml	Non-Onco	—	Registered
YEMEN	26.12.1995	Dabcolox Capsules 500 mg	Non-Onco	—	Registered
YEMEN	26.12.1995	Nuren 200	Non-Onco	—	Registered
YEMEN	26.12.1995	Nuren 400	Non-Onco	—	Registered
YEMEN	26.12.1995	O-Lyte 27.9 gm sachet	Non-Onco	—	Registered
YEMEN	26.12.1995	Kemoplat Injection 10 mg	Onco	—	Registered
YEMEN	26.12.1995	Fluorouracil Injection 250	Onco	—	Registered
YEMEN	26.12.1995	Dabcolox Dry Syrup	Non-Onco	—	Submitted
YEMEN	26.12.1995	Uzol Capsule 20 mg	Non-Onco	—	Submitted
YEMEN	26.12.1995	Uligel Liquid	Non-Onco	—	Submitted
YEMEN	26.12.1995	Kemoplat Injection 50 mg	Onco	—	Submitted
YEMEN	26.12.1995	Adrim Injection 10	Onco	—	Submitted
YEMEN	26.12.1995	Adrim Injection 50	Onco	—	Submitted
YEMEN	26.12.1995	Cyclosporin Oral Liquid	Non-Onco	—	Submitted
YEMEN	26.12.1995	Ledoxan Inj. 200, 500 mg & 1g	Onco	—	Submitted
YEMEN	26.12.1995	Ciprofloxacin Tablets 250 & 500 mg	Non-Onco	—	Submitted
YEMEN	26.12.1995	Zexale Inj. 50	Onco	—	Submitted
YEMEN	26.12.1995	Fluorouracil Inj. 500	Onco	—	Submitted
YEMEN	26.12.1995	Bleomycin Injection 15 units	Onco	—	Submitted
YEMEN	09.10.1997	Sirox 250 & 500	Non-Onco	17.10.1997	Submitted
YUGOSLAVIA	29.03.1996	Melthotrexate inj	Onco	—	Submitted
YUGOSLAVIA	29.03.1996	Adrim inj. 5ml	Onco	—	Submitted
YUGOSLAVIA	29.03.1996	Adrim inj. 25ml	Onco	—	Submitted
YUGOSLAVIA	29.03.1996	Cyclophosphamide inj. 200 mg	Onco	—	Submitted
YUGOSLAVIA	29.03.1996	Cyclophosphamide inj. 500 mg	Onco	—	Submitted
YUGOSLAVIA	29.03.1996	Cyclophosphamide inj. 1 g	Onco	—	Submitted
YUGOSLAVIA	29.03.1996	Fytosid inj. 20mg/ml	Onco	—	Submitted
YUGOSLAVIA	29.03.1996	Cisplatin inj. 10 mg	Onco	—	Submitted
YUGOSLAVIA	29.03.1996	Cisplatin inj. 50 mg	Onco	—	Submitted
YUGOSLAVIA	29.03.1996	Fivoflu inj. 250 mg	Onco	—	Submitted
YUGOSLAVIA	29.03.1996	Fivoflu inj. 500 mg	Onco	—	Submitted
YUGOSLAVIA	29.03.1996	Mesna inj. 100 mg/ml	Adjuvant	—	Submitted
ZAMBIA	03.05.1995	Dabcolin 250 mg	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Dabcolin 500 mg	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Dabcolin Dry syrup	Non-Onco	26.08.1995	Registered
ZAMBIA	—	Dabcolin Distab	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Alexin 250 mg	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Alexin 500 mg	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Alexin Dispersible 125 mg	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Alexin Dry syrup	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Atecard 25 mg	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Atecard 50 mg	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Atecard 100 mg	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Uligel Liquids Orange flavour	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Uligel Tablets Orange flavour	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Tinavale Cream	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Tinavale lotion	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Dabcolox 500 mg	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Dabcolox Dry syrup	Non-Onco	26.08.1995	Registered
ZAMBIA	—	Dabcolox Distab	Non-Onco	26.08.1995	Registered
ZAMBIA	—	Damoxy 250 mg	Non-Onco	—	Registered
ZAMBIA	03.05.1995	Damoxy 500 mg	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Damoxy Dry syrup	Non-Onco	26.08.1995	Registered
ZAMBIA	—	Damoxy Distab 125 mg	Non-Onco	26.08.1995	Registered
ZAMBIA	—	Damoxy Distab 250 mg	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Onyza Expectoant	Non-Onco	26.08.1995	Registered
ZAMBIA	03.05.1995	Fruital	Non-Onco	26.08.1995	Registered

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
ZIMBABWE	07.10.1999	Kemoplat 10 mg	Onco	20.01.2000	Registered
ZIMBABWE	07.10.1999	Fytosid	Onco	20.01.2000	Registered
ZIMBABWE	07.10.1999	Adrim 10 mg & 50 mg	Onco	20.01.2000	Submitted
ZIMBABWE	06.03.2000	Fivoflu 500 mg	Onco	29.09.2000	Submitted
ZIMBABWE	06.03.2000	Zexale inj 50 mg	Onco	29.09.2000	Submitted

TENDER'S

Name of the Country	Date of request	Name of the Products	Category	Date of submission	Status
BANGLADESH	05.10.1995	Adrim 50 (tender papers)	Onco	22.11.1995	Registered
BANGLADESH	05.10.1995	Kemoplat 20 ml (tender papers)	Onco	22.11.1995	Registered
BANGLADESH	05.10.1995	Kemoplat 10mg (tender papers)	Onco	22.11.1995	Submitted
BANGLADESH	05.10.1995	Adrim 10 mg (tender papers)	Onco	22.11.1995	Submitted
BANGLADESH	05.10.1995	Zexale inj. 50 mg (tender papers)	Onco	22.11.1995	Submitted
BANGLADESH	05.10.1995	Fivoflu 250 & 500 mg (tender papers)	Onco	22.11.1995	Submitted
BANGLADESH	05.10.1995	Fytosid 100 mg (tender papers)	Onco	22.11.1995	Submitted
COLOMBIA	04.10.2000	Adrim 10 mg (for tender)	Onco	17.10.2000	Submitted
COLOMBIA	04.10.2000	Adrim 50 mg (for tender)	Onco	17.10.2000	Submitted
COLOMBIA	04.10.2000	Fivoflu 500 mg (for tender)	Onco	17.10.2000	Submitted
COLOMBIA	04.10.2000	Fytosid 100 (for tender)	Onco	17.10.2000	Submitted
COLOMBIA	04.10.2000	Kemoplat 10 mg (for tender)	Onco	17.10.2000	Submitted
COLOMBIA	04.10.2000	Gynalam 10 (for tender)	Onco	17.10.2000	Submitted
HONDURAS & COSTA RICA	—	Intaxel	Onco	—	Submitted
ECUADOR	29.08.2000	Adrim 10/50 (for tender)	Onco	31.08.2000	Submitted
ECUADOR	29.08.2000	Fytosid 100 mg (for tender)	Onco	31.08.2000	Submitted
ECUADOR	29.08.2000	Fivoflu 250 (for tender)	Onco	31.08.2000	Submitted
ECUADOR	29.08.2000	Zexale inj 50 mg (for tender)	Onco	31.08.2000	Submitted
ECUADOR	29.08.2000	Zexale 2.5 mg Tab (for tender)	Onco	31.08.2000	Submitted
ECUADOR	29.08.2000	Intaxel 30 mg (for tender)	Onco	31.08.2000	Submitted
ECUADOR	29.08.2000	Cytarine 100mg (for tender)	Onco	31.08.2000	Submitted
ECUADOR	29.08.2000	Cytarine 500mg (for tender)	Onco	31.08.2000	Submitted
ECUADOR	29.08.2000	Cytarine 1g (for tender)	Onco	31.08.2000	Submitted
ECUADOR	29.08.2000	Empurine tab. (for tender)	Onco	31.08.2000	Submitted
ECUADOR	29.08.2000	Kemocarb 150 (for tender)	Onco	31.08.2000	Submitted
ECUADOR	29.08.2000	Kemoplat 10 (for tender)	Onco	31.08.2000	Submitted
ECUADOR	29.08.2000	Ledoxan Tab 50 mg (for tender)	Onco	31.08.2000	Submitted
PAPUA NEW GUINEA	25.09.1998	Cetanil tablet (tender papers)	Non-Onco	29.09.1998	Submitted
PAPUA NEW GUINEA	25.09.1998	Damoxo Capsules (tender papers)	Non-Onco	29.09.1998	Submitted
PERU	21.04.2001	Intaxel 40 & 100 (For tender)	Onco	24.04.2001	Submitted
PERU	21.04.2001	Kemocarb 150 & 450 (tender)	Onco	24.04.2001	Submitted
PERU	21.04.2001	Kemoplat 10mg/20ml (tender)	Onco	24.04.2001	Submitted
PERU	21.04.2001	Docetaxel 20 & 80 (For tender)	Onco	24.04.2001	Submitted
PERU	21.04.2001	Adrim 10 & 50 (For tender)	Onco	24.04.2001	Submitted
PERU	21.04.2001	Fytosid 100 (For tender)	Onco	24.04.2001	Submitted
PERU	21.04.2001	Fivoflu 250 mg (For tender)	Onco	24.04.2001	Submitted
PERU	21.04.2001	Zexale 15 (For tender)	Onco	24.04.2001	Submitted
PERU	21.04.2001	Intaxel 30 (For tender)	Onco	24.04.2001	Submitted
PERU	21.04.2001	Topotecan 4 (For tender)	Onco	24.04.2001	Submitted
PERU	21.04.2001	Ledoxan 50 (For tender)	Onco	24.04.2001	Submitted
PERU	21.04.2001	Gynalam 20 (For tender)	Onco	24.04.2001	Submitted
URUGUAY	13.07.2000	Ledoxan 50 mg (tender)	Onco	11.08.2000	Submitted
URUGUAY	13.07.2000	Zexale Tab 2.5 (tender)	Onco	11.08.2000	Submitted

DOSSIERS SUBMITTED FROM FEBRUARY 2002 TO APRIL 2003

S/No	Country	Products	No. of dossiers	No. of products	Dossier sent on
1	Thailand	Topotel 4	1	1	18.02.2002
2	Jamaica	Kemocarb 450	1	1	04.02.2002
3	Philippines	Vinorelbina 10 & 50	1	2	28.02.2002
4	Liberia	Damoxyl BP 250 Damoxyl BP500 Nuren BP200 Nuren BP400	4	4	06.03.2002
5	Nepal	Contrastin 76% 100 ml Radiopaque 300mg/ml (100ml) Radiopaque 350mg/ml (100ml) Radiopaque 300mg/ml (40ml)	6	6	08.02.2002
		Magniscan 10 & 20 ml	—	—	11.03.2002
		Beck Aid 5g & 25 g	—	—	25.03.2002
6	T&T	Vinorelbina-10	6	6	27.03.2001
		Vinorelbina -50 Irinotel - 40 Irinotel -100	—	—	18.03.2002
		Cytarabine B.P. 500 mg Cytarabine B.P. 1g	—	—	—
7	Macao	Kemocarb 450 Radiopaque 300 (40 ml)	2	2	25.03.2002
8	Peru	Irinotel-100	5	5	29.03.2002
9	Iraq	Cytarabine -100 Vinorelbina-10 Vinorelbina-50 Intaxel -260 ADRIAM 10 mg ADRIAM 50 mg FIVOSID 100 mg FIVOFU 250 mg (amp.) KEMOPLAT 10 mg KEMOPLAT 50 mg ZEXATE 2.5 mg tablets ZEXATE 50 mg	8	8	15.07.2002
10	T&T	KEMOPLAT 10mg/20 ml FIVOFU 500 mg(Amp.) KEMOCARB 450 mg	3	3	18.03.2002
11	Venezuela & Badan	DAXOTEL 20 & 80	1	2	02.03.2002
12	Brazil	Familis 90	1	1	28.08.2002
13	Brazil	Topotel 4 Irinotel 100 mg Daxotel 20 & 80 mg	3	4	19.07.2002
14	Brazil	Intaxel 30	1	1	12.08.2002
15	Brazil	Intaxel 100	1	1	13.09.2002
16	Brazil	Intaxel 100	1	1	13.09.2002
17	Burkina Faso	Adrim 10	7	10	06.05.2002
		Cytarabine BP 100, 500 & 1g Fivoflu 250 & 500 mg ampoule Fytosid 100 mg Leucovorin inj 50 Zexate 50 Zexate tablet 2.5 mg	—	—	—
18	Burkina Faso	Alecard 50	8	8	10.05.2002
		Alecard 100 Damoxyl caps 500 Damoxyl dry syrup Nuren 200 Nuren 400 Strax 250 Strax 500	—	—	—
19	Costa Rica	Daxotel 20	6	6	12.04.2002
20	Hong Kong	Daxotel 80 Irinotel 40 Irinotel 100 Topotel 4 Empurina 50 CytarabineBP 100, 500 & 1 gm Fivoflu 250mg & 500mg amp. Leucovorin Calcium inj,3mg Leucovorin Calcium inj. 15mg Leucovorin Calcium inj. 50mg Fytosid 100mg Adrim 10mg and 50mg Zexate 50mg Zexate 15mg Vinorelbine inj 10mg & 50mg Mesna Injection 200mg Kemoplat (0.5mg)20 & 100ml Intaxel inj 30,100mg & 260mg Kemocarb 150mg and 450mg	14	23	12.07.2002
21	Jordan	Kemocarb 150 Kemocarb 450	2	2	26.04.2002
22	Jordan	Kemoplat 10mg/20ml Kemoplat 50mg/100ml Zexate 50mg Zexate 500mg	4	4	18.07.2002
23	Jordan	Intaxel 260	1	1	18.07.2002
24	Kazakhstan	Zexate 50	1	1	26.04.2002
25	Kazakhstan	Adrim 10 & 50	6	12	03.08.2002
		Fytosid 100 Intaxel 30,100 & 260 Kemocarb 150 & 450 Kemoplat 20 ml & 100ml Zexate 50 & 15	—	—	—
26	Kazakhstan	Adrim 10 & 50	6	12	21.09.2002
		Fytosid 100 Intaxel 30,100 & 260 Kemocarb 150 & 450 Kemoplat 20 ml & 100ml Zexate 50 & 15	—	—	—
27	Malaysia	Fivoflu 250mg & 500mg (Vials)	1	2	19.06.2002
28	Malaysia	Stage 3 INTAXEL 260MG VINOIRELBINE 10MG AND 50MG ZEXATE-500MG KEMOPLAT 1MG/ML (10 & 50 MG)	4	6	16.04.2002
			—	—	24.04.2002
			—	—	30.04.2002

SlNo	Country	Products	No. of dossiers	No. of products	Dossier sent on
29.	Malaysia	Part II of stage 3 Kemoplal Injection 1mg/ml	1	1	17.07.2002
30.	Morocco	Kemoplal 50mg/50ml	1	1	03.06.2002
31.	Nepal	Emetra 4 & 8mg Bleomycin for Inj. 15 units	2	3	12.07.2002
32.	Nepal	Trozol 2.5 mg	1	1	25.09.2002
33.	Singapore	Zexate -500	1	1	31.05.2002
34.	Sri Lanka	Nasarel 20 & 60	1	2	27.05.2002
35.	Sri Lanka	For Re- registration Tinavate Solution USP Damoxy Dry Syrup BP Alexin Dry Syrup BP Alexin 250 Alexin 500	5	5	12.08.2002
36.	Sudan	ADRIAM 10MG FIVOFU 250MG ampoule KEMOPLAT 10MG/20ml	3	3	18.04.2002
37.	Thailand	Vinorelbine 10 & 50	1	2	26.04.2002
38.	Thailand	Zexate 500	1	1	Oct 2002
39.	Sri Lanka	Stroz 250 Stroz 500	2	2	09.10.2002
40.	Singapore	Kemoplal 10 & 50 (1mg/ml)	1	2	-
41.	Venezuela	Cytarabine 100/500/1 g	1	3	28.10.2002
42.	Afghanistan	Fivofu Vials 250 & 500 Fytosid 100mg Kemocarb 150 & 450 Kemoplal 10/20 & 50/100ml Zexate 50 Gynatam 10 Gynatam 20 Ledoxan Tab. 50 mg Zexate Tab. 2.5 mg	9	12	02.11.2002
43.	Sri Lanka	Atecard 25, 50 & 100 (re-registration) Alermes 120 & Alermes 180 Etemas	4	6	Nov. 2002
44.	Burkina Faso	Zexate 2.5 Ledoxan 50	2	2	21.11.2002
45.	Maldives	Tinavate Cream Tinavate Solution Atecard 25 Atecard 50 Atecard 100	5	5	22.11.2002
46.	Nepal	Ioscan 300 & 370 (50 & 100 ml for both strength)	1	4	27.11.2002
47.	Malaysia	Stage 3 Fivofu Injection 250 & 500 (Vials)	1	2	10.12.2002
48.	Maldives	Alexin dry syrup Alexin 250 Alexin 500	3	3	11.12.2002
49.	Philippines	Daxosel 20 & 60	1	2	13.12.2002
50.	Philippines	Re-registration Gynatam Tablets 10 & 20 mg Mesna Injection 200 Adrim Injection 10 & 50 mg Fytosid Injection 100 mg Fivofu Injection 250 & 500 mg (Ampoules)	5	8	16.12.2002
51.	IRAQ	Ledoxan Injection 200 Ledoxan Injection 500 Ledoxan Tabs 50 mg Cytarabine 100 Ipamide Injection	5	5	27.12.2002
52.	IRAQ	Empurine Tablets Mesna Injection Leucovorin Calcium Injection USP 3mg Leucovorin Calcium Injection USP 15mg Leucovorin Calcium Injection USP 50mg	5	5	27.12.2002
53.	Myanmar	Vinorelbine -10 Vinorelbine - 50	2	2	23.12.2002
54.	Malaysia	Docetaxel Injection 20mg and 80mg Topotel Injection 4mg and 2.5mg	2	4	27.12.2002
55.	Peru	Leucovorin Calcium Injection USP 50mg Mesna Injection 200mg	2	2	30.12.2002
56.	Jamaica	Irinotecan 40 & 100 Zexate 15 & 500 Empurine Gynatam 10 & 20 mg	4	7	15.01.2003
57.	Venezuela	Kemoplal 10 and 50 (1 mg/ml) Irinotecan 40 & 100 Topotel 2.5 & 4	3	6	27.01.2003
58.	Mexico	Vinorelbine 10 & 50 Irinotecan 40 & 100 Fivofu 5ml amp., 5ml vial, 10ml amp. and 10ml vial Cytarabine 100 mg, 500 mg and 1 g Kemoplal 20 ml, 100ml, 10ml and 50ml	5	15	03.02.2003

S.N	Country	Products	No. of dossiers	No. of products	Dossier sent on
59	Kazakhstan	Intaxel 30, 100 & 260 Fytosid 100 Kemocarb 150 & 450 Zexale 15 & 50 Kemoplat 10 & 50 Adrim 10 & 50	6	12	07.02.2003
60	Colombia	Vineltine 10 & 50, Fivoflu Vials 250 & 500 Cytarine 100 mg, 500mg & 1g Irinotel 40 & 100 Leucovorin Calcium Injection 3, 15 and 50mg Mesna	6	13	02.2003
61	El Salvador	Vineltine 10 & 50 Zexale 50 Gynatam 10 Adrim 10mg & 50mg Cytarine 100mg, 500mg & 1g Kemocarb 150mg & 450mg Fivoflu 5ml Amp. & 10ml Amp. Fivoflu 5ml Vial & 10ml Vial Intaxel 30mg, 100mg & 260mg Fytosid Injection	10	19	10.03.2003
62	Zimbabwe	Cytarine 100 mg	1	1	27.03.2003
63	Russia	Daxotel 20 & 80	1	2	27.03.2003
64	Lithuania	Fytosid 100 Intaxel 30, 100 & 260 Kemoplat 20 & 100 ml Kemocarb 150 & 450	4	8	11.04.2002
65	Ukraine	Daxotel 20 & 80 Irinotel 40 & 100	2	4	18.04.2003
66	El Salvador	Daxotel 20 & 80	1	2	02.04.2003
67	Cuba	Empurine Tablet Ledoxan Tablet	2	2	23.04.2003
68	Sri Lanka	Uigel Tablet -Cardamom flavour Ulzol Capsule IP	2	2	23.04.2003

Dated this the 17th day of October 2003.
(By order of the Court)

Sd/-
Joint Registrar (Co.)
for Registrar
Examiner

1

DASTI No. 18 / 48 / T
Dt. 03 / 10 / 08

From :
The Registrar General
Delhi High Court, New Delhi

To, Sh. Sudhir K. Makar & Associates Advocate
D-16 H, Hauz Khas, New Delhi-110016

Sub : C. P. 324/03
IN THE MATTER OF M/S. DABUR INDIA LTD.

Sir,

I am directed to forward herewith a copy of order passed by the Hon'ble Company Judge on 22/09/2008 for information and necessary compliance.

Please acknowledge the receipt.

Yours faithfully,
Sd/-

% 22.09.2008

Admn. Officer Judl. (Co.) for Registrar General

Present : Mr. S. K. Makkar, Advocate, for the applicants
Ms. Manisha Tyagi, Advocate for the Official Liquidator
Mr. Faisuddin, Asstl. Registrar of Companies

+CA No. 1243/2007 In CP 324/2003 & CA No. 1247/2007 In CP 325/2003

1. The petitioner companies had filed Company Petition Nos. 324 & 325/2003 on 7th August, 2003 U/s 391 to 394 of the Companies Act, 1956 praying for sanction of the Scheme of Arrangement between Dabur India Limited (the transferor company) and Dabur Pharma Limited (the transferee company). The registered offices of the aforesaid two companies are located at New Delhi, within the territorial jurisdiction of this court.

2. The proposed Scheme of Arrangement had been approved by the Board of Directors, shareholders and the secured and unsecured creditors of the transferor and the transferee companies. The said Scheme of Arrangement, as proposed, was sanctioned by this court vide order dated 17th October, 2003.

The petitioners have thereafter filed the present applications seeking modification of the order dated 17th October, 2003 to the effect that property bearing Plot No. 11, Echelon Institutional Area, Sector-32, Gurgaon, Haryana, which was mentioned at item No. 3 of Schedule-C of the Scheme of Arrangement shall stand omitted from the definition of "Demerged Undertaking" as defined in Clause-1 (c) of the Scheme of Arrangement and shall not form part of the transfer of undertaking contemplated in the Scheme of Arrangement as sanctioned by this court and shall be deemed to have been kept outside the purview of the transfer.

3. The petitioners have contended that this plot was allotted on terms & conditions contained in a lease deed dated 23rd June, 1995. Clause 13 thereof contains a prohibition on transfer of the plot / building or any right title and interest therein.

Learned counsel for the petitioner submits that after the sanction of the Scheme, it was realized that in case the plot in question is transferred in the name of the transferee company as part of the Scheme, it may entail the forfeiture of the plot. It is further submitted that petitioners have been given to understand by the Haryana Urban Development Authority that under the terms of allotment, it is not lawful for any allottee to transfer the institutional plot in favour of any body else, even if such transfer is by way of Scheme of Arrangement. The further submission is that this aspect has been considered by the Board of Directors of both the transferor and transferee companies in view of the serious apprehension regarding the stand taken by HUDA with regard to transferability of the plot in question. Consequently, the boards have sought modification of the Scheme of Arrangement to the extent that the said property be kept outside the purview of the undertaking as stipulated in the Scheme of Arrangement.

Learned counsel further submits that these prayers would be in the larger interest of the transferor and transferee companies and their shareholders, who are stated to be substantially the same, the said property be kept outside the purview of the Scheme of Arrangement. It is further proposed that an amount of Rs.3.66 crores representing the value of the property at the time of demerger, inclusive

of costs incurred by the transferor company for improvement of the said property in the meantime, be debited to the account of the transferor company on account of withdrawal of the said property from the Scheme. Copies of the resolutions dated 24th October, 2007 and 26th October, 2007 passed by the Board of Directors of the transferor and transferee companies whereby they approve the proposed amendment to the Scheme of Arrangement have been filed on record.

4. The petitioners have pointed out that the property in question had been acquired by the transferor company at a tentative price of Rs.1.88 crores. Its valuation under the Scheme was fixed as Rs. 3.10 crores and a further expense of Rs.56 lacs is stated to have been incurred towards improvement of the property. Consequently, valuation of the property has been fixed at an amount of Rs. 3.66 crores as of now. Reliance is also placed on the balance sheet of the company as on 31.03.2007, which has been placed on record, according to which the fixed assets of the transferor company are to the tune of Rs.379 crores and the net profit after taxation and before extraordinary item is to the tune of Rs. 282 crores. The reserve and surplus of the transferor company are to the tune of Rs.393 cores.
5. It would, therefore, appear that so far as the creditors of the transferor company are concerned, their interest is not adversely affected in any manner by the aforesaid modification in the Scheme.
6. The proposed amendment in the Scheme of Arrangement was approved by the secured and unsecured creditors of the transferee company and the requirement of convening the meetings of the shareholders to approve the amended Scheme was also dispensed with since the interest of the shareholders was suitably protected as the property prices rose considerably in the meantime. Accordingly, the meetings of the shareholders, secured and unsecured creditors of the transferee company were dispensed with since their respective interest were adequately protected and were not adversely affected in any manner by the aforesaid modification of the Scheme of Arrangement.
7. So far as the transferor company is concerned, the requirement of convening the meeting of the secured creditors was dispensed with in view of their written no objection certificates placed on record. However, vide order dated 11 th March, 2008 the meeting of the equity shareholders and unsecured creditors of the transferor company was directed to be convened on 18th May, 2008 to consider and approve the proposed amendment to the Scheme of Arrangement. The meetings as directed, were convened and the Chairpersons appointed for the meetings have submitted their reports, placing on record the approval given by the equity shareholders and the unsecured creditors to the Scheme of Arrangement.
8. So far as the Official Liquidator and the Regional Director, Norther Region are concerned, Ms. Manisha Tyagi, Advocate and Mr. Raisuddin, Assit. Registrar of Companies have respectively appeared on their behalf and on examination of the application have stated that they have no objection to the proposed amendment / modification in the Scheme of Arrangement which was sanctioned by this court vide order dated 17th October, 2003. No legal impediment to the grant of these applications is urged.

It is noteworthy that Dabur Pharma Limited - the transferee company is a wholly owned subsidiary of Dabur India Limited the transferor company. The Scheme of Arrangement sanctioned by this court on the 17th of October, 2003 postulates transfer of pharmaceutical undertaking of the transferor company on a going concern basis into the transferee company and the Dabur India Limited - the transferor company would then focus on the remaining business. It is pointed out that a substantial number of the shareholders of the companies are common and the modification would be in the larger interest of the shareholders.

Consequently, in view of the approval granted to the amendment to the Scheme of Arrangement by the equity shareholders, secured and unsecured creditors of the transferor and transferee companies & their being no objection to the same by the Official Liquidator and the Regional Director the application is allowed and order dated 17th October, 2003 is amended to the effect that property bearing Plot No. II, Echelon institutional Area, Sactor-32, Gurgaon, Haryana, which was mentioned at Item No. 3 of Schedule-C of the scheme of Arrangement shall stand omitted from the definition of "Demerged Undertaking" as defined in Clause-1 (c) of the Scheme of Arrangement and shall not form part of the transfer of undertaking. The said property have been kept outside the purview of the transfer.

The application stands disposed of in the above terms.

Dasti.

GITA MITTAL
September 22, 2008

IN THE HIGH COURT OF DELHI AT NEW DELHI

ORIGINAL COMPANY JURISDICTION

COMPANY PETITION NO 181 OF 2006

CONNECTED WITH

COMPANY APPLICATION NO. 90 OF 2006

MEMO OF PARTIES

IN THE MATTER OF SCHEME OF AMALGAMATION AND ARRANGEMENT

BETWEEN :

BALSARA HYGIENE PRODUCTS LIMITED a Company incorporated under the Companies Act, 1956 having its Registered Office at Survey No. 225/4/1, Village Sayli, Dadra & Nagar Haveli, Dist. Silvassa, Silvassa (U.T.) - 396 240 ... Transferor Company No.1

AND

BESTA COSMETICS LIMITED, a Company incorporated under the Companies Act, 1956 having its Registered Office at Survey No. 225/4/1, Village Sayli, Dadra & Nagar Haveli, Dist. Silvassa, Silvassa (U.T.) -396 240 ... Transferor Company No. 2

AND

BALSARA HOME PRODUCTS LIMITED , a Company incorporated under the Companies Act, 1956 having its Registered Office at Balsara House, 43, Nagindas Master Road, Fort, Mumbai - 400 001 ... Transferor Company No. 3

DABUR INDIA LIMITED, a Company incorporated under the Companies Act, 1956 having its Registered Office at 8/3, Asaf Ali Road, New Delhi - 110002 ...Petitioner/Transferee Company

(MAHESH AGARWAL)
AGARWAL LAW ASSOCIATES
34, BABAR LANE FIRST FLOOR
BENGALI MARKET,
NEW DELHI - 110 001
PH. : 23354330, 23738122

New Delhi

Date : 22/7/2006

IN THE COURT OF DELHI AT NEW DELHI
ORIGINAL COMPANY JURISDICTION
COMPANY PETITION NO. 181/2006

In the matter of The Companies Act, 1956;

under Sections 391 to 394 of the Companies Act, 1956;

Scheme of Amalgamation of :
M/s Dabur India Limited ...

Petitioner/Transferee Company
Mr. Mahesh Aggarwal Adv.
Mr. R.D. Kashyap, Dy. ROC.
Ms. Marisha Tyagi, Adv. for the O.L.

SANJIV KHANNA J. (ORAL)

1. This petition under Sections 391-394 of the Companies Act, 1956 (hereinafter referred to as the Act) has been filed by M/s Dabur India Limited (hereinafter referred to as the Transferee Company).
2. The registered office the transferee company is located in Delhi, within the jurisdiction of this Court.
3. I am informed that similar petitions were filed by M/s Balsara Hygiene Products Limited, M/s Besta Cosmetics Limited and M/s Balsara Home Products Limited (hereinafter collectively referred to as the Transferor companies) before the Mumbai High Court and the scheme has been sanctioned and approved vide order dated 8.9.2006, subject to order being passed in case of the transferee company.
4. The transferee company had earlier filed CA(M) No. 90/2006. The said application was disposed of vide order dated 10.5.2006. This Court dispensed with the requirement to convene and hold meeting of the secured creditors of the transferee company in view of the consent letters/no objection certificates given by the secured creditors. However, meetings of the shareholders and unsecured creditors of the transferee company were directed to be held.
5. The aforesaid meetings as directed were held and the Chairperson appointed by this Court has filed his report.
6. As per the said report, the meeting was attended by 1213 shareholders. 140 votes were declared to be invalid and out of 1073 votes casts, 1071 shareholders had voted in favour of the scheme and two shareholders had voted against the scheme. The shareholders who have voted in favor of the scheme together hold 4,35,391,733 shares. The two shareholders who voted against the scheme hold only 8 shares. The scheme was therefore, approved by 99.81% of the shareholders present and voting.

7. Similarly, the meeting of the unsecured creditors was attended by 116 unsecured creditors. Two votes were declared to be invalid. 113 unsecured creditors representing Rs. 520,554,981 of the amount due and payable by the transferee company had voted in favor of the scheme. One unsecured creditors to whom Rs. 770408 was payable had voted against the scheme. The scheme was approved by 99.85% unsecured creditors present and voting.
8. After filing of the present application, citations were directed to be published. As per affidavit of service, citations have been published in the newspapers 'The Statesman' (English) and "Jansatta" (Hindi).
9. Notice was also issued to the Regional Director(NR). The Regional Director has filed his report pointing out that the two shareholders having 8 shares have voted against the scheme. Similarly it is stated that one unsecured creditor to whom Rs. 770408/- was due and payable by the transferee company has voted against the scheme.
10. It is clear from reading of the report of the Regional Director that except stating the factual position and informing this court that two shareholders and one unsecured creditor had voted against the scheme, no objection has been raised.
11. Having regard to the averments made in the petition, the material placed on record and the affidavits filed on behalf of the company, I am satisfied that the prayer made in the petition deserves to be allowed. I do not find any legal impediment to sanction the scheme for amalgamation. Hence sanction is hereby granted to the scheme of amalgamation under Sections 391-394 of the Act. The transferee company will comply with statutory requirements in accordance with law. Copy of this order be filed with the Registrar of companies within 5 weeks. It is also clarified that this order will not be construed as granting exemption from payment of stamp duty and/or transfer fee etc. payable in accordance with law.
12. The petition is disposed of.

DASTI

September 12, 2006
RN

Sd/-
Sanjiv Khanna, J.

IN THE HIGH COURT OF DELHI AT NEW DELHI

ORIGINAL JURISDICTION

IN THE MATTER OF THE COMPANIES ACT, 1956

AND

IN THE MATTER OF SCHEME OF AMALGAMATION/ARRANGEMENT

OF

IN THE MATTER OF

M/s Balsara Hygiene Products Ltd. having its
Regd. Office at Survey No. 225/4/1, Village Sayli,
Dadra & Nagar Haveli, Distt. Silvassa, Silvassa
(U.T.) - 396 240

Transferor Company No. 1
(Outside the jurisdiction of this Court)

IN THE MATTER OF

M/s Besta Cosmetics Ltd., having its Regd. Office
at Survey No. 225/4/1, Village Sayli, Dadra & Nagar
Haveli, Distt. Silvassa, Silvassa (U.T.) -396240

Transferor Company No. 2
(Outside the jurisdiction of this Court)

IN THE MATTER OF

M/s Balsara Home Products Ltd., having its Regd.
Office at Balsara House, 43, Nagindas Master
Road, Fort, Mumbai - 400 001

Transferor Company No. 3
(Outside the jurisdiction of this Court)

WITH

COMPANY PETITION NO. 181/2006

CONNECTED WITH

COMPANY APPLICATION (M) NO. 90/2006

IN THE MATTER OF

M/s Dabur India Ltd., having its Regd. Office
at 8/3, Asaf Ali Road, New Delhi - 110 002

Petitioner/Transferee Company
(Within the jurisdiction of this Court)

BEFORE HON'BLE MR. JUSTICE SANJIV KHANNA
DATED THIS 12TH DAY OF SEPTEMBER, 2006

ORDER UNDER SECTION 394 OF THE COMPANIES ACT, 1956

The above petition coming up for hearing on 12/9/06 for sanction of scheme of amalgamation/arrangement proposed to be made of M/s Balsara Hygiene Products Ltd., M/s Besta Cosmetics Ltd. and M/s Balsara Home Products Ltd. (hereinafter referred to as the Transferor Companies) (Outside the jurisdiction of this Court) with M/s Dabur India Ltd. (hereinafter referred to as the Transferee Company) (within the jurisdiction of this Court), upon reading the said petition, the order dt. 10/5/06 whereby the requirement of convening and holding the meetings of the secured creditors of Transferee Company was dispensed with and the meeting of shareholders and unsecured creditors of the Transferee Company was ordered to be convened for the purpose of considering, and if thought fit, approving, with or without modification, the Scheme of amalgamation/arrangement annexed to the affidavit of Sh. A.K. Jain, Additional General Manager (Finance) and Company Secretary of the petitioner company filed on the 8th day of May, 06 and the publication in the newspapers namely (1) Statesman (English) (2) Jansatta (Hindi) both dt. 8/6/06 each containing the advertisement of the said notice of the petition convening the said meetings directed to be held by the said order dt. 10/5/06, the reports of Sh. Raman Kapoor, Chairperson filed on 4/7/06 showing the publication and despatch of the notices convening the said meeting, the reports of the chairperson of the said meetings as to the result of the said meetings and upon hearing Sh. Mahesh Aggarwal, Advocate for the petitioner, Mr. R. D. Kashyap, Dy. Registrar of Companies and Ms. Manisha Tyagi, Advocate for the Official Liquidator and it appearing from the report that the proposed scheme of amalgamation/arrangement has been approved by 99.81% and 99.85% respectively without any modification by the said shareholders and unsecured creditors of the Transferee Company present and voting either in person or by proxy and upon reading the affidavit dated 7/9/2006 of Sh. Rakesh Chandra, Regional Director Northern Region, Ministry of Company Affairs, Noida on behalf of Central Government stating inter-alia that the Central Government has no objection to the proposed scheme of amalgamation/arrangement. However, he has pointed out the factual position that the two shareholders having 8 shares have voted against the scheme and one unsecured creditors to whom Rs 7,70,408/- was due and payable by the Transferee Company has voted against the scheme and there being no investigation proceedings pending in relation to the petitioner company under Section 235 to 251 of the Companies Act, 1956. The scheme of amalgamation/arrangement in respect of the Transferor Companies has already been sanctioned by Mumbai High Court vide order dt. 8/9/2006.

THIS COURT BOTH HEREBY SANCTION THE SCHEME OF AMALGAMATION/ARRANGEMENT setforth in Schedule-I, annexed hereto and BOTH HEREBY DECLARE the same to be binding on all the shareholders and creditors of the Transferee Company and all concerned and does approve the said scheme of amalgamation/arrangement with effect from the appointed date i.e.1/4/2006

AND THIS COURT BOTH FURTHER ORDER :

1. That all the property, rights and powers of the Transferor Companies specified in the first, second and third parts of the Schedule-II hereto and all other property, rights and powers of the Transferor Companies be transferred without further act or deed to the Transferee Company and accordingly the same shall pursuant to Section 394 (2) of the Companies Act, 1956 be transferred to and vest in the Transferee Company for all the estate and interest of the Transferor Companies therein but subject nevertheless to all charges now effecting the same; and
2. That all the liabilities and duties of the Transferor Companies be transferred without further act or deed to the Transferee Company and accordingly the same shall pursuant in Section 394 (2) of the Companies Act, 1956 be transferred to and become the liabilities and duties of the Transferee Company; and
3. That all the proceedings now pending by or against the Transferor Companies be continued by or against the Transferee Company; and
4. That the Transferee Company do without further application allot to such members of the Transferor Companies as have not given such notice of dissent as is required by clause 5.1, 5.2 & 5.3 given in the scheme of amalgamation/arrangement herein the shares in the Transferee Company to which they are entitled under the said amalgamation/arrangement; and
5. That the Transferor Companies do within 5 weeks after the date of this order cause a certified copy of this order alongwith the certified copy of order dt. 8/9/06 of Mumbai High Court in respect of Transferor Companies to be delivered to the Registrar of Companies for registration and on such certified copy being so delivered the Transferor Companies shall be dissolved without the process of winding up and the Registrar of Company shall place all documents relating to the Transferor Companies and registered with him on the file kept by him in relation to the Transferee Company and the files relating to the said transferor and Transferee Companies shall be consolidated accordingly; and
6. That any person interested shall be at liberty to apply to the Court in the above matter for any directions that may be necessary.

SCHEDULE - 1
SCHEME OF AMALGAMATION AND ARRANGEMENT
OF
BALSARA HYGIENE PRODUCTS LIMITED
AND
BESTA COSMETICS LIMITED
AND
BALSARA HOME PRODUCTS LIMITED
WITH
DABUR INDIA LIMITED
AND
THEIR RESPECTIVE SHAREHOLDERS

This Scheme of Amalgamation and Arrangement provides for the amalgamation of Balsara Hygiene Products Limited, Besta Cosmetics Limited and Balsara Home Products Limited with Dabur India Limited pursuant to Sections 391 to 394 and other applicable provisions of the Companies Act, 1956.

1. Definition

- 1.1 "Act" means the Companies Act, 1956 and shall include any statutory modifications, re-enactment or amendments thereof for the time being in force.
- 1.2 "Appointed Date" means the 1st day of April, 2006 or such other date as may be approved by the High Court of Judicature at Bombay and High Court of Delhi or any other appropriate authority.
- 1.3 "Balsara Hygiene" or "BHPL" means Balsara Hygiene Products Limited, a company incorporated under the Companies Act, 1956 and having its registered office at Survey No. 225/4/1, Village Sayli, Dadra & Nagar Haveli, Dist. Silvassa, Silvassa (U.T.), 396 240.
- 1.4 "Besta" means Besta Cosmetics Limited having its registered office at Survey No. 225/4/1, Village Sayli, Dadra & Nagar Haveli, Dist. Silvassa, Silvassa (U.T.), 396 240
- 1.5 "Balsara Home" means Balsara Home Products Limited having its registered office at Balsara House, 43, Nagindas Master Road, Fort, Mumbai - 400 001.
- 1.6 "Dabur" or "Transferee Company" means Dabur India Limited having its registered office at 8/3, Asaf Ali Road, New Delhi-110002.
- 1.7 "Effective Date" means the dates on which certified copies of the Orders of the High Court of Judicature at Bombay and High Court of Delhi or any other appropriate authority under Sections 391 to 394 of the Act sanctioning the Scheme are filed with the Registrar of Companies, Maharashtra at Mumbai, Registrar of Companies, Gujarat at Ahmedabad and the Registrar of Companies, NCT of Delhi & Haryana at New Delhi respectively.
- 1.8 "High Court" means the High Court of Judicature at Bombay and High Court of Delhi and such other High Court having jurisdiction in the matter.
- 1.9 "Record Date" means the date to be fixed by the Board of Directors of Dabur for the purpose of issue of Equity Shares to the Equity Shareholders of BHPL.
- 1.10 "Scheme" or "the Scheme" or "this Scheme" means this Scheme of Amalgamation and Arrangement in its present form submitted to the High Court or any other

appropriate authority or with any modification(s) made under Clause 15 of this Scheme.

1.11 "Transferor Companies" or "Balsara Group Companies" means BHPL, Besta and Balsara Home collectively.

2. DATE OF TAKING EFFECT AND OPERATIVE DATE

The Scheme set out herein in its present form or with any modification(s) approved or imposed or directed by the High Court or any other appropriate authority shall be operative from the Appointed Date but shall be effective from the Effective Date.

3. SHARE CAPITAL

3.1 The share capital of BHPL as on March 31, 2005 is as under:

	(Amount in Rs. Lacs)
	As on March 31, 2005
Authorised Capital	
5,000,000 Equity Shares of Rs. 10 each	500.00
	<u>500.00</u>
Issued, Subscribed and Paid-up	
3,860,800 Equity Shares of Rs. 10 each	388.08
	<u>388.08</u>

As on date, 3,860,400 equity shares of Rs 10/- each fully paid-up are held by Dabur, making BHPL the subsidiary of Dabur, and 4 equity shares of Rs. 10/- each fully paid-up are held by Balsara Home jointly with its nominees.

3.2 The share capital of Besta as on March 31, 2005 is as under:

	(Amount in Rs. Lacs)
	As on March 31, 2005
Authorised Capital	
1,200,000 Equity shares of Rs 10 each	120.00
	<u>120.00</u>
Issued, Subscribed and Paid up	
900,000 Equity Shares of Rs. 10 each	90.00
	<u>90.00</u>

As on date, 431,800 equity shares of Rs 10/- each fully paid-up are held by Dabur and 19,196 equity shares of Rs 10/- each fully paid-up are held by Balsara Home and 449,000 equity shares of Rs 10/- each fully paid-up are held by BHPL and 4 equity shares of Rs.10/- each fully paid-up are held by Balsara Home jointly with its nominees.

3.3 The share capital of Balsara Home as on March 31, 2005 is as under:

	(Amount in Rs. Lacs) As on March 31, 2005
Authorised Capital	
14,400,000 Equity Shares of Rs. 10 each	1440.00
600,000 6.5% Non-Cumulative redeemable preference shares of Rs. 10 each	<u>60.00</u>
	<u>1500.00</u>
Issued, Subscribed and Paid-up	
2,450,011 Equity Shares of Rs. 10 each	245.00
600,000 6.5% Non-Cumulative redeemable preference shares of Rs. 10 each	<u>60.00</u>
	<u>305.00</u>

Subsequent to March 31, 2005, the company has issued 10,000,000 equity shares of Rs. 10/- each fully paid-up.

As on date, 159,300 equity shares of Rs. 10/- each fully paid-up are held by BHPL and 12,290,711 equity shares of Rs. 10/- each fully paid-up are held by Dabur along with its nominees.

3.4 The share capital of Dabur as on March 31, 2005 is as under:

	(Amount in Rs. Lacs) As on March 31, 2005
Authorised Capital	
500,000,000 Equity Shares of Rs. 1 each	5,000.00
	<u>5000.00</u>
Issued, Subscribed and Paid-up	
286,419,713 Equity Shares of Rs. 1 each	2864.20
	<u>2864.20</u>

Subsequent to March 31, 2005, the company has issued 231,679 equity shares of Re 1 each fully paid-up to employees under Employees Stock Option Scheme and 286,651,392 equity shares of Re 1 each as bonus shares. Consequently, the Authorised Share Capital of the Company has also been increased. The revised Share Capital of Dabur is as under:

	(Amount in Rs. Lacs)
Authorised Capital	
1,250,000,000 Equity Shares of Rs. 1 each	12,500.00
	<u>12,500.00</u>
Issued, Subscribed and Paid-up	
573,302,784 Equity Shares of Rs. 1 each	5733.03
	<u>5733.03</u>

4. VESTING OF UNDERTAKINGS

- 4.1 With effect from the Appointed Date, the entire business and whole of the undertakings of the Transferor Companies including all its properties and assets (whether movable or immovable, tangible or intangible) of whatsoever nature including but not

limited to any brand name, trade mark or copy right, registrations, permits, quotas, approvals, actionable claims, all rights / title or interest in property(ies) by virtue of any court order / Decree, contractual arrangement, allotment, grant, possession or otherwise, lease, tenancy rights, permissions, incentives, licenses including but not limited to export license, import license, Industrial and other licenses, bids, tenders, municipal and other statutory permissions, approvals including but not limited to right to use and avail electricity connections, water connections, telephone connections, facsimile connections, telexes, e-mail, internet, leased line connections and installations, all records, files, papers, engineering and process information, computer programs, manuals, data, catalogues, quotations, rates and advertising materials, list of present and former customers and suppliers, customer credit information and all other rights, title, interest, contracts, consent, approvals or powers of every kind, nature and descriptions whatsoever, shall under the provisions of Sections 391 to 394 of the Act and pursuant to the orders of the High Courts or any other appropriate authority sanctioning this Scheme and without further act, instrument or deed, but subject to the charges affecting the same as on the Effective Date be transferred and/or deemed to be transferred to and vested in the Transferee Company so as to become the properties and assets of the Transferee Company. The benefit of all brands, copyrights, trademarks, actionable claims, all rights / title or interest in property(ies) by virtue of any court order / Decree, contractual arrangement, allotment, grant, possession or otherwise, statutory and regulatory permissions, factory licences, environmental approvals and consents, sales tax registrations or other licences and consents shall vest in and become available to Transferee Company pursuant to this Scheme.

- 4.2 With effect from the Appointed Date, all debts, liabilities, contingent liabilities, duties and obligations of the Transferor Companies as on the close of business on the date preceding the Appointed Date whether or not provided in the books of the Transferor Companies shall be deemed to be the debt, liabilities, duties and obligations of the Transferee Company and it shall not be necessary to obtain the consent of any third party or other person who is a party to any contract or arrangement by virtue of which such debts, liabilities, contingent liabilities, duties and obligations have arisen in order to give effect to the provisions of this sub-clause
- 4.3 In respect of all the moveable assets of the Transferor Companies and the assets which are otherwise capable of transfer by physical delivery or endorsement and delivery, including cash on hand, shall be so transferred to the Transferee Company and deemed to have been physically handed over by physical delivery or by endorsement and delivery, as the case may be, to the Transferee Company to the end and intent that the property and benefit therein passes to the Transferee Company with effect from the Appointed Date.
- 4.4 Such delivery and transfer shall be made on a date mutually agreed upon between the respective Boards of Directors of the Transferor Companies and the Transferee Company. However such date shall be within thirty days from the Effective Date.
- 4.5 In respect of any intangible moveable assets of the Transferor Companies other than those mentioned in Clause 4.3 above, including actionable claims, sundry debtors, outstanding loans, advances recoverable in cash or kind or for value to be received and deposits with the Government, semi-Government, local and other authorities and bodies and customers, the Transferor Companies shall if so required by the Transferee Company, and the Transferee Company may, issue notices in such form as the Transferee Company may deem fit and proper stating that pursuant to the High Court of Judicature at Bombay and High Court of Delhi having sanctioned this Scheme between the Transferor Companies and the Transferee Company under Section 394 of the Act, the relevant debt, loan, advance or other asset, be paid or made good or held on account of the Transferee Company, as the person entitled thereto, to the end and intent that the right of the Transferor Companies to recover or realise the same stands transferred to the Transferee Company and that appropriate entries should be passed in their respective books to record the aforesaid changes.

- 4.6 It is clarified that since the Transferee Company beneficially owns over 90% of the issued share capital of the Transferor Companies, the transfer of the undertakings of the Transferor Companies, in pursuance of this Scheme shall be eligible to the benefit under Notification No. 1, dated January 16, 1937 issued under Section 9(a) of the Indian Stamp Act, 1899.

5. DISCHARGE OF CONSIDERATION

- 5.1 Upon this Scheme becoming operative and in consideration of the amalgamation, Dabur shall issue and allot to the equity shareholders of BHPL, other than the Transferee Company holding fully paid up equity shares in BHPL and whose name appears in the Register of Members of BHPL as on the Record Date, his/her heirs, executors, administrators or the successors-in-title, as the case may be, 7 (seven) Equity Share(s) of the face value of Rs. 1 each of Dabur credited as fully paid-up, for every 2 (two) Equity Shares of the face value of Rs. 10 each of BHPL.
- 5.2 It is clarified that no Equity Shares will be issued to Dabur in its capacity as shareholder of BHPL since Dabur cannot issue shares to itself.
- 5.3 It is further clarified that, save and except as provided in clause 5.1 above, shares of the Transferor Companies held by the Transferee Company on the Record Date shall be cancelled without any further act or deed, and the Transferee Company shall not issue shares to the extent of shares held by itself in the Transferor Companies as well as shares held by the Transferor Companies inter-se as on the Record Date.
- 5.4 The shareholders of BHPL, to whom equity shares are to be issued by the Transferee Company pursuant to Clause 5.1 above shall be issued in dematerialized form. However, shareholders of BHPL shall have an option to receive the certificate(s) of shares or receive credit in their demat accounts. Those, who wish to receive their equity shares in dematerialized form, shall provide all details relating to their account with depository participant, to the Transferee Company. In case no response is received, the Transferee Company shall issue the shares in the form in which the BHPL shares were held as on the Record Date by the concerned shareholder.
- 5.5 Any fraction arising on issue of Equity Shares as above will be rounded off to the nearest integer.
- 5.6 The Equity Shares to be issued and allotted in terms hereof will be subject to the Memorandum and Articles of Association of the Transferee Company.
- 5.7 The Transferee Company shall, if and to the extent required, apply for and obtain any approvals from concerned regulatory authorities for the issue and allotment of Equity Shares to the members of the BHPL under the Scheme.
- 5.8 The approval of this Scheme by the shareholders of the Transferee Company shall be

deemed to be due compliance of the provision of Section 81 (1A) and other relevant and applicable provision of the Act for the issue and allotment of Equity Shares by Dabur to the shareholder of BHPL, as provided in this Scheme.

6. ACCOUNTING TREATMENT IN THE BOOKS OF DABUR

6.1 On the Scheme becoming effective, the Transferee Company shall account for the merger in its books of accounts as under:

- (a) The face value of Equity Shares issued pursuant to Clause 5.1 above will be recorded as Share Capital.
- (b) The investments held by Dabur in the Transferor Companies as well as investments held by the Transferor Companies inter-se will stand cancelled and there shall be no further obligation/outstanding in that behalf;
- (c) All the assets and liabilities as on the Appointed Date, recorded in the books of the Transferor Companies shall be recorded by the Transferee Company at their book values as appearing in the books of the Transferor Companies;

It is clarified that the above assets will not include the inter-se shareholding between the Transferor Companies, which will stand cancelled;

- (d) Inter-company balances if any, will stand cancelled;
- (e) The difference between the value of shares issued as per sub-clause (a) above and the book value of net assets taken over as per sub-clause (c), after accounting for the cancellation in sub-clauses (b) and (d) above shall be debited to the Share Premium Account, the Capital Redemption Reserve Account and General Reserve and the balance if any, shall be adjusted against the accumulated credit balance in the Profit and Loss Account,;
- (f) If considered appropriate for the purpose of application of uniform accounting methods and policies between the Transferor Companies and the Transferee Company, the Transferee Company may make suitable adjustments and reflect the effect thereof in the General Reserve of the Transferee Company.
- (g) The application and reduction of the Share Premium Account (or any other name by whatsoever called) and the Capital Redemption Reserve Account, as per sub-clause (e) above, shall be effected as an integral part of the Scheme itself as the same does not involve either diminution of liability in respect of unpaid share capital or payment to any shareholder of any paid up share capital and the order of the Court sanctioning the Scheme shall be deemed to be an order under Section 102 of the Act confirming the reduction.

7. BUSINESS AND PROPERTY IN TRUST FOR DABUR

7.1 With effect from the Appointed Date and upto the Effective Date:

- i) The Transferor Companies shall carry on and be deemed to have carried on its business and activities belonging to each of the Transferor Companies and shall be deemed to have held and stood possessed of and shall hold and stand possessed of the entire business and undertakings or the appropriate part thereof belonging to each of the Transferor Companies for and on account of and in trust for the Transferee Company;
- ii) All the profits or income accruing or arising to the Transferor Companies or expenditure or losses incurred by the Transferor Companies in respect of its business and activities belonging to each of the Transferor Companies, shall for all purposes be treated and deemed to be the profits or income or expenditure or losses of the Transferee Company as the case may be.

7.2 Dabur shall be entitled, pending the sanction of the Scheme, to apply to the Central Government and all other agencies, departments and authorities concerned as are necessary under any law for such consents, approvals and sanctions which Dabur may require to carry on the business of the Transferor Companies.

8. CONDUCT OF BUSINESS

8.1 As and from the date of acceptance of this Scheme by the Board of Directors of the Transferor Companies and the Board of Directors of Dabur till the Effective Date:

- (a) The Transferor Companies shall carry on their business with reasonable diligence and in the same manner as it had been doing hithertofore, and the Transferor Companies shall not alter or expand the business except with the concurrence of Dabur.
- (b) The Transferor Companies shall not, without the written concurrence of Board of Dabur, alienate, charge or encumber any of its properties referred to in Clause 4 above except in the ordinary course of business or pursuant to any pre-existing obligation undertaken prior to the date of acceptance of the Scheme by the respective Boards of Directors of the Transferor Companies and Dabur.
- (c) The Transferor Companies shall not vary or alter, except in the ordinary course of its business and as may be required for reorganization, the terms and conditions of employment of any of its employees.

8.2 With effect from the Effective Date, Dabur shall commence and carry on and shall be authorised to carry on the businesses carried on by the Transferor Companies.

9. STAFF, WORKMEN & EMPLOYEES

9.1 On the Scheme becoming operative, all staff, workmen and employees of the Transferor Companies in service on the Effective Date shall be deemed to have become

staff, workmen and employees of Dabur with effect from the Appointed Date without any break in their service and on the basis of continuity of service, and the terms and conditions of their employment with Dabur shall not be less favourable than those applicable to them with reference to the Transferor Companies on the Effective Date.

- 9.2 It is expressly provided that, on the Scheme becoming effective, the Provident Fund, Gratuity Fund, Superannuation Fund or any other Special Fund or Trusts created or existing for the benefit of the staff, workmen and employees of the Transferor Companies shall be transferred to and shall get consolidated with the corresponding funds of Dabur. Dabur shall have the obligation to make contributions to the said Fund or Funds in accordance with the provisions thereof as per the terms provided in the respective Trust Deeds, if any, to the end and intent that all rights, duties, powers and obligations of the Transferor Companies in relation to such Fund or Funds shall become those of Dabur. It is clarified that the services of the staff, workmen and employees of the Transferor Companies will be treated as having been continuous for the purpose of the said Fund or Funds. Until such time that Dabur creates/arranges for its own funds, Dabur may, subject to necessary approvals and permissions if any, continue to make contributions pertaining to the employees of the Transferor Companies to the relevant fund of the Transferor Companies. Such contributions and other balances pertaining to the employees of the Transferor Companies shall be transferred to the funds created by Dabur on creation of relevant funds/arrangements by Dabur.

10. LEGAL PROCEEDINGS

- 10.1 If any suit, appeal or other proceeding of whatever nature by or against the Transferor Companies is pending, the same shall not abate or be discontinued or in any way be prejudicially affected by reason of or by anything contained in this Scheme, but the said suit, appeal or other legal proceedings may be continued, prosecuted and enforced by or against Dabur, as the case may be, in the same manner and to the same extent as it would or might have been continued, prosecuted and enforced by or against the Transferor Companies as if this Scheme had not been made.

11. CONTRACTS, DEEDS, ETC.

Subject to the other provisions of the Scheme, all contracts, including contracts for tenancies and licenses, deeds, bonds, agreements and other instruments of whatsoever nature to which the Transferor Companies are party, or the benefit to which the Transferor Companies may be eligible, subsisting or operative immediately on or before the Effective Date, shall be in full force and effect against or in favour of Dabur as the case may be and may be enforced as fully and effectively as if instead of the Transferor Companies, Dabur had been a party or beneficiary thereto.

The Transferee Company shall enter into and/or issue and/or execute deeds, writings or confirmation or enter into any tripartite agreement, confirmations or novations, to which the Transferor Companies as the case may be will, if necessary, also be a party in order to give formal effect to the provisions of this Scheme, if so required or

becomes necessary. Further, the Transferee Company shall be deemed to be authorised to execute any such deeds, writings or confirmations on behalf of the Transferor Companies and to implement or carry out all formalities required on the part of the Transferor Companies to give effect to the provisions of this Scheme.

12. SAVING OF CONCLUDED TRANSACTIONS

The transfer of the entire business and the undertaking of the Transferor Companies to Dabur and the continuance of all contracts or proceedings by or against the Transferor Companies shall not affect any contracts or proceedings already concluded by the Transferor Companies on or after the Appointed Date till the effective date, to the end and intent that Dabur accepts and adopts all acts, deeds, matters and things done and/or executed by the Transferor Companies in regard thereto as having been done or executed on behalf of Dabur.

13. GENERAL TERMS

13.1 It is clarified that all taxes payable by the Transferor Companies, relating to the transferred undertaking, from the Appointed Date onwards including all or any refunds and claims shall, for all purposes, be treated as the tax liabilities or refunds and claims of the Transferee Company. Accordingly, upon the Scheme becoming effective, the Transferee Company is expressly permitted to revise its VAT and Sales tax returns, Excise & Modvat/ Cenvat returns, other tax returns, and to claim refunds/credits, pursuant to the provisions of this Scheme, if any

13.2 In accordance with the Modvat / Cenvat Rules framed under the Central Excise Act, 1944, as are prevalent on the Effective Date, the unutilized credits relating to excise duties paid on inputs/ capital goods lying to the account of the Transferor Companies, if any, shall be permitted to be transferred to the credit of the Transferee Company, as if all such unutilized credits were lying to the account of the Transferee Company. The Transferee Company shall accordingly be entitled to set off all such unutilized credits against the excise duty payable by it.

14. WINDING UP

On the Scheme becoming effective, the Transferor Companies shall stand dissolved without being wound up.

15. APPLICATION TO THE HIGH COURT

The Transferor Companies and the Transferee Company shall, with all reasonable dispatch, make applications to the High Court under whose jurisdiction the registered offices of The Transferor Companies and the Transferee Company are situated.

for sanctioning this Scheme under Sections 391 to 394 of the Act and for dissolution of the Transferor Companies without being wound up.

16. MODIFICATIONS/AMENDMENTS TO THE SCHEME

The Transferor Companies and the Transferee Company by their respective Board of Directors may make and/or consent to any modifications/ amendments to the Scheme or to any conditions or limitations that the Courts or any other authority may deem fit to direct or impose or which may otherwise be considered necessary, desirable or appropriate by them (i.e. the Board of Directors). The Transferor Companies and the Transferee Company by their respective Board of Directors shall be authorised to take all such steps as may be necessary, desirable or proper to resolve any doubts, difficulties or questions whether by reason of any directive or order of any other authority or otherwise however arising out of or under or by virtue of the Scheme and/ or any matter concerned or connected therewith.

17. CONDITIONALITY OF THE SCHEME

The Scheme is and shall be conditional upon and subject to:

- i) The Scheme being approved by the requisite majorities in number and value of such classes of persons including the respective members and/or creditors of the Transferor Companies and the Transferee Company as may be directed by the High Court.
- ii) The sanction of the High Court under Sections 391 to 394 of the said Act in favour of the Transferor Companies and the Transferee Company under the said provisions and to the necessary Order under Section 394 of the said Act being obtained.
- iii) Certified or authenticated copy of the Order of the High Court sanctioning the Scheme being filed with the Registrar of Companies, Maharashtra at Mumbai, Registrar of Companies, Gujarat at Ahmedabad and the Registrar of Companies, NCT of Delhi & Haryana at New Delhi by Transferor Companies and the Transferee Company respectively.

18. EFFECT OF NON-RECEIPT OF APPROVALS/SANCTIONS

In the event of any of the said sanctions and approvals referred to in Clause (16) not being obtained and/ or the Scheme not being sanctioned by the High Court of Judicature at Bombay or the High Court of Delhi or such other competent authority, this Scheme shall stand revoked, cancelled and be of no effect, save and except in respect of any act or deed done prior thereto as is contemplated hereunder or as to any rights and/ or liabilities which might have arisen or accrued pursuant thereto and which shall be governed and be preserved or worked out as is specifically provided in the Scheme or as may otherwise arise in law. Each party shall bear and pay its respective costs, charges and expenses for and or in connection with the Scheme.

19. COSTS, CHARGES & EXPENSES

All costs, charges, taxes including duties, levies and all other expenses, if any of the Transferor Companies and the Transferee Company arising out of or incurred in connection with and implementing this Scheme and matters incidental thereto shall be borne by the Transferee Company.

SCHEDULE-II

SCHEDULE

Balsara Hygiene Products Limited

PART I

(Description of the freehold property of the transferor company)

1. Land
Holiday Home
Villa No. 18, P.O Reiz Magos,
Near Bamboo Motel, Verem Berdez, Goa 403 114
2. Building
 - a. Head office, 43 N.M Road, Fort, Mumbai
 - b. Holiday Home, Villa No. 18, P.O Reiz Magos,
Near Bamboo Motel, Verem Berdez, Goa 403 114

PART II

(Description of the leasehold property of the transferor company)

1. Land
R&D Centre
B/67, Road No- 16, Wagle Ind. Estate,
Kasan Nagar No. -02, Thane - 400 604
2. Building
 - a. R&D Centre, B/67, Road No. 16, Wagle Ind. Estate,
Kasan Nagar No 02, Thane - 400604
 - b. North Zone, A 5&6 , Pragati Chambers, Ranjit Nagar, Delhi

PART III

(Description of all stocks, debentures and other charges in action of the transferor company)

1. Fixed Assets
 - a. Goodwill
 - b. Plant and Machinery
 - c. Factory Equipments and Appliances
 - d. Electrical Installations
 - e. Furniture and Fixtures
 - f. Office Equipments
 - g. Air Conditioners
 - h. Vehicles
 - i. Trademarks
2. Investments
 - a. 449,000 shares of Rs. 10 each in Besta Cosmetics Ltd
 - b. 159,300 shares of Rs. 10 each in Balsara Home Products Ltd.
 - c. 600,000, 6.5% convertible preference shares of Rs. 10 each in Balsara Home Products Limited
 - d. 1,000 shares of Rs. 10 each in Saraswat Co-Op Bank Limited
3. Cash and Bank Balances
4. Loans and Advances

SCHEDULE

Besta Cosmetics Limited

PART I

(Description of the freehold property of the transferor company)

Not Applicable

PART II

(Description of the leasehold property of the transferor company)

1. Building
 - a. Residential Quarters – VAPI, Gujarat
 - b. North Zone, A -5&6 , Pragati Chambers,
Ranjit Nagar, Delhi

PART III

(Description of all stocks, debentures and other charges in action of the transferor company)

1. Fixed Assets
 - a. Furniture and fixtures
2. Cash and Bank Balances
3. Loans and Advances

SCHEDULE

Balsara Home Products Limited

PART I

(Description of the freehold property of the transferor company)

1. Land

- a. Factory Land
225/4/1, Village Saily, Silvassa, U.T of Dadra and Nagar Haveli
- b. Road Construction at above land
225/4/1, Village Saily, Silvassa, U.T of Dadra and Nagar Haveli
- c. Factory Land
Village Rania, Tehsil – Akbarpur, Dist. Kanpur Dehat (U.P.)
- d. Factory Land
Village Rania, Tehsil – Akbarpur, Dist. Kanpur Dehat (U.P.)
- e. Beddi Factory Land
595,596,599 & 601, Village - Malku Majra, Pargana,
Dharampur, Tehsil : Nalagarh, Dist. Solan (H.P)

2. Building

- a. Beddi Factory
595,596,599 & 601, Village - Malku Majra, Pargana, Dharampur
- b. Depot at Kanpur
Village Rania, Tehsil – Akbarpur, Dist. Kanpur Dehat (U.P.)
- c. Factory Building at Kanpur
Village Rania, Tehsil – Akbarpur, Dist. Kanpur Dehat (U.P.)
- d. Factory Building at Silvassa
225/4/1, Village Saily, Silvassa, U.T of Dadra and Nagar Haveli

PART II

(Description of the leasehold property of the transferor company)

1. Building

Delhi Office Premises, A-5&6, Pragati Chambers,
Ranjit Nagar, Delhi

PART III

(Description of all stocks, debentures and other charges in action of the transferor company)

1. **Fixed Assets**
 - a. Plant and Machinery
 - b. Factory Equipments and Appliances
 - c. Electrical Installations
 - d. Furniture and Fixtures
 - e. Office Equipments
 - f. Air Conditioners
 - g. Vehicles

2. **Investments**
 - a. 19,200 Equity shares of Rs 10 each in Besta Cosmetics Ltd
 - b. National Saving Certificate
 - c. Kisan Vikas Certificate

3. **Inventories**
 - a. Stores and Spares
 - b. Raw Materials
 - c. Packing Material
 - d. Work in process
 - e. Finished Goods

4. **Sundry Debtors**

5. **Cash and Bank balances**

6. **Loans and Advances**

Dated this the 12th Day of September, 2006
(By order of the court)

Sd/-
Joint Registrar (Co.)

1

IN THE HIGH COURT OF DELHI AT NEW DELHI
ORIGINAL JURISDICTION
COMPANY PETITION NO. 266 OF 2007
CONNECTED WITH
COMPANY APPLICATION (M) NO. 141 OF 2007

In the matter of the Companies Act, 1956

AND

In the matter of Section 391 to 394 of the Companies Act, 1956 read with Rules 67 to 87 of the Companies (Court) Rules, 1959

AND

In the matter of the Scheme of Amalgamation between Dabur India Limited and Dabur Foods Limited

AND

In the matter of Dabur Foods Limited, a company incorporated under the Companies Act, 1956, having its registered office at 8/3, Asaf Ali Road, New Delhi-110 002

Transferor Company/
Petitioner Company No. 1

AND

In the matter of Dabur India Limited, a company incorporated under the Companies Act, 1956, having its registered office at 8/3, Asaf Ali Road, New Delhi-110 002

Transferee Company/
Petitioner Company No. 2

MEMO OF PARTIES

IN THE MATTER OF :

DABUR FOODS LIMITED

A COMPANY INCORPORATED UNDER THE COMPANIES ACT, 1956, HAVING ITS REGISTERED OFFICE AT 8/3, ASAF ALI ROAD, NEW DELHI-110 002

**TRANSFEROR COMPANY/
PETITIONER COMPANY NO. 1**

AND

IN THE MATTER OF :

DABUR INDIA LIMITED

A COMPANY INCORPORATED UNDER THE COMPANIES ACT, 1956, HAVING ITS REGISTERED OFFICE AT 8/3, ASAF ALI ROAD, NEW DELHI-110 002

**TRANSFEREE COMPANY/
PETITIONER COMPANY NO. 2**

New Delhi

Dated : 13/11/2007

FILED BY :
NIDHESH GUPTA
ADVOCATE FOR THE APPLICANT COMPANY
D-4/1, VASANT VIHAR,
NEW DELHI

C-22

22.01.2008

Present : Mr. Nidesh Gupta, for the Petitioner
 Mr. R.D. Kashyap, Deputy Registrar of Companies
 for Regional Director (NR)
 Ms. Manisha Tyagi Counsel for the Official Liquidator

*** Co.Pet. No. 266/2007**

The report filed by the O.L. has not come on record. Let the same be brought on record. However, Ms. Manisha Tyagi, Counsel for the Official Liquidator states that the O.L. has no objection to the scheme. Learned counsel for the applicant says that the only objection raised by the Regional Director is that there is no mention as to whether the Petitioner Company has complied with the accounting standard 14 issued by the Institute of Chartered Accountants of India. He submits that this is factually incorrect. He refers to para 6 of the scheme, which deals with accounting treatment and particularly to paras (C), (d) and (e) which read as follows :

"6. Accounting Treatment

- (C) The Transferee Company shall record the reserves of the Transferor Company in the same form and at the same values as they appear in the financial statements of the Transferor Company at the close of business of the day immediately preceding the Appointed Date. The balances in the Profit and Loss Account of the Transferor Company shall be similarly aggregated with the balances in Profit and Loss Account of the Transferee Company.
- (d) The excess, if any, of the value of the assets over the value of the liabilities of the Transferor Company vested in the Transferee Company pursuant to this Scheme as recorded in the books of account of the Transferee Company shall, after adjusting the amounts recorded in terms of Clause (C) above and investments canceled in terms of Clause (f) below, be treated in the balance sheet of the Transferee Company in accordance with "The Pooling of Interests" method as prescribed under Accounting Standard 14 issued by the Institute of Chartered Accountants of India.
- (e) The deficit, if any, in the value of the assets over the value of the liabilities of the Transferor Company vested in the Transferee Company pursuant to this Scheme as recorded in the books of account of the Transferee Company shall, after adjusting the amounts recorded in terms of Clause(c) above and investments canceled in terms of Clause (f) below, be treated in the balance sheet of the Transferee Company in accordance with "The Pooling of Interest" method as prescribed under the Accounting Standard - 14 issued by The Institute of Chartered Accountants of India."

In view of the aforesaid the Regional Director has no subsisting objection to the Scheme Accordingly the Scheme is sanctioned by a detailed separate order, passed today. The O.L. may be paid an expenses amounting to Rs. 10,000/- within two weeks.

VIPIN SANGHI, J.

January 22, 2008
 P. K. BABBAR

* **IN THE HIGH COURT OF DELHI AT NEW DELHI**

COMPANY JURISDICTION

+ **CP No. 266 of 2007**

% **DATED 22.01.2008**

In the matter of the Companies Act, 1956:

Scheme of Amalgamation of:

Dabur Foods Ltd, ... Transferor Company/Petitioner Company no.1

And

Dabur India Ltd. ... Transferee Company/Petitioner Company no.2

Through : Mr. Nidhesh Gupta, Advocate for the applicant company

VIPIN SANGHI, J. (ORAL)

1. This is a petition under Sections 391 and 394 of the Companies Act, 1956 seeking sanction of the Scheme of Amalgamation of Dabur Foods Ltd. (transferor company) and Dabur India Ltd. (transferee company).
2. The registered office of the transferor and transferee company are situated at Delhi within the jurisdiction of this Court.
3. The petitioner companies had filed Company Application (M) No. 141/2007 which was allowed by order dated 18, September 2007. By the aforesaid order, the requirement of conducting statutory meetings of equity shareholders and secured creditors of the Transferor Company and the meetings of the equity shareholders, secured creditors and the unsecured creditors of the Transferee Company was dispensed with, on account of consent given by all of the above-mentioned concerned persons/entities.
4. However, the Transferor company was directed to convene the meeting of its unsecured creditors at Punjabi Bhawan, 10 Rouse Avenue, New Delhi on 3rd November 2007 for the purpose of considering and, if thought fit, approving the said Scheme of Amalgamation. Ms Lalit Mohini Bhat, Advocate and Ms Pooja Aganpal, Advocate were appointed as the Chairperson and the Alternate Chairperson respectively of the said meeting of unsecured creditors of the Transferor company.
5. The report of the appointed Chairperson of the meeting of the unsecured creditors of the Transferor company, Ms. Lalit Mohini Bhat, was filed with this Hon'ble Court on 6th November 2007. On the basis of that report of Ms. Bhat, this Court is satisfied on the following aspects :
 - a) The requisite quorum of 20 unsecured creditors present personally or through proxy representing 15% of the total value of the unsecured debts, as required by the above-mentioned order, was present.
 - b) The meeting was attended by 80 unsecured creditors which totaled to Rs. 23,91,12,591/- of unsecured debts. The votes were cast by 57 unsecured creditors of the value of Rs. 23,54,94,464/- and representing 45.26% of the total value of the unsecured debts. The creditors cut off date was set as 31st August, 2007. The votes of the remaining 23 unsecured creditors were declared invalid, since they weren't creditors as on the Creditors cut off date, and they attended the meeting on the basis of the aforesaid advertisements in the newspapers.
 - c) The said scheme of amalgamation was approved unanimously by the unsecured creditors, who were present and voting, in the meeting. The list of such unsecured creditors has been filed for record.

6. After the present petition was filed citations were directed to be published vide order dated 21st November 2007 in "The Statesman" (English edition) and "Jansatta" (Hindi edition), in terms of Companies (Court) Rules, 1959. An affidavit dated 3rd January, 2008 has been filed by the Chairperson appointed for the meeting about the publication of the citations in "The Statesman" (English) and "Jansatta" (Hindi) on 21st December, 2007. The said publication containing the said citations were also produced along with the affidavit.
7. Notices were issued to the OL and the Regional Director (Northern Region) vide order dated 21st November 2007. Pursuant to the notice issued to the OL, a report dated 8th January 2008 has been filed by the Official Liquidator. The Official Liquidator sought information from the petitioner complaint vide its letter no. OL/TECH/AMAL/88/274 dated 12th December 2007, upon which the requisite information was furnished by the Petitioner Companies.
8. The transferor company was incorporated on 03.12.1996. The registered office of the company is situated at 8/3, Asaf Ali Road, New Delhi - 110002. The registered office of the company is situated within the jurisdiction of this Court.
9. The authorised share capital of the transferor company as on 31st March, 2007 was Rs. 20,00,00,000/- divided into 2,00,00,000 equity shares of Rs. 10/- each. The issued, subscribed and paid up equity share capital of the Transferor company as on 31st March 2007 was Rs. 20,00,00,000/- divided into 2,00,00,000 equity shares of Rs. 10/- each.
10. The transferee company was incorporated on 16.09.1996. The registered office of the company is situated at 8/3, Asaf Ali Road, New Delhi - 110002. The registered office of the company is situated within the jurisdiction of this Court.
11. The authorised share capital of the transferee company as on 31st March, 2007 is Rs. 1,25,00,00,000/- divided into 1,25,00,00,000 equity shares of Rs. 1/- each. The issued, subscribed and paid-up equity share capital of the Transferee company as on 31st March 2007 was Rs. 86,28,83,808/- divided into 86,28,83,808 equity shares of Re. 1/- each.
12. The OL has considered the report of the Chairperson of the meeting of unsecured creditors of the Transferor company, as well as the accounts of Petitioner Companies as on 31st March 2007. The OL in its report has stated that he has not received any complaint against the scheme of amalgamation from any person/parties interested in the scheme in any manner and on the basis of information submitted by the petitioner companies. Thus, it was inferred that the affairs of the Transferor company do not appear to have been conducted in a manner prejudicial to the interest of the members, creditors, or public interest in accordance with the provisions of Section 394(i) of the Companies Act, 1956.
13. The report has also been filed by the Regional Director (Northern Region) by an affidavit Shri Dhan Raj, dated 2nd January 2008, contending that by virtue of power delegated to him under Section 394A of the Companies Act, 1956 he is competent to make the affidavit. Relying on Clause 13.1 of Section D of the Scheme of Amalgamation, it is contended that all the employees of the Transferor Company shall become the employees of the Transferee Company without any break or interruption in their services upon the sanctioning of the said Scheme of Amalgamation.
14. Relying on Para 6 of Section C of the said Scheme, which provides for the Accounting Treatment, the Regional Director objected to the Scheme of Amalgamation on the ground that there was no mention in the relied paragraph whether the Petitioner Companies have complied with the Accounting standard-14 issued by the Chartered Accountants of India.
15. The objection of the Regional Director is answered by the Petitioner Companies and an affidavit of Ms Shalu Malhotra and Mr. Ashok Kumar Jain, Authorized Signatories of the Transferor and the Transferee Company, dated 8th January 2008, in reply to the objection taken on behalf of Regional Director, has been filed.

16. In the affidavits, it was submitted that clauses (c) to (e) of para 6 of Section-C of the said Scheme clearly lay down that any excess/deficit of the value of the assets over the value of the liabilities and reserves of the Transferor company vested in the Transferee company shall be treated in the books of the Transferee company in accordance with "Pooling of Interests Method" as prescribed under Accounting for Amalgamation issued by the Institute of Chartered Accountants of India. Clauses (c), (d) and (e) of para 6 read as follows:

"6. Accounting Treatment

- (c) The Transferee Company shall record the reserves of the Transferor Company in the same form and at the same values as they appear in the financial statements of the Transferor Company at the close of business of the day immediately preceding the Appointed Date. The balances in the Profit and Loss Account of the Transferor Company shall be similarly aggregated with the balances in Profit and Loss Account of the Transferee Company.
- (d) The excess, if any, of the value of the assets over the value of the liabilities of the Transferor Company vested in the Transferee Company pursuant to this Scheme as recorded in the books of account of the Transferee Company shall, after adjusting the amounts recoded in terms of Clause (c) above and investments canceled in terms of Clause (f) below, be treated in the balance sheet of the Transferee Company in accordance with "The Pooling of Interests" method as prescribed under Accounting Standard - 14 issued by the Institute of Chartered Accountants of India.
- (e) The deficit, if any, in the value of the assets over the value of the liabilities of the Transferor Company vested in the Transferee Company pursuant to this Scheme as recorded in the books of account of the Transferee Company shall, after adjusting the amounts recorded in terms of Clause (c) above and investments canceled in terms of Clause (f) below, be treated in the balance sheet of the Transferee Company in accordance with "The Pooling of Interests" method as prescribed under the 'Accounting Standard - 14 issued by The Institute of Chartered Accountants of India.
17. In view of the aforesaid, the Regional Director has no subsisting objection.
18. There is no other legal impediment to sanction of the Scheme of Amalgamation which is annexed to the petition. Consequently, sanction is hereby granted to the Scheme of Amalgamation under, Sections 391 and 394 of the Companies Act, 1956. the Transferee company will comply with the statutory requirements in accordance with law. Certified copies of this order be filed with the Registrar of Companies within five weeks. It is also clarified that this order will not be construed as an order granting exemption from payment of stamp duty that is payable in accordance to law. Upon sanction becoming effective from the appointed date of merger, that is 1st April 2007, the Transferor company stands dissolved without being wound up. The OL may be paid expenses amounting to Rs. 10,000/- within two weeks.
19. The petition is disposed of in terms of the above order.

January 22, 2008

ab/P.K. BABBAR

- sd -

VIPIN SANGHI, J.

IN THE HIGH COURT OF DELHI AT NEW DELHI
(ORIGINAL JURISDICTION)
IN THE MATTER OF THE COMPANIES, ACT 1956
AND,
IN THE MATTER OF SCHEME OF AMAGAMATION
OF
COMPANY PETITION NO. 266/2007 CONNECTED WITH
COMPANY APPLICATION (M) NO. 141/2007

IN THE MATTER OF	M/s. Dabur Foods Ltd., having its Regd. Office at 8/3, Asaf Ali Road, New Delhi-110002	Petitioner/Transferor Company
	With	
IN THE MATTER OF	M/s. Dabur India Ltd., having its Regd. Office at 8/3, Asaf Ali Road, New Delhi-110002	Petitioner/Transferee Company

BEFORE HON'BLE MR. JUSTICE VIPIN SANGHI
DATED THIS THE 22ND DAY OF JANUARY, 2008

ORDER UNDER SECTION 394 OF THE COMPANIES ACT, 1956

The above petition coming up for hearing on 22/1/2008 for sanction of scheme of amalgamation proposed to be made of M/s. Dabur Foods Ltd. (hereinafter referred to as the Transferor Company), with M/s. Dabur India Ltd. (hereinafter referred to as the Transferee Company) upon reading the said petition, the order dt. 18/9/2007 whereby the requirement of convening and holding the meetings of the equity shareholders and secured creditors of the Transferor Company and equity shareholders, secured and unsecured creditors of the Transferee Company was dispensed with and the meeting of unsecured creditors of the Transferor Company was ordered be convened for the purpose of considering and if thought fit approving with or without modification, the Scheme of amalgamation annexed to the affidavit of Ms. Shalu Malhotra, Company Secretary and authorized signatory of the Transferor Company and Mr. Ashok Kr. Jain, Authorized signatory of the Transferee Company filed on 14th day of September, 2007 and the publication in the newspapers namely (1) Statesman (English) and (2) Jansatta (Hindi) both dt. 5/10/2007 each containing the advertisement of the said notice convening the said meeting directed to be held by the said order dt. 18/9/2007, the affidavit of Ms. Lalit Mohini Bhat, Chairperson filed on 6/11/2007 showing the publication and despatch of the notice convening the said meeting, the report of the Chairperson of the said meeting as to the result of the said meeting and upon hearing Sh. Nidhesh Gupta, Advocate for the petitioner, Ms. Manisha Tyagi, Advocate for the Official Liquidator and Mr. R. D. Kashyap, Dy. Registrar of Companies - in person and it appearing from the report that the proposed scheme of amalgamation has been approved by requisite majority without any modification by the said unsecured creditors of the Transferor Company present and voting either in person or by proxy and upon reading the affidavit dated 2/1/2008 of Sh. Dhan Raj, Regional Director, Northern Region, Ministry of Company Affairs, Noida filed on 8/1/2008 on behalf of Central Government stating that there was no mention in the paragraph 6 of Section-C whether the petitioner company had complied with the Accounting Standard-14 issued by the Chartered Accountants of India. An affidavit of Ms. Shalu Malhotra and Mr. Ashok Kumar Jain, authorized signatory of the Transferor and Transferee Company dated 9/1/2008, in reply to the objection taken on behalf of Regional Director has been filed. In the affidavit, it was submitted that clause (c) to (e) of Para 6 of Section-C of the said scheme clearly lay down that any excess/deficit of the value of the assets over the value of the liabilities and reserves of the Transferor Company vested in the Transferee Company shall be treated in the books of the Transferee

Company in accordance with "Pooling of the Interest Method" as prescribed under Accounting for amalgamation issued by the Institute of Chartered Accountants of India. The Court observed that in view of the aforesaid, the Regional Director has no subsisting objection; and considering the affidavit of Sh. A. K. Chaturvedi, Official Liquidator filed on 9/1/2008 stating therein that the affairs of the Transferor Company have not been conducted in a manner prejudicial to the interest of its shareholders or creditors or to public interest; and there being no investigation proceedings pending in relation to the petitioner companies under Section 235 to 251 of the Companies Act, 1956.

THIS COURT DOTH HEREBY SANCTION THE SCHEME OF AMALGAMATION set forth in Schedule-I annexed hereto and DOTH HEREBY DECLARE the same to be binding on all shareholders and creditors of the Transferor and Transferee Companies and all concerned and Doth approve the said scheme of amalgamation with effect from the appointed date i.e. 1.4.2007.

AND THIS COURT DOTH FURTHER ORDER :

1. That all the property, rights and powers of the Transferor Company specified in the First, Second and Third parts of the Schedule-II hereto and all other property, rights and powers of the Transferor Company be transferred without further act or deed to the Transferee Company and accordingly the same shall pursuant to Section 394 (2) of the Companies Act, 1956 be transferred to and vest in the Transferee Company for all the estate and interest of Transferor Company therein but subject nevertheless to all charges now affecting the same; and
2. That all the liabilities and duties of the Transferor Company be transferred without further act or deed to the Transferee Company and accordingly the same shall pursuant to Section 394 (2) of the Companies Act, 1956 be transferred to and become the liabilities and duties of the Transferee Company ; and
3. That all the proceedings now pending by or against the Transferor Company be continued by or against the Transferee Company ; and
4. That upon the coming into effect of the Scheme and in consideration of the transfer of the Undertaking in the Transferee Company, the Transferee Company shall not be required to issue and allot equity shares to the shareholders and the Transferor Company since the Transferor Company is a wholly owned subsidiary of the Transferee Company ; and.
5. That the Transferor Company do within five weeks after the date of this order cause a certified copy of this order to be delivered to the Registrar of Companies for registration and on such certified copy being so delivered, the Transferor Company shall be dissolved without the process of winding up and the Registrar of Companies shall place all documents relating to the Transferor Company and registered with him on the file kept by him in relation to the Transferee Company and the files relating to the said Transferor and Transferee Companies shall be consolidated accordingly. It is clarified that this order will not be construed as an order granting exemption from payment to stamp duty that is payable in accordance to law ; and.
6. That any person interested shall be at liberty to apply to the Court in the above matter for any directions that may be necessary ; and
7. That the scheme of amalgamation has been sanctioned and it has been ordered that the cost of Rs. 10,000/- has to be paid by the petitioners to the Official Liquidator, which will be deposited in the Common Pool Fund of the Official Liquidator.

**SCHEME OF AMALGAMATION
BETWEEN
DABUR FOODS LIMITED
("Transferor Company")
AND
DABUR INDIA LIMITED
("Transferee Company")**

Annexure 'A'
Schedule - I

UNDER SECTION 391 READ WITH SECTION 394 OF THE COMPANIES ACT, 1956 AND THEIR RESPECTIVE SHAREHOLDERS AND CREDITORS IN RESPECT OF MERGER OF DABUR FOODS LIMITED INTO DABUR INDIA LIMITED

PREAMBLE

Dabur India Limited ("DIL") is a company engaged in the business of manufacturing personal care and healthcare products. DIL is listed on National Stock Exchange and Mumbai Stock Exchange in India.

Dabur Foods Limited ("DFL") is engaged in the business of manufacturing and trading of Fruit Juices, Pastes, Pulps etc in India. DFL is a wholly owned subsidiary of DIL.

The Board of Directors of both the companies are of the opinion that the merger would result in benefit to the shareholders, creditors, and employees of both the companies. The management of both the companies have examined the relative business strengths and the potential commercial & other synergies of the consolidated entity and, accordingly, the possibility of consolidating their businesses under a single entity was mooted.

This Scheme provides for the merger of DFL into DIL. This Scheme also provides for matters connected therewith, with a view to maximizing value for the shareholders.

Accordingly, this Scheme is divided into the following sections:

Section A	:	General
Section B	:	Transfer and vesting of DFL into DIL
Section C	:	Accounting treatment
Section D	:	Other provisions for merger of DFL into DIL

SECTION A- GENERAL

1) DEFINITIONS

In this Scheme, unless repugnant to the context or meaning thereof, the following expressions shall have the following meanings:

- (a) "Act" means the Companies Act, 1956, including any statutory modifications, re-enactments or amendments thereof.
- (b) "Appointed Date" means the 1st day of April 2007 or such other date as may be approved by the High Court at New Delhi.
- (c) "Effective Date" means the last of the dates on which all the conditions and matters referred to in Clause 18 hereof have been fulfilled. References in this Scheme to the date of "coming into effect of the Scheme" or "effectiveness of this Scheme" shall mean "the Effective Date".
- (d) "Transferor Company" or "DFL" means Dabur Foods Limited, a company incorporated under the Act and having its registered office at 8/3, Asaf Ali Road, New Delhi - 110 002.
- (e) "Transferee Company" or "DIL" means Dabur India Limited, a company incorporated under the Act and having its registered office at 8/3, Asaf Ali Road, New Delhi - 110 002.

- (f) "Scheme of Amalgamation" or "this Scheme" or "the Scheme" means this Scheme of Amalgamation in its present form or with any modifications, as may be made.
- (g) "Undertaking" means and includes the whole of the business and undertaking of DFL, as a going concern, being carried on by DFL and shall include (without limitation):
- all secured and unsecured debts, present and future liabilities, contingent liabilities, duties and obligations (including duties/ rights/ obligations under any agreements, contracts, applications, letters of intent or any other contracts) and all the assets and properties, wherever situate, whether movable or immovable, real or personal, in possession or reversion, corporeal or incorporeal, tangible or intangible, present or contingent and including but without being limited to all land and buildings (including land and buildings specified in Schedule A), all plant and machinery, computers and accessories, software, leasehold improvements, vehicles, fixed assets, work in progress, appliances, accessories, sundry debtors, inventories, current assets, deferred tax assets, investments including investments in overseas subsidiaries, overseas offices, reserves, provisions, funds, as on the Appointed Date;
 - offices, import entitlements, import licenses, other licenses, registrations, brands, copyrights, patents, trade names, trade marks (including brands/ trademarks specified in Schedule B), applications for copyrights, patents, trade names and trade marks, benefits of any research and development efforts, any other intellectual property whether registered or otherwise, labels, label designs, quality certifications, leases, licenses, tenancy rights, premises, hire purchase and lease arrangements, office equipment, electrical fittings, furniture and fittings, capital work in progress, telephones, telexes, email and facsimile connections, communication facilities, equipment and installations and utilities, electricity, water and other service connections, benefits of agreements, contracts and arrangements including customer contracts, powers, authorities, permits, Central government/ State government incentives/ schemes/ benefits under any law in force, allotments, approvals, certifications, consents, privileges, balances with all regulatory authorities, liberties, advantages, easements and all the right, title, interest, goodwill, benefit and advantage, deposits, receivables, funds, cash, bank balances and bank accounts, bills of exchange, benefit of any deposits, financial assets, benefit of any bank guarantees, loans and advances, accounts, subsidies, grants, tax credits (including MODVAT/ CENVAT, Service Tax credits) and all other rights, claims and powers, of whatsoever nature and wheresoever situated belonging to or in the possession of or granted in favour of or enjoyed by DFL, as on the Appointed Date and all earnest money and/ or deposits including security deposits paid by DFL;
 - all employees on the rolls of DFL on the date immediately preceding the Effective Date;
 - all necessary records, files, papers, engineering and process information, computer programme, manuals, data, catalogues, quotations, sales and advertising materials, list of present and former customers and suppliers, customer credit information, customer pricing information, all supplier information and other records in connection with or relating to DFL.

It is intended that the definition of Undertaking under this clause would enable the transfer of all property, assets, liabilities, employees etc of DFL to DIL pursuant to this Scheme.

1.1. EXPRESSIONS NOT DEFINED IN THIS SCHEME

The expressions which are used in this Scheme and not defined in this Scheme, shall, unless repugnant or contrary to the context or meaning hereof, have the same meaning ascribed to them under the Act and other applicable laws, rules, regulations, bye-laws, as the case may be, or any statutory modification or re-enactment thereof from time to time. In particular, wherever reference is made to High Court in the Scheme, the reference would include, if appropriate, reference to the National Company Law Tribunal or such other forum or authority as may be vested with the powers of the Hon'ble High Court under the Act.

2) DATE OF COMING INTO EFFECT

The Scheme shall come into legal operation from the Appointed Date but shall become effective from the Effective Date.

3) COMPLIANCE WITH TAX LAW

This Scheme, has been drawn up to comply with the conditions relating to "Amalgamation" as specified under the tax laws, specifically section 2(1B) of the Income Tax Act, 1961, which include the following:

- a. all the property of the amalgamating company or companies immediately before the amalgamation becomes the property of the amalgamated company by virtue of the amalgamation;
- b. all the liabilities of the amalgamating company or companies immediately before the amalgamation become the liabilities of the amalgamated company by virtue of the amalgamation;
- c. shareholders holding not less than three-fourths in value of the shares in the amalgamating company or companies (other than shares already held therein immediately before the amalgamation by, or by a nominee for, the amalgamated company or its subsidiary) become shareholders of the amalgamated company by virtue of the amalgamation, otherwise than as a result of the acquisition of the property of one company by the other company pursuant to the purchase of such property by the other company or as a result of the distribution of such property to the other company after the winding up of the first mentioned company,

and other relevant sections including section 72A of the Income Tax Act, 1961. If any terms or provisions of the Scheme are found to be or interpreted to be inconsistent with any of the said provisions at a later date, whether as a result of any amendment of law or any judicial or executive interpretation or for any other reason whatsoever, the aforesaid provisions of the tax laws shall prevail. The Scheme shall then stand modified to the extent determined necessary to comply with the said provisions. Such modification will however not affect other parts of the Scheme. Notwithstanding the other provisions of this Scheme, the power to make such amendments as may become necessary shall vest with the Board of Directors of DIL, which power shall be exercised reasonably in the best interests of the companies and their stakeholders, and which power can be exercised at any time, whether before or after the Effective Date.

4) SHARE CAPITAL

4.1 Share Capital of the Transferor Company

The Authorised, Issued, Subscribed and Paid up Share Capital of the Transferor Company as on the Appointed Date is as under :

PARTICULARS	AMOUNT (Rs)
AUTHORISED CAPITAL	
20,000,000 Equity Shares of Rs 10 each	200,000,000
ISSUED, SUBSCRIBED AND PAID-UP CAPITAL	
20,000,000 Equity Shares of Rs 10 each	200,000,000

4.2 Share Capital of Transferee Company

The Authorised, Issued, Subscribed and Paid up Share Capital of the Transferee Company as on the Appointed Date is as under :

PARTICULARS	AMOUNT (Rs)
AUTHORISED CAPITAL	
1,250,000,000 Equity Shares of Re 1 each	1,250,000,000
ISSUED, SUBSCRIBED AND PAID-UP CAPITAL	
862,883,808 Equity Shares of Re 1 each	862,883,808

The Authorised, Issued, Subscribed and Paid up Share Capital of the Transferee Company as on July 11, 2007 is as under :

PARTICULARS	AMOUNT (Rs)
AUTHORISED CAPITAL	
1,250,000,000 Equity Shares of Re 1 each	1,250,000,000
ISSUED, SUBSCRIBED AND PAID-UP CAPITAL	
863,898,761 Equity Shares of Re 1 each	863,898,761

It is clarified that the Transferee Company beneficially owns 100% of the issued share capital of the Transferor Company as on the Appointed Date, the transfer of the Undertaking in pursuance of this Scheme shall be eligible to the benefit under Notification No 1, dated January 16, 1937 issued under Section 9(a) of the Indian Stamp Act, 1899.

SECTION B - TRANSFER AND VESTING OF DFL INTO DIL

5) TRANSFER OF UNDERTAKING

Upon the coming into effect of the Scheme and with effect from the Appointed Date, the entire Undertaking shall, pursuant to the provisions contained in section 394(2) of the Act and other provisions of law for the time being in force and without any further act or deed, be transferred to and vested in or be deemed to have been transferred to and vested in DIL on the Appointed Date, on a going concern basis, so as to become as and from the Appointed Date, the undertaking of DIL, in the following manner :

- (a) With effect from the Appointed Date, the whole of Undertaking, comprising all assets and liabilities of whatsoever nature including Government dues and wheresoever situated, shall, under the provisions of section 391 read with section 394 and all other applicable provisions, if any, of the Act, without any further act or deed, be transferred to and vested in and/ or be deemed to be transferred to and vested in DIL as a going concern so as to become as and from the Appointed Date the assets and liabilities of DIL and to vest in DIL all the rights, title, interest or obligations of DFL therein. All assets acquired by DFL after the Appointed Date and prior to the Effective Date shall also stand transferred to and vested in DIL upon the coming into effect of the Scheme. As regards transfer of specified movable assets, clauses (b) and (c) below provide for the physical mode of effecting transfer.
- (b) All the movable assets including investments, cash in hand, if any, of DFL, capable of passing by manual delivery or by endorsement and delivery, shall be so delivered or endorsed and delivered, as the case may be, to the Transferee Company as an integral part of the Undertaking. Such delivery shall be made on a date mutually agreed upon between the Board of Directors of Transferee Company or a committee thereof and the Board of Directors of DFL or a committee thereof within thirty days from the Effective Date or such other extended date as may be mutually agreed.
- (c) All debts, loans and advances recoverable in cash or in kind or for value to be received, deposits, outstanding and receivables of DFL other than the movable assets specified in sub-clause (b) above, shall on and from the Appointed Date stand transferred to and vested in DIL without any notice or other intimation to the debtors (although DIL may, if so deems appropriate, give notice to the third party that the debts, outstanding and receivables do stand transferred to and vested in DIL), and the debtors shall be obliged to make payments to DIL on and after the Effective Date.
- (d) With effect from the Appointed Date, all debts, liabilities, contingent liabilities, duties and obligations of every kind, nature and description of DFL shall also, under the provisions of sections 391 to 394 of the Act, without any further act or deed, be transferred to or be deemed to be transferred to the Transferee Company so as to become as and from the Appointed Date the debts, liabilities, contingent liabilities, duties and obligations of the Transferee Company and it shall not be necessary to obtain the consent of any third party or other person who is a party to any contract or arrangement by virtue of

which such debts, liabilities, contingent liabilities, duties and obligations have arisen, in order to give effect to the provisions of this Sub Clause.

- (e) The transfer and vesting of Undertaking as aforesaid, shall be subject to the existing securities, charges and mortgages, if any, subsisting over or in respect of the property and assets or any part thereof of DFL.

Provided however, any reference in any security documents or arrangements (to which DFL is a party) to the assets of DFL offered or agreed to be offered as security for any financial assistance or obligations, shall be construed as reference only to the assets pertaining to the Undertaking as are vested in the Transferee Company by virtue of the aforesaid Clauses, to the end and intent that such security, charge and mortgage shall not extend or be deemed to extend, to any of the other assets of DFL or any of the assets of the Transferee Company.

Provided further that the securities, charges and mortgages (if any subsisting) over and in respect of the assets or any part thereof of the Transferee Company shall continue with respect to such assets or part thereof and this Scheme shall not operate to enlarge such securities, charges or mortgages to the end and intent that such securities, charges and mortgages shall not extend or be deemed to extend, to any of the assets of DFL vested in the Transferee Company.

Provided always that this Scheme shall not operate to enlarge the security for any loan, deposit or facility created by DFL which shall vest in the Transferee Company by virtue of the amalgamation of DFL with the Transferee Company and the Transferee Company shall not be obliged to create any further or additional security therefore after the Scheme has become operative.

- (f) Upon the coming into effect of this Scheme, DFL shall be deemed to have been carrying on the business of Undertaking with effect from the Appointed Date and be entitled to avail/ claim all the benefits, registrations, permissions, licenses, concessions, exemptions, benefits under the various laws, as applicable with respect to the Undertaking, as were being availed/ claimed by DFL.
- (g) In so far as the various incentives, including all Income Tax, Sales tax or other tax exemptions and/ or deferments pursuant to the Industrial Policy or any other policy, all licenses, subsidies (including applications for subsidies), grants, special status and other benefits or privileges enjoyed, granted by any Government body, local authority or by any other person, or availed of by DFL are concerned, the same shall, without any further act or deed, vest with and be available to DFL on the same terms and conditions.
- (h) Loans or other obligations, if any, due between or amongst DFL and the Transferee Company shall stand discharged and there shall be no liability in that behalf.
- (i) Where any of the liabilities and obligations of DFL as on the Appointed Date deemed to be transferred to the Transferee Company have been discharged by DFL after the Appointed Date and prior to the Effective Date, such discharge shall be deemed to have been for and on account of the Transferee Company and all loans raised and used and all liabilities and obligations incurred by DFL for the operations of the Undertaking after the Appointed Date and prior to the Effective Date shall be deemed to have been raised, used or incurred for and on behalf of the Transferee Company and to the extent they are outstanding on the Effective Date, shall also without any further act or deed be and stand transferred to the Transferee Company and shall become its liabilities and obligations.
- (j) Upon the coming into effect of this Scheme, in so far as the security in respect of the liabilities of DFL as on the Appointed Date is concerned, it is hereby clarified that DFL and Transferee Company shall, subject to confirmation by the concerned creditor(s), mutually agree upon and arrange for such security as may be considered necessary to secure such liabilities, and obtain such consents under law as may be prescribed.
- (k) Upon the coming into effect of this Scheme, the borrowing limits of Transferee Company in terms of section 293(1) (d) of the Act shall be deemed without any further act or deed to have been enhanced

- by the aggregate liabilities of DFL which are being transferred to the Transferee Company pursuant to the Scheme, such limits being incremental to the existing limits of Transferee Company, with effect from the Appointed Date.
- (f) In so far as the various rights, quality certifications, licenses (including but not limited to Pollution license, Trade license, Factory license, Explosives license, Manufacturing license, Industrial license and Boiler Operation license), registrations, incentives, subsidies (including capital and interest subsidy available under West Bengal Incentive Scheme 2000), rehabilitation schemes, special status and other benefits or privileges (granted by any Government body, local authority or by any other person) enjoyed or availed by the Transferor Company are concerned, the same shall vest with and be available to the Transferee Company on the same terms and conditions as were applicable to the Transferor Company without any need for any further approvals.

SECTION C - ACCOUNTING TREATMENT

- 6) ACCOUNTING TREATMENT**
- (a) The Transferee Company shall, upon the Scheme coming into effect, record the assets and liabilities of the Transferor Company vested in it pursuant to this Scheme, at the respective book values thereof as appearing in the books of the Transferor Company at the close of business of the day immediately preceding the Appointed Date.
- (b) Upon the coming into effect of the Scheme and in consideration of the transfer of the Undertaking in the Transferee Company, the Transferee Company shall not be required to issue and allot equity shares to the shareholders of the Transferor Company since the Transferor Company is a wholly owned subsidiary of the Transferee Company.
- (c) The Transferee Company shall record the reserves of the Transferor Company in the same form and at the same values as they appear in the financial statements of the Transferor Company at the close of business of the day immediately preceding the Appointed Date. The balances in the Profit and Loss Account of the Transferor Company shall be similarly aggregated with the balances in Profit and Loss Account of the Transferee Company.
- (d) The excess, if any, of the value of the assets over the value of the liabilities of the Transferor Company vested in the Transferee Company pursuant to this Scheme as recorded in the books of account of the Transferee Company shall, after adjusting the amounts recorded in terms of Clause (c) above and investments cancelled in terms of Clause (f) below, be treated in the balance sheet of the Transferee Company in accordance with "The Pooling of Interests" method as prescribed under Accounting Standard - 14 issued by The Institute of Chartered Accountants of India.
- (e) The deficit, if any, in the value of the assets over the value of the liabilities of the Transferor Company vested in the Transferee Company pursuant to this Scheme as recorded in the books of account of the Transferee Company shall, after adjusting the amounts recorded in terms of Clause (c) above and investments cancelled in terms of Clause (f) below, be treated in the balance sheet of the Transferee Company in accordance with "The Pooling of Interests" method as prescribed under Accounting Standard - 14 issued by The Institute of Chartered Accountants of India.
- (f) Upon the coming into effect of this Scheme, the investment in the books of the Transferee Company, representing equity shares of DFL will stand cancelled and no shares or consideration shall be issued/paid by the Transferee Company in respect of such cancelled shares.
- (g) In case of any differences in accounting policy between the Transferor Company and the Transferee Company, the impact of the same till the merger will be quantified and adjusted in the General Reserve of the Transferee Company to ensure that the financial statements of the Transferee Company reflect the financial position on the basis of consistent accounting policy.
- (h) To the extent that there are inter-corporate loans or balances between the Transferor Company and

the Transferee Company, the obligations in respect thereof shall come to an end and corresponding effect shall be given in the books of account of the Transferee Company for the reduction of any assets or liabilities, as the case may be.

- (i) It is clarified that there would be no accrual of income or expense on account of any transactions, including inter alia any transactions in the nature of sale or transfer of any goods or services between the Transferor Company and Transferee Company, during the period between the Appointed Date and the Effective Date.
- (j) It is hereby clarified that pursuant to the provisions of Clause 5, all transactions during the period between the Appointed Date and Effective Date relating to the Undertaking would be duly reflected in the financial statements of the Transferee Company, upon the Scheme coming into effect.
- (k) Notwithstanding the above, the Board of Directors of DIL, in consultation with its Statutory Auditors, is authorised to account for any of these balances in any manner whatsoever, as may be deemed fit, in accordance with the prescribed Accounting Standards issued by The Institute of Chartered Accountants of India and generally accepted accounting principles.

SECTION D - OTHER PROVISIONS FOR MERGER OF DFL INTO DIL

7) BUSINESS AND PROPERTY IN TRUST FOR TRANSFEREE COMPANY

As and from the Appointed Date and upto and including the Effective Date :

- (a) The Transferor Company shall carry on and be deemed to have carried on its business and activities and shall stand possessed of all its assets and properties referred to in Clause 5 above, in trust for the Transferee Company and shall account for the same to the Transferee Company.
- (b) Any income or profit accruing or arising to the Transferor Company and all costs, charges, expenses and losses or taxes (including deferred tax balances, if any) incurred by the Transferor Company shall for all purposes be treated as the income, profits, costs, charges, expenses and losses or taxes (including deferred tax balances, if any), as the case may be, of the Transferee Company and shall be available to the Transferee Company for being disposed off in any manner as it thinks fit.

8) CONDUCT OF BUSINESS

With effect from the date of approval of the Scheme by the Board of Directors of DFL, and upto the Effective Date :

- (a) DFL shall carry on its business with reasonable diligence and in the same manner as it had been doing hitherto.
- (b) DFL shall not alter or substantially expand the business except with the written concurrence of the Transferee Company.
- (c) DFL shall not, without the written concurrence of Transferee Company, alienate, charge or encumber any of their properties, except in the ordinary course of business or pursuant to any pre-existing obligation undertaken prior to the date of acceptance of the Scheme by the Board of Directors of DFL.
- (d) DFL shall not vary or alter, except in the ordinary course of its business or pursuant to any pre-existing obligation undertaken prior to the date of acceptance of the Scheme by the Board of Directors of DFL, the terms and conditions of employment of any of its employees, nor shall it conclude settlement with employees.
- (e) DFL shall not revalue their respective assets and liabilities in their balance sheets without the express written consent of DIL.
- (f) DFL shall not declare any dividend without the prior written consent of the Transferee Company.

9) LEGAL PROCEEDINGS

- 9.1 All legal proceedings of whatsoever nature by or against the Transferor Company pending and/ or arising at the Appointed Date and relating to the Transferor Company or its properties, assets, debts, liabilities, duties and obligations referred to in Clause 5, shall be continued and/ or enforced until the Effective Date as desired by the Transferee Company and as and from the Effective Date shall be continued and enforced by or against the Transferee Company in the same manner and to the same extent as would or might have been continued and enforced by or against the Transferor Company. On and from the Effective Date, the Transferee Company shall and may, if required, initiate any legal proceedings in its name in relation to the Transferor Company in the same manner and to the same extent as would or might have been initiated by the Transferor Company.
- 9.2 After the Appointed Date, if any proceedings are taken against the Transferor Company above, the same shall be defended by and at the cost of the Transferee Company.

10) CONTRACTS AND DEEDS

- 10.1 Subject to the other provisions of this Scheme, all contracts, deeds, bonds, agreements, insurance policies and other instruments, if any, of whatsoever nature to which the Transferor Company is a party and subsisting or having effect on the Effective Date shall be in full force and effect against or in favour of the Transferee Company, as the case may be, and may be enforced by or against the Transferee Company as fully and effectually as if, instead of the Transferor Company, the Transferee Company had been a party thereto.
- 10.2 The Transferee Company may enter into and/ or issue and/ or execute deeds, writings or confirmations or enter into any tripartite arrangements, confirmations or novations, to which the Transferor Company will, if necessary, also be party in order to give formal effect to the provisions of this Scheme, if so required or if so considered necessary. The Transferee Company shall be deemed to be authorised to execute any such deeds, writings or confirmations on behalf of the Transferor Company and to implement or carry out all formalities required on the part of the Transferor Company to give effect to the provisions of this Scheme. It is clarified that any inter-se contracts between the Transferor Company and the Transferee Company as on the Effective Date shall stand merged and vest in the Transferee Company.
- 10.3 All subsisting agreements/ arrangements of the Transferor Company relating to the use of patents, patent applications, trade marks (including logos), brands, copyrights, and / or technology and all other intellectual property and rights, shall accrue to and for the benefit of the Transferee Company.

11) SAVING OF CONCLUDED TRANSACTIONS

The transfer of properties and liabilities under Clause 5 above and the continuance of proceedings by or against the Transferee Company under Clause 9 above shall not affect any transaction or proceedings already concluded by the Transferor Company on or before the Appointed Date and after the Appointed Date till the Effective Date, to the end and intent that the Transferee Company accepts and adopts all acts, deeds and things done and executed by the Transferor Company in respect thereto as done and executed on behalf of itself.

12) DISSOLUTION OF TRANSFEROR COMPANY

On the Scheme coming into effect, the Transferor Company shall, without any further act or deed, stand dissolved without winding up.

13) STAFF, WORKMEN AND EMPLOYEES

- 13.1 On the Scheme coming into effect, all staff and employees of DFL in service on such date shall be deemed to have become staff and employees of DIL without any break in their service and on the basis of continuity of service and the terms and conditions of their employment with DIL shall not be less favourable than those applicable to them with reference to DFL on the Effective Date.

- 13.2 Upon the Scheme coming into effect, the existing Provident Fund, Gratuity Fund and/ or schemes and trusts, including employee's welfare trust, created by DFL for its employees shall be transferred to DIL. DFL shall take all steps necessary for the transfer, where applicable, of the Provident Fund, Gratuity Fund and/ or schemes and trusts, including employee's welfare trust, pursuant to the Scheme, to DIL. All obligations of DFL with regard to the said fund or funds as defined in the respective trust deed and rules shall be taken over by DIL from the Effective Date to the end and intent that all rights, duties, powers and obligations of DFL in relation to such Fund or Funds shall become those of DIL and all the rights, duties and benefits of the employees employed in DFL under such Funds and Trusts shall be fully protected, subject to the provisions of law for the time being in force. It is clarified that the services of the staff, workmen and employees of DFL will be treated as having been continuous for the purpose of the said Fund or Funds.

14) TREATMENT OF TAXES

- 14.1 Any tax liabilities under the Income-tax Act, 1961, Customs Act, 1962, Central Excise Act, 1944, State Sales Tax laws, Central Sales Tax Act, 1956 or other applicable laws/ regulations dealing with taxes/ duties/ levies (hereinafter in this Clause referred to as "Tax Laws") allocable or related to the business of DFL to the extent not provided for or covered by tax provision in the accounts made as on the date immediately preceding the Appointed Date shall be that of DIL. Any surplus in the provision for taxation/ duties/ levies account including advance tax and withholding tax as on the date immediately preceding the Appointed Date will also be transferred to the account of DIL. Any refund under the Tax Laws due to DFL consequent to the assessments made on DFL and for which no credit is taken in the accounts as on the date immediately preceding the Appointed Date shall also belong to and be received by DIL.

- 14.2 All taxes (including income tax, sales tax, excise duty, customs duty, service tax, VAT, etc) paid or payable by DFL in respect of the operations and/or the profits of the business before the Appointed Date, shall be on account of DFL and, insofar as it relates to the tax payment (including, without limitation, sales tax, excise duty, custom duty, income tax, service tax, VAT, etc.), whether by way of deduction at source, advance tax or otherwise howsoever, by DFL in respect of the profits or activities or operation of the business after the Appointed Date, the same shall be deemed to be the corresponding item paid by DIL, and, shall, in all proceedings, be dealt with accordingly.

Upon the Scheme becoming effective, DIL is also expressly permitted to revise its income tax returns, fringe benefit tax returns and other returns filed under the tax laws and to claim refunds, advance tax and withholding tax credits, etc, pursuant to the provisions of this Scheme.

15) NO CHANGE TO BE EFFECTED IN THE CAPITAL STRUCTURE

The Transferor company shall not make any change in its capital structure (by way of issue of bonus shares, convertible debentures, detachable warrants, equity or preference shares, options and calls, fresh issue of rights shares, secured premium notes, zero interest bonds, or any other instruments of raising capital) through any increase, decrease, reduction, reclassification, subdivision, consolidation, re-organization, or in any other manner, without the express written consent of the Transferee Company.

16) GENERAL TERMS

- 16.1 Upon the Scheme coming into effect, the Transferee Company shall be entitled to use all packed/ labeled goods, packing materials, cartons, stickers, wrappers, labels, containers, point of sale material, sign board, samples, closures, other publicity material, etc lying unused with the Transferor Company or its vendors, suppliers or third party or in its supply chain or distribution channel and which the Transferor Company is entitled to use under any statutes/ regulations, till such time as all of such stock exhaust without making any amendment on those goods or materials.

- 16.2 It is clarified that all taxes payable by the Transferor Company from the Appointed Date onwards including all or any refunds and claims shall, for all purposes, be treated as the tax liabilities or refunds and claims of the Transferee Company. Accordingly, upon the Scheme becoming effective,

the Transferee Company is expressly permitted to revise its Sales tax returns or any other tax returns, and to claim refunds/ credits, pursuant to the provisions of this Scheme.

17) APPLICATIONS TO HIGH COURTS

17.1 The Transferee Company and the Transferor Company shall, with all reasonable dispatch, make applications to the High Court at New Delhi under Section 391 of the Act, seeking orders for dispensing with or convening, holding and conducting of the meetings of the respective classes of the shareholders and/ or creditors of the Transferor Company and the Transferee Company as may be directed by the High Court at New Delhi.

17.2 On the Scheme being agreed to by the requisite majorities of the classes of the shareholders and/ or creditors of the Transferee Company and the Transferor Company as directed by the High Court at New Delhi, the Transferee Company and the Transferor Company shall, with all reasonable dispatch, apply to the High Court at New Delhi, for sanctioning the Scheme of Amalgamation under Sections 391 to 394 of the Act, and for such other order or orders, as the said High Court may deem fit for carrying this Scheme into effect and for dissolution of the Transferor Company without winding up.

18) CONDITIONALITY OF SCHEME

18.1 The Scheme is conditional upon and subject to:

- (a) the Scheme being agreed to by the respective requisite majority of shareholders and creditors of the Transferee Company and the Transferor Company; and
- (b) the Scheme being approved by the High Court at New Delhi.

18.2 This Scheme, although to come into operation from the Appointed Date, shall not become effective until the date on which all necessary certified copies of orders under Sections 391 to 394 of the Act are duly filed with the Registrar of Companies, Delhi and Haryana. The date of such filing shall be the "Effective Date" for the purpose of this Scheme.

19) EFFECT OF NON-APPROVALS

19.1 In the event any of the said sanctions and approvals referred to in Clause 18 above not being obtained and/ or the Scheme not being passed as aforesaid before March 31, 2008 or within such further period or periods as may be agreed upon between Transferee Company by its Directors and the Transferor Company by its Directors (and which the Board of Directors of the Company are hereby empowered and authorised to agree to and extend from time to time without any limitations), this Scheme of Amalgamation shall stand revoked, cancelled and be of no effect and null and void save and except in respect of any act or deed done prior thereto as is contemplated hereunder or as to any right, liability or obligation which has arisen or accrued pursuant thereto and which shall be governed and be preserved or worked out as may otherwise arise in law and in such event each party shall bear their respective costs, charges and expenses in connection with the Scheme.

19.2 If any part or section of this Scheme is found to be unworkable for any reason whatsoever, the same shall not, subject to the decision of the respective Boards of Directors of the Transferee Company and the Transferor Company, as the case may be, affect the adoption or validity or interpretation of the other parts and/or provisions of this Scheme. It is hereby clarified that the Board of Directors of the Transferee Company and the Transferor Company, as the case may be, may in their absolute discretion, adopt any part of this Scheme or declare the entire Scheme to be null and void and in that event no rights and liabilities whatsoever shall accrue to or be incurred inter se by the parties or their shareholders or creditors or employees or any other person. In such case each Company shall bear its own cost or bear costs as may be mutually agreed.

20) MODIFICATION OR AMENDMENT

The Transferor Company (by its Directors) and the Transferee Company (by its Directors) may assent to any modification(s) or amendment(s) in this Scheme which the Court and/or any other authorities may deem fit to direct or impose or which may otherwise be considered necessary or desirable for settling any question or doubt or difficulty that may arise for implementing and/ or carrying out the Scheme and the Transferor Company (by its Directors) and the Transferee Company (by its Directors) and after the dissolution of the Transferor Company, the Transferee Company (by its Directors) be and are hereby authorised to take such steps and do all acts, deeds and things as may be necessary, desirable or proper to give effect to this Scheme and to resolve any doubts, difficulties or questions whether by reason of any orders of the Court or of any directive or orders of any other authorities or otherwise howsoever arising out of, under or by virtue of this Scheme and/ or any matters concerning or connected therewith.

21) CONSOLIDATION OF AUTHORISED SHARE CAPITAL

Upon the Scheme becoming effective, the authorized share capital of DFL would be added to the authorized share capital of DIL and the authorized share capital of DIL would stand increased to that extent as an integral part of this Scheme and would be deemed to have been carried out in accordance with the applicable provisions of the Act or any other law, statute, rules, regulations for the time being in force and without requiring the payment of any additional tax, stamp duty, registration fee or other charges under any law for the time being in force.

Accordingly, the authorized share capital of DIL shall stand increased from Rs 125,00,00,000 (Rupees One Hundred Twenty Five Crores Only) divided into 125,00,00,000 (One Hundred Twenty Five Crores) equity shares of Re 1 each to Rs 145,00,00,000 (Rupees One Hundred Forty Five Crores Only) divided into 145,00,00,000 (One Hundred Forty Five Crores) equity shares of Re 1 each.

Accordingly, Clause V of the Memorandum of Association of DIL shall upon the coming into effect of this Scheme be altered and substituted as follows:

"The Authorized share capital of the Company is Rs 145,00,00,000/- (Rupees One Hundred Forty Five Crores Only) divided into 145,00,00,000 (One Hundred Forty Five Crores) equity shares of Re. 1 each."

Similarly, Article 4 of the Articles of Association of DIL shall upon the coming into effect of this Scheme be altered and substituted as follows:

"The Authorized share Capital of the Company is Rs 145,00,00,000/- (Rupees One Hundred Forty Five Crores Only) divided into 145,00,00,000 (One Hundred Forty Five Crores) equity shares of Re. 1 each with the rights, privileges and conditions attaching thereto as are provided by the Articles of Association of the Company with power to increase and reduce the capital of the Company and divide the shares in the capital for the time being into several classes and to attach thereto respectively such preferential, deferred, qualified or special rights, privileges or conditions as may be determined by or in accordance with the Articles of Association of the Company for the time being and to vary, modify or abrogate any such rights, privileges or conditions in such manner as may be permitted by the Companies Act, 1956 or provided by the Articles of Association of the Company for the time being."

22) COSTS, CHARGES AND EXPENSES

Except in the circumstances mentioned in Clause 19 above, all costs, charges, taxes including duties (including the stamp duty and/ or transfer charges, if any, applicable in relation to this Scheme), levies and all other expenses, if any (save as expressly otherwise agreed) of DIL and DFL arising out of or incurred in carrying out and implementing this Scheme and matters incidental thereto shall be borne and paid by DIL.

SCHEDULE - A

Dabur Foods Limited - Illustrative list of immovable property

S. No.	Property	Details
1.	Land and Building	<p>West Bengal</p> <ul style="list-style-type: none"> • Plot No 2449, Kht No LR 342, J.L. No 22, Mouza Ambari Falkata, Block Rajganj, District Jalpaiguri - Area 0.43 acres • Plot No LR 1521, Kht No LR 277, J.L. No 19, Mouza Mehandigarha, Block Rajganj, District Jalpaiguri - Area 1.71 acres • Kht No LR 730, J.L. No 21, Mouza Mahanvita, Block Rajganj, District Jalpaiguri : • Plot No 341 - Area 0.44 acres • Plot No 359 - Area 0.21 acres • Plot No 342 - Area 0.30 acres • Plot No 355 - Area 0.20 acres • Plot No 336 - Area 0.28 acres • Plot No 357 - Area 0.33 acres • Plot No 352 - Area 0.04 acres • Plot No 356 - Area 0.08 acres • Plot No 338 - Area 0.74 acres • Plot No 339 - Area 0.39 acres • Plot No 362 - Area 1.99 acres • Plot No 344 - Area 0.56 acres • Plot No 337 - Area 0.27 acres • Plot No 358 - Area 0.53 acres • Plot No 335 - Area 0.01 acres • Plot No 354 - Area 0.64 acres • Plot No 343 - Area 0.94 acres • Plot No 353 - Area 0.58 acres • Plot No 360 - Area 0.33 acres • Plot No 340 - Area 0.20 acres • Plot No 345 - Area 0.04 acres <p>Rajasthan G 50-59, IID Centre, RIICO Industrial Area, NH - 12, Newai Dist Tonk, Rajasthan - 304 020</p>

SCHEDULE - B

Dabur Foods Limited - Illustrative list of intangible assets

S. No.	Trade Marks	Registration No.	Registration/ Application Date
1	Fundoo	857931	25.05.1999
2	Koolerz	857932	25.05.1999
3	Dabur Sip It	857935	25.05.1999
4	Fruit Exotics	1238357	19.09.2003
5	Nature's Best Logo	1280251	22.04.2004
6	Nature's Best Logo	1280252	22.04.2004
7	Activ	1280254	22.04.2004
8	Nature's Best Tomato Ketchup Label	1285705	21.05.2004
9	Coolers Logo	1421890	16.02.2006
10	Coolers Watermelon Mint Carton	1450091	02.05.2006
11	Coolers Rose Litchi Carton	1450094	02.05.2006
12	Coolers Lemon Barley Carton	1450093	02.05.2006
13	Coolers Aampanna Carton	1450092	02.05.2006

SCHEDULE - II

SCHEDULE OF ASSETS OF DABUR FOODS LIMITED (TRANSFEROR COMPANY) TO BE TRANSFERRED TO AND VESTED IN DABUR INDIA LIMITED (TRANFERREE COMPANY) AS ON THE APPOINTED DATE FOR THE SCHEME OF AMALGAMATION BETWEEN DABUR FOODS LIMITED AND DABUR INDIA LIMITED

PART I

Short description of the freehold property of the Transferor Company to be transferred to the Transferee Company
Description of freehold property being transferred by the Transferor Company to the Transferee Company under the Scheme of Amalgamation, is as under :

Particulars	Amount (Rs. in Lacs)
Freehold Land & Building thereon	
<ul style="list-style-type: none"> • Plot No. 2449, Kht No. LR 342, J.L. No. 22, Mouza Ambari Falkala, Block Rajaganj, District Jalpaiguri, West Bengal - 735135 - Area 0.43 acres • Plot No. LR 1521, Kht No. LR 277, J.L. No. 19, Mouza Mehandigarha, Block Rajaganj, District Jalpaiguri West Bengal - 735135 - Area 1.71 acres • Kht No. LR 730, J.L. No. 21, Mouza, Mahanvita Block Rajganj, District Jalpaiguri, West Bengal - 735135 <ul style="list-style-type: none"> • Plot No. 341 - Area 0.44 acres • Plot No. 359 - Area 0.21 acres • Plot No. 342 - Area 0.30 acres • Plot No. 355 - Area 0.20 acres • Plot No. 336 - Area 0.28 acres • Plot No. 357 - Area 0.33 acres • Plot No. 352 - Area 0.04 acres • Plot No. 356 - Area 0.08 acres • Plot No. 338 - Area 0.74 acres • Plot No. 339 - Area 0.39 acres • Plot No. 362 - Area 1.99 acres • Plot No. 344 - Area 0.56 acres • Plot No. 337 - Area 0.27 acres • Plot No. 358 - Area 0.53 acres • Plot No. 335 - Area 0.01 acres • Plot No. 354 - Area 0.64 acres • Plot No. 343 - Area 0.94 acres • Plot No. 353 - Area 0.58 acres • Plot No. 360 - Area 0.33 acres • Plot No. 340 - Area 0.20 acres • Plot No. 345 - Area 0.04 acres 	555.97
Total	555.97

PART II

Short description of the Leasehold property of the Transferor Company to be transferred the Transferee Company

Particulars	Amount (Rs. in Lacs)
Leasehold Land & Building thereon	
G-50-59, IID Centre, RIICO Industrial Area, NH-12, Newai Dist Tionk, Rajasthan - 304 020	215.02
Total	215.02

PART III

Short description of all the stocks, shares, debentures and other charges in action of the Transferor Company to be transferred to the Transferee Company.

Description of all stocks, shares, debenture and other charges in action of the Transferor Company to be transferred to the Transferee Company under the Scheme of Amalgamation is as under :

Particulars	Amount (Rs. in Lacs)
Plant & Machinery	2606.00
Furniture & Fixture	5.32
Office equipment	1.29
Computers	27.48
Vehicles	3.99
Capital Work-in-progress	194.75
Investments	0.20
Deferred Tax Assets	7.42
Inventories	2972.39
Sundry Debtors	2937.49
Cash & Bank Balance	379.25
Loans & Advances	1131.159
Total	10267.17

Dated this the 22nd day of January, 2008
(by order of the court)

sd/-
Deputy Registrar (Co.)

**IN THE HIGH COURT OF DELHI AT NEW DELHI
(ORDINARY ORIGINAL COMPANY JURISDICTION)
COMPANY PETITION No. 72 of 2009
MEMO OF PARTIES
IN THE MATTER OF SCHEME OF AMALGAMATION BETWEEN:**

DABUR INDIA LIMITED

A COMPANY INCORPORATED UNDER THE COMPANIES ACT, 1956 AND
HAVING ITS REGISTERED OFFICE AT 8/3, ASAF ALI ROAD,
NEW DELHI - 110 002

..... Petitioner/ Transferee Company

AND

FEM CARE PHARMA LIMITED

A COMPANY INCORPORATED UNDER THE COMPANIES Act, 1956 AND
HAVING ITS REGISTERED OFFICE AT PLOT No. D- 55, ADDL,
INDUSTRIAL AREA, MIDC, AMBAD, NASHIK - 422010 MAHARASHTRA

..... Transferor Company

Sd/-

(MAHESH AGARWAL)

AGARWAL LAW ASSOCIATES

34, BABAR LANE FIRST FLOOR, BENGALI MARKET,

NEW DELHI - 110 001

PH: 23354330, 23738122

New Delhi

Date: 15/02/2010

IN THE HIGH COURT OF DELHI AT NEW DELHI
(ORIGINAL JURISDICTION)
IN THE MATTER OF THE COMPANIES ACT, 1956
AND
IN THE MATTER OF SCHEME OF AMALGAMATION
OF
COMPANY PETITION NO. 72/2010
CONNECTED WITH
COMPANY APPLICATION (M) No. 195/2009.

IN THE MATTER OF :

M/s Fem Care Pharma Ltd.,
having its Regd. Office at:
Plot No. D-55, Addl. Industrial Area,
MIDC, Ambad, Nashik - 422010
Maharashtra

..... Non- Petitioner/ Transferor Company
(Outside the Jurisdiction of this Court)

WITH

IN THE MATTER OF

M/s Dabur India Ltd.
having its Regd. Office at :
8/3, Asaf Ali Road, New Delhi - 110002

..... Petitioner/ Transferee Company
(Within the Jurisdiction of this Court)

BEFORE HON'BLE MR. JUSTICE SUDERSHAN KUMAR MISRA
DATED THIS THE 19TH DAY OF APRIL, 2010.

ORDER UNDER SECTION 394 OF THE COMPANIES ACT, 1956

The above petition came up for hearing on 19/04/2010 for sanction of Scheme of Amalgamation proposed to be made of M/s Fem Care Pharma Ltd. (hereinafter referred to as Transferor Company; Outside the Jurisdiction of this Court) with M/s Dabur India Ltd., (hereinafter referred to as Transferee Company; Within the Jurisdiction of this Court). The Court examined the petition; the order dated 22/12/2009, passed in CA (M) 195/2009, whereby the requirement of convening and holding the meetings of the Secured Creditors of the Transferee Company was dispensed with; and the meetings of the Equity Shareholders and Unsecured Creditors of the Transferee Company were ordered to be convened for the purpose of considering and if thought fit approving with or without modification, the Scheme of Amalgamation annexed to the affidavit of Sh. A.K. Jain, General Manager (Finance) & Company Secretary of the Petitioner Company, filed on 5th day of December, 2009; and the publication in the newspapers namely Statesman (English) dated 06/01/2010 and Jansatta (Hindi) dated 07/01/2010 containing the notice of the Petition; the affidavits of Sh. Rajiv Bansal, Chairperson, filed on 19/01/2010 and Sh. J.K. Aggarwal, Chairperson, filed on 15/02/2010 showing the publication and dispatch of the notices convening the said meetings and also the report of the Chairpersons as to the result of the said meetings.

The court also examined the affidavit dated 16/03/2010 of Dr. Navrang Saini, Regional Director, Northern Region, Ministry of Corporate Affairs, Noida on behalf of Central Government stating inter-alia that the Central Government has no objection to the proposed Scheme of Amalgamation.

Upon hearing Mr. Mahesh Aggarwal with Mr. B.S. Shukla and Mr. Rajeev Kumar, Advocates for the Petitioner and Mr. V.K. Gupta, Dy. Registrar of Companies in person; and in view of the approval of the Scheme of Amalgamation without any modification; by the Secured Creditors of the Transferee Company and there being no investigation proceedings pending in relation to the Petitioner Transferee Company under Section 235 to 251 of the Companies Act, 1956.

THIS COURT DOETH HEREBY SANCTION THE SCHEME OF AMALGAMATION (Subject to sanction of the Scheme of Amalgamation in respect of the Transferor Company from the Court of Competent Jurisdiction) set forth in Schedule - I, annexed hereto and Doth hereby declare the same to be binding on all the Shareholders & Creditors of the Transferor and Transferee Companies and all concerned and doth approve the said Scheme of Amalgamation with effect from the appointed date i.e. 01/04/2009.

AND THIS COURT DOETH FURTHER ORDER:

1. That all the liabilities and duties of the Transferor Company be transferred without further act or deed to the Transferee Company and accordingly the same shall pursuant to Section 394 (2) of the Companies Act, 1956 be transferred to and become the liabilities and duties of the Transferee Company; and
2. That all the proceedings now pending by or against the Transferor Company be continued by or against the Transferee Company; and
3. That the Transferee Company do without further application allot to such members of the Transferor Company as have not given such notice of dissent as is required by Clause 5.1 given in the Scheme of Amalgamation herein the shares in the Transferee Company to which they are entitled under the said Amalgamation; and
4. That on approval of the Scheme in respect of the Transferor Company from the Court of Competent Jurisdiction, the Transferor Company shall cause a certified copy of the Order to be delivered to the Registrar of Companies for registration and on such certified copy being so delivered, the Transferor Company shall be dissolved without undergoing the process of winding up and the Concerned Registrar of Companies shall place all documents relating to the Transferor Company and registered with him on the file kept in relation to the Transferee Company and the files relating to the said Transferor Company and Transferee Company shall be consolidated accordingly; and
5. It is also clarified that this order will not be construed as an order granting exemption from payment of stamp duty that is payable in accordance with law; and
6. That any person interested shall be at liberty to apply to the Court in the above matter for any directions that may be necessary.

Dated this the 19th April, 2010
(By order of the Court)

Sd/-
Joint Registrar (Co.)
For Registrar General

**SCHEME OF AMALGAMATION
OF
FEM CARE PHARMA LIMITED
WITH
DABUR INDIA LIMITED
AND
THEIR RESPECTIVE SHAREHOLDERS**

Preamble

This Scheme of Amalgamation between Fem Care Pharma Limited and Dabur India Limited and their shareholders (hereinafter referred to as "Scheme" or "the Scheme" or "this Scheme") provides for the amalgamation of Fem Care Pharma Limited with Dabur India Limited pursuant to Sections 391 to 394 and other applicable provisions of the Companies Act, 1956.

Fem Care Pharma Limited, (hereinafter referred to as "Transferor Company" or "Fem") a Company incorporated under the provisions of the Indian Companies Act, 1956 having its Registered Office at Plot No. D-55, Addl. Industrial Area MIDC, AMBAD, Nashik - Maharashtra 422 010 is currently engaged in the business of Consumer products i.e. Skin Care, Cosmetic products and Pharmaceutical formulations.

Dabur India Ltd (hereinafter referred to as "Transferee Company" or "Dabur") a Company incorporated under the provisions of the Indian Companies Act, 1956 having its Registered Office at 8/3 Asaf Ali Road, New Delhi - 110002, is currently engaged in the business of manufacturing and marketing consumer goods in the segments of hair care, oral care, health supplements, digestives, foods, home care and skin and baby care. It also has a consumer health division which focuses on Over The Counter (OTC) and Ethical Ayurvedic portfolio.

Rationale for the Scheme of Amalgamation

The amalgamation of Fem Care Pharma Limited with Dabur India Limited is being proposed for the purpose of developing the potential for further growth and expansion of their respective businesses and to have better synergies, optimization of resources and fund raising capabilities. The amalgamation would result in the following benefits, amongst others, to Fem Care Pharma Limited and Dabur India Limited and their respective members:

- (a) Enable the two companies to consolidate their business operations and provide significant impetus to their growth since both the companies are engaged in the similar areas of business.
- (b) Result in enhancing the scale of operations and reduction in overheads, administrative, managerial and other expenditure, operational rationalization, organizational efficiency, and optimal utilization of various resources.
- (c) Result in improved shareholder value for both the companies by way of improved financial structure and cash flows, increased asset base and stronger consolidated revenue and profitability.
- (d) Result in enhanced leveraging capability of the combined entity which in turn will allow the combined entity to undertake future expansion strategies and to tap bigger opportunities in the consumer goods industry.
- (e) Consolidate the managerial expertise of the companies involved thereby giving additional strength to the operations and management of the amalgamated Company.

In consideration of the above mentioned business rationale and related benefits, this Scheme between Fem and Dabur is being proposed in accordance with the terms set out hereunder.

PART - I**DEFINITIONS AND SHARE CAPITAL****1. Definitions**

In the Scheme, unless inconsistent with the meaning or context, the following expressions shall have the following meaning:

- 1.1 "Act" means the Companies Act, 1956 and shall include any statutory modification(s), re-enactment(s) or amendment(s) thereof for the time being in force.
- 1.2 "Appointed Date" means the 1st day of April, 2009 or such other date as the High Court may direct.
- 1.3 "Dabur" or "Transferee Company" means Dabur India Limited, a company incorporated under the Companies Act, 1956 and having its registered office at 8/3 Asaf Ali Road, New Delhi - 110002.
- 1.4 "Effective Date" means the later of the dates on which certified copies of the Orders of the High Court of Judicature at Bombay and High Court of Delhi or any other appropriate authority under Sections 391 to

394 of the Act sanctioning the Scheme are filed with the Registrar of Companies, Maharashtra at Mumbai and the Registrar of Companies, NCT of Delhi & Haryana at New Delhi respectively.

- 1.5 "Fem" or "Transferor Company" means Fem Care Pharma Limited, a company incorporated under the Companies Act, 1956 and having its Registered Office at Plot No. D-55, Adff. Industrial Area MIDC, AMBAD, Nashik, Maharashtra 422 010.
- 1.6 "High Court" or "Court" means the High Court of Judicature at Bombay and High Court of Judicature at Delhi and shall include National Company Law Tribunal, if applicable.
- 1.7 "Record Date" means the date to be fixed by the Board of Directors of Dabur for the purpose of Issue of Equity Shares to the Equity Shareholders of Fem in terms of this Scheme.
- 1.8 "Scheme" or "the Scheme" or "this Scheme" means this Scheme of Amalgamation in its present form submitted to the High Court or any other appropriate authority or with any modification(s) made under Clause 16 of this Scheme.

All terms and words not defined in this Scheme shall, unless repugnant or contrary to the context or meaning thereof, have the same meaning ascribed to them under the Act, the Securities Contracts Regulation Act, 1956, the Depositories Act, 1996 and other applicable laws, rules, regulations, bye-laws, as the case may be or any statutory modification or re-enactment thereof from time to time.

2. DATE OF TAKING EFFECT AND OPERATIVE DATE

2.1 The Scheme set out herein in its present form or with any modification(s) approved or imposed or directed by the High Court or any other appropriate authority shall be operative from the Appointed Date but shall be effective from the Effective Date.

2.2 Any reference in this Scheme to "upon the Scheme becoming effective" or "effectiveness of the Scheme" or "upon the coming into effect of the Scheme" shall mean the Effective Date.

3. SHARE CAPITAL

3.1 The share capital of Fem as on March 31, 2009 is as under:

Particulars	Amount (Rs. in Lacs)
Authorized Capital	
7,000,000 Equity Shares of Rs. 10 each	700.00
	<u>700.00</u>
Issued, Subscribed and Paid-up	
3,529,400 Equity Shares of Rs. 10 each	352.94
Add: amount paid-up on forfeited shares	0.15
	<u>353.09</u>

As on date, 3,252,476 equity shares of Rs 10/- each fully paid-up are held by Dabur, making Fem the subsidiary of Dabur.

As on the date of the Scheme being approved by the Board of Directors of Fem and Dabur, there is no change in authorized, issued, subscribed and paid-up equity- capital of Fem.

3.2 The share capital of Dabur as on March 31, 2009 is as under:

Particulars	Amount (Rs. in Lacs)
Authorized Capital	
1,450,000,000 Equity Shares of Rs. 1 each	14,500.00
	<u>14,500.00</u>
Issued, Subscribed and Paid-up	
865,076, 249 Equity Shares of Rs. 1 each	8,650.76
	<u>8,650.76</u>

Subsequent to March 31, 2009, Dabur has issued 697,379 fully paid up equity shares of Rs 1 each and thus the paid up share capital has increased to 865,763,628 shares of Rs 1 each aggregating to Rs 865,763,628.

PART - II
AMALGAMATION OF FEM WITH DABUR

4. TRANSFER AND VESTING

- 4.1 Upon the scheme becoming effective, and with effect from the Appointed Date, the entire business and whole of the Undertakings of the Transferor Company including all its properties and assets of whatsoever nature whether movable or immovable, real or personal, in possession or reversion, corporeal or incorporeal, tangible or intangible, present or contingent and including but without being limited to land and building (whether owned, leased, licensed) all fixed and movable plant and machinery, vehicles, fixed assets, work in progress, current assets, tax credits, investments, reserves, provisions, funds, licenses, registrations, copyrights, any brand name, patents, trademarks and other rights and licenses in respect thereof, permits, quotas, approvals, actionable claims, all rights / title or interest in property(ies) by virtue of any court order / decree, contractual arrangement, allotment, grant, possession or otherwise, lease, tenancy rights, permissions, incentives, licenses including but not limited to export license, import license, Industrial and other licenses, bids, tenders, municipal and other statutory permissions, approvals including but not limited to right to use and avail electricity connections, water connections, telephone connections, facsimile connections, telexes, e-mail, internet, leased line connections and installations, all records, files, papers, engineering and process information, computer programs, manuals, data, catalogues, quotations, sales and advertising materials, list of present and former customers and suppliers, customer credit information, other records whether in physical, electronic form in connection/ relating to the Transferor Company and all other rights, title, interest, contracts, consent, approvals or powers of every kind, nature and descriptions whatsoever, situated belonging to or in the possession of or granted in favour of or enjoyed by the Transferor Company, shall under the provisions of Sections 391 to 394 of the Act and pursuant to the orders of the High Courts or any other appropriate authority sanctioning this Scheme and without further act, instrument or deed, be transferred to and vested in and/or deemed to be transferred to and vested in the Transferee Company.
- 4.2 Upon the scheme becoming effective and with effect from the Appointed Date, all debts, liabilities, contingent liabilities, duties and obligations of the Transferor Company as on the close of business on the date preceding the Appointed Date whether or not provided in the books of the Transferor Company shall be deemed to be the debt, liabilities, duties and obligations of the Transferee Company and it shall not be necessary to obtain the consent of any third party or other person who is a party to any contract or arrangement by virtue of which such debts, liabilities, contingent liabilities, duties and obligations have arisen in order to give effect to the provisions of this sub-clause.
- 4.3 Upon the coming into effect of this Scheme, the borrowing limits of Transferee Company in terms of section 293(1)(d) of the Act shall be deemed without any further act or deed to have been enhanced by the aggregate liabilities of the Transferor Company which are being transferred to the Transferee Company pursuant to the Scheme, such limits being incremental to the existing limits of Transferee Company, with effect from the Appointed Date.
- 4.4 The transfer and vesting of the entire business and assets and liabilities as aforesaid of the Transferor Company, shall be subject to the existing securities, charges and mortgages, if any, subsisting over or in respect of the property and assets or any part thereof of the Transferor Company.
Provided however, any reference in any security documents or arrangements (to which the Transferor Company is a party) to the assets of the Transferor Company offered or agreed to be offered as security for any financial assistance or obligations, shall be construed as reference only to the assets pertaining to the Transferor Company as are vested in the Transferee Company by virtue of the aforesaid Clauses, to the end and intent that such security, charge and mortgage shall not extend or be deemed to extend, to any of the other assets of the Transferor Company or any of the assets of the Transferee Company.
Provided further that the securities, charges and mortgages (if any subsisting) over and in respect of the assets or any part thereof of the Transferee Company shall continue with respect to such assets or part thereof and this Scheme shall not operate to enlarge such securities, charges or mortgages to the end and intent that such securities, charges and mortgages shall not extend or be deemed to extend, to any of the assets of the Transferor Company vested in the Transferee Company.
Provided always that this Scheme shall not operate to enlarge the security for any loan, deposit or facility created by the Transferor Company which shall vest in the Transferee Company by virtue of the amalgamation of the Transferor Company with the Transferee Company and the Transferee Company shall not be obliged to create any further or additional security therefore after the Scheme has become operative.
- 4.5 In respect of all the movable assets of the Transferor Company and the assets which are otherwise

capable of transfer by physical delivery or endorsement and delivery, including cash on hand (together with duly executed transfer forms or other documents as may be required), shall be so transferred to the Transferee Company and deemed to have been physically handed over by physical delivery or by endorsement and delivery, as the case may be, to the Transferee Company to the end and intent that the property and benefit therein passes to the Transferee Company with effect from the Appointed Date.

Such delivery and transfer shall be made within thirty days from the Effective Date or such other extended date as may be mutually agreed upon between the respective Boards of Directors of the Transferor Company or a committee thereof and the Board of Directors of the Transferee Company or a committee thereof.

- 4.5 In respect of any intangible moveable assets of the Transferor Company other than those mentioned in Clause 4.5 above, including actionable claims, sundry debtors, outstanding loans, advances recoverable in cash or kind or for value to be received and deposits with the Government, semi-Government, local and other authorities and bodies and customers, the Transferor Company shall if so required by the Transferee Company, and the Transferee Company may, issue notices in such form as the Transferee Company may deem fit and proper stating that pursuant to the High Court having sanctioned this Scheme, the relevant debt, loan, advance or other asset, be paid or made good or held on account of the Transferee Company, as the person entitled thereto, to the end and intent that the right of the Transferor Company to recover or realise the same stands transferred to the Transferee Company and that appropriate entries should be passed in their respective books to record the aforesaid changes.
- 4.7 Upon the Scheme becoming effective, with effect from the Appointed Date, any brands, copyrights, trademarks, statutory licenses, permissions, approvals, quotas or consents to carry on the operations and business of Transferor Companies shall stand vested in or transferred to Transferee Company without any further act or deed and shall be appropriately mutated by the Statutory Authorities concerned in favour of Transferee Company. The benefit of all brands, copyrights, trademarks, statutory and regulatory permissions, factory licenses, environmental approvals and consents, sales tax registrations, excise registrations and service tax registrations or other licenses and consents shall vest in and become available to Transferee Company pursuant to this Scheme.
- 4.8 Upon the Scheme becoming effective, all taxes payable by the Transferor Company under the Income-tax Act, 1961, Customs Act, 1962, Central Excise Act, 1944, State Sales Tax laws, Central Sales Tax Act, 1956 or other applicable laws/ regulations dealing with taxes/ duties/ levies (hereinafter in this Clause referred to as "Tax Laws") shall be to the account of the Transferee Company; similarly all credits for tax deduction at source on income of Transferor Company, or obligation for deduction of tax at source on any payment made by or to be made by the Transferor Company shall be made or deemed to have been made and duly complied with by the Transferee Company if so made by Transferor Company. Similarly any advance tax payment required to be made for by the specified due dates in the tax laws shall also be deemed to have been made by the Transferee Company if so made by the Transferor Company. Any refunds under the Tax Laws due to the Transferor Company consequent to the assessments made on the Transferor Company and for which no credit is taken in the accounts as on the date immediately preceding the Appointed Date shall also belong to and be received by the Transferee Company.
- 4.9 All taxes of any nature, duties, cesses or any other like payment or deductions made by Transferor Company to any statutory authorities such as Income Tax, Sales tax, service tax etc. or any tax deduction / collection at source, tax credits under Tax laws, relating to the period after the Appointed Date up to the Effective date shall be deemed to have been on account of or paid by the Transferee Company and the relevant authorities shall be bound to transfer to the account of and give credit for the same to Transferee Company upon the passing of the orders on this Scheme by the High Court upon relevant proof and documents being provided to the said authorities.
- 5 DISCHARGE OF CONSIDERATION**
- 5.1 Upon this Scheme becoming effective and in consideration of the amalgamation, Transferee Company shall issue and allot to the equity shareholders of Transferor Company, other than the Transferee Company holding fully paid up equity shares in Transferor Company and whose name appears in the Register of Members of Transferor Company as on the Record Date, his/her heirs, executors, administrators or the successors-in-title, as the case may be, 5 (Five) Equity Share(s) of the face value of Re. 1 each of Transferee Company credited as fully paid-up, for every 1 (One) Equity Share of the face value of Rs. 10 each of the Transferor Company ("Share Exchange Ratio"). It is clarified that no Equity Shares will be issued to the Transferee Company in its capacity as shareholder of the Transferor Company since Transferee Company cannot issue shares to itself.
- 5.2 It is further clarified that, save and except as provided in clause 5.1 above, shares of the Transferor Company held by the Transferee Company on the Record Date shall be cancelled without any further act

- or deed, and the Transferee Company shall not issue shares to the extent of shares held by itself in the Transferor Company.
- 5.3 The shareholders of Transferor Company, to whom equity shares are to be issued by the Transferee Company pursuant to Clause 5.1 above shall be issued in dematerialized form. However, shareholders of Transferor Company shall have an option to receive the certificate(s) of shares or receive credit in their demat accounts. Those, who wish to receive their equity shares in dematerialized form, shall provide all details relating to their account with depository participant, to the Transferee Company. In case no response is received, the Transferee Company shall issue the shares in the form in which Transferor Company shares were held as on the Record Date by the concerned shareholder.
- 5.4 Any fraction arising on issue of Equity Shares as above will be rounded off to the nearest integer.
- 5.5 The Equity Shares to be issued and allotted in terms hereof will be subject to the Memorandum and Articles of Association of the Transferee Company and shall rank *pari passu* in all respects, including dividend, with the then existing equity shares of the Transferee Company.
- 5.6 The Transferee Company shall take necessary steps to increase or alter or re-classify, (if necessary), its Authorized Share Capital suitably to enable it to issue and allot the shares required to be issued and allotted by it under this Scheme.
- 5.7 The approval of this Scheme by the shareholders of the Transferee Company shall be deemed to be due compliance of the provision of Section 81 (1A) and other relevant and applicable provision of the Act for the issue and allotment of Equity Shares by Transferee Company to the shareholders of the Transferor Company, as provided in this Scheme.
- 5.8 In the event of there being any pending share transfers, whether lodged or outstanding, of any shareholder of the Transferor Company, the Board of Directors of the Transferee Company or any Committee / person duly authorized in this regard by the Board of Directors of the Transferee Company shall be empowered in appropriate cases, prior to or even subsequent to the Record Date, to effectuate such a transfer as if changes in the registered holder were operative as on the Record Date, in order to remove any difficulties arising to the transferor or transferee of equity shares in the Transferor Company, after the effectiveness of this Scheme.
- 5.9 The equity shares of the Transferee Company issued pursuant to Clause 5.1 above, shall be listed and / or admitted to trading on all the stock exchanges on which the shares of the Transferee Company are listed as on the Effective Date. Such equity shares shall, however, be listed subject to the Transferee Company complying with all the applicable regulations and obtaining the requisite approvals from all the relevant regulatory authorities pertaining to the listing of the equity shares issued pursuant to the scheme.
- 6. ACCOUNTING TREATMENT IN THE BOOKS OF TRANSFEE COMPANY**
- 6.1 On the Scheme becoming effective, the Transferee Company shall account for the amalgamation in its books of accounts as under:
- (a) The face value of Equity Shares issued pursuant to Clause 5.1 above will be recorded as Share Capital.
 - (b) The investments held by Transferee Company in the Transferor Company will stand cancelled and there shall be no further obligation/outstanding in that behalf.
 - (c) Transferee Company shall, record the assets and liabilities of Transferor Company vested in it pursuant to this Scheme, at their respective book values.
 - (d) Inter-company balances if any, will stand cancelled.
 - (e) The difference between the book value of net assets taken over as per sub-clause (c) and the value of shares issued as per sub-clause (a) above, after accounting for the cancellation in sub-clauses (b) and (d) above shall be debited to the Share Premium Account, the Capital Reserve Account and General Reserve and the balance if any, shall be adjusted against the accumulated credit balance in the Profit and Loss Account.
 - (f) If considered appropriate for the purpose of application of uniform accounting methods and policies between the Transferor Companies and the Transferee Company, the Transferee Company may make suitable adjustments and reflect the effect thereof in the accumulated credit balance in the Profit and Loss Account of the Transferee Company.
 - (g) Upon the Scheme being effective the Authorized share capital of the Transferor Company would add to the authorized share capital of the Transferee Company and the authorized share capital of the Transferee Company would stand increased to that extent without any further act or deed.
 - (h) The application and reduction of the Share Premium Account as per sub-clause (e) above, shall be effected as an integral part of the Scheme itself in accordance with the provisions of Section 78 and Section 100, 102 and 103 of the Act, as the same does not involve either diminution of liability in

respect of unpaid share capital or payment to any shareholder of any paid up share capital and the order of the Court sanctioning the Scheme shall be deemed to be an order under Section 102 of the Act confirming the reduction and sufficient compliance of the provisions of Section 100 to 103 of the Companies Act, 1956, rule 85 of the Companies (Court) Rules, 1959, and other applicable provisions, if any, relating to the reduction of share capital.

- (i) Notwithstanding the reduction as mentioned above, the Transferee Company shall not be required to add "and reduced" as a suffix to its name and the Transferee Company shall continue in its existing name.

7. BUSINESS AND PROPERTY IN TRUST FOR TRANSFEEE COMPANY

7.1 With effect from the Appointed Date and upto the Effective Date:

- (i) The Transferor Company shall carry on and be deemed to have carried on its business and activities belonging to the Transferor Company and shall be deemed to have held and stood possessed of and shall hold and stand possessed of the entire business and undertakings or the appropriate part thereof belonging to the Transferor Company for and on account of and in trust for the Transferee Company;
- (ii) All the profits or income accruing or arising to the Transferor Company or expenditure or losses incurred by the Transferor Company in respect of its business and activities belonging to the Transferor Company, shall for all purposes be treated and deemed to be the profits or income or expenditure or losses of the Transferee Company as the case may be.
- (iii) It is clarified that there would be no accrual of income or expense on account of any transactions, including inter-alia any transactions in the nature of sale or transfer of any goods or services between the Transferor Company and Transferee Company, during the period between the Appointed Date and the Effective Date;
- (iv) Transferee Company shall be entitled, pending the sanction of the Scheme, to apply to the Central Government and all other agencies, departments and authorities concerned as are necessary under any law for such consents, approvals and sanctions which the Transferee Company may require to carry on the business of the Transferor Company.

8. CONDUCT OF BUSINESS

8.1 As and from the date of acceptance of this Scheme by the Board of Directors of the Transferor Company and the Board of Directors of Transferee Company till the Effective Date:

- (a) The Transferor Company shall carry on their business with reasonable diligence and in the same manner as it had been doing hitherto, and the Transferor Company shall not alter or expand the business except with the concurrence of the Transferee Company.
- (b) The Transferor Company shall not, without the written concurrence of Board of the Transferee Company, alienate, charge or encumber any of its properties referred to in Clause 4 above except in the ordinary course of business or pursuant to any pre-existing obligation undertaken prior to the date of acceptance of the Scheme by the respective Boards of Directors of the Transferor Company and the Transferee Company.
- (c) The Transferor Company shall not vary or alter, except in the ordinary course of its business and as may be required for reorganization, the terms and conditions of employment of any of its employees.
- (d) Except the cancellation of shares of the Transferee Company in the Transferor Company, as a part of this Scheme, the Transferor Company shall not make any change in its capital structure either by any increase, (by issue of equity or shares on a rights basis, bonus shares, convertible debentures or otherwise) decrease, reduction, reclassification, subdivision or consolidation, re-organization, or in any other manner which may, in any way, affect the Share Exchange Ratio (as defined in Clause 5.1 above), except by mutual consent of the respective Boards of Directors of the Transferor Company and the Transferee Company or except as may be expressly permitted.

8.2 With effect from the Effective Date, Transferee Company shall commence and carry on and shall be authorised to carry on the businesses carried on by the Transferor Company.

9. STAFF, WORKMEN & EMPLOYEES

9.1 On the Scheme becoming effective, all staff, workmen and employees of the Transferor Company in service on the Effective Date shall be deemed to have become staff, workmen and employees of the Transferee Company with effect from the Appointed Date without any break in their service and on the basis of continuity of service, and the terms and conditions of their employment with the Transferee Company shall not be less favourable than those applicable to them with reference to the Transferor Company on the Effective Date.

9.2 The services of all such Employees with the Transferor Company prior to the transfer, as aforesaid, shall

be taken into account for the purposes of all benefits to which the said Employees may be eligible, including in relation to the level of remuneration and contractual and statutory benefits, incentive plans, terminal benefits, gratuity plans, provident plans, superannuation plans and any other retirement benefits and accordingly, shall be reckoned therefore from the date of their respective appointment in the Transferor Company.

- 9.3 It is expressly provided that, on the Scheme becoming effective, the Provident Fund, Gratuity Fund, Superannuation Fund or any other Special Fund or Trusts created or existing for the benefit of the staff, workmen and employees of the Transferor Company shall be transferred to and shall get consolidated with the corresponding funds of the Transferee Company. Transferee Company shall have the obligation to make contributions to the said Fund or Funds in accordance with the provisions thereof as per the terms provided in the respective Trust Deeds, if any, to the end and intent that all rights, duties, powers and obligations of the Transferor Company in relation to such Fund or Funds shall become those of the Transferee Company. It is clarified that the services of the staff, workmen and employees of the Transferor Company will be treated as having been continuous for the purpose of the said Fund or Funds. Until such time that the Transferee Company creates/arranges for its own funds, Transferee Company may, subject to necessary approvals and permissions if any, continue to make contributions pertaining to the employees of the Transferor Company to the relevant fund of the Transferor Company. Such contributions and other balances pertaining to the employees of the Transferor Company shall be transferred to the funds created by the Transferee Company on creation of relevant funds/arrangements by the Transferee Company.

10. LEGAL PROCEEDINGS

- 10.1 If any suit, appeal or other proceeding of whatever nature by or against the Transferor Company is pending, the same shall not abate or be discontinued or in any way be prejudicially affected by reason of or by anything contained in this Scheme, but the said suit, appeal or other legal proceedings may be continued, prosecuted and enforced by or against the Transferee Company, as the case may be, in the same manner and to the same extent as it would or might have been continued, prosecuted and enforced by or against the Transferor Company as if this Scheme had not been made.

11. CONTRACTS, DEEDS, ETC.

- 11.1 Subject to the other provisions of the Scheme, all contracts, including contracts for tenancies and licenses, deeds, bonds, agreements and other instruments of whatsoever nature to which the Transferor Company are party, or the benefit to which the Transferor Company may be eligible, subsisting or operative immediately on or before the Effective Date, shall be in full force and effect against or in favour of the Transferee Company as the case may be and may be enforced as fully and effectively as if instead of the Transferor Company, the Transferee Company had been a party or beneficiary thereto.
- 11.2 The Transferee Company shall enter into and/or issue and/or execute deeds, writings or confirmation or enter into any tripartite agreement, confirmations or novations, to which the Transferor Company as the case may be will, if necessary, also be a party in order to give formal effect to the provisions of this Scheme, if so required or becomes necessary. Further, the Transferee Company shall be deemed to be authorised to execute any such deeds, writings or confirmations on behalf of the Transferor Company and to implement or carry out all formalities required on the part of the Transferor Company to give effect to the provisions of this Scheme.
- 11.3 All subsisting agreements/ arrangements of the Transferor Company relating to the use of patents, patent applications, trade marks (including logos), brands, designs, copyrights, and / or technology and all other intellectual property and rights, shall accrue to and for the benefit of the Transferee Company.

12. SAVING OF CONCLUDED TRANSACTIONS

The transfer of the entire business and the undertaking of the Transferor Company to the Transferee Company and the continuance of all contracts or proceedings by or against the Transferor Company shall not affect any contracts or proceedings already concluded by the Transferor Company on or after the Appointed Date till the effective date, to the end and intent that the Transferee Company accepts and adopts all acts, deeds, matters and things done and/or executed by the Transferor Company in regard thereto as having been done or executed on behalf of the Transferee Company.

13. WINDING UP

On the Scheme becoming effective, the Transferor Company shall stand dissolved without being wound up.

PART III GENERAL CLAUSES, TERMS AND CONDITIONS

14. GENERAL CLAUSES

- 14.1 Upon the Scheme coming into effect, the Transferee Company shall be entitled to use all packed/ labeled goods, packing materials, cartons, stickers, wrappers, labels, containers, point of sale material, sign board, samples, closures, other publicity material, etc lying unused with the Transferor Company or its vendors, suppliers or third party or in its supply chain or distribution channel and which the Transferor Company is entitled to use under any statutes/ regulations, till such time as all of such stock exhaust without making any amendment on those goods or materials.
- 14.2 Upon the Scheme becoming effective, the Transferee Company is also expressly permitted to revise its income tax returns, fringe benefit tax returns and other returns filed under the Tax laws and to claim refunds, advance tax and withholding tax credits, etc as applicable, pursuant to the provisions of this Scheme.
- 14.3 In accordance with Modvat / Cenvat Rules framed under the Central Excise Act, 1944, as are prevalent on the Effective Date, the unutilized credits relating to excise duties paid on inputs/ capital goods lying to the account of the Transferor Company, if any, shall be permitted to be transferred to the credit of Transferee Company, as if all such unutilized credits were lying to the account of Transferee Company. The Transferee Company shall accordingly be entitled to set off all such unutilized credits against the excise duty payable by it.
- 15. APPLICATION TO THE HIGH COURT**
The Transferor Company and the Transferee Company shall, with all reasonable dispatch, make applications to the High Court under whose jurisdiction the registered offices of The Transferor Company and the Transferee Company are situated, for sanctioning this Scheme under Sections 391 to 394 and applicable provisions of the Act and for dissolution of the Transferor Company without being wound up.
- 16. MODIFICATIONS/AMENDMENTS TO THE SCHEME**
The Transferor Company and the Transferee Company by their respective Board of Directors may make and/or consent to any modifications/ amendments to the Scheme or to any conditions or limitations that the Courts or any other authority may deem fit to direct or impose or which may otherwise be considered necessary, desirable or appropriate by them (i.e. the Board of Directors). The Transferor Company and the Transferee Company by their respective Board of Directors shall be authorised to take all such steps as may be necessary, desirable or proper to resolve any doubts, difficulties or questions whether by reason of any directive or order of any other authority or otherwise however arising out of or under or by virtue of the Scheme and/or any matter concerned or connected therewith.
- 17. CONDITIONALITY OF THE SCHEME**
The Scheme is and shall be conditional upon and subject to:
- i) The Scheme being approved by the requisite majorities in number and value of such classes of persons including the respective members and/or creditors of the Transferor Company and the Transferee Company as may be directed by the High Court.
 - ii) The sanction of the High Court under Sections 391 to 394 of the said Act in favour of the Transferor Company and the Transferee Company under the said provisions and to the necessary Order under Section 394 of the said Act being obtained.
 - iii) The requisite consent, approval or permission of any other statutory or regulatory authority, which by law may be necessary for the implementation of this Scheme;
 - iv) Certified copies of the Orders of the High Court sanctioning the Scheme being filed with the Registrar of Companies, Maharashtra at Mumbai and the Registrar of Companies, NCT of Delhi & Haryana at New Delhi by Transferor Company and the Transferee Company respectively.
- 18. EFFECT OF NON-RECEIPT OF APPROVALS/SANCTIONS**
In the event of any of the said sanctions and approvals referred to in Clause 17 not being obtained and/ or the Scheme not being sanctioned by the High Court of Judicature at Bombay or the High Court of Delhi or such other competent authority, this Scheme shall stand revoked, cancelled and be of no effect, save and except in respect of any act or deed done prior thereto as is contemplated hereunder or as to any rights and/ or liabilities which might have arisen or accrued pursuant thereto and which shall be governed and be preserved or worked out as is specifically provided in the Scheme or as may otherwise arise in law. Each party shall bear and pay its respective costs, charges and expenses for and or in connection with the Scheme.
- 19. COSTS, CHARGES & EXPENSES**
Except in the circumstances mentioned in Clause 18 above, all costs, charges, taxes including duties, levies and all other expenses, if any of the Transferor Company and the Transferee Company arising out of or incurred in connection with and implementing this Scheme and matters incidental thereto shall be borne by the Transferee Company.